US20050239732A1 - Immunostimulatory nucleic acid molecules - Google Patents
Immunostimulatory nucleic acid moleculesDownload PDFInfo
- Publication number
- US20050239732A1 US20050239732A1US10/956,745US95674504AUS2005239732A1US 20050239732 A1US20050239732 A1US 20050239732A1US 95674504 AUS95674504 AUS 95674504AUS 2005239732 A1US2005239732 A1US 2005239732A1
- Authority
- US
- United States
- Prior art keywords
- odn
- cpg
- dna
- cells
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- oligonucleotidesLike DNA, oligodeoxyribonucleotides (ODNs) are able to enter cells in a saturable, sequence independent, and temperature and energy dependent fashion (reviewed in Jaroszewski, J. W., and J. S. Cohen. 1991.
- Lymphocyte ODN uptakehas been shown to be regulated by cell activation.
- Spleen cells stimulated with the B cell mitogen LPShad dramatically enhanced ODN uptake in the B cell population, while spleen cells treated with the T cell mitogen Con A showed enhanced ODN uptake by T but not B cells (Krieg, A. M., F. Gmelig-Meyling, M. F. Gourley, W. J. Kisch, L. A. Chrisey, and A. D. Steinberg. 1991. “Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible”. Antisense Research and Development 1:161).
- poly (I,C)which is a potent inducer of IFN production as well as a macrophage activator and inducer of NK activity
- I,Ca potent inducer of IFN production as well as a macrophage activator and inducer of NK activity
- Guanine ribonucleotides substituted at the C8 position with either a bromine or a thiol groupare B cell mitogens and may replace.
- B cell differentiation factors(Feldbush, T. L., and Z. K. Ballas. 1985. “Lymphokine-like activity of 8-mercaptoguanosine: induction of T and B cell differentiation”. J. Immunol. 134:3204; and Goodman, M. G. 1986. “Mechanism of synergy between T cell signals and C8-substituted guanine nucleosides in humoral immunity: B lymphotropic cytokines induce responsiveness to 8-mercaptoguanosine”. J. Immunol. 136:3335).
- 8-mercaptoguanosine and 8-bromoguanosinealso can substitute for the cytokine requirement for the generation of MHC restricted CTL (Feldbush, T. L., 1985. cited supra), augment murine NK activity (Koo, G. C., M. E. Jewell, C. L. Manyak, N. H. Sigal, and L. S. Wicker. 1988. “Activation of murine natural killer cells and macrophages by 8-bromoguanosine”. J. Immunol. 140:3249), and synergize with IL-2 in inducing murine LAK generation (Thompson, R. A., and Z. K. Ballas. 1990. “Lymphokine-activated killer (LAK) cells.
- Pisetsky et al.reported that pure mammalian DNA has no detectable immune effects, but that DNA from certain bacteria induces B cell activation and immunoglobulin secretion (Messina, J. P., G. S. Gilkeson, and D. S. Pisetsky. 1991. “Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA”. J. Immunol. 147:1759). Assuming that these data did not result from some unusual contaminant, these studies suggested that a particular structure or other characteristic of bacterial DNA renders it capable of triggering B cell activation.
- CREBcAMP response element binding protein
- ATFactivating transcription factor
- CREB/ATF family of transcription factorsis a ubiquitously expressed class of transcription factors of which 11 members have so far been cloned (reviewed in de Groot, R. P., and P. Sassone-Corsi: “Hormonal control of gene expression: Multiplicity and versatility of cyclic adenosine 3′,5′-monophosphate-responsive nuclear regulators”. Mol. Endocrin. 7:145, 1993; Lee, K. A. W., and N. Masson: “Transcriptional regulation by CREB and its relatives”. Biochim. Biophys. Acta 1174:221, 1993.).
- bZipbasic region/leucine zipper
- All cellsappear to express one or more CREB/ATF proteins, but the members expressed and the regulation of mRNA splicing appear to be tissue-specific. Differential splicing of activation domains can determine whether a particular CREB/ATF protein will be a transcriptional inhibitor or activator. Many CREB/ATF proteins activate viral transcription, but some splicing variants which lack the activation domain are inhibitory.
- CREB/ATF proteinscan bind DNA as homo- or hetero-dimers through the cAMP response element, the CRE, the consensus form of which is the unmethylated sequence TGACGTC (binding is abolished if the CpG is methylated) (Iguchi-Ariga, S. M. M., and W. Schaffner: “CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation”. Genes & Develop. 3:612, 1989.).
- CREB/ATF proteinsappear to regulate the expression of multiple genes through the CRE including immunologically important genes such as fos, jun B, Rb-1, IL-6, IL-1 (Tsukada, J., K. Saito, W. R. Waterman, A. C. Webb, and P. E. Auron: “Transcription factors NF-IL6 and CREB recognize a common essential site in the human prointerleukin 1 ⁇ gene”. Mol. Cell.
- Ehrlich“Binding of AP-1/CREB proteins and of MDBP to contiguous sites downstream of the human TGF-B 1 gene”. Biochim. Biophys. Acta 1219:55, 1994.), TGF- ⁇ 2, class II MHC (Cox, P. M., and C. R. Goding: “An ATF/CREB binding motif is required for aberrant constitutive expression of the MHC class II DRa promoter and activation by SV40 T-antigen”. Nucl. Acids Res. 20:4881, 1992.), E-selectin, GM-CSF, CD-8 ⁇ , the germline Ig ⁇ constant region gene, the TCR V ⁇ gene, and the proliferating cell nuclear antigen (Huang, D., P. M.
- Activation of CREB through the cyclic AMP pathwayrequires protein kinase A (PKA), which phosphorylates CREB 341 on ser 133 and allows it to bind to a recently cloned protein, CBP (Kwok, R. P. S., J. R. Lundblad, J. C. Chrivia, J. P. Richards, H. P. Bachinger, R. G. Brennan, S. G. E. Roberts, M. R. Green, and R. H. Goodman: “Nuclear protein CBP is a coactivator for the transcription factor CREB”. Nature 370:223, 1994; Arias, J., A. S. Alberts, P. Brindle, F. X.
- PKAprotein kinase A
- CBPbasal transcription factor
- TFIIBbasal transcription factor
- CREBalso has been reported to interact with dTAFII 110, a TATA binding protein-associated factor whose binding may regulate transcription (Ferreri, K., G. Gill, and M. Montminy: “The cAMP-regulated transcription factor CREB interacts with a component of the TFIID complex”. Proc. Natl. Acad. Sci. USA 91:1210, 1994.).
- CREB/ATF proteinscan specifically bind multiple other nuclear factors (Hoeffler, J. P., J. W. Lustbader, and C.-Y. Chen: “Identification of multiple nuclear factors that interact with cyclic adenosine 3′,5′-monophosphate response element-binding protein and activating transcription factor-2 by protein-protein interactions”. Mol. Endocrinol. 5:256, 1991) but the biologic significance of most of these interactions is unknown.
- CREBis normally thought to bind DNA either as a homodimer or as a heterodimer with several other proteins.
- CREB monomers constitutively activate transcriptionKrajewski, W., and K. A. W. Lee: “A monomeric derivative of the cellular transcription factor CREB functions as a constitutive activator”. Mol. Cell. Biol. 14:7204, 1994.).
- cytomegalovirus immediate early promoterone of the strongest known mammalian promoters, contains eleven copies of the CRE which are essential for promoter function (Chang, Y.-N., S. Crawford, J. Stall, D. R. Rawlins, K.-T. Jeang, and G. S. Hayward: “The palindromic series I repeats in the simian cytomegalovirus major immediate-early promoter behave as both strong basal enhancers and cyclic AMP response elements”. J. Virol. 64:264, 1990).
- At least some of the transcriptional activating effects of the adenovirus EIA protein, which induces many promoters,are due to its binding to the DNA binding domain of the CREB/ATF protein, ATF-2, which mediates E1A inducible transcription activation (Liu, F., and M. R. Green: “Promoter targeting by adenovirus E1a through interaction with different cellular DNA-binding domains”. Nature 368:520, 1994). It has also been suggested that E1A binds to the CREB-binding protein, CBP (Arany, Z., W. R. Sellers, D. M. Livingston, and R.
- HTLV-1Human T lymphotropic virus-I
- Taxthe retrovirus which binds to CREB/ATF proteins and redirects them from their normal cellular binding sites to different DNA sequences (flanked by G- and C-rich sequences) present within the HTLV transcriptional enhancer
- the instant inventionis based on the finding that certain nucleic acids containing unmethylated cytosine-guanine (CpG) dinucleotides activate lymphocytes in a subject and redirect a subject's immune response from a Th2 to a Th1 (e.g. by inducing monocytic cells and other cells to produce Th1 cytokines, including IL-12, IFN- ⁇ and GM-CSF).
- CpGcytosine-guanine
- the immunostimulatory nucleic acidcontains a consensus mitogenic CpG motif represented by the formula: 5′ X 1 CGX 2 3′
- an immunostimulatory nucleic acid moleculecontains a consensus mitogenic CpG motif represented by the formula: 5′ X 1 X 2 CGX 3 X 4 3′
- X 1 X 2is selected from the group consisting of GpT, GpG, GpA and ApA and/or X 3 X 4 is selected from the group consisting of TpT, CpT and GpT (Table 5).
- CpG containing immunostimulatory nucleic acid moleculesare preferably in the range of 8 to 40 base pairs in size.
- nucleic acids of any sizeare immunostimulatory if sufficient immunostimulatory motifs are present, since such larger nucleic acids are degraded into oligonucleotides inside of cells.
- Preferred synthetic oligonucleotidesdo not include a GCG trinucleotide sequence at or near the 5′ and/or 3′ terminals and/or the consensus mitogenic CpG motif is not a palindrome.
- Prolonged immunostimulationcan be obtained using stabilized oligonucleotides, particularly phosphorothioate stabilized oligonucleotides.
- the inventionfeatures useful therapies, which are based on the immunostimulatory activity of the nucleic acid molecules.
- the immunostimulatory nucleic acid moleculescan be used to treat, prevent or ameliorate an immune system deficiency (e.g., a tumor or cancer or a viral, fungal, bacterial or parasitic infection in a subject).
- an immune system deficiencye.g., a tumor or cancer or a viral, fungal, bacterial or parasitic infection in a subject.
- immunostimulatory nucleic acid moleculescan be administered to stimulate a subject's response to a vaccine.
- the instant claimed nucleic acid moleculescan be administered to treat or prevent the symptoms of asthma.
- the instant claimed nucleic acid moleculescan be administered in conjunction with a particular allergen to a subject as a type of desensitization therapy to treat or prevent the occurrence of an allergic reaction.
- immunostimulatory nucleic acid moleculesto induce leukemic cells to enter the cell cycle supports the use of immunostimulatory nucleic acid molecules in treating leukemia by increasing the sensitivity of chronic leukemia cells and then administering conventional ablative chemotherapy, or combining the immunostimulatory nucleic acid molecules with another immunotherapy.
- FIG. 1A -Care graphs plotting dose-dependent IL-6 production in response to various DNA sequences in T cell depleted spleen cell cultures.
- ODNphosphodiester oligodeoxynucleotide
- SEQ ID NO:1ATGGAAGGTCCAGTGTTCTC 3′
- CpG ODN5′ ATCGACCTACGTGCGTTCTC 3′
- SEQ ID NO:35′ TCCATAACGTTCCTGATGCT 3′
- FIG. 2is a graph plotting IL-6 production induced by CpG DNA in vivo as determined 1-8 hrs after injection. Data represent the mean from duplicate analyses of sera from two mice.
- BALB/c micetwo mice/group were injected iv. with 100 ⁇ l of PBS ( ⁇ ) or 200 ⁇ g of CpG phosphorothioate ODN 5′ TCCATGACGTTCCTGATGCT 3′ (SEQ ID NO:7) ( ⁇ ) or non-CpG phosphorothioate ODN 5′ TCCATGAGCTTCCTGAGTCT 3′ (SEQ ID NO:8) ( ⁇ ).
- FIG. 3is an autoradiograph showing IL-6 mRNA expression as determined by reverse transcription polymerase chain reaction in liver, spleen, and thymus at various time periods after in vivo stimulation of BALB/c mice (two mice/group) injected iv with 100 ⁇ l of PBS, 200 ⁇ g of CpG phosphorothioate ODN 5′ TCCATGACGTTCCTGATGCT 3′ (SEQ ID NO:7) or non-CpG phosphorothioate ODN 5′ TCCATGAGCTTCCTGAGTCT 3′ (SEQ ID NO:8).
- FIG. 4Ais a graph plotting dose-dependent inhibition of CpG-induced IgM production by anti-IL-6.
- Splenic B-cells from DBA/2 micewere stimulated with CpG ODN 5′ TCCAAGACGTTCCTGATGCT 3′ (SEQ ID NO:9) in the presence of the indicated concentrations of neutralizing anti-IL-6 ( ⁇ ) or isotype control Ab ( ⁇ ) and IgM levels in culture supernatants determined by ELISA.
- ⁇neutralizing anti-IL-6
- ⁇isotype control Ab
- IgM levelsin culture supernatants determined by ELISA.
- the anti-IL-6 Abhad no effect on IgM secretion ( ⁇ ).
- FIG. 4Bis a graph plotting the stimulation index of CpG-induced splenic B cells cultured with anti-IL-6 and CpG S-ODN 5′ TCCATGACGTTCCTGATGCT 3′ (SEQ ID NO:7) ( ⁇ ) or anti-IL-6 antibody only ( ⁇ ). Data present the mean ⁇ standard deviation of triplicates.
- FIG. 5is a bar graph plotting chloramphenicol acetyltransferase (CAT) activity in WEHI-231 cells transfected with a promoter-less CAT construct (pCAT), positive control plasmid (RSV), or IL-6 promoter-CAT construct alone or cultured with CpG 5′ TCCATGACGTTCCTGATGCT 3′ (SEQ ID NO:7) or non-CpG 5′ TCCATGAGCTTCCTGAGTCT 3′ (SEQ ID NO:8) phosphorothioate ODN at the indicated concentrations. Data present the mean of triplicates.
- FIG. 6is a schematic overview of the immune effects of the immunostimulatory ummethylated CpG containing nucleic acids, which can directly activate both B cells and monocytic cells (including macrophages and dendritic cells) as shown.
- the immunostimulatory oligonucleotidesdo not directly activate purified NK cells, but render them competent to respond to IL-12 with a marked increase in their IFN- ⁇ production.
- the immunostimulatory nucleic acidspromote a Th1 type immune response. No direct activation of proliferation of cytokine secretion by highly purified T cells has been found. However, the induction of Th1 cytokine secretion by the immunostimulatory oligonucleotides promotes the development of a cytotoxic lymphocyte response.
- FIG. 7is an autoradiograph showing NFKB mRNA induction in monocytes treated with E. coli (EC) DNA (containing unmethylated CpG motifs), control (CT) DNA (containing no unmethylated CpG motifs) and lipopolysaccharide (LPS) at various measured times, 15 and 30 minutes after contact.
- E. coliE. coli
- CTcontrol
- LPSlipopolysaccharide
- FIG. 8Ashows the results from a flow cytometry study using mouse B cells with the dihydrorhodamine 123 dye to determine levels of reactive oxygen species.
- the dyeonly sample in Panel A of the figure shows the background level of cells positive for the dye at 28.6%.
- This level of reactive oxygen specieswas greatly increased to 80% in the cells treated for 20 minutes with PMA and ionomycin, a positive control (Panel B).
- the cells treated with the CpG oligo(TCCATGACGTTCCTGACGTT SEQ ID NO: 10) also showed an increase in the level of reactive oxygen species such that more than 50% of the cells became positive (Panel D).
- FIG. 8Bshows the results from a flow cytometry study using mouse B cells in the presence of chloroquine with the dihydrorhodamine 123 dye to determine levels of reactive oxygen species. Chloroquine slightly lowers the background level of reactive oxygen species in the cells such that the untreated cells in Panel A have only 4.3% that are positive. Chloroquine completely abolishes the induction of reactive oxygen species in the cells treated with CpG DNA (Panel B) but does not reduce the level of reactive oxygen species in the cells treated with PMA and ionomycin (Panel E).
- FIG. 9is a graph plotting lung lavage cell count over time.
- the graphshows that when the mice are initially injected with Schistosoma mansoni eggs “egg”, which induces a Th2 immune response, and subsequently inhale Schistosoma mansoni egg antigen “SEA” (open circle), many inflammatory cells are present in the lungs. However, when the mice are initially given CpG oligo (SEQ ID NO:10) along with egg, the inflammatory cells in the lung are not increased by subsequent inhalation of SEA (open triangles).
- FIG. 10is a graph plotting lung lavage eosinophil count over time. Again, the graph shows that when the mice are initially injected with egg and subsequently inhale SEA (open circle), many eosinophils are present in the lungs. However, when the mice are initially given CpG oligo (SEQ ID NO:10) along with egg, the inflammatory cells in the lung are not increased by subsequent inhalation of the SEA (open triangles).
- FIG. 11is a bar graph plotting the effect on the percentage of macrophage, lymphocyte, neutrophil and eosinophil cells induced by exposure to saline alone; egg, then SEA; egg and SEQ ID NO:11, then SEA; and egg and control oligo (SEQ ID NO:11), then SEA.
- miceare treated with the control oligo at the time of the initial exposure to the egg, there is little effect on the subsequent influx of eosinophils into the lungs after inhalation of SEA.
- mice inhale the eggs on days 14 or 21they develop an acute inflammatory response in the lungs.
- giving a CpG oligo along with the eggs at the time of initial antigen exposure on days 0 and 7almost completely abolishes the increase in eosinophils when the mice inhale the egg antigen on day 14.
- FIG. 12is a bar graph plotting eosinophil count in response to injection of various amounts of the protective oligo SEQ ID NO:10.
- FIG. 13is a graph plotting interleukin 4 (IL-4) production (pg/ml) in mice over time in response to injection of egg, then SEA (open diamond); egg and SEQ ID NO:10, then SEA (open circle); or saline, then saline (open square).
- the graphshows that the resultant inflammatory response correlates with the levels of the Th2 cytokine IL-4 in the lung.
- FIG. 14is a bar graph plotting interleukin 12 (IL-12) production (pg/ml) in mice over time in response to injection of saline; egg, then SEA; or SEQ ID NO:10 and egg, then SEA.
- the graphshows that administration of an oligonucleotide containing an unmethylated CpG motif can actually redirect the cytokine response of the lung to production of IL-12, indicating a Th1 type of immune response.
- IL-12interleukin 12
- FIG. 15is a bar graph plotting interferon gamma (IFN- ⁇ ) production (pg/ml) in mice over time in response to injection of saline; egg, then saline; or SEQ ID NO:10 and egg, then SEA.
- the graphshows that administration of an oligonucleotide containing an unmethylated CpG motif can also redirect the cytokine response of the lung to production of IFN- ⁇ , indicating a Th1 type of immune response.
- allergenrefers to a substance that can induce an allergic or asthmatic response in a susceptible subject.
- the list of allergensis enormous and can include pollens, insect venoms, animal dander, dust, fungal spores and drugs (e.g. penicillin).
- Examples of natural, animal and plant allergensinclude proteins specific to the following genera: Canine ( Canis familiaris ); Dermatophagoides (e.g. Dermatophagoides farinae ); Felis ( Felis domesticus ); Ambrosia ( Ambrosia artemiisfolia; Lolium (e.g.
- Lolium perenne or Lolium multiflorumCryptomeria ( Cryptomeria japonica ); Alternaria ( Alternaria alternata ); Alder; Alnus ( Alnus gultinosa ); Betula ( Betula verrucosa ); Quercus ( Quercus alba ); Olea ( Olea europa ); Artemisia ( Artemisia vulgaris ); Plantago (e.g. Plantago lanceolata ); Parietaria (e.g. Parietaria officinalis or Parietaria judaica ); Blattella (e.g. Blattella germanica ); Apis (e.g. Apis multiflorum ); Cupressus (e.g.
- Juniperuse.g. Juniperus sabinoides, Juniperus virginiana, Juniperus communis and Juniperus ashei ); Thuya (e.g. Thuya orientalis ); Chamaecyparis (e.g. Chamaecyparis obtusa ); Periplaneta (e.g. Periplaneta americana ); Agropyron (e.g. Agropyron repens ); Secale (e.g. Secale cereale ); Triticum (e.g. Triticum aestivum ); Dactylis (e.g. Juniperus sabinoides, Juniperus virginiana, Juniperus communis and Juniperus ashei ); Thuya (e.g. Thuya orientalis ); Chamaecyparis (e.g. Chamaecyparis obtusa ); Periplaneta (e.g. Periplaneta americana
- Avenae.g. Avena sativa
- Holcuse
- Allergic conditionsinclude eczema, allergic rhinitis or coryza, hay fever, bronchial asthma, urticaria (hives) and food allergies, and other atopic conditions.
- Asthmarefers to a disorder of the respiratory system characterized by inflammation, narrowing of the airways and increased reactivity of the airways to inhaled agents. Asthma is frequently, although not exclusively associated with atopic or allergic symptoms.
- an “immune system deficiency”shall mean a disease or disorder in which the subject's immune system is not functioning in normal capacity or in which it would be useful to boost a subject's immune response for example to eliminate a tumor or cancer (e.g. tumors of the brain, lung (e.g. small cell and non-small cell), ovary, breast, prostate, colon, as well as other carcinomas and sarcomas) or an infection in a subject.
- a tumor or cancere.g. tumors of the brain, lung (e.g. small cell and non-small cell), ovary, breast, prostate, colon, as well as other carcinomas and sarcomas
- an infection in a subjecte.g. tumors of the brain, lung (e.g. small cell and non-small cell), ovary, breast, prostate, colon, as well as other carcinomas and sarcomas
- Retroviridaee.g., human immunodeficiency viruses, such as HIV-1 (also referred to as HTLV-III, LAV or HTLV-III/LAV, or HIV-III; and other isolates, such as HIV-LP; Picornaviridae (e.g., polio viruses, hepatitis A virus; enteroviruses, human coxsackie viruses, rhinoviruses, echoviruses); Calciviridae (e.g., strains that cause gastroenteritis); Togaviridae (e.g., equine encephalitis viruses, rubella viruses); Flaviridae (e.g., dengue viruses, encephalitis viruses, yellow fever viruses); Coronaviridae (e.g., coronaviruses); Rhabdoviridae (e.g., vesicular stomatitis viruses, rabies viruses); Filoviridae (e.g., ebola viruses),
- infectious bacteriaexamples include: Helicobacter pyloris, Borelia burgdorferi, Legionella pneumophilia, Mycobacteria spp. (e.g., M. tuberculosis, M. avium, M. intracellulare, M. kansasii, M.
- infectious fungiexamples include: Cryptococcus neoformans, Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatitidis, Chlamydia trachomatis, Candida albicans .
- Other infectious organismsi.e., protists
- Plasmodium falciparum and Toxoplasma gondiiexamples include: Plasmodium falciparum and Toxoplasma gondii.
- an “immunostimulatory nucleic acid molecule”refers to a nucleic acid molecule, which contains an unmethylated cytosine, guanine dinucleotide sequence (i.e. “CpG DNA” or DNA containing a cytosine followed by guanosine and linked by a phosphate bond) and stimulates (e.g. has a mitogenic effect on, or induces or increases cytokine expression by) a vertebrate lymphocyte.
- An immunostimulatory nucleic acid moleculecan be double-stranded or single-stranded. Generally, double-stranded molecules are more stable in vivo, while single-stranded molecules have increased immune ac ivity.
- the immunostimulatory nucleic acidcontains a consensus mitogenic CpG motif represented by the formula: 5′ X 1 CGX 2 3′
- immunostimulatory nucleic acid moleculesare between 2 to 100 base pairs in size and contain a consensus mitogenic CpG motif represented by the formula: 5′ X 1 X 2 CGX 3 X 4 3′
- the immunostimulatory CpG DNAis in the range of between 8 to 40 base pairs in size if it is synthesized as an oligonucleotide.
- CpG dinucleotidescan be produced on a large scale in plasmids, which after being administered to a subject are degraded into oligonucleotides.
- Preferred immunostimulatory nucleic acid moleculese.g. for use in increasing the effectiveness of a vaccine or to treat an immune system deficiency by stimulating an antibody [humoral] response in a subject
- the stimulation index of a particular immunostimulatory CpG DNAcan be tested in various immune cell assays.
- the stimulation index of the immunostimulatory CpG DNA with regard to B-cell proliferationis at least about 5, preferably at least about 10, more preferably at least about 15 and most preferably at least about 20 as determined by incorporation of 3 H uridine in a murine B cell culture, which has been contacted with a 20 ⁇ M of ODN for 20 h at 37° C. and has been pulsed with 1 ⁇ Ci of 3 H uridine; and harvested and counted 4 h later as described in detail in Example 1.
- the immunostimulatory CpG DNAbe capable of effectively inducing cytokine secretion by monocytic cells and/or Natural Killer (NK) cell lytic activity.
- Preferred immunostimulatory CpG nucleic acidsshould effect at least about 500 pg/ml of TNF- ⁇ , 15 pg/ml IFN- ⁇ , 70 pg/ml of GM-CSF 275 pg/ml of IL-6, 200 pg/ml IL-12, depending on the therapeutic indication, as determined by the assays described in Example 12.
- Other preferred immunostimulatory CpG DNAsshould effect at least about 10%, more preferably at least about 15% and most preferably at least about 20% YAC-1 cell specific lysis or at least about 30, more preferably at least about 35 and most preferably at least about 40% 2C11 cell specific lysis as determined by the assay described in detail in Example 4.
- nucleic acidor “DNA” shall mean multiple nucleotides (i.e. molecules comprising a sugar (e.g. ribose or deoxyribose) linked to a phosphate group and to an exchangeable organic base, which is either a substituted pyrimidine (e.g. cytosine (C), thymine (T) or uracil (U)) or a substituted purine (e.g. adenine (A) or guanine (G)).
- cytosine (C), thymine (T) or uracil (U)or a substituted purine (e.g. adenine (A) or guanine (G)
- the termrefers to ribonucleotides as well as oligodeoxyribonucleotides.
- the termshall also include polynucleosides (i.e.
- Nucleic acid moleculescan be obtained from existing nucleic acid sources (e.g. genomic or cDNA), but are preferably synthetic (e.g. produced by oligonucleotide synthesis).
- nucleic acid delivery complexshall mean a nucleic acid molecule associated with (e.g. ionically or covalently bound to; or encapsulated within) a targeting means (e.g. a molecule that results in higher affinity binding to target cell (e.g. B-cell and natural killer (NK) cell) surfaces and/or increased cellular uptake by target cells).
- a targeting meanse.g. a molecule that results in higher affinity binding to target cell (e.g. B-cell and natural killer (NK) cell) surfaces and/or increased cellular uptake by target cells.
- nucleic acid delivery complexesinclude nucleic acids associated with: a sterol (e.g. cholesterol), a lipid (e.g. a cationic lipid, virosome or liposome), or a target cell specific binding agent (e.g. a ligand recognized by target cell specific receptor).
- Preferred complexesmust be sufficiently stable in vivo to prevent significant uncoupling prior to internalization by the target
- “Palindromic sequence”shall mean an inverted repeat (i.e. a sequence such as ABCDEE′D′C′B′A′ in which A and A′ are bases capable of forming the usual Watson-Crick base pairs. In vivo, such sequences may form double stranded structures.
- a “stabilized nucleic acid molecule”shall mean a nucleic acid molecule that is relatively resistant to in vivo degradation (e.g. via an exo- or endo-nuclease). Stabilization can be a function of length or secondary structure. Unmethylated CpG containing nucleic acid molecules that are tens to hundreds of kbs long are relativel resistant to in vivo degradation. For shorter immunostimulatory nucleic acid molecules, secondary structure can stabilize and increase their effect.
- nucleic acid moleculebecomes stabilized and therefore exhibits more activity.
- Preferred stabilized nucleic acid molecules of the instant inventionhave a modified backbone.
- especially preferred stabilized nucleic acid moleculesare phosphorothioate modified nucleic acid molecules (i.e. at least one of the phosphate oxygens of the nucleic acid molecule is replaced by sulfur).
- the phosphate modificationoccurs at or near the 5′ and/or 3′ end of the nucleic acid molecule.
- phosphorothioate-modified nucleic acid moleculescan increase the extent of immune stimulation of the nucleic acid molecule, which contains an unmethylated CpG dinucleotide as shown herein.
- nucleic acid moleculesinclude: nonionic DNA analogs, such as alkyl- and aryl-phosphonates (in which the charged phosphonate oxygen is replaced by an alkyl or aryl group), phosphodiester and alkylphosphotriesters, in which the charged oxygen moiety is alkylated.
- Nucleic acid molecules which contain a diol, such as tetraethyleneglycol or hexaethyleneglycol, at either or both terminihave also been shown to be substantially resistant to nuclease degradation.
- a “subject”shall mean a human or vertebrate animal including a dog, cat, horse, cow, pig, sheep, goat, chicken, monkey, rat, mouse, etc.
- vectorrefers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
- Preferred vectorsare those capable of autonomous replication and expression of nucleic acids to which they are linked (e.g., an episome).
- Vectors capable of directing the expression of genes to which they are operatively linkedare referred to herein as “expression vectors.”
- expression vectors of utility in recombinant DNA techniquesare often in the form of “plasmids” which refer generally to circular double stranded DNA loops which, in their vector form, are not bound to the chromosome.
- plasmid and vectorare used interchangeably as the plasmid is the most commonly used form of vector.
- the inventionis intended to include such other forms of expression vectors which serve equivalent functions and which become known in the art subsequently hereto.
- ODN 1 and 2were synthesized. These ODNs, including the two original “controls” (ODN 1 and 2) and two originally synthesized as “antisense” (ODN 3D and 3M; Krieg, A. M. J. Immunol. 143:2448 (1989)), were then examined for in vitro effects on spleen cells (representative sequences are listed in Table 1).
- ODNthat contained CpG dinucleotides induced B cell activation and IgM secretion; the magnitude of this stimulation typically could be increased by adding more CpG dinucleotides (Table 1; compare ODN 2 to 2a or 3D to 3Da and 3 Db). Stimulation did not appear to result from an antisense mechanism or impurity. ODN caused no detectable proliferation of ⁇ or other T cell populations.
- the optimal stimulatory motifwas determined to consist of a CpG flanked by two 5′ purines (preferably a GpA dinucleotide) and two 3′ pyrimidines (preferably a TpT or TpC dinucleotide). Mutations of ODN to bring the CpG motif closer to this ideal improved stimulation (e.g. Table 1, compare ODN 2 to 2e; 3M to 3Md) while mutations that disturbed the motif reduced stimulation (e.g. Table 1, compare ODN 3D to 3Df; 4 to 4b, 4c and 4d).
- ODNs shorter than 8 baseswere non-stimulatory (e.g. Table 1, ODN 4e).
- ODN 4ethe most stimulatory sequence identified was TCAACGTT (ODN 4) which contains the self complementary “palindrome” AACGTT.
- ODN containing Gs at both endsshowed increased stimulation, particularly if the ODN were rendered nuclease resistant by phosphorothioate modification of the terminal internucleotide linkages.
- ODN 1585(5′ GGGGTCAACGTTGAGGGGGG 3′ (SEQ ID NO:12)), in which the first two and last five internucleotide linkages are phosphorothioate modified caused an average 25.4 fold increase in mouse spleen cell proliferation compared to an average 3.2 fold increase in proliferation induced by ODN 1638, which has the same sequence as ODN 1585 except that the 10 Gs at the two ends are replaced by 10 As.
- the effect of the G-rich endsis cis; addition of an ODN with poly G ends but no CpG motif to cells along with 1638 gave no increased proliferation.
- non-palindromic motifs containing an unmethylated CpGwere found to be more immunostimulatory.
- octamer ODN containing a 6 base palindrome with a TpC dinucleotide at the 5′ endwere also active (e.g. Table 1, ODN 4b,4c).
- Other dinucleotides at the 5′ endgave reduced stimulation (e.g. ODN 4f; all sixteen possible dinucleotides were tested).
- the presence of a 3′ dinucleotidewas insufficient to compensate for the lack of a 5′ dinucleotide (e.g. Table 1, ODN 4 g).
- Disruption of the palindromeeliminated stimulation in octamer ODN (e.g. Table 1, ODN 4 h), but palindromes were not required in longer ODN.
- CpG-ODNinduced cycling in more than 95% of B cells.
- Splenic B lymphocytes sorted by flow cytometry into CD23-(marginal zone) and CD23+ (follicular) subpopulationswere equally responsive to ODN-induced stimulation, as were both resting and activated populations of B cells isolated by fractionation over Percoll gradients.
- Certain B cell lines such as WEHI-231are induced to undergo growth arrest and/or apoptosis in response to crosslinking of their antigen receptor by anti-IgM (Jakway, J. P. et al., “Growth regulation of the B lymphoma cell line WEHI-231 by anti-immunoglobulin, lipopolysaccharide and other bacterial products” J. Immunol. 137: 2225 (1986); Tsubata, T., J. Wu and T. Honjo: B-cell apoptosis induced by antigen receptor crosslinking is blocked by a T-cell signal through CD40 .” Nature 364: 645 (1993)).
- WEHI-231 cellsare rescued from this growth arrest by certain stimuli such as LPS and by the CD40 ligand.
- ODN containing the CpG motifwere also found to protect WEHI-231 from anti-IgM induced growth arrest, indicating that accessory cell populations are not required for the effect.
- CpG ODNinduce Bcl-x and myc expression, which may account for the protection from apoptosis.
- CpG nucleic acidshave been found to block apoptosis in human cells. This inhibition of apoptosis is important, since it should enhance and prolong immune activation by CpG DNA.
- IL-6 secreted by spleen cells after CpG DNA stimulationwas measured by ELISA.
- T cell depleted spleen cell cultures rather than whole spleen cellswere used for in vitro studies following preliminary studies showing that T cells contribute little or nothing to the IL-6 produced by CpG DNA-stimulated spleen cells.
- IL-6 productionwas markedly increased in cells cultured with E. coli DNA but not in cells cultured with calf thymus DNA.
- the DNAwas digested with DNAse prior to analysis. DNAse pretreatment abolished IL-6 production induced by E.
- T cell depleted spleen cells from DBA/2 micewere stimulated with phosphodiester modified oligonucleotides (O-ODN) (20 ⁇ M), calf thymus DNA (50 ⁇ g/ml) or E. coli DNA (50 ⁇ g/ml) with or without enzyme treatment, or LPS (10 ⁇ g/ml) for 24 hr.
- O-ODNphosphodiester modified oligonucleotides
- calf thymus DNA50 ⁇ g/ml
- E. coli DNA50 ⁇ g/ml
- LPS10 ⁇ g/ml
- the optimal B cell stimulatory CpG motifwas identical with the optimal CpG motif for IL-6 secretion
- a panel of ODN in which the bases flanking the CpG dinucleotide were progressively substitutedwas studied.
- This ODN panelwas analyzed for effects on B cell proliferation, Ig production, and IL-6 secretion, using both splenic B cells and CH12.LX cells.
- the optimal stimulatory motifis composed of an unmethylated CpG flanked by two 5′ purines and two 3′ pyrimidines. Generally a mutation of either 5′ purine to pyrimidine or 3′ pyrimidine to purine significantly reduced its effects.
- FIG. 1Bacterial DNA and CpG ODN induced IL-6 production in T cell depleted murine spleen cells in a dose-dependent manner, but vertebrate DNA and non-CpG ODN did not ( FIG. 1 ).
- the maximum levels of IL-6 induced by bacterial DNA and CpG ODNwere 1-1.5 ng/ml and 2-4 ng/ml respectively. These levels were significantly greater than those seen after stimulation by LPS (0.35 ng/ml) ( FIG. 1A ).
- CpG ODN with a nuclease-resistant DNA backbonewould also induce IL-6 production
- S-ODNwere added to T cell depleted murine spleen cells.
- CpG S-ODNalso induced IL-6 production in a dose-dependent manner to approximately the same level as CpG O-ODN while non-CpG S-ODN failed to induce IL-6 ( FIG. 1C ).
- CpG S-ODN at a concentration of 0.05 ⁇ Mcould induce maximal IL-6 production in these cells.
- micewere injected iv. with 100 ⁇ g of E. coli DNA, calf thymus DNA, or CpG or non-stimulatory S-ODN and bled 2 hr after stimulation.
- the level of IL-6 in the sera from the E. coli DNA injected groupwas approximately 13 ng/ml while IL-6 was not detected in the sera from calf thymus DNA or PBS injected groups (Table 4).
- CpG S-ODNalso induced IL-6 secretion in vivo.
- the IL-6 level in the sera from CpG S-ODN injected groupswas approximately 20 ng/ml.
- IL-6was not detected in the sera from non-stimulatory S-ODN stimulated group (Table 4). TABLE 4 Secretion of Murine IL-6 induced by CpG DNA stimulation in vivo. Stimulant IL-6 (pg/ml) PBS ⁇ 50 E. coli DNA 13858 ⁇ 3143 Calf Thymus DNA ⁇ 50 CpG S-ODN 20715 ⁇ 606 non-CpG S-ODN ⁇ 50
- mice(2 mice/group) were i.v. injected with 100 ⁇ l of PBS, 200 ⁇ g of E. coli DNA or calf thymus DNA, or 500 ⁇ g of CpG S-ODN or non-CpG control S-ODN. Mice were bled 2 hr after injection and 1:10 dilution of each serum was analyzed by IL-6 ELISA. Sensitivity limit of IL-6 ELISA was 5 pg/ml. Sequences of the CpG S-ODN is 5′GCATGACGTTGAGCT3′ (SEQ ID NO:48) and of the non-stimulatory S-ODN is 5′GCTAGATGTTAGCGT3′ (SEQ ID NO:49). Note that although there is a CpG in sequence 48, it is too close to the 3′ end to effect stimulation, as explained herein. Data represent mean ⁇ SD of duplicates. The experiment was done at least twice with similar results.
- micewere injected iv. with CpG or control non-CpG S-ODN. Serum IL-6 levels were significantly increased within 1 hr and peaked at 2 hr to a level of approximately 9 ng/ml in the CpG S-ODN injected group ( FIG. 2 ). IL-6 protein in sera rapidly decreased after 4 hr and returned to basal level by 12 hr after stimulation. In contrast to CpG DNA stimulated groups, no significant increase of IL-6 was observed in the sera from the non-stimulatory S-ODN or PBS injected groups (FIG. 2).
- the level of serum IL-6increased rapidly after CpG DNA stimulation.
- BALB/c micewere injected iv with CpG or non-CpG S-ODN and RNA was extracted from liver, spleen, thymus, and bone marrow at various time points after stimulation.
- FIG. 3Athe level of IL-6 mRNA in liver, spleen, and thymus was increased within 30 min. after injection of CpG S-ODN.
- liver IL-6 mRNApeaked at 2 hr post-injection and rapidly decreased and reached basal level 8 hr after stimulation ( FIG. 3A ).
- Splenic IL-6 mRNApeaked at 2 hr after stimulation and then gradually decreased ( FIG. 3A ).
- Thymus IL-6 mRNApeaked at 1 hr post-injection and then gradually decreased ( FIG. 3A ).
- IL-6 mRNAwas significantly increased in bone marrow within 1 hr after CpG S-ODN injection but then returned to basal level. In response to CpG S-ODN, liver, spleen and thymus showed more substantial increases in IL-6 mRNA expression than the bone marrow.
- CpG DNAinduces cytokine secretion by human PBMC, specifically
- oligonucleotide 1619was the best inducer of TNF- ⁇ and IFN- ⁇ secretion, and was closely followed by a nearly identical motif in oligonucleotide 1634 (GTCGCT) (Table 5).
- the motifs in oligodeoxynucleotides 1637 and 1614led to strong IL-6 secretion with relatively little induction of other cytokines.
- human lymphocyteslike murine lymphocytes, secrete cytokines differentially in response to CpG dinucleotides, depending on the surrounding bases.
- the motifs that stimulate murine cellsbest differ from those that are most effective with human cells.
- Certain CpG oligodeoxynucleotidesare poor at activating human cells (oligodeoxynucleotides 1707, 1708, which contain the palindrome forming sequences GACGTC and CACGTG respectively).
- the cells responding to the DNAappear to be monocytes, since the cytokine secretion is abolished by treatment of the cells with L-leucyl-L-leucine methyl ester-(L-LME), which is selectively toxic to monocytes (but also to cytotoxic T lymphocytes and NK cells), and does not affect B cell Ig secretion (Table 6, and data not shown).
- L-LMEL-leucyl-L-leucine methyl ester-
- coli (EC) DNArequires unmethylated CpG motifs, since it is abolished by methylation of the EC DNA (next to the bottom row, Table 6). LPS contamination of the DNA cannot explain the results since the level of contamination was identical in the native and methylated DNA, and since addition of twice the highest amount of contaminating LPS had no effect (not shown).
- CpG DNAinduces cytokine secretion by human PBMC TNF- ⁇ IL-6 IFN- ⁇ RANTES DNA (pg/ml) 1 (pg/ml) (pg/ml) (pg/ml) EC DNA (50 ⁇ g/ml) 900 12,000 700 1560 EC DNA (5 ⁇ g/ml) 850 11,000 400 750 EC DNA (0.5 ⁇ g/ml) 500 ND 200 0 EC DNA (0.05 ⁇ g/ml) 62.5 10,000 15.6 0 EC DNA (50 ⁇ g/ml) + L-LME 2 0 ND ND ND EC DNA (10 ⁇ g/ml) Methyl.
- CpG DNAinduces cytokine expression in purified human macrophages IL-6 (pg/ml) GM-CSF (pg/ml) TNF- ⁇ (pg/ml) Cells alone 0 0 0 CT DNA (50 ⁇ g/ml) 0 0 0 EC DNA (50 ⁇ g/ml) 2000 15.6 1000
- IL-6 mRNA and protein after CpG DNA stimulationcould result from transcriptional or post-transcriptional regulation.
- a murine B cell line, WEHI-231which produces IL-6 in response to CpG DNA, was transfected with an IL-6 promoter-CAT construct (pIL-6/CAT) (Pottratz, S. T. et al., 17B-estradiol) inhibits expression of human interleukin-6-promoter-reporter constructs by a receptor-dependent mechanism. J. Clin. Invest. 93:944).
- CAT assayswere performed after stimulation with various concentrations of CpG or non-CpG ODN. As shown in FIG. 5 , CpG ODN induced increased CAT activity in dose-dependent manner while non-CpG ODN failed to induce CAT activity. This confirms that CpG induces the transcriptional activity of the IL-6 promoter.
- the lymphocyte stimulating effects of these ODNwere tested at three concentrations (3.3, 10, and 30 ⁇ M) by measuring the total levels of RNA synthesis (by 3 H uridine incorporation) or DNA synthesis (by 3 H thymidine incorporation) in treated spleen cell cultures (Example 10).
- O-ODN(0/0 phosphorothioate modifications) bearing a CpG motif caused no spleen cell stimulation unless added to the cultures at concentrations of at least 10 ⁇ M (Example 10).
- this sequencewas modified with two S linkages at the 5′ end and at least three S linkages at the 3′ end, significant stimulation was seen at a dose of 3.3 ⁇ M.
- the level of stimulationshowed a progressive increase as the number of 3′ modified bases was increased, until this reached or exceeded six, at which point the stimulation index began to decline.
- the optimal number of 3′ S linkages for spleen cell stimulationwas five. At all three concentrations tested in these experiments, the S-ODN was less stimulatory than the optimal chimeric compounds.
- S-ODNPhosphorothioate modified ODN
- O-ODNphosphodiester modified ODN
- S-ODN and S—O-ODNi.e. chimeric phosphorothioate ODN in which the central linkages are phosphodiester, but the two 5′ and five 3′ linkages are phosphorothioate modified
- S—O-ODNwere far more stimulatory than O-ODN, and were even more stimulatory than S-ODN, at least at concentrations above 3.3 ⁇ M. At concentrations below 3 ⁇ M, the S-ODN with the 3M sequence was more potent than the corresponding S—O-ODN, while the S-ODN with the 3D sequence was less potent than the corresponding S—O-ODN (Example 10).
- the 3D sequenceis a perfect match for the stimulatory motif in that the CpG is flanked by two 5′ purines and two 3′ pyrimidines.
- the bases immediately flanking the CpG in ODN 3Dare not optimal; it has a 5′ pyrimidine and a 3′ purine.
- S-ODN with poor matches to the optimal CpG motifcause little or no lymphocyte activation (e.g. Sequence 3D).
- S-ODN with good matches to the motif, most critically at the positions immediately flanking the CpGare more potent than the corresponding S—O-ODN (e.g. Sequence 3M, Sequences 4 and 6), even though at higher concentrations (greater than 3 ⁇ M) the peak effect from the S—O-ODN is greater (Example 10).
- S 2 —O-ODNwere remarkably stimulatory, and caused substantially greater lymphocyte activation than the corresponding S-ODN or S—O-ODN at every tested concentration.
- nuclease resistancecan not be the only explanation, since the MP-O-ODN were actually less stimulatory than the O-ODN with CpG motifs.
- Prior studieshave shown that ODN uptake by lymphocytes is markedly affected by the backbone chemistry (Zhao et al., (1993) Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides.
- CpG DNAcan directly activate highly purified B cells and monocytic cells. There are many similarities in the mechanism through which CpG DNA activates these cell types. For example, both require NF ⁇ B activation as explained further below.
- oligo 1668with the best mouse B cell motif, is a strong inducer of both B cell and natural killer (NK) cell activation, while oligo 1758 is a weak B cell activator, but still induces excellent NK responses (Table 10).
- Vertebrate DNAis highly methylated and CpG dinucleotides are underrepresented.
- the stimulatory CpG motifis common in microbial genomic DNA, but quite rare in vertebrate DNA.
- bacterial DNAhas been reported to induce B cell proliferation and immunoglobulin (Ig) production, while mammalian DNA does not (Messina, J. P. et al., J. Immunol. 147:1759 (1991)).
- Igimmunoglobulin
- Example 3in which methylation of bacterial DNA with CpG methylase was found to abolish mitogenicity, demonstrates that the difference in CpG status is the cause of B cell stimulation by bacterial DNA. This data supports the following conclusion: that unmethylated CpG dinucleotides present within bacterial DNA are responsible for the stimulatory effects of bacterial DNA.
- lymphocyte activation by the CpG motifrepresents an immune defense mechanism that can thereby distinguish bacterial from host DNA.
- Host DNAwhich would commonly be present in many anatomic regions and areas of inflammation due to apoptosis (cell death), would generally induce little or no lymphocyte activation due to CpG suppression and methylation.
- the presence of bacterial DNA containing unmethylated CpG motifscan cause lymphocyte activation precisely in infected anatomic regions, where it is beneficial. This novel activation pathway provides a rapid alternative to T cell dependent antigen specific B cell activation.
- B cells bearing antigen receptor specific for bacterial antigenswould receive one activation signal through cell membrane Ig and a second signal from bacterial DNA, and would therefore tend to be preferentially activated.
- the interrelationship of this pathway with other pathways of B cell activationprovide a physiologic mechanism employing a polyclonal antigen to induce antigen-specific responses.
- B cell activationwould not be totally nonspecific.
- B cells bearing antigen receptors specific for bacterial productscould receive one activation signal through cell membrane Ig, and a second from bacterial DNA, thereby more vigorously triggering antigen specific immune responses.
- the response to bacterial DNAcould have undesirable consequences in some settings.
- autoimmune responses to self antigenswould also tend to be preferentially triggered by bacterial infections, since autoantigens could also provide a second activation signal to autoreactive B cells triggered by bacterial DNA.
- the induction of autoimmunity by bacterial infectionsis a common clinical observance.
- the autoimmune disease systemic lupus erythematosuswhich is: i) characterized by the production of anti-DNA antibodies; ii) induced by drugs which inhibit DNA methyltransferase (Cornacchia, E. J. et al., J. Clin. Invest. 92:38 (1993)); and iii) associated with reduced DNA methylation (Richardson, B. L. et al., Arth. Rheum 35:647 (1992)), is likely triggered at least in part by activation of DNA-specific B cells through stimulatory signals provided by CpG motifs, as well as by binding of bacterial DNA to antigen receptors.
- sepsiswhich is characterized by high morbidity and mortality due to massive and nonspecific activation of the immune system may be initiated by bacterial DNA and other products released from dying bacteria that reach concentrations sufficient to directly activate many lymphocytes. Further evidence of the role of CpG DNA in the sepsis syndrome is described in Cowdery, J., et. al., (1996) The Journal of Immunology 156:4570-4575.
- CpG-ODNdid not induce any detectable Ca 2+ flux, changes in protein tyrosine phosphorylation, or IP 3 generation.
- Flow cytometry with FITC-conjugated ODN with or without a CpG motifwas performed as described in Zhao, Q et al., ( Antisense Research and Development 3:53-66 (1993)), and showed equivalent membrane binding, cellular uptake, efflux, and intracellular localization. This suggests that there may not be cell membrane proteins specific for CpG ODN.
- NF ⁇ BNF ⁇ B activation
- theseinclude through activation of various protein kinases, or through the generation of reactive oxygen species.
- No evidence for protein kinase activation induced immediately after CpG DNA treatment of B cells or monocytic cellshave been found, and inhibitors of protein kinase A, protein kinase C, and protein tyrosine kinases had no effects on the CpG induced activation.
- CpG DNAcauses a rapid induction of the production of reactive oxygen species in both B cells and monocytic cells, as detected by the sensitive fluorescent dye dihydrorhodamine 123 as described in Royall, J. A., and Ischiropoulos, H.
- FIG. 8Ashows the results from a flow cytometry study using mouse B cells with the dihydrorhodamine 123 dye to determine levels of reactive oxygen species.
- the dye only sample in Panel A of the figureshows the background level of cells positive for the dye at 28.6%.
- this level of reactive oxygen specieswas greatly increased to 80% in the cells treated for 20 minutes with PMA and ionomycin, a positive control (Panel B).
- the cells treated with the CpG oligoalso showed an increase in the level of reactive oxygen species such that more than 50% of the cells became positive (Panel D).
- cells treated with an oligonucleotide with the identical sequence except that the CpG was switcheddid not show this significant increase in the level of reactive oxygen species (Panel E).
- Chloroquineslightly lowers the background level of reactive oxygen species in the cells such that the untreated cells in Panel A have only 4.3% that are positive. Chloroquine completely abolishes the induction of reactive oxygen species in the cells treated with CpG DNA (Panel B) but does not reduce the level of reactive oxygen species in the cells treated with PMA and ionomycin (Panel E). This demonstrates that unlike the PMA plus ionomycin, the generation of reactive oxygen species following treatment of B cells with CpG DNA requires that the DNA undergo an acidification step in the endosomes. This is a completely novel mechanism of leukocyte activation. Chloroquine, monensin, and bafilomycin also appear to block the activation of NF ⁇ B by CpG DNA as well as the subsequent proliferation and induction of cytokine secretion.
- NF ⁇ B or related proteinis a component of a protein or protein complex that binds the stimulatory CpG oligonucleotides.
- the CpG nucleic acidsmay bind to one of the TRAF proteins that bind to the cytoplasmic region of CD40 and mediate NF ⁇ B activation when CD40 is cross-linked.
- TRAF proteinsinclude TRAF-2 and TRAF-5.
- nucleic acidscan be synthesized de novo using any of a number of procedures well known in the art.
- the ⁇ -cyanoethyl phosphoramidite methodS. L. Beaucage and M. H. Caruthers, (1981) Tet. Let. 22:1859
- nucleoside H-phosphonate methodGaregg et al., (1986) Tet. Let. 27: 4051-4054
- Froehler et al.(1986) Nucl. Acid. Res. 14: 5399-5407
- Garegg et al., (1986) Tet. Let. 27: 4055-4058Gaffney et al., (1988) Tet. Let.
- oligonucleotide synthesizersavailable in the market.
- oligonucleotidescan be prepared from existing nucleic acid sequences (e.g. genomic or cDNA) using known techniques, such as those employing restriction enzymes, exonucleases or endonucleases.
- nucleic acidsare preferably relatively resistant to degradation (e.g. via endo- and exo-nucleases). Secondary structures, such as stem loops, can stabilize nucleic acids against degradation. Alternatively, nucleic acid stabilization can be accomplished via phosphate backbone modifications. A preferred stabilized nucleic acid has at least a partial phosphorothioate modified backbone. Phosphorothioates may be synthesized using automated techniques employing either phosphoramidate or H-phosphonate chemistries. Aryl- and alkyl-phosphonates can be made e.g. as described in U.S. Pat. No.
- 4,469,863; and alkylphosphotriestersin which the charged oxygen moiety is alkylated as described in U.S. Pat. No. 5,023,243 and European Patent No. 092,574 can be prepared by automated solid phase synthesis using commercially available reagents. Methods for making other DNA backbone modifications and substitutions have been described (Uhlmann, E. and Peyman, A. (1990) Chem. Rev. 90:544; Goodchild, J. (1990) Bioconjugate Chem. 1: 165). 2′-O-methyl nucleic acids with CpG motifs also cause immune activation, as do ethoxy-modified CpG nucleic acids. In fact, no backbone modifications have been found that completely abolish the CpG effect, although it is greatly reduced by replacing the C with a 5-methyl C.
- nucleic acidsmay be associated with a molecule that results in higher affinity binding to target cell (e.g. B-cell, monocytic cell and natural killer (NK) cell) surfaces and/or increased cellular uptake by target cells to form a “nucleic acid delivery complex”.
- target celle.g. B-cell, monocytic cell and natural killer (NK) cell
- Nucleic acidscan be ionically, or covalently associated with appropriate molecules using techniques which are well known in the art.
- a variety of coupling or crosslinking agentscan be used e.g. protein A, carbodiimide, and N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP).
- SPDPN-succinimidyl-3-(2-pyridyldithio)propionate
- Nucleic acidscan alternatively be encapsulated in liposomes or virosomes using well-known techniques.
- nucleic acid molecules containing at least one unmethylated CpG dinucleotidecan be administered to a subject in vivo to treat an “immune system deficiency”.
- nucleic acid molecules containing at least one unmethylated CpG dinucleotidecan be contacted with lymphocytes (e.g. B cells, monocytic cells or NK cells) obtained from a subject having an immune system deficiency ex vivo and activated lymphocytes can then be reimplanted in the subject.
- lymphocytese.g. B cells, monocytic cells or NK cells
- IL-6As reported herein, in response to unmethylated CpG containing nucleic acid molecules, an increased number of spleen cells secrete IL-6, IL-12, IFN- ⁇ , IFN- ⁇ , IFN- ⁇ , IL-1, IL-3, IL-10, TNF- ⁇ , TNF- ⁇ , GM-CSF, RANTES, and probably others.
- the increased IL-6 expressionwas found to occur in B cells, CD4 + T cells and monocytic cells.
- Immunostimulatory nucleic acid moleculescan also be administered to a subject in conjunction with a vaccine to boost a subject's immune system and thereby effect a better response from the vaccine.
- the immunostimulatory nucleic acid moleculeis administered slightly before or at the same time as the vaccine.
- a conventional adjuvantmay optionally be administered in conjunction with the vaccine, which is minimally comprised of an antigen, as the conventional adjuvant may further improve the vaccination by enhancing antigen absorption.
- the vaccineis a DNA vaccine
- the antigen encoded by the vaccinedetermines the specificity of the immune response.
- the backbone of the plasmidcontains CpG motifs, it functions as an adjuvant for the vaccine.
- CpG DNAacts as an effective “danger signal” and causes the immune system to respond vigorously to new antigens in the area. This mode of action presumably results primarily from the stimulatory local effects of CpG DNA on dendritic cells and other “professional” antigen presenting cells, as well as from the costimulatory effects on B cells.
- Immunostimulatory oligonucleotides and unmethylated CpG containing vaccineswhich directly activate lymphocytes and co-stimulate an antigen-specific response, are fundamentally different from conventional adjuvants (e.g. aluminum precipitates), which are inert when injected alone and are thought to work through absorbing the antigen and thereby presenting it more effectively to immune cells.
- conventional adjuvantse.g. aluminum precipitates
- conventional adjuvantsonly work for certain antigens, only induce an antibody (humoral) immune response (Th2), and are very poor at inducing cellular immune responses (Th1).
- Th2human immune response
- Th1for many pathogens, the humoral response contributes little to protection, and can even be detrimental.
- an immunostimulatory oligonucleotidecan be administered prior to, along with or after administration of a chemotherapy or immunotherapy to increase the responsiveness of the malignant cells to subsequent chemotherapy or immunotherapy or to speed the recovery of the bone marrow through induction of restorative cytokines such as GM-CSF.
- CpG nucleic acidsalso increase natural killer cell lytic activity and antibody dependent cellular cytotoxicity (ADCC). Induction of NK activity and ADCC may likewise be beneficial in cancer immunotherapy, alone or in conjunction with other treatments.
- Another use of the described immunostimulatory nucleic acid moleculesis in desensitization therapy for allergies, which are generally caused by IgE antibody generation against harmless allergens.
- the cytokines that are induced by unmethylated CpG nucleic acidsare predominantly of a class called “Th1” which is most marked by a cellular immune response and is associated with IL-12 and IFN- ⁇ .
- Th1The other major type of immune response is termed a Th2 immune response, which is associated with more of an antibody immune response and with the production of IL-4, IL-5 and IL-10.
- Th2 immune responsewhich is associated with more of an antibody immune response and with the production of IL-4, IL-5 and IL-10.
- allergic diseasesare mediated by Th2 type immune responses and autoimmune diseases by Th1 immune response.
- an effective dose of an immunostimulatory nucleic acid (or a vector containing a nucleic acid) alone or in conjunction with an allergencan be administered to a subject to treat or prevent an allergy.
- Nucleic acids containing unmethylated CpG motifsmay also have significant therapeutic utility in the treatment of asthma.
- Th2 cytokinesespecially IL-4 and IL-5 are elevated in the airways of asthmatic subjects. These cytokines promote important aspects of the asthmatic inflammatory response, including IgE isotype switching, eosinophil chemotaxis and activation and mast cell growth.
- Th1 cytokinesespecially FN- ⁇ and IL-12, can suppress the formation of Th2 clones and production of Th2 cytokines.
- oligonucleotides containing an unmethylated CpG motifi.e. TCCATGA CG TTCCTGA CG TT; SEQ ID NO:10), but not a control oligonucleotide (TCCATGAGCTTCCTGAGTCT; SEQ ID NO: 11) prevented the development of an inflammatory cellular infiltrate and eosinophilia in a murine model of asthma. Furthermore, the suppression of eosinophilic inflammation was associated with a suppression of a Th2 response and induction of a Th1 response.
- an effective amount of an appropriate immunostimulatory nucleic acid molecule alone or formulated as a delivery complexcan be administered to a subject by any mode allowing the oligonucleotide to be taken up by the appropriate target cells (e.g., B-cells and monocytic cells).
- Preferred routes of administrationinclude oral and transdermal (e.g., via a patch).
- Other routes of administrationinclude injection (subcutaneous, intravenous, parenteral, intraperitoneal, intrathecal, etc.). The injection can be in a bolus or a continuous infusion.
- a nucleic acid alone or as a nucleic acid delivery complexcan be administered in conjunction with a pharmaceutically acceptable carrier.
- pharmaceutically acceptable carrieris intended to include substances that can be coadministered with a nucleic acid or a nucleic acid delivery complex and allows the nucleic acid to perform its indicated function. Examples of such carriers include solutions, solvents, dispersion media, delay agents, emulsions and the like. The use of such media for pharmaceutically active substances are well known in the art. Any other conventional carrier suitable for use with the nucleic acids falls within the scope of the instant invention.
- an effective amount of a nucleic acid moleculerefers to the amount necessary or sufficient to realize a desired biologic effect.
- an effective amount of a nucleic acid containing at least one unmethylated CpG for treating an immune system deficiencycould be that amount necessary to eliminate a tumor, cancer, or bacterial, viral or fungal infection.
- An effective amount for use as a vaccine adjuvantcould be that amount useful for boosting a subjects immune response to a vaccine.
- An “effective amount” for treating asthmacan be that amount useful for redirecting a Th2 type of immune response that is associated with asthma to a Th1 type of response.
- the effective amount for any particular applicationcan vary depending on such factors as the disease or condition being treated, the particular nucleic acid being administered (e.g.
- B cellswere purified from spleens obtained from 6-12 wk old specific pathogen free DBA/2 or BXSB mice (bred in the University of Iowa animal care facility; no substantial strain differences were noted) that were depleted of T cells with anti-Thy-1.2 and complement and centrifugation over lympholyte M (Cedarlane Laboratories, Hornby, Ontario, Canada) (“B cells”). B cells contained fewer than 1% CD4 + or CD8 + cells. 8 ⁇ 10 4 B cells were dispensed in triplicate into 96 well microtiter plates in 100 ⁇ l RPMI containing 10% FBS (heat inactivated to 65° C.
- DBA/2 B cellswere cultured with no DNA or 50 ⁇ g/ml of a) Micrococcus lysodeikticus ; b) NZB/N mouse spleen; and c) NFS/N mouse spleen genomic DNAs for 48 hours, then pulsed with 3 H thymidine for 4 hours prior to cell harvest.
- Duplicate DNA sampleswere digested with DNAse I for 30 minutes at 37 C prior to addition to cell cultures.
- E coli DNAalso induced an 8.8 fold increase in the number of IgM secreting B cells by 48 hours using the ELISA-spot assay.
- DBA/2 B cellswere cultured with either no additive, 50 ⁇ g/ml LPS or the ODN 1; 1 a; 4; or 4a at 20 uM. Cells were cultured and harvested at 4, 8, 24 and 48 hours. BXSB cells were cultured as in Example 1 with 5, 10, 20, 40 or 80 ⁇ M of ODN 1; 1a; 4; or 4a or LPS. In this experiment, wells with no ODN had 3833 cpm. Each experiment was performed at least three times with similar results. Standard deviations of the triplicate wells were ⁇ 5%.
- 10 ⁇ 10 6 C57BL/6 spleen cellswere cultured in two ml RPMI (supplemented as described for Example 1) with or without 40 ⁇ M CpG or non-CpG ODN for forty-eight hours. Cells were washed, and then used as effector cells in a short term 51 Cr release assay with YAC-1 and 2C11, two NK sensitive target cell lines (Ballas, Z. K. et al. (1993) J. Immunol. 150:17). Effector cells were added at various concentrations to 10 4 51 Cr-labeled target cells in V-bottom microtiter plates in 0.2 ml, and incubated in 5% CO 2 for 4 hr. at 37° C.
- Percent specific lysiswas determined by calculating the ratio of the 5 , Cr released in the presence of effector cells minus the 51 Cr released when the target cells are cultured alone, over the total counts released after cell lysis in 2% acetic acid minus the 51 Cr cpm released when the cells are cultured alone.
- micewere weighed and injected IP with 0.25 ml of sterile PBS or the indicated phophorothioate ODN dissolved in PBS. Twenty four hours later, spleen cells were harvested, washed, and stained for flow cytometry using phycoerythrin conjugated 6B2 to gate on B cells in conjunction with biotin conjugated anti Ly-6A/E or anti-Ia d (Pharmingen, San Diego, Calif.) or anti-Bla-1 (Hardy, R. R. et al., J. Exp. Med. 159:1169 (1984). Two mice were studied for each condition and analyzed individually.
- B cellswere cultured with phosphorothioate ODN with the sequence of control ODN 1 a or the CpG ODN 1 d and 3 Db and then either pulsed after 20 hr with 3 H uridine or after 44 hr with 3 H thymidine before harvesting and determining cpm.
- WEHI-231 cells(5 ⁇ 10 4 /well) were cultured for 1 hr. at 37 C in the presence or absence of LPS or the control ODN 1a or the CpG ODN 1d and 3 Db before addition of anti-IgM (1 ⁇ /ml). Cells were cultured for a further 20 hr. before a 4 hr. pulse with 2 ⁇ Ci/well 3 H thymidine. In this experiment, cells with no ODN or anti-IgM gave 90.4 ⁇ 10 3 cpm of 3 H thymidine incorporation by addition of anti-IgM.
- the phosphodiester ODN shown in Table 1gave similar protection, though with some nonspecific suppression due to ODN degradation. Each experiment was repeated at least 3 times with similar results.
- miceDBA/2 female mice (2 mos. old) were injected IP with 500 ⁇ g CpG or control phosphorothioate ODN. At various time points after injection, the mice were bled. Two mice were studied for each time point. IL-6 was measured by Elisa, and IL-6 concentration was calculated by comparison to a standard curve generated using recombinant IL-6. The sensitivity of the assay was 10 pg/ml. Levels were undetectable after 8 hr.
- mice and cell linesDBA/2, BALB/c, and C 3 H/HeJ mice at 5-10 wk of age were used as a source of lymphocytes. All mice were obtained from The Jackson Laboratory (Bar Harbor, Me.), and bred and maintained under specific pathogen-free conditions in the University of Iowa Animal Care Unit. The mouse B cell line CH12.LX was kindly provided by Dr. G. Bishop (University of Iowa, Iowa City).
- micewere killed by cervical dislocation. Single cell suspensions were prepared aseptically from the spleens from mice. T cell depleted mouse splenocytes were prepared by using anti-Thy-1.2 and complement and centrifugation over lympholyte M (Cedarlane Laboratories, Homby, Ontario, Canada) as described (Krieg, A. M. et al., (1989) A role for endogenous retroviral sequences in the regulation of lymphocyte activation. J. Immunol. 143:2448).
- ODN and DNAPhosphodiester oligonucleotides (O-ODN) and the backbone modified phosphorothioate oligonucleotides (S-ODN) were obtained from the DNA Core facility at the University of Iowa or from Operon Technologies (Alameda, Calif.).
- E. coli DNA (Strain B) and calf thymus DNAwere purchased from Sigma (St. Louis, Mo.). All DNA and ODN were purified by extraction with phenol:chloroform:isoamyl alcohol (25:24:1) and/or ethanol precipitation.
- E. coli and calf thymus DNAwere single stranded prior to use by boiling for 10 min. followed by cooling on ice for 5 min. For some experiments, E.
- E. coli and calf thymus DNAwere digested with DNAse I (2U/ ⁇ g of DNA) at 37° C. for 2 hr in 1 ⁇ SSC with 5 mM MgCl 2 .
- DNAse I(2U/ ⁇ g of DNA)
- E. coli DNAwas treated with CpG methylase (M. SssI; 2U/ ⁇ g of DNA) in NEBuffer 2 supplemented with 160 ⁇ M S-adenosyl methionine and incubated overnight at 37° C.
- Methylated DNAwas purified as above. Efficiency of methylation was confirmed by Hpa II digestion followed by analysis by gel electrophoresis.
- LPS level in ODNwas less than 12.5 ng/mg and E. coli and calf thymus DNA contained less than 2.5 ng of LPS/mg of DNA by Limulus assay.
- cellswere treated with CpG O-ODN along with various concentrations (1-10 ⁇ g/ml) of neutralizing rat IgG1 antibody against murine IL-6 (hybridoma MP5-20F3) or control rat IgG1 mAb to E. coli ⁇ -galactosidase (hybridoma GL113; ATCC, Rockville, Md.) (20) for 5 days.
- culture supernatant fractionswere analyzed by ELISA as below.
- micewere injected intravenously (iv) with PBS, calf thymus DNA (200 ⁇ g/100 ⁇ l PBS/mouse), E. coli DNA (200 ⁇ g/100 ⁇ l PBS/mouse), or CpG or non-CpG S-ODN (200 ⁇ g/100 ⁇ l PBS/mouse).
- Micetwo/group were bled by retroorbital puncture and sacrificed by cervical dislocation at various time points. Liver, spleen, thymus, and bone marrow were removed and RNA was prepared from those organs using RNAzol B (Tel-Test, Friendswood, Tex.) according to the manufacturers protocol.
- RNAzol BTel-Test, Friendswood, Tex.
- TPBS0.5 mM MgCl2o6H 2 O, 2.68 mM KCl, 1.47 mM KH 2 PO 4 , 0.14 M NaCl, 6.6 mM K 2 HPO 4 , 0.5% Tween 20
- TPBS0.5 mM MgCl2o6H 2 O, 2.68 mM KCl, 1.47 mM KH 2 PO 4 , 0.14 M NaCl, 6.6 mM K 2 HPO 4 , 0.5% Tween 20
- the plateswere washed and 100 ⁇ l/well of biotinylated rat anti-mouse IL-6 monoclonal antibodies (MP5-32C11, Pharmingen, San Diego, Calif.) (1 ⁇ g/ml in 10% FCS) or biotinylated anti-mouse Ig (Sigma, St. Louis, Mo.) were added and incubated for 45 min. at room temperature following washes with TPBS. Horseradish peroxidase (HRP) conjugated avidin (Bio-rad Laboratories, Hercules, Calif.) at 1:4000 dilution in 10% FCS (100 ⁇ l/well) was added and incubated at room temperature for 30 min.
- HRPhorseradish peroxidase
- the plateswere washed and developed with o-phenylendiamine dihydrochloride (OPD; Sigma, St. Louis Mo.) 0.05 M phosphate-citrate buffer, pH 5.0, for 30 min.
- OPDo-phenylendiamine dihydrochloride
- the reactionwas stopped with 0.67 N H 2 SO 4 and plates were read on a microplate reader (Cambridge Technology, Inc., Watertown, Mass.) at 490-600 nm. The results are shown in FIGS. 1 and 2 .
- RNA synthesis and IL-6 PCRwas done essentially as described by Montgomery and Dallman (Montgomery, R. A. and M. S. Dallman (1991), Analysis of cytokine gene expression during fetal thymic ontogeny using the polymerase chain reaction ( J. Immunol .) 147:554).
- cDNA synthesis and IL-6 PCRwas done essentially as described by Montgomery and Dallman (Montgomery, R. A. and M. S. Dallman (1991), Analysis of cytokine gene expression during fetal thymic ontogeny using the polymerase chain reaction ( J.
- the gelwas dried and prehybridized at 47° C. for 2 hr. hybridization buffer (5 ⁇ SSPE, 0.1% SDS) containing 10 ⁇ g/ml denatured salmon sperm DNA.
- hybridization buffer5 ⁇ SSPE, 0.1% SDS
- the gelwas hybridized with 2 ⁇ 10 6 cpm/ml ⁇ -[ 32 P]ATP end-labeled internal oligonucleotide probe for IL-6 (5′CATTTCCACGATTTCCCA3′) SEQ ID NO:56) overnight at 47° C., washed 4 times (2 ⁇ SSC, 0.2% SDS) at room temperature and autoradiographed.
- the resultsare shown in FIG. 3 .
- DBA/2 mice spleen B cells(5 ⁇ 10 4 cells/100 ⁇ l/well) were treated with media, CpG or non-CpG S-ODN (0.5 ⁇ M) or O-ODN (20 ⁇ M) for 24 hr at 37° C. Cells were pulsed for the last four hr. with either [ 3 H] Thymidine or [ 3 H] Uridine (1 ⁇ Ci/well). Amounts of [ 3 H] incorporated were measured using Liquid Scintillation Analyzer (Packard Instrument Co., Downers Grove, Ill.).
- Chloramphenicol acetyltransferase (CAT) activitywas measured by a solution assay (Seed, B. and J. Y. Sheen (1988) A single phase-extraction assay for chloramphenicol acetyl transferase activity. Gene 76:271) 16 hr. after transfection. The results are presented in FIG. 5 .
- ODNwere synthesized on an Applied Biosystems Inc. (Foster City, Calif.) model 380A, 380B, or 394 DNA synthesizer using standard procedures (Beacage and Caruthers (1981) Deoxynucleoside phosphoramidites—A new class of key intermediates for deoxypolynucleotide synthesis. Tetrahedron Letters 22, 1859-1862.).
- Phosphodiester ODNwere synthesized using standard beta-cyanoethyl phosphoramidite chemistry. Phosphorothioate linkages were introduced by oxidizing the phosphite linkage with elemental sulfur instead of the standard iodine oxidation.
- the four common nucleoside phosphoramiditeswere purchased from Applied Biosystems. All phosphodiester and thioate containing ODN were deprotected by treatment with concentrated ammonia at 55° C. for 12 hours. The ODN were purified by gel exclusion chromatography and lyophilized to dryness prior to use. Phosphorodithioate linkages were introduced by using deoxynucleoside S-(b-benzoylmercaptoethyl)pyrrolidino thiophosphoramidites (Wiesler, W. T. et al., (1993) In Methods in Molecular Biology: Protocols for Oligonucleotides and Analogs- Synthesis and Properties, Agrawal, S. (ed.), Humana Press, 191-206.). Dithioate containing ODN were deprotected by treatment with concentrated ammonia at 55° C. for 12 hours followed by reverse phase HPLC purification.
- the methylphosphinodiesteris treated with the sulfurizing reagent (5% elemental sulfur, 100 millimolar N,N-diamethylaminopyridine in carbon disulfide/pyridine/triethylamine), four consecutive times for 450 seconds each to produce methylphosphonothioates.
- the methylphosphinodiesteris treated with standard oxidizing reagent (0.1 M iodine in tetrahydrofuran/2,6-lutidine/water).
- silica gel bound oligomerwas treated with distilled pyridine/concentrated ammonia, 1:1, (v/v) for four days at 4 degrees centigrade.
- the supernatantwas dried in vacuo, dissolved in water and chromatographed on a G50/50 Sephadex column.
- O-ODNrefers to ODN which are phosphodiester; S-ODN are completely phosphorothioate modified; S—O-ODN are chimeric ODN in which the central linkages are phosphodiester, but the two 5′ and five 3′ linkages are phosphorothioate modified; S 2 —O-ODN are chimeric ODN in which the central linkages are phosphodiester, but the two 5′ and five 3′ linkages are phosphorodithioate modified; and MP-O-ODN are chimeric ODN in which the central linkages are phosphodiester, but the two 5′ and five 3′ linkages are methylphosphonate modified.
- the ODN sequences studiedinclude: 3D (5′ GAGAA CG CTGGACCTTCCAT),; (SEQ ID NO:14) 3M (5′ TCCATGT CG GTCCTGATGCT),; (SEQ ID NO:22) 5 (5′ GG CG TTATTCCTGACT CG CC),; (SEQ ID NO:57) and 6 (5′ CCTA CG TTGTATG CG CCCAGCT),. (SEQ ID NO:58)
- miceDBA/2, or BXSB mice obtained from The Jackson Laboratory (Bar Harbor, Me.), and maintained under specific pathogen-free conditions were used as a source of lymphocytes at 5-10 wk of age with essentially identical results.
- mouse spleen cells(5 ⁇ 10 4 cells/100 ⁇ l/well) were cultured at 37° C. in a 5% CO 2 humidified incubator in RPMI-1640 supplemented with 10% (v/v) heat inactivated fetal calf serum (heated to 65° C. for experiments with O-ODN, or 56° C. for experiments using only modified ODN), 1.5 ⁇ M L-glutamine, 50 ⁇ M 2-mercaptoethanol, 100 U/ml penicillin and 100 ⁇ g/ml streptomycin for 24 hr or 48 hr as indicated.
- Phosphodiester ODNwere purchased from Operon Technologies (Alameda, Calif.). Phosphorothioate ODN were purchased from the DNA core facility, University of Iowa, or from The Midland Certified Reagent Company (Midland Tex.). E. coli (strain B) DNA and calf thymus DNA were purchased from Sigma (St. Louis, Mo.). All DNA and ODN were purified by extraction with phenol:chloroform:isoamyl alcohol (25:24:1) and/or ethanol precipitation. The LPS level in ODN was less than 12.5 ng/mg and E. coli and calf thymus DNA contained less than 2.5 ng of LPS/mg of DNA by Limulus assay.
- Virus-free, 4-6 week old, DBA/2, C57BL/6 (B6) and congenitally athymic BALB/C micewere obtained on contract through the Veterans Affairs from the National Cancer Institute (Bethesda, Md.). C57BL/6 SCID mice were bred in the SPF barrier facility at the University of Iowa Animal Care Unit.
- PBMCperipheral mononuclear blood leukocytes
- 1 LUwas defined as the number of cells needed to effect 30% specific lysis.
- neutralizing antibodies against IFN- ⁇Lee Biomolecular, San Diego, Calif.
- IL-12C15.1, C15.6, C17.8, and C17.15; provided by Dr. Giorgio Trinchieri, The Wistar Institute, Philadelphia, Pa.
- isotype controlswere added at the initiation of cultures to a concentration of 10 ⁇ g/ml.
- 10 ⁇ g of each of the 4 MAB (or isotype controls)were added simultaneously.
- Recombinant human IL-2was used at a concentration of 100 U/ml.
- Schistosoma mansoni eggscontain an antigen ( Schistosoma mansoni egg antigen (SEA)) that induces a Th2 immune response (e.g. production of IgE antibody).
- SEASchistosoma mansoni egg antigen
- micewere then treated with oligonucleotides (30% g in 200 ⁇ l saline by i.p. injection), which either contained an unmethylated CpG motif (i.e. TCCATGA CG TTCCTGA CG TT; SEQ ID NO.10) or did not (i.e. control, TCCATGAGCTTCCTGAGTCT; SEQ ID NO.11).
- Soluble SEA(10 ⁇ g in 25 ⁇ l of saline) was administered by intranasal instillation on days 14 and 21. Saline was used as a control.
- micewere sacrificed at various times after airway challenge.
- Whole lung lavagewas performed to harvest airway and alveolar inflammatory cells.
- Cytokine levelswere measured from lavage fluid by ELISA.
- RNAwas isolated from whole lung for Northern analysis and RT-PCR studies using CsCl gradients. Lungs were inflated and perfused with 4% paraformaldehyde for histologic examination.
- FIG. 9shows that when the mice are initially injected with the eggs i.p., and then inhale the egg antigen (open circle), many inflammatory cells are present in the lungs. However, when the mice are initially given a nucleic acid containing an unmethylated CpG motif along with the eggs, the inflammatory cells in the lung are not increased by subsequent inhalation of the egg antigen (open triangles).
- FIG. 10shows that the same results are obtained when only eosinophils present in the lung lavage are measured.
- Eosinophilsare the type of inflammatory cell most closely associated with asthma.
- FIG. 11shows that when the mice are treated with a control oligo at the time of the initial exposure to the egg, there is little effect on the subsequent influx of eosinophils into the lungs after inhalation of SEA.
- mice inhale the eggs on days 14 or 21they develop an acute inflammatory response in the lungs.
- giving a CpG oligo along with the eggs at the time of initial antigen exposure on days 0 and 7almost completely abolishes the increase in eosinophils when the mice inhale the egg antigen on day 14.
- FIG. 12shows that very low doses of oligonucleotide ( ⁇ 10 g) can give this protection.
- FIG. 13shows that the resultant inflammatory response correlates with the levels of the Th2 cytokine IL-4 in the lung.
- FIG. 14shows that administration of an oligonucleotide containing an unmethylated CpG motif can actually redirect the cytokine response of the lung to production of II-2, indicating a Th1 type of immune response.
- FIG. 15shows that administration of an oligonucleotide containing an unmethylated CpG motif can also redirect the cytokine response of the lung to production of IFN- ⁇ , indicating a Th1 type of immune response.
- Human PBMCwere prepared from whole blood by standard centrifugation over ficoll hypaque.
- Cells(5 ⁇ 10 5 /ml) were cultured in 10% autologous serum in 96 well microtiter plates with CpG or control oligodeoxynucleotides (24 ⁇ g/ml for phosphodiester oligonucleotides; 6 ⁇ g/ml for nuclease resistant phosphorothioate oligonucleotides) for 4 hr in the case of TNF- ⁇ or 24 hr.
- CpG or control oligodeoxynucleotides24 ⁇ g/ml for phosphodiester oligonucleotides; 6 ⁇ g/ml for nuclease resistant phosphorothioate oligonucleotides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
Abstract
Description
- This application is a divisional of co-pending U.S. patent application Ser. No. 08/738,652, filed Oct. 30, 1996, which is a continuation-in-part of U.S. patent application Ser. No. 08/386,063, filed Feb. 7, 1995, now issued as U.S. Pat. No. 6,194,388, which is a continuation-in-part of U.S. patent application Ser. No. 08/276,358, filed Jul. 15, 1994, now abandoned.
- The work resulting in this invention was supported in part by National Institute of Health Grant No. R29-AR42556-01. The U.S. Government may therefore be entitled to certain rights in the invention.
- DNA Binds to Cell Membranes and is Internalized
- In the 1970's, several investigators reported the binding of high molecular weight DNA to cell membranes (Lerner, R. A., W. Meinke, and D. A. Goldstein. 1971. “Membrane-associated DNA in the cytoplasm of diploid human lymphocytes”.Proc. Natl. Acad. Sci. USA68:1212; Agrawal, S. K., R. W. Wagner, P. K. McAllister, and B. Rosenberg. 1975. “Cell-surface-associated nucleic acid in tumorigenic cells made visible with platinum-pyrimidine complexes by electron microscopy”.Proc. Natl. Acad. Sci. USA72:928). In 1985, Bennett et al. presented the first evidence that DNA binding to lymphocytes is similar to a ligand receptor interaction: binding is saturable, competitive, and leads to DNA endocytosis and degradation into oligonucleotides (Bennett, R. M., G. T. Gabor, and M. M. Merritt. 1985. “DNA binding to human leukocytes. Evidence for a receptor-mediated association, internalization, and degradation of DNA”.J. Clin. Invest.76:2182). Like DNA, oligodeoxyribonucleotides (ODNs) are able to enter cells in a saturable, sequence independent, and temperature and energy dependent fashion (reviewed in Jaroszewski, J. W., and J. S. Cohen. 1991. “Cellular uptake of antisense oligodeoxynucleotides”.Advanced Drug Delivery Reviews6:235; Akhtar, S., Y. Shoji, and R. L. Juliano. 1992. “Pharmaceutical aspects of the biological stability and membrane transport characteristics of antisense oligonucleotides”. In:Gene Regulation: Biology of Antisense RNA and DNA. R. P. Erickson, and J. G. Izant, eds. Raven Press, Ltd. New York, pp. 133; and Zhao, Q., T. Waldschmidt, E. Fisher, C. J. Herrera, and A. M. Krieg., 1994. “Stage specific oligonucleotide uptake in murine bone marrow B cell precursors”.Blood,84:3660). No receptor for DNA or ODN uptake has yet been cloned, and it is not yet clear whether ODN binding and cell uptake occurs through the same or a different mechanism from that of high molecular weight DNA.
- Lymphocyte ODN uptake has been shown to be regulated by cell activation. Spleen cells stimulated with the B cell mitogen LPS had dramatically enhanced ODN uptake in the B cell population, while spleen cells treated with the T cell mitogen Con A showed enhanced ODN uptake by T but not B cells (Krieg, A. M., F. Gmelig-Meyling, M. F. Gourley, W. J. Kisch, L. A. Chrisey, and A. D. Steinberg. 1991. “Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible”.Antisense Research and Development1:161).
- Immune Effects of Nucleic Acids
- Several polynucleotides have been extensively evaluated as biological response modifiers. Perhaps the best example is poly (I,C) which is a potent inducer of IFN production as well as a macrophage activator and inducer of NK activity (Talmadge, J. E., J. Adams, H. Phillips, M. Collins, B. Lenz, M. Schneider, E. Schlick, R. Ruffiann, R. H. Wiltrout, and M. A. Chirigos. 1985. “Immunomodulatory effects in mice of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose”.Cancer Res.45:1058; Wiltrout, R. H., R. R. Salup, T. A. Twilley, and J. E. Talmadge. 1985. “Immunomodulation of natural killer activity by polyribonucleotides”.J. Biol. Resp. Mod.4:512; Krown, S. E. 1986. “Interferons and interferon inducers in cancer treatment”.Sem. Oncol.13:207; and Ewel, C. H., S. J. Urba, W. C. Kopp, J. W. Smith II, R. G. Steis, J. L. Rossio, D. L. Longo, M. J. Jones, W. G. Alvord, C. M. Pinsky, J. M. Beveridge, K. L. McNitt, and S. P. Creekmore. 1992. “Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin-2 in patients with cancer: clinical and immunological effects”.Canc. Res.52:3005). It appears that this murine NK activation may be due solely to induction of IFN-β secretion (Ishikawa, R., and C. A. Biron. 1993. “IFN induction and associated changes in splenic leukocyte distribution”.J. Immunol.150:3713). This activation was specific for the ribose sugar since deoxyribose was ineffective. Its potent in vitro antitumor activity led to several clinical trials using poly (I,C) complexed with poly-L-lysine and carboxymethylcellulose (to reduce degradation by RNAse) (Talmadge, J. E., et al., 1985. cited supra; Wiltrout, R. H., et al., 1985. cited supra); Krown, S. E., 1986. cited supra); and Ewel, C. H., et al., 1992. cited supra). Unfortunately, toxic side effects have thus far prevented poly (I,C) from becoming a useful therapeutic agent.
- Guanine ribonucleotides substituted at the C8 position with either a bromine or a thiol group are B cell mitogens and may replace. “B cell differentiation factors” (Feldbush, T. L., and Z. K. Ballas. 1985. “Lymphokine-like activity of 8-mercaptoguanosine: induction of T and B cell differentiation”.J. Immunol.134:3204; and Goodman, M. G. 1986. “Mechanism of synergy between T cell signals and C8-substituted guanine nucleosides in humoral immunity: B lymphotropic cytokines induce responsiveness to 8-mercaptoguanosine”.J. Immunol.136:3335). 8-mercaptoguanosine and 8-bromoguanosine also can substitute for the cytokine requirement for the generation of MHC restricted CTL (Feldbush, T. L., 1985. cited supra), augment murine NK activity (Koo, G. C., M. E. Jewell, C. L. Manyak, N. H. Sigal, and L. S. Wicker. 1988. “Activation of murine natural killer cells and macrophages by 8-bromoguanosine”.J. Immunol.140:3249), and synergize with IL-2 in inducing murine LAK generation (Thompson, R. A., and Z. K. Ballas. 1990. “Lymphokine-activated killer (LAK) cells. V. 8-Mercaptoguanosine as an IL-2-sparing agent in LAK generation”. J. Immunol. 145:3524). The NK and LAK augmenting activities of these C8-substituted guanosines appear to be due to their induction of IFN (Thompson, R. A., et al. 1990. cited supra). Recently, a 5′ triphosphorylated thymidine produced by a mycobacterium was found to be mitogenic for a subset of human γδ T cells (Constant, P., F. Davodeau, M.-A. Peyrat, Y. Poquet, G. Puzo, M. Bonneville, and J.-J. Foumie. 1994. “Stimulation of human γδ T cells by nonpeptidic mycobacterial ligands”Science264:267). This report indicated the possibility that the immune system may have evolved ways to preferentially respond to microbial nucleic acids.
- Several observations suggest that certain DNA structures may also have the potential to activate lymphocytes. For example, Bell et al. reported that nucleosomal protein-DNA complexes (but not naked DNA) in spleen cell supernatants caused B cell proliferation and immunoglobulin secretion (Bell, D. A., B. Morrison, and P. VandenBygaart. 1990. “Immunogenic DNA-related factors”.J. Clin. Invest.85:1487). In other cases, naked DNA has been reported to have immune effects. For example, Messina et al. have recently reported that 260 to 800 bp fragments of poly (dG)•(dC) and poly (dG•dC) were mitogenic for B cells (Messina, J. P., G. S. Gilkeson, and D. S. Pisetsky. 1993. “The influence of DNA structure on the in vitro stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens”.Cell. Immunol.147:148). Tokunaga, et al. have reported that dG•dC induces IFN-γ and NK activity (Tokunaga, S. Yamamoto, and K. Namba. 1988. “A synthetic single-stranded DNA, poly(dG,dC), induces interferon-α/β and -γ, augments natural killer activity, and suppresses tumor growth”Jpn. J. Cancer Res.79:682). Aside from such artificial homopolymer sequences, Pisetsky et al. reported that pure mammalian DNA has no detectable immune effects, but that DNA from certain bacteria induces B cell activation and immunoglobulin secretion (Messina, J. P., G. S. Gilkeson, and D. S. Pisetsky. 1991. “Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA”.J. Immunol.147:1759). Assuming that these data did not result from some unusual contaminant, these studies suggested that a particular structure or other characteristic of bacterial DNA renders it capable of triggering B cell activation. Investigations of mycobacterial DNA sequences have demonstrated that ODN which contain certain palindrome sequences can activate NK cells (Yamamoto, S., T. Yamamoto, T. Kataoka, E. Kuramoto, O. Yano, and T. Tokunaga. 1992. “Unique palindromic sequences in synthetic oligonucleotides are required to induce INF and augment INF-mediated natural killer activity”.J. Immunol.148:4072; Kuramoto, E., O. Yano, Y. Kimura, M. Baba, T. Makino, S. Yamamoto, T. Yamamoto, T. Kataoka, and T. Tokunaga. 1992. “Oligonucleotide sequences required for natural killer cell activation”.Jpn. J. Cancer Res.83:1128).
- Several phosphorothioate modified ODN have been reported to induce in vitro or in vivo B cell stimulation (Tanaka, T., C. C. Chu, and W. E. Paul. 1992. “An antisense oligonucleotide complementary to a sequence in Iγ2b increases γ2b germline transcripts, stimulates B cell DNA synthesis, and inhibits immunoglobulin secretion”.J. Exp. Med.175:597; Branda, R. F., A. L. Moore, L. Mathews, J. J. McCormack, and G. Zon. 1993. “Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1”. Biochem. Pharmacol.45:2037; McIntyre, K. W., K. Lombard-Gillooly, J. R. Perez, C. Kunsch, U. M. Sarmiento, J. D. Larigan, K. T. Landreth, and R. Narayanan. 1993. “A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NFκB T65 causes sequence-specific immune stimulation”.Antisense Res. Develop.3:309; and Pisetsky, D. S., and C. F. Reich. 1993. “Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus”.Life Sciences54:101). These reports do not suggest a common structural motif or sequence element in these ODN that might explain their effects.
- The CREB/ATF Family of Transcription Factors and Their Role in Replication
- The cAMP response element binding protein (CREB) and activating transcription factor (ATF) or CREB/ATF family of transcription factors is a ubiquitously expressed class of transcription factors of which 11 members have so far been cloned (reviewed in de Groot, R. P., and P. Sassone-Corsi: “Hormonal control of gene expression: Multiplicity and versatility of
cyclic adenosine 3′,5′-monophosphate-responsive nuclear regulators”.Mol. Endocrin.7:145, 1993; Lee, K. A. W., and N. Masson: “Transcriptional regulation by CREB and its relatives”.Biochim. Biophys. Acta1174:221, 1993.). They all belong to the basic region/leucine zipper (bZip) class of proteins. All cells appear to express one or more CREB/ATF proteins, but the members expressed and the regulation of mRNA splicing appear to be tissue-specific. Differential splicing of activation domains can determine whether a particular CREB/ATF protein will be a transcriptional inhibitor or activator. Many CREB/ATF proteins activate viral transcription, but some splicing variants which lack the activation domain are inhibitory. CREB/ATF proteins can bind DNA as homo- or hetero-dimers through the cAMP response element, the CRE, the consensus form of which is the unmethylated sequence TGACGTC (binding is abolished if the CpG is methylated) (Iguchi-Ariga, S. M. M., and W. Schaffner: “CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation”.Genes&Develop.3:612, 1989.). - The transcriptional activity of the CRE is increased during B cell activation (Xie, H. T. C. Chiles, and T. L. Rothstein: “Induction of CREB activity via the surface Ig receptor of B cells”.J. Immunol.151:880, 1993.). CREB/ATF proteins appear to regulate the expression of multiple genes through the CRE including immunologically important genes such as fos, jun B, Rb-1, IL-6, IL-1 (Tsukada, J., K. Saito, W. R. Waterman, A. C. Webb, and P. E. Auron: “Transcription factors NF-IL6 and CREB recognize a common essential site in the
human prointerleukin 1 β gene”.Mol. Cell. Biol.14:7285, 1994; Gray, G. D., O. M. Hernandez, D. Hebel, M. Root, J. M. Pow-Sang, and E. Wickstrom: “Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice”.Cancer Res.53:577, 1993), IFN-β (Du, W., and T. Maniatis: “An ATF/CREB binding site protein is required for virus induction of the human interferon B gene”.Proc. Natl. Acad. Sci. USA89:2150, 1992), TGF-β1 (Asiedu, C. K., L. Scott, R. K. Assoian, M. Ehrlich: “Binding of AP-1/CREB proteins and of MDBP to contiguous sites downstream of the human TGF-B 1 gene”.Biochim. Biophys. Acta1219:55, 1994.), TGF-β2, class II MHC (Cox, P. M., and C. R. Goding: “An ATF/CREB binding motif is required for aberrant constitutive expression of the MHC class II DRa promoter and activation by SV40 T-antigen”.Nucl. Acids Res.20:4881, 1992.), E-selectin, GM-CSF, CD-8α, the germline Igα constant region gene, the TCR Vβ gene, and the proliferating cell nuclear antigen (Huang, D., P. M. Shipman-Appasamy, D. J. Orten, S. H. Hinrichs, and M. B. Prystowsky: “Promoter activity of the proliferating-cell nuclear antigen gene is associated with inducible CRE-binding proteins in interleukin 2-stimulated T lymphocytes”.Mol. Cell. Biol.14:4233, 1994.). In addition to activation through the cAMP pathway, CREB can also mediate transcriptional responses to changes in intracellular Ca++ concentration (Sheng, M., G. McFadden, and M. E. Greenberg: “Membrane depolarization and calcium induce c-fos transcription via phosphorylation of transcription factor CREB”.Neuron4:571, 1990). - The role of protein-protein interactions in transcriptional activation by CREB/ATF proteins appears to be extremely important. There are several published studies reporting direct or indirect interactions between NFKB proteins and CREB/ATF proteins (Whitley, et. al., (1994)Mol.&Cell. Biol.14:6464; Cogswell, et al., (1994)J. Immun.153:712; Hines, et al., (1993)Oncogene8:3189; and Du, et al., (1993)Cell74:887. Activation of CREB through the cyclic AMP pathway requires protein kinase A (PKA), which phosphorylates CREB341on ser133and allows it to bind to a recently cloned protein, CBP (Kwok, R. P. S., J. R. Lundblad, J. C. Chrivia, J. P. Richards, H. P. Bachinger, R. G. Brennan, S. G. E. Roberts, M. R. Green, and R. H. Goodman: “Nuclear protein CBP is a coactivator for the transcription factor CREB”.Nature370:223, 1994; Arias, J., A. S. Alberts, P. Brindle, F. X. Claret, T. Smea, M. Karin, J. Feramisco, and M. Montminy: “Activation of cAMP and mitogen responsive genes relies on a common nuclear factor”.Nature370:226, 1994.). CBP in turn interacts with the basal transcription factor TFIIB causing increased transcription. CREB also has been reported to interact with
dTAFII 110, a TATA binding protein-associated factor whose binding may regulate transcription (Ferreri, K., G. Gill, and M. Montminy: “The cAMP-regulated transcription factor CREB interacts with a component of the TFIID complex”.Proc. Natl. Acad. Sci. USA91:1210, 1994.). In addition to these interactions, CREB/ATF proteins can specifically bind multiple other nuclear factors (Hoeffler, J. P., J. W. Lustbader, and C.-Y. Chen: “Identification of multiple nuclear factors that interact withcyclic adenosine 3′,5′-monophosphate response element-binding protein and activating transcription factor-2 by protein-protein interactions”.Mol. Endocrinol.5:256, 1991) but the biologic significance of most of these interactions is unknown. CREB is normally thought to bind DNA either as a homodimer or as a heterodimer with several other proteins. Surprisingly, CREB monomers constitutively activate transcription (Krajewski, W., and K. A. W. Lee: “A monomeric derivative of the cellular transcription factor CREB functions as a constitutive activator”.Mol. Cell. Biol.14:7204, 1994.). - Aside from their critical role in regulating cellular transcription, it has recently been shown that CREB/ATF proteins are subverted by some infectious viruses and retroviruses, which require them for viral replication. For example, the cytomegalovirus immediate early promoter, one of the strongest known mammalian promoters, contains eleven copies of the CRE which are essential for promoter function (Chang, Y.-N., S. Crawford, J. Stall, D. R. Rawlins, K.-T. Jeang, and G. S. Hayward: “The palindromic series I repeats in the simian cytomegalovirus major immediate-early promoter behave as both strong basal enhancers and cyclic AMP response elements”.J. Virol.64:264, 1990). At least some of the transcriptional activating effects of the adenovirus EIA protein, which induces many promoters, are due to its binding to the DNA binding domain of the CREB/ATF protein, ATF-2, which mediates E1A inducible transcription activation (Liu, F., and M. R. Green: “Promoter targeting by adenovirus E1a through interaction with different cellular DNA-binding domains”.Nature368:520, 1994). It has also been suggested that E1A binds to the CREB-binding protein, CBP (Arany, Z., W. R. Sellers, D. M. Livingston, and R. Eckner: “E1A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators”.Cell77:799, 1994). Human T lymphotropic virus-I (HTLV-1), the retrovirus which causes human T cell leukemia and tropical spastic paresis, also requires CREB/ATF proteins for replication. In this case, the retrovirus produces a protein, Tax, which binds to CREB/ATF proteins and redirects them from their normal cellular binding sites to different DNA sequences (flanked by G- and C-rich sequences) present within the HTLV transcriptional enhancer (Paca-Uccaralertkun, S., L.-J. Zhao, N. Adya, J. V. Cross, B. R. Cullen, I. M. Boros, and C.-Z. Giam: “In vitro selection of DNA elements highly responsive to the human T-cell lymphotropic virus type I transcriptional activator, Tax”.Mol. Cell. Biol.14:456, 1994; Adya, N., L.-J. Zhao, W. Huang, I. Boros, and C.-Z. Giam: “Expansion of CREB's DNA recognition specificity by Tax results from interaction with Ala-Ala-Arg at positions 282-284 near the conserved DNA-binding domain of CREB”.Proc. Natl. Acad. Sci. USA91:5642,1994).
- The instant invention is based on the finding that certain nucleic acids containing unmethylated cytosine-guanine (CpG) dinucleotides activate lymphocytes in a subject and redirect a subject's immune response from a Th2 to a Th1 (e.g. by inducing monocytic cells and other cells to produce Th1 cytokines, including IL-12, IFN-γ and GM-CSF). Based on this finding, the invention features, in one aspect, novel immunostimulatory nucleic acid compositions.
- In a preferred embodiment, the immunostimulatory nucleic acid contains a consensus mitogenic CpG motif represented by the formula:
5′ X1CGX23′ - wherein X1is selected from the group consisting of A,G and T; and X2is C or T.
- In a particularly preferred embodiment an immunostimulatory nucleic acid molecule contains a consensus mitogenic CpG motif represented by the formula:
5′ X1X2CGX3X43′ - wherein C and G are unmethylated; and X1, X2, X3and X4are nucleotides.
- Enhanced immunostimulatory activity of human cells occurs where X1X2is selected from the group consisting of GpT, GpG, GpA and ApA and/or X3X4is selected from the group consisting of TpT, CpT and GpT (Table 5). For facilitating uptake into cells, CpG containing immunostimulatory nucleic acid molecules are preferably in the range of 8 to 40 base pairs in size. However, nucleic acids of any size (even many kb long) are immunostimulatory if sufficient immunostimulatory motifs are present, since such larger nucleic acids are degraded into oligonucleotides inside of cells. Preferred synthetic oligonucleotides do not include a GCG trinucleotide sequence at or near the 5′ and/or 3′ terminals and/or the consensus mitogenic CpG motif is not a palindrome. Prolonged immunostimulation can be obtained using stabilized oligonucleotides, particularly phosphorothioate stabilized oligonucleotides.
- In a second aspect, the invention features useful therapies, which are based on the immunostimulatory activity of the nucleic acid molecules. For example, the immunostimulatory nucleic acid molecules can be used to treat, prevent or ameliorate an immune system deficiency (e.g., a tumor or cancer or a viral, fungal, bacterial or parasitic infection in a subject). In addition, immunostimulatory nucleic acid molecules can be administered to stimulate a subject's response to a vaccine.
- Further, by redirecting a subject's immune response from Th2 to Th1, the instant claimed nucleic acid molecules can be administered to treat or prevent the symptoms of asthma. In addition, the instant claimed nucleic acid molecules can be administered in conjunction with a particular allergen to a subject as a type of desensitization therapy to treat or prevent the occurrence of an allergic reaction.
- Further, the ability of immunostimulatory nucleic acid molecules to induce leukemic cells to enter the cell cycle supports the use of immunostimulatory nucleic acid molecules in treating leukemia by increasing the sensitivity of chronic leukemia cells and then administering conventional ablative chemotherapy, or combining the immunostimulatory nucleic acid molecules with another immunotherapy.
- Other features and advantages of the invention will become more apparent from the following detailed description and claims.
FIG. 1A -C are graphs plotting dose-dependent IL-6 production in response to various DNA sequences in T cell depleted spleen cell cultures. A.E. coliDNA (●) and calf thymus DNA (▪) sequences and LPS (at 10× the concentration ofE. coliand calf thymus DNA). (♦). B. Control phosphodiester oligodeoxynucleotide (ODN)5′ATGGAAGGTCCAGTGTTCTC3′ (SEQ ID NO:1) (▪) and two phosphodiester CpG ODN5′ATCGACCTACGTGCGTTCTC3′ (SEQ ID NO:2) (♦) and5′TCCATAACGTTCCTGATGCT3′ (SEQ ID NO:3) (●). C. Control phosphorothioate ODN5′GCTAGATGTTAGCGT3′ (SEQ ID NO:4) (▪) and two phosphorothioate CpG ODN5′GAGAACGTCGACCTTCGAT3′ (SEQ ID NO:5) (♦) and5′GCATGACGTTGAGCT3′ (SEQ ID NO:6) (●). Data present the mean±standard deviation of triplicates.FIG. 2 is a graph plotting IL-6 production induced by CpG DNA in vivo as determined 1-8 hrs after injection. Data represent the mean from duplicate analyses of sera from two mice. BALB/c mice (two mice/group) were injected iv. with 100 μl of PBS (□) or 200 μg ofCpG phosphorothioate ODN 5′TCCATGACGTTCCTGATGCT 3′ (SEQ ID NO:7) (▪) ornon-CpG phosphorothioate ODN 5′TCCATGAGCTTCCTGAGTCT 3′ (SEQ ID NO:8) (♦).FIG. 3 is an autoradiograph showing IL-6 mRNA expression as determined by reverse transcription polymerase chain reaction in liver, spleen, and thymus at various time periods after in vivo stimulation of BALB/c mice (two mice/group) injected iv with 100 μl of PBS, 200 μg ofCpG phosphorothioate ODN 5′TCCATGACGTTCCTGATGCT 3′ (SEQ ID NO:7) ornon-CpG phosphorothioate ODN 5′TCCATGAGCTTCCTGAGTCT 3′ (SEQ ID NO:8).FIG. 4A is a graph plotting dose-dependent inhibition of CpG-induced IgM production by anti-IL-6. Splenic B-cells from DBA/2 mice were stimulated with CpG ODN5′TCCAAGACGTTCCTGATGCT3′ (SEQ ID NO:9) in the presence of the indicated concentrations of neutralizing anti-IL-6 (♦) or isotype control Ab (●) and IgM levels in culture supernatants determined by ELISA. In the absence of CpG ODN, the anti-IL-6 Ab had no effect on IgM secretion (▪).FIG. 4B is a graph plotting the stimulation index of CpG-induced splenic B cells cultured with anti-IL-6 and CpG S-ODN 5′TCCATGACGTTCCTGATGCT 3′ (SEQ ID NO:7) (♦) or anti-IL-6 antibody only (▪). Data present the mean±standard deviation of triplicates.FIG. 5 is a bar graph plotting chloramphenicol acetyltransferase (CAT) activity in WEHI-231 cells transfected with a promoter-less CAT construct (pCAT), positive control plasmid (RSV), or IL-6 promoter-CAT construct alone or cultured withCpG 5′TCCATGACGTTCCTGATGCT 3′ (SEQ ID NO:7) or non-CpG 5′TCCATGAGCTTCCTGAGTCT 3′ (SEQ ID NO:8) phosphorothioate ODN at the indicated concentrations. Data present the mean of triplicates.FIG. 6 is a schematic overview of the immune effects of the immunostimulatory ummethylated CpG containing nucleic acids, which can directly activate both B cells and monocytic cells (including macrophages and dendritic cells) as shown. The immunostimulatory oligonucleotides do not directly activate purified NK cells, but render them competent to respond to IL-12 with a marked increase in their IFN-γ production. By inducing IL-12 production and the subsequent increased IFN-γ secretion by NK cells, the immunostimulatory nucleic acids promote a Th1 type immune response. No direct activation of proliferation of cytokine secretion by highly purified T cells has been found. However, the induction of Th1 cytokine secretion by the immunostimulatory oligonucleotides promotes the development of a cytotoxic lymphocyte response.FIG. 7 is an autoradiograph showing NFKB mRNA induction in monocytes treated withE. coli(EC) DNA (containing unmethylated CpG motifs), control (CT) DNA (containing no unmethylated CpG motifs) and lipopolysaccharide (LPS) at various measured times, 15 and 30 minutes after contact.FIG. 8A shows the results from a flow cytometry study using mouse B cells with the dihydrorhodamine 123 dye to determine levels of reactive oxygen species. The dye only sample in Panel A of the figure shows the background level of cells positive for the dye at 28.6%. This level of reactive oxygen species was greatly increased to 80% in the cells treated for 20 minutes with PMA and ionomycin, a positive control (Panel B). The cells treated with the CpG oligo (TCCATGACGTTCCTGACGTT SEQ ID NO: 10) also showed an increase in the level of reactive oxygen species such that more than 50% of the cells became positive (Panel D). However, cells treated with an oligonucleotide with the identical sequence except that the CpGs were switched (TCCATGAGCTTCCTGAGTGCT SEQ ID NO:11) did not show this significant increase in the level of reactive oxygen species (Panel E).FIG. 8B shows the results from a flow cytometry study using mouse B cells in the presence of chloroquine with the dihydrorhodamine 123 dye to determine levels of reactive oxygen species. Chloroquine slightly lowers the background level of reactive oxygen species in the cells such that the untreated cells in Panel A have only 4.3% that are positive. Chloroquine completely abolishes the induction of reactive oxygen species in the cells treated with CpG DNA (Panel B) but does not reduce the level of reactive oxygen species in the cells treated with PMA and ionomycin (Panel E).FIG. 9 is a graph plotting lung lavage cell count over time. The graph shows that when the mice are initially injected withSchistosoma mansonieggs “egg”, which induces a Th2 immune response, and subsequently inhaleSchistosoma mansoniegg antigen “SEA” (open circle), many inflammatory cells are present in the lungs. However, when the mice are initially given CpG oligo (SEQ ID NO:10) along with egg, the inflammatory cells in the lung are not increased by subsequent inhalation of SEA (open triangles).FIG. 10 is a graph plotting lung lavage eosinophil count over time. Again, the graph shows that when the mice are initially injected with egg and subsequently inhale SEA (open circle), many eosinophils are present in the lungs. However, when the mice are initially given CpG oligo (SEQ ID NO:10) along with egg, the inflammatory cells in the lung are not increased by subsequent inhalation of the SEA (open triangles).FIG. 11 is a bar graph plotting the effect on the percentage of macrophage, lymphocyte, neutrophil and eosinophil cells induced by exposure to saline alone; egg, then SEA; egg and SEQ ID NO:11, then SEA; and egg and control oligo (SEQ ID NO:11), then SEA. When the mice are treated with the control oligo at the time of the initial exposure to the egg, there is little effect on the subsequent influx of eosinophils into the lungs after inhalation of SEA. Thus, when mice inhale the eggs on days 14 or 21, they develop an acute inflammatory response in the lungs. However, giving a CpG oligo along with the eggs at the time of initial antigen exposure ondays 0 and 7 almost completely abolishes the increase in eosinophils when the mice inhale the egg antigen on day 14.FIG. 12 is a bar graph plotting eosinophil count in response to injection of various amounts of the protective oligo SEQ ID NO:10.FIG. 13 is a graph plotting interleukin 4 (IL-4) production (pg/ml) in mice over time in response to injection of egg, then SEA (open diamond); egg and SEQ ID NO:10, then SEA (open circle); or saline, then saline (open square). The graph shows that the resultant inflammatory response correlates with the levels of the Th2 cytokine IL-4 in the lung.FIG. 14 is a bar graph plotting interleukin 12 (IL-12) production (pg/ml) in mice over time in response to injection of saline; egg, then SEA; or SEQ ID NO:10 and egg, then SEA. The graph shows that administration of an oligonucleotide containing an unmethylated CpG motif can actually redirect the cytokine response of the lung to production of IL-12, indicating a Th1 type of immune response.FIG. 15 is a bar graph plotting interferon gamma (IFN-γ) production (pg/ml) in mice over time in response to injection of saline; egg, then saline; or SEQ ID NO:10 and egg, then SEA. The graph shows that administration of an oligonucleotide containing an unmethylated CpG motif can also redirect the cytokine response of the lung to production of IFN-γ, indicating a Th1 type of immune response.- Definitions
- As used herein, the following terms and phrases shall have the meanings set forth below:
- An “allergen” refers to a substance that can induce an allergic or asthmatic response in a susceptible subject. The list of allergens is enormous and can include pollens, insect venoms, animal dander, dust, fungal spores and drugs (e.g. penicillin). Examples of natural, animal and plant allergens include proteins specific to the following genera: Canine (Canis familiaris);Dermatophagoides(e.g.Dermatophagoides farinae);Felis(Felis domesticus);Ambrosia(Ambrosia artemiisfolia; Lolium(e.g.Lolium perenneorLolium multiflorum);Cryptomeria(Cryptomeria japonica);Alternaria(Alternaria alternata);Alder; Alnus(Alnus gultinosa);Betula(Betula verrucosa);Quercus(Quercus alba);Olea(Olea europa);Artemisia(Artemisia vulgaris);Plantago(e.g.Plantago lanceolata);Parietaria(e.g.Parietaria officinalisorParietaria judaica);Blattella(e.g.Blattella germanica);Apis(e.g.Apis multiflorum);Cupressus(e.g.Cupressus sempervirens, Cupressus arizonicaandCupressus macrocarpa);Juniperus(e.g.Juniperus sabinoides, Juniperus virginiana, Juniperus communisandJuniperus ashei);Thuya(e.g.Thuya orientalis);Chamaecyparis(e.g.Chamaecyparis obtusa);Periplaneta(e.g.Periplaneta americana);Agropyron(e.g.Agropyron repens);Secale(e.g.Secale cereale);Triticum(e.g.Triticum aestivum);Dactylis(e.g.Dactylis glomerata);Festuca(e.g.Festuca elatior);Poa(e.g.Poa pratensisorPoa compressa);Avena(e.g.Avena sativa);Holcus(e.g.Holcus lanatus);Anthoxanthum(e.g.Anthoxanthum odoratum);Arrhenatherum(e.g.Arrhenatherum elatius);Agrostis(e.g.Agrostis alba);Phleum(e.g.Phleum pratense);Phalaris(e.g.Phalaris arundinacea);Paspalum(e.g.Paspalum notatum);Sorghum(e.g.Sorghum halepensis); andBromus(e.g.Bromus inermis).
- An “allergy” refers to acquired hypersensitivity to a substance (allergen). Allergic conditions include eczema, allergic rhinitis or coryza, hay fever, bronchial asthma, urticaria (hives) and food allergies, and other atopic conditions.
- “Asthma”—refers to a disorder of the respiratory system characterized by inflammation, narrowing of the airways and increased reactivity of the airways to inhaled agents. Asthma is frequently, although not exclusively associated with atopic or allergic symptoms.
- An “immune system deficiency” shall mean a disease or disorder in which the subject's immune system is not functioning in normal capacity or in which it would be useful to boost a subject's immune response for example to eliminate a tumor or cancer (e.g. tumors of the brain, lung (e.g. small cell and non-small cell), ovary, breast, prostate, colon, as well as other carcinomas and sarcomas) or an infection in a subject.
- Examples of infectious virus include: Retroviridae (e.g., human immunodeficiency viruses, such as HIV-1 (also referred to as HTLV-III, LAV or HTLV-III/LAV, or HIV-III; and other isolates, such as HIV-LP; Picornaviridae (e.g., polio viruses, hepatitis A virus; enteroviruses, human coxsackie viruses, rhinoviruses, echoviruses); Calciviridae (e.g., strains that cause gastroenteritis); Togaviridae (e.g., equine encephalitis viruses, rubella viruses); Flaviridae (e.g., dengue viruses, encephalitis viruses, yellow fever viruses); Coronaviridae (e.g., coronaviruses); Rhabdoviridae (e.g., vesicular stomatitis viruses, rabies viruses); Filoviridae (e.g., ebola viruses); Paramyxoviridae (e.g., parainfluenza viruses, mumps virus, measles virus, respiratory syncytial virus); Orthomyxoviridae (e.g., influenza viruses); Bungaviridae (e.g., Hantaan viruses, bunga viruses, phleboviruses and Nairo viruses); Arena viridae (hemorrhagic fever viruses); Reoviridae (e.g., reoviruses, orbiviurses and rotaviruses); Birnaviridae; Hepadnaviridae (Hepatitis B virus); Parvoviridae (parvoviruses); Papovaviridae (papilloma viruses, polyoma viruses); Adenoviridae (most adenoviruses); Herpesviridae (herpes simplex virus (HSV) 1 and 2, varicella zoster virus, cytomegalovirus (CMV), herpes viruses); Poxyiridae (variola viruses, vaccinia viruses, pox viruses); and Iridoviridae (e.g., African swine fever virus); and unclassified viruses (e.g., the etiological agents of Spongiform encephalopathies, the agent of delta hepatitis (thought to be a defective satellite of hepatitis B virus), the agents of non-A, non-B hepatitis (class 1=internally transmitted; class 2=parenterally transmitted (i.e., Hepatitis C); Norwalk and related viruses, and astroviruses).
- Examples of infectious bacteria include:Helicobacter pyloris, Borelia burgdorferi, Legionella pneumophilia, Mycobacteriaspp. (e.g.,M. tuberculosis, M. avium, M. intracellulare, M. kansasii, M. gordonae),Staphylococcus aureus, Neisseria gonorrhoeae, Neisseria meningitidis, Listeria monocytogenes, Streptococcus pyogenes(Group AStreptococcus),Streptococcus agalactiae(Group BStreptococcus),Streptococcus(viridans group),Streptococcus faecalis, Streptococcus bovis, Streptococcus(anaerobic spp.),Streptococcus pneumoniae, pathogenicCampylobactersp.,Enterococcussp.,Haemophilus influenzae, Bacillus anthracis, Corynebacterium diphtheriae, Corynebacteriumsp.,Erysipelothrix rhusiopathiae, Clostridium perfringens, Clostridium tetani, Enterobacter aerogenes, Klebsiella pneumoniae, Pasturella multocida, Bacteroidessp.,Fusobacterium nucleatum, Streptobacillus moniliformis, Treponema pallidum, Treponema pertenue, Leptospira, andActinomyces israelli.
- Examples of infectious fungi include:Cryptococcus neoformans, Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatitidis, Chlamydia trachomatis, Candida albicans. Other infectious organisms (i.e., protists) include:Plasmodium falciparumandToxoplasma gondii.
- An “immunostimulatory nucleic acid molecule” refers to a nucleic acid molecule, which contains an unmethylated cytosine, guanine dinucleotide sequence (i.e. “CpG DNA” or DNA containing a cytosine followed by guanosine and linked by a phosphate bond) and stimulates (e.g. has a mitogenic effect on, or induces or increases cytokine expression by) a vertebrate lymphocyte. An immunostimulatory nucleic acid molecule can be double-stranded or single-stranded. Generally, double-stranded molecules are more stable in vivo, while single-stranded molecules have increased immune ac ivity.
- In a preferred embodiment, the immunostimulatory nucleic acid contains a consensus mitogenic CpG motif represented by the formula:
5′ X1CGX23′ - wherein X1is selected from the group consisting of A,G and T; and X2is C or T.
- In a particularly preferred embodiment, immunostimulatory nucleic acid molecules are between 2 to 100 base pairs in size and contain a consensus mitogenic CpG motif represented by the formula:
5′ X1X2CGX3X43′ - wherein C and G are unmethylated, X1, X2, X3and X4are nucleotides.
- For economic reasons, preferably the immunostimulatory CpG DNA is in the range of between 8 to 40 base pairs in size if it is synthesized as an oligonucleotide. Alternatively, CpG dinucleotides can be produced on a large scale in plasmids, which after being administered to a subject are degraded into oligonucleotides. Preferred immunostimulatory nucleic acid molecules (e.g. for use in increasing the effectiveness of a vaccine or to treat an immune system deficiency by stimulating an antibody [humoral] response in a subject) have a relatively high stimulation index with regard to B cell, monocyte and/or natural killer cell responses (e.g. cytokine, proliferative, lytic or other responses).
- The stimulation index of a particular immunostimulatory CpG DNA can be tested in various immune cell assays. Preferably, the stimulation index of the immunostimulatory CpG DNA with regard to B-cell proliferation is at least about 5, preferably at least about 10, more preferably at least about 15 and most preferably at least about 20 as determined by incorporation of3H uridine in a murine B cell culture, which has been contacted with a 20 μM of ODN for 20 h at 37° C. and has been pulsed with 1μCi of3H uridine; and harvested and counted 4 h later as described in detail in Example 1. For use in vivo, for example to treat an immune system deficiency by stimulating a cell-mediated (local) immune response in a subject, it is important that the immunostimulatory CpG DNA be capable of effectively inducing cytokine secretion by monocytic cells and/or Natural Killer (NK) cell lytic activity.
- Preferred immunostimulatory CpG nucleic acids should effect at least about 500 pg/ml of TNF-α, 15 pg/ml IFN-γ, 70 pg/ml of GM-CSF 275 pg/ml of IL-6, 200 pg/ml IL-12, depending on the therapeutic indication, as determined by the assays described in Example 12. Other preferred immunostimulatory CpG DNAs should effect at least about 10%, more preferably at least about 15% and most preferably at least about 20% YAC-1 cell specific lysis or at least about 30, more preferably at least about 35 and most preferably at least about 40% 2C11 cell specific lysis as determined by the assay described in detail in Example 4.
- A “nucleic acid” or “DNA” shall mean multiple nucleotides (i.e. molecules comprising a sugar (e.g. ribose or deoxyribose) linked to a phosphate group and to an exchangeable organic base, which is either a substituted pyrimidine (e.g. cytosine (C), thymine (T) or uracil (U)) or a substituted purine (e.g. adenine (A) or guanine (G)). As used herein, the term refers to ribonucleotides as well as oligodeoxyribonucleotides. The term shall also include polynucleosides (i.e. a polynucleotide minus the phosphate) and any other organic base containing polymer. Nucleic acid molecules can be obtained from existing nucleic acid sources (e.g. genomic or cDNA), but are preferably synthetic (e.g. produced by oligonucleotide synthesis).
- A “nucleic acid delivery complex” shall mean a nucleic acid molecule associated with (e.g. ionically or covalently bound to; or encapsulated within) a targeting means (e.g. a molecule that results in higher affinity binding to target cell (e.g. B-cell and natural killer (NK) cell) surfaces and/or increased cellular uptake by target cells). Examples of nucleic acid delivery complexes include nucleic acids associated with: a sterol (e.g. cholesterol), a lipid (e.g. a cationic lipid, virosome or liposome), or a target cell specific binding agent (e.g. a ligand recognized by target cell specific receptor). Preferred complexes must be sufficiently stable in vivo to prevent significant uncoupling prior to internalization by the target cell. However, the complex should be cleavable under appropriate conditions within the cell so that the nucleic acid is released in a functional form.
- “Palindromic sequence” shall mean an inverted repeat (i.e. a sequence such as ABCDEE′D′C′B′A′ in which A and A′ are bases capable of forming the usual Watson-Crick base pairs. In vivo, such sequences may form double stranded structures.
- A “stabilized nucleic acid molecule” shall mean a nucleic acid molecule that is relatively resistant to in vivo degradation (e.g. via an exo- or endo-nuclease). Stabilization can be a function of length or secondary structure. Unmethylated CpG containing nucleic acid molecules that are tens to hundreds of kbs long are relativel resistant to in vivo degradation. For shorter immunostimulatory nucleic acid molecules, secondary structure can stabilize and increase their effect. For example, if the 3′ end of a nucleic acid molecule has self-complementarity to an upstream region, so that it can fold back and form a sort of stem loop sturcture, then the nucleic acid molecule becomes stabilized and therefore exhibits more activity.
- Preferred stabilized nucleic acid molecules of the instant invention have a modified backbone. For use in immune stimulation, especially preferred stabilized nucleic acid molecules are phosphorothioate modified nucleic acid molecules (i.e. at least one of the phosphate oxygens of the nucleic acid molecule is replaced by sulfur). Preferably the phosphate modification occurs at or near the 5′ and/or 3′ end of the nucleic acid molecule. In addition to stabilizing nucleic acid molecules, as reported further herein, phosphorothioate-modified nucleic acid molecules (including phosphorodithioate-modified) can increase the extent of immune stimulation of the nucleic acid molecule, which contains an unmethylated CpG dinucleotide as shown herein. International Patent Application Publication Number: WO 95/26204 entitled “Immune Stimulation By Phosphorothioate Oligonucleotide Analogs” also reports on the non-sequence specific immunostimulatory effect of phosphorothioate modified oligonucleotides. As reported herein, unmethylated CpG containing nucleic acid molecules having a phosphorothioate backbone have been found to preferentially activate B-cell activity, while unmethylated CpG containing nucleic acid molecules having a phosphodiester backbone have been found to preferentially activate monocytic (macrophages, dendritic cells and monocytes) and NK cells. Phosphorothioate CpG oligonucleotides with preferred human motifs are also strong activators of monocytic and NK cells.
- Other stabilized nucleic acid molecules include: nonionic DNA analogs, such as alkyl- and aryl-phosphonates (in which the charged phosphonate oxygen is replaced by an alkyl or aryl group), phosphodiester and alkylphosphotriesters, in which the charged oxygen moiety is alkylated. Nucleic acid molecules which contain a diol, such as tetraethyleneglycol or hexaethyleneglycol, at either or both termini have also been shown to be substantially resistant to nuclease degradation.
- A “subject” shall mean a human or vertebrate animal including a dog, cat, horse, cow, pig, sheep, goat, chicken, monkey, rat, mouse, etc.
- As used herein, the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. Preferred vectors are those capable of autonomous replication and expression of nucleic acids to which they are linked (e.g., an episome). Vectors capable of directing the expression of genes to which they are operatively linked are referred to herein as “expression vectors.” In general, expression vectors of utility in recombinant DNA techniques are often in the form of “plasmids” which refer generally to circular double stranded DNA loops which, in their vector form, are not bound to the chromosome. In the present specification, “plasmid” and “vector” are used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors which serve equivalent functions and which become known in the art subsequently hereto.
- Certain Unmethylated CpG Containing Nucleic Acids Have B Cell Stimulatory Activity as Shown In Vitro and In Vivo
- In the course of investigating the lymphocyte stimulatory effects of two antisense oligonucleotides specific for endogenous retroviral sequences, using protocols described in the attached Examples 1 and 2, it was surprisingly found that two out of twenty-four “controls” (including various scrambled, sense, and mismatch controls for a panel of “antisense” ODN) also mediated B cell activation and IgM secretion, while the other “controls” had no effect.
- Two observations suggested that the mechanism of this B cell activation by the “control” ODN may not involve antisense effects 1) comparison of vertebrate DNA sequences listed in GenBank showed no greater homology than that seen with non-stimulatory ODN and 2) the two controls showed no hybridization to Northern blots with 10 μg of spleen poly A+ RNA. Resynthesis of these ODN on a different synthesizer or extensive purification by polyacrylamide gel electrophoresis or high pressure liquid chromatography gave identical stimulation, eliminating the possibility of an impurity. Similar stimulation was seen using B cells from C3H/HeJ mice, eliminating the possibility that lipopolysaccharide (LPS) contamination could account for the results.
- The fact that two “control” ODN caused B cell activation similar to that of the two “antisense” ODN raised the possibility that all four ODN were stimulating B cells through some non-antisense mechanism involving a sequence motif that was absent in all of the other nonstimulatory control ODN. In comparing these sequences, it was discovered that all of the four stimulatory ODN contained CpG dinucleotides that were in a different sequence context from the nonstimulatory control.
- To determine whether the CpG motif present in the stimulatory ODN was responsible for the observed stimulation, over 300 ODN ranging in length from 5 to 42 bases that contained methylated, unmethylated, or no CpG dinucleotides in various sequence contexts were synthesized. These ODNs, including the two original “controls” (
ODN 1 and 2) and two originally synthesized as “antisense” (ODN 3D and 3M; Krieg, A. M.J. Immunol.143:2448 (1989)), were then examined for in vitro effects on spleen cells (representative sequences are listed in Table 1). Several ODN that contained CpG dinucleotides induced B cell activation and IgM secretion; the magnitude of this stimulation typically could be increased by adding more CpG dinucleotides (Table 1; compareODN 2 to 2a or 3D to 3Da and 3 Db). Stimulation did not appear to result from an antisense mechanism or impurity. ODN caused no detectable proliferation of γδ or other T cell populations. - Mitogenic ODN sequences uniformly became nonstimulatory if the CpG dinucleotide was mutated (Table 1; compare
ODN 1 to 1a; 3D to 3Dc; 3M to 3Ma; and 4 to 4a) or if the cytosine of the CpG dinucleotide was replaced by 5-methylcytosine (Table 1; ODN 1b, 2b, 3Dd, and 3 Mb). Partial methylation of CpG motifs caused a partial loss of stimulatory effect (compare 2a to 2c, Table 1). In contrast, methylation of other cytosines did not reduce ODN activity (ODN 1c, 2d, 3De and 3Mc). These data confirmed that a CpG motif is the essential element present in ODN that activate B cells. - In the course of these studies, it became clear that the bases flanking the CpG dinucleotide played an important role in determining the murine B cell activation induced by an ODN. The optimal stimulatory motif was determined to consist of a CpG flanked by two 5′ purines (preferably a GpA dinucleotide) and two 3′ pyrimidines (preferably a TpT or TpC dinucleotide). Mutations of ODN to bring the CpG motif closer to this ideal improved stimulation (e.g. Table 1, compare
ODN 2 to 2e; 3M to 3Md) while mutations that disturbed the motif reduced stimulation (e.g. Table 1, compare ODN 3D to 3Df; 4 to 4b, 4c and 4d). On the other hand, mutations outside the CpG motif did not reduce stimulation (e.g. Table 1, compareODN 1 to 1d; 3D to 3Dg; 3M to 3Me). For activation of human cells, the best flanking bases are slightly different (See Table 5). - Of those tested, ODNs shorter than 8 bases were non-stimulatory (e.g. Table 1, ODN 4e). Among the forty-eight 8 base ODN tested, the most stimulatory sequence identified was TCAACGTT (ODN 4) which contains the self complementary “palindrome” AACGTT. In further optimizing this motif, it was found that ODN containing Gs at both ends showed increased stimulation, particularly if the ODN were rendered nuclease resistant by phosphorothioate modification of the terminal internucleotide linkages. ODN 1585 (5′
GGGGTCAACGTTGAGGGGGG 3′ (SEQ ID NO:12)), in which the first two and last five internucleotide linkages are phosphorothioate modified caused an average 25.4 fold increase in mouse spleen cell proliferation compared to an average 3.2 fold increase in proliferation induced by ODN 1638, which has the same sequence as ODN 1585 except that the 10 Gs at the two ends are replaced by 10 As. The effect of the G-rich ends is cis; addition of an ODN with poly G ends but no CpG motif to cells along with 1638 gave no increased proliferation. For nucleic acid molecules longer than 8 base pairs, non-palindromic motifs containing an unmethylated CpG were found to be more immunostimulatory. - Other octamer ODN containing a 6 base palindrome with a TpC dinucleotide at the 5′ end were also active (e.g. Table 1, ODN 4b,4c). Other dinucleotides at the 5′ end gave reduced stimulation (e.g. ODN 4f; all sixteen possible dinucleotides were tested). The presence of a 3′ dinucleotide was insufficient to compensate for the lack of a 5′ dinucleotide (e.g. Table 1, ODN 4 g). Disruption of the palindrome eliminated stimulation in octamer ODN (e.g. Table 1, ODN 4 h), but palindromes were not required in longer ODN.
TABLE 1 Oligonucleotide Stimulation of Mouse B Cells ODN Stimulation Index′ production Sequence (5′ to 3′)† 3H Uridine IgM 1 (SEQ ID NO:13) GCTAGACGTTAGCGT 6.1 ± 0.8 17.9 ± 3.6 1a (SEQ. ID NO:4) ......T........ 1.2 ± 0.2 1.7 ± 0.5 1b (SEQ ID NO:14) ......Z........ 1.2 ± 0.1 1.8 ± 0.0 1c (SEQ ID NO:15) ............Z.. 10.3 ± 4.4 9.5 ± 1.8 1d (SEQ ID NO:16) ..AT......GAGC. 13.0 ± 2.3 18.3 ± 7.5 2 (SEQ ID NO:17) ATGGAAGGTCCAGCGTTCTC 2.9 ± 0.2 13.6 ± 2.0 2a (SEQ ID NO:18) ..C..CTC..G......... 7.7 ± 0.8 24.2 ± 3.2 2b (SEQ ID NO:19) ..Z..CTC.ZG..Z...... 1.6 ± 0.5 2.8 ± 2.2 2c (SEQ ID NO:20) ..Z..CTC..G......... 3.1 ± 0.6 7.3 ± 1.4 2d (SEQ ID NO:21) ..C..CTC..G......Z.. 7.4 ± 1.4 27.7 ± 5.4 2e (SEQ ID NO:22) ............A....... 5.6 ± 2.0 ND 3D (SEQ ID NO:23) GAGAACGCTGGACCTTCCAT 4.9 ± 0.5 19.9 ± 3.6 3Da (SEQ ID NO:24) .........C.......... 6.6 ± 1.5 33.9 ± 6.8 3Db (SEQ ID NO:25) .........C.......G.. 10.1 ± 2.8 25.4 ± 0.8 3Dc (SEQ ID NO:26) ...C.A.............. 1.0 ± 0.1 1.2 ± 0.5 3Dd (SEQ ID NO:27) .....Z.............. 1.2 ± 0.2 1.0 ± 0.4 3De (SEQ ID NO:28) .............Z...... 4.4 ± 1.2 18.8 ± 4.4 3Df (SEQ ID NO:29) .......A............ 1.6 ± 0.1 7.7 ± 0.4 3Dg (SEQ ID NO:30) .........CC.G.ACTG.. 6.1 ± 1.5 18.6 ± 1.5 3M (SEQ ID NO:31) TCCATGTCGGTCCTGATGCT 4.1 ± 0.2 23.2 ± 4.9 3Ma (SEQ ID NO:32) ......CT............ 0.9 ± 0.1 1.8 ± 0.5 3Mb (SEQ ID NO:33) .......Z............ 1.3 ± 0.3 1.5 ± 0.6 3Mc (SEQ ID NO:34) ...........Z........ 5.4 ± 1.5 8.5 ± 2.6 3Md (SEQ ID NO:35) ......A..T.......... 17.2 ± 9.4 ND 3Me (SEQ ID NO:36) ...............C..A. 3.6 ± 0.2 14.2 ± 5.2 4 TCAACGTT 6.1 ± 1.4 19.2 ± 5.2 4a ....GC.. 1.1 ± 0.2 1.5 ± 1.1 4b ...GCGC. 4.5. ± 0.2 9.6 ± 3.4 4c ...TCGA. 2.7. ± 1.0 ND 4d ..TT..AA 1.3 ± 0.2 ND 4e -....... 1.3 ± 0.2 1.1 ± 0.5 4f C....... 3.9 ± 1.4 ND 4g --......CT 1.4 ± 0.3 ND 4h .......C 1.2 ± 0.2 ND LPS 7.8 ± 2.5 4.8 ± 1.0
′Stimulation indexes are the means and std. dev. derived from at least 3 separate experiments, and are compared to wells cultured with no added ODN.
ND= not done.
CpG dinucleotides are underlined.
Dots indicate identity; dashes indicate deletions.
Z indicates 5 methyl cytosine. TABLE 2 Identification of the optimal CpG motif for Murine IL-6 production and B cell activation. IL-6 (pg/ml)a ODN SEQUENCE (5′-3′) CH12.LX SPLENIC B CELL SIb Igm (ng/ml)c 512 (SEQ ID NO:37) TCCATGTCGGTCCTGATGCT 1300 ± 106 627 ± 43 5.8 ± 0.3 7315 ± 1324 1637 (SEQ ID NO:38) ......C............. 136 ± 27 46 ± 6 1.7 ± 0.2 770 ± 72 1615 (SEQ ID NO:39) ......G............. 1201 ± 155 850 ± 202 3.7 ± 0.3 3212 ± 617 1614 (SEQ ID NO:40) ......A............. 1533 ± 321 1812 ± 103 10.8 ± 0.6 7558 ± 414 1636 (SEQ ID NO:41) .........A.......... 1181 ± 76 947 ± 132 5.4 ± 0.4 3983 ± 485 1634 (sEQ ID NO:42) .........C.......... 1049 ± 223 1671 ± 175 9.2 ± 0.9 6256 ± 261 1619 (SEQ ID NO:43) .........T.......... 1555 ± 304 2908 ± 129 12.5 ± 1.0 8243 ± 698 1618 (SEQ ID NO:44) ......A..T.......... 2109 ± 291 2596 ± 166 12.9 ± 0.7 10425 ± 674 1639 (SEQ ID NO:45) .....AA..T.......... 1827 ± 83 2012 ± 132 11.5 ± 0.4 9489 ± 103 1707 (SEQ ID NO:46) ......A..TC......... ND 1147 ± 175 4.0 ± 0.2 3534 ± 217 1708 (SEQ ID NO:47) .....CA..TG......... ND 59 ± 3 1.5 ± 0.1 466 ± 109
Dots indicate identity; CpG dinucleotides are underlined; ND = not done
aThe experiment was done at least three times with similar results. The level of IL-6 of unstimulated control cultures of both CH12.LX and splenic B cells was ≦ 10 pg/ml. The IgM level of unstimulated culture was 547 ± 82 ng/ml. CpG dinucleotides are underlined and dots indicate identity.
b[3H] Uridine uptake was indicated as a fold increase (SI: stimulation index) from unstimulated control (2322.67 ± 213.68 cpm). Cells were stimulated with 20 μM of various CpG O-ODN. Data present the mean ± SD of triplicates
cMeasured by ELISA.- The kinetics of lymphocyte activation were investigated using mouse spleen cells. When the cells were pulsed at the same time as ODN addition and harvested just four hours later, there was already a two-fold increase in3H uridine incorporation. Stimulation peaked at 12-48 hours and then decreased. After 24 hours, no intact ODN were detected, perhaps accounting for the subsequent fall in stimulation when purified B cells with or without anti-IgM (at a submitogenic dose) were cultured with CpG ODN, proliferation was found to synergistically increase about 10-fold by the two mitogens in combination after 48 hours. The magnitude of stimulation was concentration dependent and consistently exceeded that of LPS under optimal conditions for both. Oligonucleotides containing a nuclease resistant phosphorothioate backbone were approximately two hundred times more potent than unmodified oligonucleotides.
- Cell cycle analysis was used to determine the proportion of B cells activated by CpG-ODN. CpG-ODN induced cycling in more than 95% of B cells. Splenic B lymphocytes sorted by flow cytometry into CD23-(marginal zone) and CD23+ (follicular) subpopulations were equally responsive to ODN-induced stimulation, as were both resting and activated populations of B cells isolated by fractionation over Percoll gradients. These studies demonstrated that CpG-ODN induce essentially all B cells to enter the cell cycle.
- Immunostimulatory Nucleic Acid Molecules Block Murine B Cell Apoptosis
- Certain B cell lines such as WEHI-231 are induced to undergo growth arrest and/or apoptosis in response to crosslinking of their antigen receptor by anti-IgM (Jakway, J. P. et al., “Growth regulation of the B lymphoma cell line WEHI-231 by anti-immunoglobulin, lipopolysaccharide and other bacterial products”J. Immunol.137: 2225 (1986); Tsubata, T., J. Wu and T. Honjo: B-cell apoptosis induced by antigen receptor crosslinking is blocked by a T-cell signal through CD40.” Nature364: 645 (1993)). WEHI-231 cells are rescued from this growth arrest by certain stimuli such as LPS and by the CD40 ligand. ODN containing the CpG motif were also found to protect WEHI-231 from anti-IgM induced growth arrest, indicating that accessory cell populations are not required for the effect. Subsequent work indicates that CpG ODN induce Bcl-x and myc expression, which may account for the protection from apoptosis. Also, CpG nucleic acids have been found to block apoptosis in human cells. This inhibition of apoptosis is important, since it should enhance and prolong immune activation by CpG DNA.
- Induction of Murine Cvtokine Secretion by CpG motifs in Bacterial DNA or Oligonucleotides.
- As described in Example 9, the amount of IL-6 secreted by spleen cells after CpG DNA stimulation was measured by ELISA. T cell depleted spleen cell cultures rather than whole spleen cells were used for in vitro studies following preliminary studies showing that T cells contribute little or nothing to the IL-6 produced by CpG DNA-stimulated spleen cells. As shown in Table 3, IL-6 production was markedly increased in cells cultured withE. coliDNA but not in cells cultured with calf thymus DNA. To confirm that the increased IL-6 production observed withE. coliDNA was not due to contamination by other bacterial products, the DNA was digested with DNAse prior to analysis. DNAse pretreatment abolished IL-6 production induced byE. coliDNA (Table 3). In addition, spleen cells from LPS-nonresponseive C3H/HeJ mouse produced similar levels of IL-6 in response to bacterial DNA. To analyze whether the IL-6 secretion induced byE. coliDNA was mediateu by the umethylated CpG dinucleotides in bacterial DNA, methylatedE. coliDNA and a panel of synthetic ODN were examined. As shown in Table 3, CpG ODN significantly induced IL-6 secretion (ODN 5a, 5b, 5c) while CpG methylatedE. coliDNA, or ODN containing methylated CpG (ODN 5f) or no CpG (ODN 5d) did not. Changes at sites other than CpG dinucleotides (ODN 5b) or methylation of other cytosines (ODN 5 g) did not reduce the effect of CpG ODN. Methylation of a single CpG in an ODN with three CpGs resulted in a partial reduction in the stimulation (compare ODN 5c to 5e; Table 3).
TABLE 3 Induction of Murine IL-6 secretion by CpG motifs in bacterial DNA or oligonucleotides. Treatment IL-6 (pg/ml) calf thymus ≦10 DNA calf thymus ≦10 DNA + DNase E. coliDNA 1169.5 ± 94.1 E. coliDNA + ≦10 DNase CpG methylated ≦10 E. coliDNA LPS 280.1 ± 17.1 Media (no DNA) ≦10 ODN SEQ ID NO:1 ATGGACTCTCCAGCGTTCTC 1096.4 ± 372.0 5a 5b SEQ ID NO:2 .....AGG....A....... 1124.5 ± 126.2 5c SEQ ID NO:3 ..C.......G......... 1783.0 ± 189.5 5d SEQ ID.NO:4 .....AGG..C..T...... ≦10 5e SEQ ID NO:5 ..C.......G..Z...... 851.1 ± 114.4 5f SEQ ID NO:6 ..Z......ZG..Z...... ≦10 5g SEQ ID NO:7 ..C.......G......Z.. 1862.3 + 87.26
T cell depleted spleen cells from DBA/2 mice were stimulated with phosphodiester modified oligonucleotides (O-ODN) (20 μM), calf thymus DNA (50 μg/ml) orE. coliDNA (50 μg/ml) with or without enzyme treatment, or LPS (10 μg/ml) for 24 hr. Data represent the mean (pg/ml) ± SD of triplicates. CpG dinucleotides are underlined and dots indicate identity. Z indicates 5-methylcytosine. - Identification of the Optimal CpG motif for induction of Murine IL-6 and
- IgM Secretion and B Cell Proliferation.
- To evaluate whether the optimal B cell stimulatory CpG motif was identical with the optimal CpG motif for IL-6 secretion, a panel of ODN in which the bases flanking the CpG dinucleotide were progressively substituted was studied. This ODN panel was analyzed for effects on B cell proliferation, Ig production, and IL-6 secretion, using both splenic B cells and CH12.LX cells. As shown in Table 2, the optimal stimulatory motif is composed of an unmethylated CpG flanked by two 5′ purines and two 3′ pyrimidines. Generally a mutation of either 5′ purine to pyrimidine or 3′ pyrimidine to purine significantly reduced its effects. Changes in 5′ purines to C were especially deleterious, but changes in 5′ purines to T or 3′ pyrimidines to purines had less marked effects. Based on analyses of these and scores of other ODN, it was determined that the optimal CpG motif for induction of IL-6 secretion is TGACGTT, which is identical with the optimal mitogenic and IgM-inducing CpG motif (Table 2). This motif was more stimulatory than any of the palindrome containing sequences studied (1639, 1707 and 1708).
- Titration of Induction of Murine IL-6 Secretion by CpG Motifs.
- Bacterial DNA and CpG ODN induced IL-6 production in T cell depleted murine spleen cells in a dose-dependent manner, but vertebrate DNA and non-CpG ODN did not (
FIG. 1 ). IL-6 production plateaued at approximately 50 μg/ml of bacterial DNA or 40 μM of CpG O-ODN. The maximum levels of IL-6 induced by bacterial DNA and CpG ODN were 1-1.5 ng/ml and 2-4 ng/ml respectively. These levels were significantly greater than those seen after stimulation by LPS (0.35 ng/ml) (FIG. 1A ). To evaluate whether CpG ODN with a nuclease-resistant DNA backbone would also induce IL-6 production, S-ODN were added to T cell depleted murine spleen cells. CpG S-ODN also induced IL-6 production in a dose-dependent manner to approximately the same level as CpG O-ODN while non-CpG S-ODN failed to induce IL-6 (FIG. 1C ). CpG S-ODN at a concentration of 0.05 μM could induce maximal IL-6 production in these cells. This result indicated that the nuclease-resistant DNA backbone modification retains the sequence specific ability of CpG DNA to induce IL-6 secretion and that CpG S-ODN are more than 80-fold more potent than CpG O-ODN in this assay system. - Induction of Murine IL-6 Secretion by CpG DNA In Vivo.
- To evaluate the ability of bacterial DNA and CpG S-ODN to induce IL-6 secretion in vivo, BALB/c mice were injected iv. with 100 μg ofE. coliDNA, calf thymus DNA, or CpG or non-stimulatory S-ODN and bled 2 hr after stimulation. The level of IL-6 in the sera from theE. coliDNA injected group was approximately 13 ng/ml while IL-6 was not detected in the sera from calf thymus DNA or PBS injected groups (Table 4). CpG S-ODN also induced IL-6 secretion in vivo. The IL-6 level in the sera from CpG S-ODN injected groups was approximately 20 ng/ml. In contrast, IL-6 was not detected in the sera from non-stimulatory S-ODN stimulated group (Table 4).
TABLE 4 Secretion of Murine IL-6 induced by CpG DNA stimulation in vivo. Stimulant IL-6 (pg/ml) PBS <50 E. coliDNA 13858 ± 3143 Calf Thymus DNA <50 CpG S-ODN 20715 ± 606 non-CpG S-ODN <50 - Mice (2 mice/group) were i.v. injected with 100 μl of PBS, 200 μg ofE. coliDNA or calf thymus DNA, or 500 μg of CpG S-ODN or non-CpG control S-ODN. Mice were bled 2 hr after injection and 1:10 dilution of each serum was analyzed by IL-6 ELISA. Sensitivity limit of IL-6 ELISA was 5 pg/ml. Sequences of the CpG S-ODN is 5′GCATGACGTTGAGCT3′ (SEQ ID NO:48) and of the non-stimulatory S-ODN is 5′GCTAGATGTTAGCGT3′ (SEQ ID NO:49). Note that although there is a CpG in sequence 48, it is too close to the 3′ end to effect stimulation, as explained herein. Data represent mean±SD of duplicates. The experiment was done at least twice with similar results.
- Kinetics of Murine IL-6 Secretion After Stimulation by C G Motifs In Vivo.
- To evaluate the kinetics of induction of IL-6 secretion by CpG DNA in vivo, BALB/c mice were injected iv. with CpG or control non-CpG S-ODN. Serum IL-6 levels were significantly increased within 1 hr and peaked at 2 hr to a level of approximately 9 ng/ml in the CpG S-ODN injected group (
FIG. 2 ). IL-6 protein in sera rapidly decreased after 4 hr and returned to basal level by 12 hr after stimulation. In contrast to CpG DNA stimulated groups, no significant increase of IL-6 was observed in the sera from the non-stimulatory S-ODN or PBS injected groups (FIG. 2). - Tissue Distribution and Kinetics of IL-6 mRNA Expression Induced by CpG Motifs In Vivo.
- As shown in
FIG. 2 , the level of serum IL-6 increased rapidly after CpG DNA stimulation. To investigate the possible tissue origin of this serum IL-6, and the kinetics of IL-6 gene expression in vivo after CpG DNA stimulation, BALB/c mice were injected iv with CpG or non-CpG S-ODN and RNA was extracted from liver, spleen, thymus, and bone marrow at various time points after stimulation. As shown inFIG. 3A , the level of IL-6 mRNA in liver, spleen, and thymus was increased within 30 min. after injection of CpG S-ODN. The liver IL-6 mRNA peaked at 2 hr post-injection and rapidly decreased and reachedbasal level 8 hr after stimulation (FIG. 3A ). Splenic IL-6 mRNA peaked at 2 hr after stimulation and then gradually decreased (FIG. 3A ). Thymus IL-6 mRNA peaked at 1 hr post-injection and then gradually decreased (FIG. 3A ). IL-6 mRNA was significantly increased in bone marrow within 1 hr after CpG S-ODN injection but then returned to basal level. In response to CpG S-ODN, liver, spleen and thymus showed more substantial increases in IL-6 mRNA expression than the bone marrow. - Patterns of Murine Cytokine Expression Induced by CpG DNA
- In vivo or in whole spleen cells, no significant increase in the protein levels of the following interleukins: IL-2, IL-3, IL-4, IL-5, or IL-10 was detected within the first six hours (Klinman, D. M. et al., (1996)Proc. Natl. Acad. Sci. USA93:2879-2883). However, the level of TNF-α is increased within 30 minutes and the level of IL-6 increased strikingly within 2 hours in the serum of mice injected with CpG ODN. Increased expression of IL-12 and interferon gamma (IFN-γ) mRNA by spleen cells was also detected within the first two hours.
TABLE 5 Induction of human PBMC cytokine secrtetion by CpG oligos ODN Sequence (5′-3′) IL-61 TNF-α1 IFN-γ1 GM-CSF IL-12 512 TCCATGTCGGTCCTGATGCT 500 140 15.6 70 250 SEQ ID NO:37 1637 ......C............. 550 16 7.8 15.6 35 SEQ ID NO:38 1615 ......G............. 600 145 7.8 45 250 SEQ ID NO:39 1614 ......A............. 550 31 0 50 250 SEQ ID NO:40 1636 .........A.......... 325 250 35 40 0 SEQ ID NO:41 1634 .........C.......... 300 400 40 85 200 SEQ ID NO:42 1619 .........T.......... 275 450 200 80 >500 SEQ ID NO:43 1618 ......A..T.......... 300 60 15.6 15.6 62 SEQ ID NO:44 1639 .....AA..T.......... 625 220 15.6 40 60 SEQ ID NO:45 1707 ......A..TC......... 300 70 17 0 0 SEQ ID NO:46 1708 .....CA..TG......... 270 10 17 0 0 SEQ ID NO:47
dots indicate identity; CpG dinucleotides are underlined
1measured by ELISA using Quantikine kits from R&D Systems (pg/ml) Cells were cultured in 10% autologous serum with the indicated oligodeoxynucleotides (12 μg/ml) for 4 hr in the case of TNF-α or 24 hr for the other cytokines before supernatant harvest and assay. Data are presented as the level of cytokine above that in wells with no added oligodeoxynucleotide. - CpG DNA induces cytokine secretion by human PBMC, specifically
- monocytes The same panels of ODN used for studying mouse cytokine expression were used to determine whether human cells also are induced by CpG motifs to express cytokine (or proliferate), and to identify the CpG motif(s) responsible. Oligonucleotide 1619 (GTCGTT) was the best inducer of TNF-α and IFN-γ secretion, and was closely followed by a nearly identical motif in oligonucleotide 1634 (GTCGCT) (Table 5). The motifs in oligodeoxynucleotides 1637 and 1614 (GCCGGT and GACGGT) led to strong IL-6 secretion with relatively little induction of other cytokines. Thus, it appears that human lymphocytes, like murine lymphocytes, secrete cytokines differentially in response to CpG dinucleotides, depending on the surrounding bases. Moreover, the motifs that stimulate murine cells best differ from those that are most effective with human cells. Certain CpG oligodeoxynucleotides are poor at activating human cells (oligodeoxynucleotides 1707, 1708, which contain the palindrome forming sequences GACGTC and CACGTG respectively).
- The cells responding to the DNA appear to be monocytes, since the cytokine secretion is abolished by treatment of the cells with L-leucyl-L-leucine methyl ester-(L-LME), which is selectively toxic to monocytes (but also to cytotoxic T lymphocytes and NK cells), and does not affect B cell Ig secretion (Table 6, and data not shown). The cells surviving L-LME treatment had >95% viability by trypan blue exclusion, indicating that the lack of a cytokine response among these cells did not simply reflect a nonspecific death all all cell types. Cytokine secretion in response toE. coli(EC) DNA requires unmethylated CpG motifs, since it is abolished by methylation of the EC DNA (next to the bottom row, Table 6). LPS contamination of the DNA cannot explain the results since the level of contamination was identical in the native and methylated DNA, and since addition of twice the highest amount of contaminating LPS had no effect (not shown).
TABLE 6 CpG DNA induces cytokine secretion by human PBMC TNF-α IL-6 IFN-γ RANTES DNA (pg/ml)1 (pg/ml) (pg/ml) (pg/ml) EC DNA (50 μg/ml) 900 12,000 700 1560 EC DNA (5 μg/ml) 850 11,000 400 750 EC DNA (0.5 μg/ml) 500 ND 200 0 EC DNA (0.05 μg/ml) 62.5 10,000 15.6 0 EC DNA (50 μg/ml) + L- LME 20 ND ND ND EC DNA (10 μg/ml) Methyl.3 0 5 ND ND CT DNA (50 μg/ml) 0 600 0 0
1Levels of all cytokines were determined by ELISA using Quantikine kits from R&D Systems as described in the previous table. Results are representative using PBMC from different donors.
2Cells were pretreated for 15 min. with L-leucyl-L-leucine methyl ester (M-LME) to determine whether the cytokine production under these conditions was from monocytes (or other L-LME-sensitive cells).
3EC DNA was methylated using 2 U/μg DNA of CpG methylase (New England Biolabs) according to the manufacturer's directions, and methylation confirmed by digestion with Hpa-II and Msp-I. As a negative control, samples were included containing twice the maximal amount of LPS contained in the highest concentration of EC DNA which failed to induce detectable cytokine production under these experimental conditions.
ND = not done - The loss of cytokine production in the PBMC treated with L-LME suggested that monocytes may be responsible for cytokine production in response to CpG DNA. To test this hypothesis more directly, the effects of CpG DNA on highly purified human monocytes and macrophages was tested. As hypothesized, CpG DNA directly activated production of the cytokines IL-6, GM-CSF, and TNF-α by human macrophages, whereas non-CpG DNA did not (Table 7).
TABLE 7 CpG DNA induces cytokine expression in purified human macrophages IL-6 (pg/ml) GM-CSF (pg/ml) TNF-α (pg/ml) Cells alone 0 0 0 CT DNA (50 μg/ml) 0 0 0 EC DNA (50 μg/ml) 2000 15.6 1000 - Biological Role of IL-6 in Inducing Murine IgM Production in Response to CpG Motifs.
- The kinetic studies described above revealed that induction of IL-6 secretion, which occurs within 1 hr post CpG stimulation, precedes IgM secretion. Since the optimal CpG motif for ODN inducing secretion of IL-6 is the same as that for IgM (Table 2), whether the CpG motifs independently induce IgM and IL-6 production or whether the IgM production is dependent on prior IL-6 secretion was examined. The addition of neutralizing anti-IL-6 antibodies inhibited in vitro IgM production mediated by CpG ODN in a dose-dependent manner but a control antibody did not (
FIG. 4A ). In contrast, anti-IL-6 addition-did not affect either the basal level or the CpG-induced B cell proliferation (FIG. 4B ). - Increased Transcriptional Activity of the IL-6 Promoter in Response to CpG DNA.
- The increased level of IL-6 mRNA and protein after CpG DNA stimulation could result from transcriptional or post-transcriptional regulation. To determine if the transcriptional activity of the IL-6 promoter was upregulated in B cells cultured with CpG ODN, a murine B cell line, WEHI-231, which produces IL-6 in response to CpG DNA, was transfected with an IL-6 promoter-CAT construct (pIL-6/CAT) (Pottratz, S. T. et al., 17B-estradiol) inhibits expression of human interleukin-6-promoter-reporter constructs by a receptor-dependent mechanism.J. Clin. Invest.93:944). CAT assays were performed after stimulation with various concentrations of CpG or non-CpG ODN. As shown in
FIG. 5 , CpG ODN induced increased CAT activity in dose-dependent manner while non-CpG ODN failed to induce CAT activity. This confirms that CpG induces the transcriptional activity of the IL-6 promoter. - Dependence of B Cell Activation by CpG ODN on the Number of 5′ and 3′ Phosphorothioate Internucleotide Linkages.
- To determine whether partial sulfur modification of the ODN backbone would be sufficient to enhance B cell activation, the effects of a series of ODN with the same sequence, but with differing numbers of S internucleotide linkages at the 5′ and 3′ ends were tested. Based on previous studies of nuclease degradation of ODN, it was determined that at least two phosphorothioate linkages at the 5′ end of ODN were required to provide optimal protection of the ODN from degradation by intracellular exo- and endo-nucleases. Only chimeric ODN containing two 5′ phosphorothioate-modified linkages, and a variable number of 3′ modified linkages were therefore examined.
- The lymphocyte stimulating effects of these ODN were tested at three concentrations (3.3, 10, and 30 μM) by measuring the total levels of RNA synthesis (by3H uridine incorporation) or DNA synthesis (by3H thymidine incorporation) in treated spleen cell cultures (Example 10). O-ODN (0/0 phosphorothioate modifications) bearing a CpG motif caused no spleen cell stimulation unless added to the cultures at concentrations of at least 10 μM (Example 10). However, when this sequence was modified with two S linkages at the 5′ end and at least three S linkages at the 3′ end, significant stimulation was seen at a dose of 3.3 μM. At this low dose, the level of stimulation showed a progressive increase as the number of 3′ modified bases was increased, until this reached or exceeded six, at which point the stimulation index began to decline. In general, the optimal number of 3′ S linkages for spleen cell stimulation was five. At all three concentrations tested in these experiments, the S-ODN was less stimulatory than the optimal chimeric compounds.
- Dependence of CpG-Mediated Lymphocyte Activation on the Type of Backbone Modification.
- Phosphorothioate modified ODN (S-ODN) are far more nuclease resistant than phosphodiester modified ODN (O-ODN). Thus, the increased immune stimulation caused by S-ODN and S—O-ODN (i.e. chimeric phosphorothioate ODN in which the central linkages are phosphodiester, but the two 5′ and five 3′ linkages are phosphorothioate modified) compared to O-ODN may result from the nuclease resistance of the former. To determine the role of ODN nuclease resistance in immune stimulation by CpG ODN, the stimulatory effects of chimeric ODN in which the 5′ and 3′ ends were rendered nuclease resistant with either methylphosphonate (MP-), methylphosphorothioate (MPS-), phosphorothioate (S-), or phosphorodithioate (S2-) internucleotide linkages were tested (Example 10). These studies showed that despite their nuclease resistance, MP-O-ODN were actually less immune stimulatory than O-ODN. However, combining the MP and S modifications by replacing both
nonbridging 0 molecules with 5′ and 3′ MPS internucleotide linkages restored immune stimulation to a slightly higher level than that triggered by O-ODN. - S—O-ODN were far more stimulatory than O-ODN, and were even more stimulatory than S-ODN, at least at concentrations above 3.3 μM. At concentrations below 3 μM, the S-ODN with the 3M sequence was more potent than the corresponding S—O-ODN, while the S-ODN with the 3D sequence was less potent than the corresponding S—O-ODN (Example 10). In comparing the stimulatory CpG motifs of these two sequences, it was noted that the 3D sequence is a perfect match for the stimulatory motif in that the CpG is flanked by two 5′ purines and two 3′ pyrimidines. However, the bases immediately flanking the CpG in ODN 3D are not optimal; it has a 5′ pyrimidine and a 3′ purine. Based on further testing, it was found that the sequence requirement for immune stimulation is more stringent for S-ODN than for S—O— or O-ODN. S-ODN with poor matches to the optimal CpG motif cause little or no lymphocyte activation (e.g. Sequence 3D). However, S-ODN with good matches to the motif, most critically at the positions immediately flanking the CpG, are more potent than the corresponding S—O-ODN (e.g. Sequence 3M,
Sequences 4 and 6), even though at higher concentrations (greater than 3 μM) the peak effect from the S—O-ODN is greater (Example 10). - S2—O-ODN were remarkably stimulatory, and caused substantially greater lymphocyte activation than the corresponding S-ODN or S—O-ODN at every tested concentration.
- The increased B cell stimulation seen with CpG ODN bearing S or S2 substitutions could result from any or all of the following effects: nuclease resistance, increased cellular uptake, increased protein binding, and altered intracellular localization. However, nuclease resistance can not be the only explanation, since the MP-O-ODN were actually less stimulatory than the O-ODN with CpG motifs. Prior studies have shown that ODN uptake by lymphocytes is markedly affected by the backbone chemistry (Zhao et al., (1993) Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. (Antisense Research and
Development 3, 53-66; Zhao et al., (1994) Stage specific oligonucleotide uptake in murine bone marrow B cell precursors. Blood 84, 3660-3666.) The highest cell membrane binding and uptake was seen with S-ODN, followed by S—O-ODN, O-ODN, and MP-ODN. This differential uptake correlates well with the degree of immune stimulation. - Unmethylated CpG Containing Oligos Have NK Cell Stimulatory Activity
- Experiments were conducted to determine whether CpG containing oligonucleotides stimulated the activity of natural killer (NK) cells in addition to B cells. As shown in Table 8, a marked induction of NK activity among spleen cells cultured with
CpG ODN 1 and 3Dd was observed. In contrast, there was relatively no induction in effectors that had been treated with non-CpG control ODN.TABLE 8 Induction Of NK Activity By CpG Oligodeoxynucleotides (ODN) % YAC-1 % 2C11 Specific Lysis* Specific Lysis Effector:Target Effector:Target ODN 50:1 100:1 50:1 100:1 None −1.1 −1.4 15.3 16.6 1 16.1 24.5 38.7 47.2 3Dd 17.1 27.0 37.0 40.0 non-CpG ODN −1.6 −1.7 14.8 15.4 - Induction of NK activity by DNA containing CpG motifs, but not by non-CpG DNA.
- Bacterial DNA cultured for 18 hrs. at 37° C. and then assayed for killing of K562 (human) or Yac-1 (mouse) target cells induced NK lytic activity in both mouse spleen cells depleted of B cells and human PBMC, but vertebrate DNA did not (Table 9). To determine whether the stimulatory activity of bacterial DNA may be a consequence of its increased level of unmethylated CpG dinucleotides, the activating properties of more than 50 synthetic ODN containing unmethylated, methylated, or no CpG dinucleotides was tested. The results, summarized in Table 9, demonstrate that synthetic ODN can stimulate significant NK activity, as long as they contain at least one unmethylated CpG dinucleotide. No difference was observed in the stimulatory effects of ODN in which the CpG was within a palindrome (such as ODN 1585, which contains the palindrome AACGTT) from those ODN without palindromes (such as 1613 or 1619), with the caveat that optimal stimulation was generally seen with ODN in which the CpG was flanked by two 5′ purines or a 5′ GpT dinucleotide and two 3′ pyrimidines. Kinetic experiments demonstrated that NK activity peaked around 18 hrs. after addition of the ODN. The data indicates that the murine NK response is dependent on the prior activation of monocytes by CpG DNA, leading to the production of IL-12, TNF-α, and IFN-α/β (Example 11).
TABLE 9 Induction of NK Activity by DNA Containing CpG Motifs but not by Non-CpG DNA LU/106 DNA or Cytokine Added Mouse Cells Human Cells Expt. 1 None 0.00 0.00 IL-2 16.68 15.82 E. coli DNA - 7.23 5.05 Calf thymus DNA 0.00 0.00 Expt. 2 None 0.00 3.28 1585 gggGTCAACGTTGAgggggG (SEQ ID NO:12) 7.38 17.98 1629 .......gtc.......... (SEQ ID NO:50) 0.00 4.4 Expt. 3 None 0.00 1613 GCTAGACGTTAGTGT (SEQ ID NO:51) 5.22 1769 .......z....... (SEQ ID NO:52) 0.02 ND 1619 TCCATGTCGTTCCTGATGCT (SEQ ID NO:43) 3.35 1765 .......z............ (SEQ ID NO:53) 0.11
CpG dinucleotides in ODN sequences are indicated by underlying; Z indicates methylcytosine. Lower case letters indicate nuclease resistant phosphorothioate modified internucleotide linkages which, in titration experiments, were more than 20 times as potent as non-modified ODN, depending on the flanking bases. Poly G ends (g) were used in some ODN, because they significantly increase the level of ODN uptake. - From all of these studies, a more complete understanding of the immune effects of CpG DNA has been developed, which is summarized in
FIG. 6 . - Identification of B Cell and Monocyte/NK Cell-Specific Oligonucleotides
- As shown in
FIG. 6 , CpG DNA can directly activate highly purified B cells and monocytic cells. There are many similarities in the mechanism through which CpG DNA activates these cell types. For example, both require NFκB activation as explained further below. - In further studies of different immune effects of CpG DNA, it was found that there is more than one type of CpG motif. Specifically, oligo 1668, with the best mouse B cell motif, is a strong inducer of both B cell and natural killer (NK) cell activation, while oligo 1758 is a weak B cell activator, but still induces excellent NK responses (Table 10).
TABLE 10 Different CpG motifs stimulate optimal murine B cell and NK activation B cell NK ODN Sequence activation1 activation2 1668 TCCATGACGTTCCTGATGCT 42,849 2.52 (SEQ ID NO:54) 1758 TCTCCCAGCGTGCGCCAT 1,747 6.66 (SEQ ID NO:55) NONE 367 0.00
CpG dinucleotides are underlined; oligonucleotides were synthesized with phosphorothioate modified backbones to improve their nuclease resistance.
1Measured by3H thymidine incorporation after 48 hr culture with oligodeoxynucleotides at a 200 nM concentration as described in Example 1.
2Measured in lytic units. - Teleological Basis of Immunostimulatory. Nucleic Acids
- Vertebrate DNA is highly methylated and CpG dinucleotides are underrepresented. However, the stimulatory CpG motif is common in microbial genomic DNA, but quite rare in vertebrate DNA. In addition, bacterial DNA has been reported to induce B cell proliferation and immunoglobulin (Ig) production, while mammalian DNA does not (Messina, J. P. et al.,J. Immunol.147:1759 (1991)). Experiments further described in Example 3, in which methylation of bacterial DNA with CpG methylase was found to abolish mitogenicity, demonstrates that the difference in CpG status is the cause of B cell stimulation by bacterial DNA. This data supports the following conclusion: that unmethylated CpG dinucleotides present within bacterial DNA are responsible for the stimulatory effects of bacterial DNA.
- Teleologically, it appears likely that lymphocyte activation by the CpG motif represents an immune defense mechanism that can thereby distinguish bacterial from host DNA. Host DNA, which would commonly be present in many anatomic regions and areas of inflammation due to apoptosis (cell death), would generally induce little or no lymphocyte activation due to CpG suppression and methylation. However, the presence of bacterial DNA containing unmethylated CpG motifs can cause lymphocyte activation precisely in infected anatomic regions, where it is beneficial. This novel activation pathway provides a rapid alternative to T cell dependent antigen specific B cell activation. Since the CpG pathway synergizes with B cell activation through the antigen receptor, B cells bearing antigen receptor specific for bacterial antigens would receive one activation signal through cell membrane Ig and a second signal from bacterial DNA, and would therefore tend to be preferentially activated. The interrelationship of this pathway with other pathways of B cell activation provide a physiologic mechanism employing a polyclonal antigen to induce antigen-specific responses.
- However, it is likely that B cell activation would not be totally nonspecific. B cells bearing antigen receptors specific for bacterial products could receive one activation signal through cell membrane Ig, and a second from bacterial DNA, thereby more vigorously triggering antigen specific immune responses. As with other immune defense mechanisms, the response to bacterial DNA could have undesirable consequences in some settings. For example, autoimmune responses to self antigens would also tend to be preferentially triggered by bacterial infections, since autoantigens could also provide a second activation signal to autoreactive B cells triggered by bacterial DNA. Indeed the induction of autoimmunity by bacterial infections is a common clinical observance. For example, the autoimmune disease systemic lupus erythematosus, which is: i) characterized by the production of anti-DNA antibodies; ii) induced by drugs which inhibit DNA methyltransferase (Cornacchia, E. J. et al.,J. Clin. Invest.92:38 (1993)); and iii) associated with reduced DNA methylation (Richardson, B. L. et al.,Arth. Rheum35:647 (1992)), is likely triggered at least in part by activation of DNA-specific B cells through stimulatory signals provided by CpG motifs, as well as by binding of bacterial DNA to antigen receptors.
- Further, sepsis, which is characterized by high morbidity and mortality due to massive and nonspecific activation of the immune system may be initiated by bacterial DNA and other products released from dying bacteria that reach concentrations sufficient to directly activate many lymphocytes. Further evidence of the role of CpG DNA in the sepsis syndrome is described in Cowdery, J., et. al., (1996)The Journal of Immunology156:4570-4575.
- Proposed Mechanisms of Action
- Unlike antigens that trigger B cells through their surface Ig receptor, CpG-ODN did not induce any detectable Ca2+ flux, changes in protein tyrosine phosphorylation, or
IP 3 generation. Flow cytometry with FITC-conjugated ODN with or without a CpG motif was performed as described in Zhao, Q et al., (Antisense Research and Development3:53-66 (1993)), and showed equivalent membrane binding, cellular uptake, efflux, and intracellular localization. This suggests that there may not be cell membrane proteins specific for CpG ODN. Rather than acting through the cell membrane, that data suggests that unmethylated CpG containing oligonucleotides require cell uptake for activity: ODN covalently linked to a solid Teflon support were nonstimulatory, as were biotinylated ODN immobilized on either avidin beads or avidin coated petri dishes. CpG ODN conjugated to either FITC or biotin retained full mitogenic properties, indicating no steric hindrance. - Recent data indicate the involvement of the transcription factor NFκB as a direct or indirect mediator of the CpG effect. For example, within 15 minutes of treating B cells or monocytes with CpG DNA, the level of NFkB binding activity is increased (
FIG. 7 ). However, it is not increased by DNA that does not contain CpG motifs. In addition, it was found that two different inhibitors of NFκB activation, PDTC and gliotoxin, completely block the lymphocyte stimulation by CpG DNA as measured by B cell proliferation or monocytic cell cytokine secretion, suggesting that NFκB activation is required for both cell types. - There are several possible mechanisms through which NFκB can be activated. These include through activation of various protein kinases, or through the generation of reactive oxygen species. No evidence for protein kinase activation induced immediately after CpG DNA treatment of B cells or monocytic cells have been found, and inhibitors of protein kinase A, protein kinase C, and protein tyrosine kinases had no effects on the CpG induced activation. However, CpG DNA causes a rapid induction of the production of reactive oxygen species in both B cells and monocytic cells, as detected by the sensitive fluorescent dye dihydrorhodamine 123 as described in Royall, J. A., and Ischiropoulos, H. (Archives of Biochemistry and Biophysics302:348-355 (1993)). Moreover, inhibitors of the generation of these reactive oxygen species completely block the induction of NFκB and the later induction of cell proliferation and cytokine secretion by CpG DNA.
- Working backwards, the next question was how CpG DNA leads to the generation of reactive oxygen species so quickly. Previous studies by the inventors demonstrated that oligonucleotides and plasmid or bacterial DNA are taken up by cells into endosomes. These endosomes rapidly become acidified inside the cell. To determine whether this acidification step may be important in the mechanism through which CpG DNA activates reactive oxygen species, the acidification step was blocked with specific inhibitors of endosome acidification including chloroquine, monensin, and bafilomycin, which work through different mechanisms.
FIG. 8A shows the results from a flow cytometry study using mouse B cells with the dihydrorhodamine 123 dye to determine levels of reactive oxygen species. The dye only sample in Panel A of the figure shows the background level of cells positive for the dye at 28.6%. As expected, this level of reactive oxygen species was greatly increased to 80% in the cells treated for 20 minutes with PMA and ionomycin, a positive control (Panel B). The cells treated with the CpG oligo also showed an increase in the level of reactive oxygen species such that more than 50% of the cells became positive (Panel D). However, cells treated with an oligonucleotide with the identical sequence except that the CpG was switched did not show this significant increase in the level of reactive oxygen species (Panel E). - In the presence of chloroquine, the results are very different (
FIG. 8B ). Chloroquine slightly lowers the background level of reactive oxygen species in the cells such that the untreated cells in Panel A have only 4.3% that are positive. Chloroquine completely abolishes the induction of reactive oxygen species in the cells treated with CpG DNA (Panel B) but does not reduce the level of reactive oxygen species in the cells treated with PMA and ionomycin (Panel E). This demonstrates that unlike the PMA plus ionomycin, the generation of reactive oxygen species following treatment of B cells with CpG DNA requires that the DNA undergo an acidification step in the endosomes. This is a completely novel mechanism of leukocyte activation. Chloroquine, monensin, and bafilomycin also appear to block the activation of NFκB by CpG DNA as well as the subsequent proliferation and induction of cytokine secretion. - Presumably, there is a protein in or near the endosomes that specifically recognizes DNA containing CpG motifs and leads to the generation of reactive oxygen species. To detect any protein in the cell cytoplasm that may specifically bind CpG DNA, we used electrophoretic mobility shift assays (EMSA) with 5′ radioactively labeled oligonucleotides with or without CpG motifs. A band was found that appears to represent a protein binding specifically to single stranded oligonucleotides that have CpG motifs, but not to oligonucleotides that lack CpG motifs or to oligonucleotides in which the CpG motif has been methylated. This binding activity is blocked if excess of oligonucleotides that contain the NFκB binding site was added. This suggests that an NFκB or related protein is a component of a protein or protein complex that binds the stimulatory CpG oligonucleotides.
- No activation of CREB/ATF proteins was found at time points where NFκB was strongly activated. These data therefore do not provide proof that NFκB proteins actually bind to the CpG nucleic acids, but rather that the proteins are required in some way for the CpG activity. It is possible that a CREB/ATF or related protein may interact in some way with NFκB proteins or other proteins thus explaining the remarkable similarity in the binding motifs for CREB proteins and the optimal CpG motif. It remains possible that the oligos bind to a CREB/ATF or related protein, and that this leads to NFκB activation.
- Alternatively, it is very possible that the CpG nucleic acids may bind to one of the TRAF proteins that bind to the cytoplasmic region of CD40 and mediate NFκB activation when CD40 is cross-linked. Examples of such TRAF proteins include TRAF-2 and TRAF-5.
- Method for Making Immunostimulatory Nucleic Acids
- For use in the instant invention, nucleic acids can be synthesized de novo using any of a number of procedures well known in the art. For example, the β-cyanoethyl phosphoramidite method (S. L. Beaucage and M. H. Caruthers, (1981)Tet. Let.22:1859); nucleoside H-phosphonate method (Garegg et al., (1986)Tet. Let.27: 4051-4054; Froehler et al., (1986)Nucl. Acid. Res.14: 5399-5407; Garegg et al., (1986)Tet. Let.27: 4055-4058, Gaffney et al., (1988)Tet. Let.29:2619-2622). These chemistries can be performed by a variety of automated oligonucleotide synthesizers available in the market. Alternatively, oligonucleotides can be prepared from existing nucleic acid sequences (e.g. genomic or cDNA) using known techniques, such as those employing restriction enzymes, exonucleases or endonucleases.
- For use in vivo, nucleic acids are preferably relatively resistant to degradation (e.g. via endo- and exo-nucleases). Secondary structures, such as stem loops, can stabilize nucleic acids against degradation. Alternatively, nucleic acid stabilization can be accomplished via phosphate backbone modifications. A preferred stabilized nucleic acid has at least a partial phosphorothioate modified backbone. Phosphorothioates may be synthesized using automated techniques employing either phosphoramidate or H-phosphonate chemistries. Aryl- and alkyl-phosphonates can be made e.g. as described in U.S. Pat. No. 4,469,863; and alkylphosphotriesters (in which the charged oxygen moiety is alkylated as described in U.S. Pat. No. 5,023,243 and European Patent No. 092,574) can be prepared by automated solid phase synthesis using commercially available reagents. Methods for making other DNA backbone modifications and substitutions have been described (Uhlmann, E. and Peyman, A. (1990)Chem. Rev.90:544; Goodchild, J. (1990)Bioconjugate Chem.1: 165). 2′-O-methyl nucleic acids with CpG motifs also cause immune activation, as do ethoxy-modified CpG nucleic acids. In fact, no backbone modifications have been found that completely abolish the CpG effect, although it is greatly reduced by replacing the C with a 5-methyl C.
- For administration in vivo, nucleic acids may be associated with a molecule that results in higher affinity binding to target cell (e.g. B-cell, monocytic cell and natural killer (NK) cell) surfaces and/or increased cellular uptake by target cells to form a “nucleic acid delivery complex”. Nucleic acids can be ionically, or covalently associated with appropriate molecules using techniques which are well known in the art. A variety of coupling or crosslinking agents can be used e.g. protein A, carbodiimide, and N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP). Nucleic acids can alternatively be encapsulated in liposomes or virosomes using well-known techniques.
- Therapeutic Uses of Immunostimulatory Nucleic Acid Molecules
- Based on their immunostimulatory properties, nucleic acid molecules containing at least one unmethylated CpG dinucleotide can be administered to a subject in vivo to treat an “immune system deficiency”. Alternatively, nucleic acid molecules containing at least one unmethylated CpG dinucleotide can be contacted with lymphocytes (e.g. B cells, monocytic cells or NK cells) obtained from a subject having an immune system deficiency ex vivo and activated lymphocytes can then be reimplanted in the subject.
- As reported herein, in response to unmethylated CpG containing nucleic acid molecules, an increased number of spleen cells secrete IL-6, IL-12, IFN-γ, IFN-α, IFN-β, IL-1, IL-3, IL-10, TNF-α, TNF-β, GM-CSF, RANTES, and probably others. The increased IL-6 expression was found to occur in B cells, CD4+ T cells and monocytic cells.
- Immunostimulatory nucleic acid molecules can also be administered to a subject in conjunction with a vaccine to boost a subject's immune system and thereby effect a better response from the vaccine. Preferably the immunostimulatory nucleic acid molecule is administered slightly before or at the same time as the vaccine. A conventional adjuvant may optionally be administered in conjunction with the vaccine, which is minimally comprised of an antigen, as the conventional adjuvant may further improve the vaccination by enhancing antigen absorption.
- When the vaccine is a DNA vaccine at least two components determine its efficacy. First, the antigen encoded by the vaccine determines the specificity of the immune response. Second, if the backbone of the plasmid contains CpG motifs, it functions as an adjuvant for the vaccine. Thus, CpG DNA acts as an effective “danger signal” and causes the immune system to respond vigorously to new antigens in the area. This mode of action presumably results primarily from the stimulatory local effects of CpG DNA on dendritic cells and other “professional” antigen presenting cells, as well as from the costimulatory effects on B cells.
- Immunostimulatory oligonucleotides and unmethylated CpG containing vaccines, which directly activate lymphocytes and co-stimulate an antigen-specific response, are fundamentally different from conventional adjuvants (e.g. aluminum precipitates), which are inert when injected alone and are thought to work through absorbing the antigen and thereby presenting it more effectively to immune cells. Further, conventional adjuvants only work for certain antigens, only induce an antibody (humoral) immune response (Th2), and are very poor at inducing cellular immune responses (Th1). For many pathogens, the humoral response contributes little to protection, and can even be detrimental.
- In addition, an immunostimulatory oligonucleotide can be administered prior to, along with or after administration of a chemotherapy or immunotherapy to increase the responsiveness of the malignant cells to subsequent chemotherapy or immunotherapy or to speed the recovery of the bone marrow through induction of restorative cytokines such as GM-CSF. CpG nucleic acids also increase natural killer cell lytic activity and antibody dependent cellular cytotoxicity (ADCC). Induction of NK activity and ADCC may likewise be beneficial in cancer immunotherapy, alone or in conjunction with other treatments.
- Another use of the described immunostimulatory nucleic acid molecules is in desensitization therapy for allergies, which are generally caused by IgE antibody generation against harmless allergens. The cytokines that are induced by unmethylated CpG nucleic acids are predominantly of a class called “Th1” which is most marked by a cellular immune response and is associated with IL-12 and IFN-γ. The other major type of immune response is termed a Th2 immune response, which is associated with more of an antibody immune response and with the production of IL-4, IL-5 and IL-10. In general, it appears that allergic diseases are mediated by Th2 type immune responses and autoimmune diseases by Th1 immune response. Based on the ability of the immunostimulatory nucleic acid molecules to shift the immune response in a subject from a Th2 (which is associated with production of IgE antibodies and allergy) to a Th1 response (which is protective against allergic reactions), an effective dose of an immunostimulatory nucleic acid (or a vector containing a nucleic acid) alone or in conjunction with an allergen can be administered to a subject to treat or prevent an allergy.
- Nucleic acids containing unmethylated CpG motifs may also have significant therapeutic utility in the treatment of asthma. Th2 cytokines, especially IL-4 and IL-5 are elevated in the airways of asthmatic subjects. These cytokines promote important aspects of the asthmatic inflammatory response, including IgE isotype switching, eosinophil chemotaxis and activation and mast cell growth. Th1 cytokines, especially FN-γ and IL-12, can suppress the formation of Th2 clones and production of Th2 cytokines.
- As described in detail in the following Example 12, oligonucleotides containing an unmethylated CpG motif (i.e. TCCATGACGTTCCTGACGTT; SEQ ID NO:10), but not a control oligonucleotide (TCCATGAGCTTCCTGAGTCT; SEQ ID NO: 11) prevented the development of an inflammatory cellular infiltrate and eosinophilia in a murine model of asthma. Furthermore, the suppression of eosinophilic inflammation was associated with a suppression of a Th2 response and induction of a Th1 response.
- For use in therapy, an effective amount of an appropriate immunostimulatory nucleic acid molecule alone or formulated as a delivery complex can be administered to a subject by any mode allowing the oligonucleotide to be taken up by the appropriate target cells (e.g., B-cells and monocytic cells). Preferred routes of administration include oral and transdermal (e.g., via a patch). Examples of other routes of administration include injection (subcutaneous, intravenous, parenteral, intraperitoneal, intrathecal, etc.). The injection can be in a bolus or a continuous infusion.
- A nucleic acid alone or as a nucleic acid delivery complex can be administered in conjunction with a pharmaceutically acceptable carrier. As used herein, the phrase “pharmaceutically acceptable carrier” is intended to include substances that can be coadministered with a nucleic acid or a nucleic acid delivery complex and allows the nucleic acid to perform its indicated function. Examples of such carriers include solutions, solvents, dispersion media, delay agents, emulsions and the like. The use of such media for pharmaceutically active substances are well known in the art. Any other conventional carrier suitable for use with the nucleic acids falls within the scope of the instant invention.
- The language “effective amount” of a nucleic acid molecule refers to the amount necessary or sufficient to realize a desired biologic effect. For example, an effective amount of a nucleic acid containing at least one unmethylated CpG for treating an immune system deficiency could be that amount necessary to eliminate a tumor, cancer, or bacterial, viral or fungal infection. An effective amount for use as a vaccine adjuvant could be that amount useful for boosting a subjects immune response to a vaccine. An “effective amount” for treating asthma can be that amount useful for redirecting a Th2 type of immune response that is associated with asthma to a Th1 type of response. The effective amount for any particular application can vary depending on such factors as the disease or condition being treated, the particular nucleic acid being administered (e.g. the number of unmethylated CpG motifs or their location in the nucleic acid), the size of the subject, or the severity of the disease or condition. One of ordinary skill in the art can empirically determine the effective amount of a particular oligonucleotide without necessitating undue experimentation.
- The present invention is further illustrated by the following Examples which in no way should be construed as further limiting. The entire contents of all of the references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated by reference.
- B cells were purified from spleens obtained from 6-12 wk old specific pathogen free DBA/2 or BXSB mice (bred in the University of Iowa animal care facility; no substantial strain differences were noted) that were depleted of T cells with anti-Thy-1.2 and complement and centrifugation over lympholyte M (Cedarlane Laboratories, Hornby, Ontario, Canada) (“B cells”). B cells contained fewer than 1% CD4+ or CD8+ cells. 8×104B cells were dispensed in triplicate into 96 well microtiter plates in 100 μl RPMI containing 10% FBS (heat inactivated to 65° C. for 30 min.), 50 μM 2-mercaptoethanol, 100 U/ml penicillin, 100 ug/ml streptomycin, and 2 mM L-glutamate. 20 μM ODN were added at the start of culture for 20 h at 37° C., cells pulsed with 1 μCi of3H uridine, and harvested and counted 4 hr later. Ig secreting B cells were enumerated using the ELISA spot assay after culture of whole spleen cells with ODN at 20 μM for 48 hr. Data, reported in Table 1, represent the stimulation index compared to cells cultured without ODN.3H thymidine incorporation assays showed similar results, but with some nonspecific inhibition by thymidine released from degraded ODN (Matson. S and A. M. Krieg (1992) Nonspecific suppression of3H-thymidine incorporation by control oligonucleotides.Antisense Research and Development2:325).
- Single cell suspensions from the spleens of freshly killed mice were treated with anti-Thyl, anti-CD4, and anti-CD8 and complement by the method of Leibson et al.,J. Exp. Med.154:1681 (1981)). Resting B cells (<O2% T cell contamination) were isolated from the 63-70% band of a discontinuous Percoll gradient by the procedure of DeFranco et al,J. Exp. Med.155:1523 (1982). These were cultured as described above in 30 μM ODN or 20 μg/ml LPS for 48 hr. The number of B cells actively secreting IgM was maximal at this time point, as determined by ELIspot assay (Klinman, D. M. et al.J. Immunol.144:506 (1990)). In that assay, B cells were incubated for 6 hrs on anti-Ig coated microtiter plates. The Ig they produced (>99% IgM) was detected using phosphatase-labelled anti-Ig (Southern Biotechnology Associated, Birmingham, Ala.). The antibodies produced by individual B cells were visualized by addition of BCIP (Sigma Chemical Co., St. Louis Mo.) which forms an insoluble blue precipitate in the presence of phosphatase. The dilution of cells producing 20-40 spots/well was used to determine the total number of antibody-secreting B cells/sample. All assays were performed in triplicate (data reported in Table 1). In some experiments, culture supernatants were assayed for IgM by ELISA, and showed similar increases in response to CpG-ODN.
- DBA/2 B cells were cultured with no DNA or 50 μg/ml of a)Micrococcus lysodeikticus; b) NZB/N mouse spleen; and c) NFS/N mouse spleen genomic DNAs for 48 hours, then pulsed with3H thymidine for 4 hours prior to cell harvest. Duplicate DNA samples were digested with DNAse I for 30 minutes at 37 C prior to addition to cell cultures.E coliDNA also induced an 8.8 fold increase in the number of IgM secreting B cells by 48 hours using the ELISA-spot assay.
- DBA/2 B cells were cultured with either no additive, 50 μg/ml LPS or the
ODN 1; 1 a; 4; or 4a at 20 uM. Cells were cultured and harvested at 4, 8, 24 and 48 hours. BXSB cells were cultured as in Example 1 with 5, 10, 20, 40 or 80 μM ofODN 1; 1a; 4; or 4a or LPS. In this experiment, wells with no ODN had 3833 cpm. Each experiment was performed at least three times with similar results. Standard deviations of the triplicate wells were <5%. - 10×106C57BL/6 spleen cells were cultured in two ml RPMI (supplemented as described for Example 1) with or without 40 μM CpG or non-CpG ODN for forty-eight hours. Cells were washed, and then used as effector cells in a short term51Cr release assay with YAC-1 and 2C11, two NK sensitive target cell lines (Ballas, Z. K. et al. (1993)J. Immunol.150:17). Effector cells were added at various concentrations to 104 51Cr-labeled target cells in V-bottom microtiter plates in 0.2 ml, and incubated in 5% CO2for 4 hr. at 37° C. Plates were then centrifuged, and an aliquot of the supernatant counted for radioactivity. Percent specific lysis was determined by calculating the ratio of the5, Cr released in the presence of effector cells minus the51Cr released when the target cells are cultured alone, over the total counts released after cell lysis in 2% acetic acid minus the51Cr cpm released when the cells are cultured alone.
- Mice were weighed and injected IP with 0.25 ml of sterile PBS or the indicated phophorothioate ODN dissolved in PBS. Twenty four hours later, spleen cells were harvested, washed, and stained for flow cytometry using phycoerythrin conjugated 6B2 to gate on B cells in conjunction with biotin conjugated anti Ly-6A/E or anti-Iad(Pharmingen, San Diego, Calif.) or anti-Bla-1 (Hardy, R. R. et al.,J. Exp. Med.159:1169 (1984). Two mice were studied for each condition and analyzed individually.
- B cells were cultured with phosphorothioate ODN with the sequence of control ODN 1 a or the
CpG ODN 1 d and 3 Db and then either pulsed after 20 hr with3H uridine or after 44 hr with3H thymidine before harvesting and determining cpm. - WEHI-231 cells (5×104/well) were cultured for 1 hr. at 37 C in the presence or absence of LPS or the control ODN 1a or the
CpG ODN 1d and 3 Db before addition of anti-IgM (1μ/ml). Cells were cultured for a further 20 hr. before a 4 hr. pulse with 2 μCi/well3H thymidine. In this experiment, cells with no ODN or anti-IgM gave 90.4×103cpm of3H thymidine incorporation by addition of anti-IgM. The phosphodiester ODN shown in Table 1 gave similar protection, though with some nonspecific suppression due to ODN degradation. Each experiment was repeated at least 3 times with similar results. - DBA/2 female mice (2 mos. old) were injected IP with 500 μg CpG or control phosphorothioate ODN. At various time points after injection, the mice were bled. Two mice were studied for each time point. IL-6 was measured by Elisa, and IL-6 concentration was calculated by comparison to a standard curve generated using recombinant IL-6. The sensitivity of the assay was 10 pg/ml. Levels were undetectable after 8 hr.
- Mice and cell lines. DBA/2, BALB/c, and C3H/HeJ mice at 5-10 wk of age were used as a source of lymphocytes. All mice were obtained from The Jackson Laboratory (Bar Harbor, Me.), and bred and maintained under specific pathogen-free conditions in the University of Iowa Animal Care Unit. The mouse B cell line CH12.LX was kindly provided by Dr. G. Bishop (University of Iowa, Iowa City).
- Cell preparation. Mice were killed by cervical dislocation. Single cell suspensions were prepared aseptically from the spleens from mice. T cell depleted mouse splenocytes were prepared by using anti-Thy-1.2 and complement and centrifugation over lympholyte M (Cedarlane Laboratories, Homby, Ontario, Canada) as described (Krieg, A. M. et al., (1989) A role for endogenous retroviral sequences in the regulation of lymphocyte activation.J. Immunol.143:2448).
- ODN and DNA. Phosphodiester oligonucleotides (O-ODN) and the backbone modified phosphorothioate oligonucleotides (S-ODN) were obtained from the DNA Core facility at the University of Iowa or from Operon Technologies (Alameda, Calif.).E. coliDNA (Strain B) and calf thymus DNA were purchased from Sigma (St. Louis, Mo.). All DNA and ODN were purified by extraction with phenol:chloroform:isoamyl alcohol (25:24:1) and/or ethanol precipitation.E. coliand calf thymus DNA were single stranded prior to use by boiling for 10 min. followed by cooling on ice for 5 min. For some experiments,E. coliand calf thymus DNA were digested with DNAse I (2U/μg of DNA) at 37° C. for 2 hr in 1×SSC with 5 mM MgCl2. To methylate the cytosine in CpG dinucleotides inE. coliDNA,E. coliDNA was treated with CpG methylase (M. SssI; 2U/μg of DNA) in
NEBuffer 2 supplemented with 160 μM S-adenosyl methionine and incubated overnight at 37° C. Methylated DNA was purified as above. Efficiency of methylation was confirmed by Hpa II digestion followed by analysis by gel electrophoresis. All enzymes were purchased from New England Biolabs (Beverly, Mass.). LPS level in ODN was less than 12.5 ng/mg andE. coliand calf thymus DNA contained less than 2.5 ng of LPS/mg of DNA byLimulusassay. - Cell Culture. All cells were cultured at 37° C. in a 5% CO2humidified incubator maintained in RPMI-1640 supplemented with 10% (v/v) heat inactivated fetal calf serum (FCS), 1.5 mM L-glutamine, 50 μg/ml), CpG or non-CpG phosphodiester ODN (O-ODN) (20 μM), phosphorothioate ODN (S-ODN) (0.5 μM), orE. colior calf thymus DNA (50 μg/ml) at 37° C. for 24 hr. (for IL-6 production) or 5 days (for IgM production). Concentrations of stimulants were chosen based on preliminary studies with titrations. In some cases, cells were treated with CpG O-ODN along with various concentrations (1-10 μg/ml) of neutralizing rat IgG1 antibody against murine IL-6 (hybridoma MP5-20F3) or control rat IgG1 mAb toE. coliβ-galactosidase (hybridoma GL113; ATCC, Rockville, Md.) (20) for 5 days. At the end of incubation, culture supernatant fractions were analyzed by ELISA as below.
- In vivo induction of IL-6 and IgM. BALB/c mice were injected intravenously (iv) with PBS, calf thymus DNA (200 μg/100 μl PBS/mouse),E. coliDNA (200 μg/100 μl PBS/mouse), or CpG or non-CpG S-ODN (200 μg/100 μl PBS/mouse). Mice (two/group) were bled by retroorbital puncture and sacrificed by cervical dislocation at various time points. Liver, spleen, thymus, and bone marrow were removed and RNA was prepared from those organs using RNAzol B (Tel-Test, Friendswood, Tex.) according to the manufacturers protocol.
- ELISA. Flat-bottomed
Immun 1 plates (Dynatech Laboratories, Inc., Chantilly, Va.) were coated with 100 μl/well of anti-mouse IL-6 mAb (MP5-20F3) (2 μg/ml) or anti-mouse IgM μ-chain specific (5 μg/ml; Sigma, St. Louis, Mo.) in carbonate-bicarbonate, pH 9.6 buffer (15 nM Na2CO3, 35 mM NaHCO3) overnight at 4° C. The plates were then washed with TPBS (0.5 mM MgCl2o6H2O, 2.68 mM KCl, 1.47 mM KH2PO4, 0.14 M NaCl, 6.6 mM K2HPO4, 0.5% Tween 20) and blocked with 10% FCS in TPBS for 2 hr at room temperature and then washed again. Culture supernatants, mouse sera, recombinant mouse IL-6 (Pharmingen, San Diego, Calif.) or purified mouse IgM (Calbiochem, San Diego, Calif.) were appropriately diluted in 10% FCS and incubated in triplicate wells for 6 hr at room temperature. The plates were washed and 100 μl/well of biotinylated rat anti-mouse IL-6 monoclonal antibodies (MP5-32C11, Pharmingen, San Diego, Calif.) (1 μg/ml in 10% FCS) or biotinylated anti-mouse Ig (Sigma, St. Louis, Mo.) were added and incubated for 45 min. at room temperature following washes with TPBS. Horseradish peroxidase (HRP) conjugated avidin (Bio-rad Laboratories, Hercules, Calif.) at 1:4000 dilution in 10% FCS (100 μl/well) was added and incubated at room temperature for 30 min. The plates were washed and developed with o-phenylendiamine dihydrochloride (OPD; Sigma, St. Louis Mo.) 0.05 M phosphate-citrate buffer, pH 5.0, for 30 min. The reaction was stopped with 0.67 N H2SO4and plates were read on a microplate reader (Cambridge Technology, Inc., Watertown, Mass.) at 490-600 nm. The results are shown inFIGS. 1 and 2 . - RT-PCR. A sense primer, an antisense primer, and an internal oligonucleotide probe for IL-6 were synthesized using published sequences (Montgomery, R. A. and M. S. Dallman (1991), Analysis of cytokine gene expression during fetal thymic ontogeny using the polymerase chain reaction (J. Immunol.) 147:554). cDNA synthesis and IL-6 PCR was done essentially as described by Montgomery and Dallman (Montgomery, R. A. and M. S. Dallman (1991), Analysis of cytokine gene expression during fetal thymic ontogeny using the polymerase chain reaction (J. Immunol.) 147:554) using RT-PCR reagents from Perkin-Elmer Corp. (Hayward, Calif.). Samples were analyzed after 30 cycles of amplification by gel electrophoresis followed by unblot analysis (Stoye, J. P. et al., (11991) DNA hybridization in dried gels with fragmented probes: an improvement over blotting techniques,Techniques3:123). Briefly, the gel was hybridized at room temperature for 30 min. in denaturation buffer (0.05 M NaOH, 1.5M NaCl) followed by incubation for 30 min. in renaturation buffer (1.5 M NaCl, 1 M Tris, pH 8) and a 30 min. wash in double distilled water. The gel was dried and prehybridized at 47° C. for 2 hr. hybridization buffer (5×SSPE, 0.1% SDS) containing 10 μg/ml denatured salmon sperm DNA. The gel was hybridized with 2×106cpm/ml γ-[32P]ATP end-labeled internal oligonucleotide probe for IL-6 (5′CATTTCCACGATTTCCCA3′) SEQ ID NO:56) overnight at 47° C., washed 4 times (2×SSC, 0.2% SDS) at room temperature and autoradiographed. The results are shown in
FIG. 3 . - Cell Proliferation assay. DBA/2 mice spleen B cells (5×104cells/100 μl/well) were treated with media, CpG or non-CpG S-ODN (0.5 μM) or O-ODN (20 μM) for 24 hr at 37° C. Cells were pulsed for the last four hr. with either [3H] Thymidine or [3H] Uridine (1 μCi/well). Amounts of [3H] incorporated were measured using Liquid Scintillation Analyzer (Packard Instrument Co., Downers Grove, Ill.).
- Transfections and CAT assays. WEHI-231 cells (107cells) were electroporated with 20 μg of control or human IL-6 promoter-CAT construct (kindly provided by S. Manolagas, Univ. of Arkansas) (Pottratz, S. T. et al., (1994) 17B-estradiol inhibits expression of human interleukin-6 promoter-reporter constructs by a receptor-dependent mechanism.J. Clin. Invest.93:944) at 250 mV and 960 μF. Cells were stimulated with various concentrations or CpG or non-CpG ODN after electroporation. Chloramphenicol acetyltransferase (CAT) activity was measured by a solution assay (Seed, B. and J. Y. Sheen (1988) A single phase-extraction assay for chloramphenicol acetyl transferase activity.Gene76:271) 16 hr. after transfection. The results are presented in
FIG. 5 . - ODN were synthesized on an Applied Biosystems Inc. (Foster City, Calif.) model 380A, 380B, or 394 DNA synthesizer using standard procedures (Beacage and Caruthers (1981) Deoxynucleoside phosphoramidites—A new class of key intermediates for deoxypolynucleotide synthesis. Tetrahedron Letters 22, 1859-1862.). Phosphodiester ODN were synthesized using standard beta-cyanoethyl phosphoramidite chemistry. Phosphorothioate linkages were introduced by oxidizing the phosphite linkage with elemental sulfur instead of the standard iodine oxidation. The four common nucleoside phosphoramidites were purchased from Applied Biosystems. All phosphodiester and thioate containing ODN were deprotected by treatment with concentrated ammonia at 55° C. for 12 hours. The ODN were purified by gel exclusion chromatography and lyophilized to dryness prior to use. Phosphorodithioate linkages were introduced by using deoxynucleoside S-(b-benzoylmercaptoethyl)pyrrolidino thiophosphoramidites (Wiesler, W. T. et al., (1993) In Methods in Molecular Biology: Protocols for Oligonucleotides and Analogs- Synthesis and Properties, Agrawal, S. (ed.), Humana Press, 191-206.). Dithioate containing ODN were deprotected by treatment with concentrated ammonia at 55° C. for 12 hours followed by reverse phase HPLC purification.
- In order to synthesize oligomers containing methylphosphonothioates or methylphosphonates as well as phosphodiesters at any desired internucleotide linkage, two different synthetic cycles were used. The major synthetic differences in the two cycles are the coupling reagent where dialkylaminomethylnucleoside phosphines are used and the oxidation reagents in the case of methylphosphonothioates. In order to synthesize either derivative, the condensation time has been increased for the dialkylaminomethylnucleoside phosphines due to the slower kinetics of coupling (Jager and Engels, (1984) Synthesis of deoxynucleoside methylphosphonates via a phosphonamidite approach.
Tetrahedron Letters 24, 1437-1440). After the coupling step has been completed, the methylphosphinodiester is treated with the sulfurizing reagent (5% elemental sulfur, 100 millimolar N,N-diamethylaminopyridine in carbon disulfide/pyridine/triethylamine), four consecutive times for 450 seconds each to produce methylphosphonothioates. To produce methylphosphonate linkages, the methylphosphinodiester is treated with standard oxidizing reagent (0.1 M iodine in tetrahydrofuran/2,6-lutidine/water). - The silica gel bound oligomer was treated with distilled pyridine/concentrated ammonia, 1:1, (v/v) for four days at 4 degrees centigrade. The supernatant was dried in vacuo, dissolved in water and chromatographed on a G50/50 Sephadex column.
- As used herein, O-ODN refers to ODN which are phosphodiester; S-ODN are completely phosphorothioate modified; S—O-ODN are chimeric ODN in which the central linkages are phosphodiester, but the two 5′ and five 3′ linkages are phosphorothioate modified; S2—O-ODN are chimeric ODN in which the central linkages are phosphodiester, but the two 5′ and five 3′ linkages are phosphorodithioate modified; and MP-O-ODN are chimeric ODN in which the central linkages are phosphodiester, but the two 5′ and five 3′ linkages are methylphosphonate modified. The ODN sequences studied (with CpG dinucleotides indicated by underlining) include:
3D (5′ GAGAACGCTGGACCTTCCAT),; (SEQ ID NO:14) 3M (5′ TCCATGTCGGTCCTGATGCT),; (SEQ ID NO:22) 5 (5′ GGCGTTATTCCTGACTCGCC),; (SEQ ID NO:57) and 6 (5′ CCTACGTTGTATGCGCCCAGCT),. (SEQ ID NO:58) - These sequences are representative of literally hundreds of CpG and non-CpG ODN that have been tested in the course of these studies.
- Mice. DBA/2, or BXSB mice obtained from The Jackson Laboratory (Bar Harbor, Me.), and maintained under specific pathogen-free conditions were used as a source of lymphocytes at 5-10 wk of age with essentially identical results.
- Cell proliferation assay. For cell proliferation assays, mouse spleen cells (5×104cells/100 μl/well) were cultured at 37° C. in a 5% CO2humidified incubator in RPMI-1640 supplemented with 10% (v/v) heat inactivated fetal calf serum (heated to 65° C. for experiments with O-ODN, or 56° C. for experiments using only modified ODN), 1.5 μM L-glutamine, 50 μM 2-mercaptoethanol, 100 U/ml penicillin and 100 μg/ml streptomycin for 24 hr or 48 hr as indicated. 1 μCi of3H uridine or thymidine (as indicated) was added to each well, and the cells harvested after an additional 4 hours of culture. Filters were counted by scintillation counting. Standard deviations of the triplicate wells were <5%. The results are presented in
FIGS. 6-8 . - Phosphodiester ODN were purchased from Operon Technologies (Alameda, Calif.). Phosphorothioate ODN were purchased from the DNA core facility, University of Iowa, or from The Midland Certified Reagent Company (Midland Tex.).E. coli(strain B) DNA and calf thymus DNA were purchased from Sigma (St. Louis, Mo.). All DNA and ODN were purified by extraction with phenol:chloroform:isoamyl alcohol (25:24:1) and/or ethanol precipitation. The LPS level in ODN was less than 12.5 ng/mg andE. coliand calf thymus DNA contained less than 2.5 ng of LPS/mg of DNA byLimulusassay.
- Virus-free, 4-6 week old, DBA/2, C57BL/6 (B6) and congenitally athymic BALB/C mice were obtained on contract through the Veterans Affairs from the National Cancer Institute (Bethesda, Md.). C57BL/6 SCID mice were bred in the SPF barrier facility at the University of Iowa Animal Care Unit.
- Human peripheral mononuclear blood leukocytes (PBMC) were obtained as previously described (Ballas, Z. K. et al., (1990)J. Allergy Clin. Immunol.85:453; Ballas, Z. K. and W. Rasmussen (1990)J. Immunol.145:1039; Ballas, Z. K. and W. Rasmussen (1993)J. Immunol.150;17). Human or murine cells were cultured at 5×106/well, at 37° C. in a 5% CO2humidified atmosphere in 24-well plates (Ballas, Z. K. et al., (1990)J. Allergy Clin. Immunol.85:453; Ballas, Z. K. and W. Rasmussen (1990)J Immunol145:1039; and Ballas, Z. K. and W. Rasmussen (1993)J. Immunol,150:17), with medium alone or with CpG or non-CpG ODN at the indicated concentrations, or withE. colior calf thymus (50 μg/ml) at 37° C. for 24 hr. All cultures were harvested at 18 hr. and the cells were used as effectors in a standard 4 hr.51Cr-release assay against K562 (human) or YAC-1 (mouse) target cells as previously described. For calculation of lytic units (LU), 1 LU was defined as the number of cells needed to effect 30% specific lysis. Where indicated, neutralizing antibodies against IFN-β (Lee Biomolecular, San Diego, Calif.) or IL-12 (C15.1, C15.6, C17.8, and C17.15; provided by Dr. Giorgio Trinchieri, The Wistar Institute, Philadelphia, Pa.) or their isotype controls were added at the initiation of cultures to a concentration of 10 μg/ml. For anti-IL-12 addition, 10 μg of each of the 4 MAB (or isotype controls) were added simultaneously. Recombinant human IL-2 was used at a concentration of 100 U/ml.
- 6-8 week old C56BL/6 mice (from The Jackson Laboratory, Bar Harbor, Me.) were immunized with 5,000Schistosoma mansonieggs by intraperitoneal (i.p.) injection on
days 0 and 7.Schistosoma mansonieggs contain an antigen (Schistosoma mansoniegg antigen (SEA)) that induces a Th2 immune response (e.g. production of IgE antibody). IgE antibody production is known to be an important cause of asthma. - The immunized mice were then treated with oligonucleotides (30% g in 200 μl saline by i.p. injection), which either contained an unmethylated CpG motif (i.e. TCCATGACGTTCCTGACGTT; SEQ ID NO.10) or did not (i.e. control, TCCATGAGCTTCCTGAGTCT; SEQ ID NO.11). Soluble SEA (10 μg in 25 μl of saline) was administered by intranasal instillation on days 14 and 21. Saline was used as a control.
- Mice were sacrificed at various times after airway challenge. Whole lung lavage was performed to harvest airway and alveolar inflammatory cells. Cytokine levels were measured from lavage fluid by ELISA. RNA was isolated from whole lung for Northern analysis and RT-PCR studies using CsCl gradients. Lungs were inflated and perfused with 4% paraformaldehyde for histologic examination.
FIG. 9 shows that when the mice are initially injected with the eggs i.p., and then inhale the egg antigen (open circle), many inflammatory cells are present in the lungs. However, when the mice are initially given a nucleic acid containing an unmethylated CpG motif along with the eggs, the inflammatory cells in the lung are not increased by subsequent inhalation of the egg antigen (open triangles).FIG. 10 shows that the same results are obtained when only eosinophils present in the lung lavage are measured. Eosinophils are the type of inflammatory cell most closely associated with asthma.FIG. 11 shows that when the mice are treated with a control oligo at the time of the initial exposure to the egg, there is little effect on the subsequent influx of eosinophils into the lungs after inhalation of SEA. Thus, when mice inhale the eggs on days 14 or 21, they develop an acute inflammatory response in the lungs. However, giving a CpG oligo along with the eggs at the time of initial antigen exposure ondays 0 and 7 almost completely abolishes the increase in eosinophils when the mice inhale the egg antigen on day 14.FIG. 12 shows that very low doses of oligonucleotide (<10 g) can give this protection.FIG. 13 shows that the resultant inflammatory response correlates with the levels of the Th2 cytokine IL-4 in the lung.FIG. 14 shows that administration of an oligonucleotide containing an unmethylated CpG motif can actually redirect the cytokine response of the lung to production of II-2, indicating a Th1 type of immune response.FIG. 15 shows that administration of an oligonucleotide containing an unmethylated CpG motif can also redirect the cytokine response of the lung to production of IFN-γ, indicating a Th1 type of immune response.- Human PBMC were prepared from whole blood by standard centrifugation over ficoll hypaque. Cells (5×105/ml) were cultured in 10% autologous serum in 96 well microtiter plates with CpG or control oligodeoxynucleotides (24 μg/ml for phosphodiester oligonucleotides; 6 μg/ml for nuclease resistant phosphorothioate oligonucleotides) for 4 hr in the case of TNF-α or 24 hr. for the other cytokines before supernatant harvest and assay, measured by ELISA using Quantikine kits or reagents from R&D Systems (pg/ml) or cytokine ELISA kits from Biosource (for IL-12 assay). Assays were performed as per the manufacturer's instructions. Data are presented in Table 6 as the level of cytokine above that in wells with no added oligodeoxynucleotide.
- Equivalents
- Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents of the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
Claims (14)
1-18. (canceled)
19. An immunostimulatory oligonucleotide of 8-100 nucleotides in length, including a sequence of the following formula:
5′ X1X2CGX2X43′
wherein C is unmethylated, wherein X1, X2, X3, and X4are nucleotides, and wherein the immunostimulatory oligonucleotide includes a phosphate backbone modification, wherein the immunostimulatory oligonucleotide promotes a Th1 type response and a cytotoxic lymphocyte response in a subject when administered in conjunction with an antigen.
20. The immunostimulatory oligonucleotide ofclaim 19 , wherein X1and X2are purines and X3and X4are pyrimidines.
21. The immunostimulatory oligonucleotide ofclaim 20 , wherein the phosphate backbone modification is selected from the group consisting of a phosphorothioate and a phosphorodithioate modification.
22. The nucleic acid vector ofclaim 19 , wherein the sequence is AACGTT.
23. A method for promoting a Th1 immune response and a cytotoxic lymphocyte response in a subject comprising administering to a subject an antigen and an immunostimulatory oligonucleotide of 8-100 nucleotides in length having a sequence of the following formula:
5′ X1X2CGX3X43′
wherein C is unmethylated, wherein X1, X2, X3, and X4are nucleotides, whereby the immunostimulatory oligonucleotide promotes a Th1 immune response and a cytotoxic lymphocyte response in the subject.
24. The method according toclaim 23 , wherein the sequence is not a palindrome.
25. The method according toclaim 23 , wherein the immunostimulatory oligonucleotide has a phosphate backbone modification.
26. The method according toclaim 24 , wherein the immunostimulatory oligonucleotide has a phosphate backbone modification.
27. The method according toclaim 25 , wherein the phosphate backbone modification is selected from the group consisting of a phosphorothioate and a phosphorodithioate modification.
28. The method according toclaim 26 , wherein the phosphate backbone modification is selected from the group consisting of a phosphorothioate and a phosphorodithioate modification.
29. The method according toclaim 23 , wherein wherein X1and X2are purines and X3and X4are pyrimidines.
30. The method according toclaim 29 , wherein the sequence is AACGTT.
31. An immunostimulatory oligonucleotide of 8-100 nucleotides in length, including a sequence of the following formula:
5′ X1X2CGX3X43′
wherein C is unmethylated, wherein X1, X2, X3, and X4are nucleotides, and wherein the immunostimulatory oligonucleotide includes a phosphate backbone modification.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/956,745US20050239732A1 (en) | 1994-07-15 | 2004-10-01 | Immunostimulatory nucleic acid molecules |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27635894A | 1994-07-15 | 1994-07-15 | |
| US08/386,063US6194388B1 (en) | 1994-07-15 | 1995-02-07 | Immunomodulatory oligonucleotides |
| US08/738,652US6207646B1 (en) | 1994-07-15 | 1996-10-30 | Immunostimulatory nucleic acid molecules |
| US09/818,918US20030050261A1 (en) | 1994-07-15 | 2001-03-27 | Immunostimulatory nucleic acid molecules |
| US10/956,745US20050239732A1 (en) | 1994-07-15 | 2004-10-01 | Immunostimulatory nucleic acid molecules |
Related Parent Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US27635894AContinuation-In-Part | 1994-07-15 | 1994-07-15 | |
| US09/818,918ContinuationUS20030050261A1 (en) | 1994-07-15 | 2001-03-27 | Immunostimulatory nucleic acid molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20050239732A1true US20050239732A1 (en) | 2005-10-27 |
Family
ID=24968901
Family Applications (32)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/738,652Expired - LifetimeUS6207646B1 (en) | 1994-07-15 | 1996-10-30 | Immunostimulatory nucleic acid molecules |
| US09/818,918AbandonedUS20030050261A1 (en) | 1994-07-15 | 2001-03-27 | Immunostimulatory nucleic acid molecules |
| US10/435,656AbandonedUS20050277604A1 (en) | 1994-07-15 | 2003-05-09 | Immunostimulatory nucleic acid molecules |
| US10/613,916AbandonedUS20050070491A1 (en) | 1994-07-15 | 2003-07-03 | Immunostimulatory nucleic acid molecules |
| US10/679,710AbandonedUS20040147468A1 (en) | 1994-07-15 | 2003-10-03 | Immunostimulatory nucleic acid molecules |
| US10/743,625AbandonedUS20040132685A1 (en) | 1994-07-15 | 2003-12-22 | Immunostimulatory nucleic acid |
| US10/769,282Expired - Fee RelatedUS7674777B2 (en) | 1994-07-15 | 2004-01-30 | Immunostimulatory nucleic acid molecules |
| US10/817,165AbandonedUS20040198688A1 (en) | 1994-07-15 | 2004-04-02 | Immunostimulatory nucleic acid molecules |
| US10/831,647Expired - Fee RelatedUS7402572B2 (en) | 1994-07-15 | 2004-04-23 | Immunostimulatory nucleic acid molecules |
| US10/847,642AbandonedUS20050004061A1 (en) | 1994-07-15 | 2004-05-17 | Immunostimulatory nucleic acid molecules |
| US10/877,407AbandonedUS20040229835A1 (en) | 1994-07-15 | 2004-06-24 | Immunostimulatory nucleic acid molecules |
| US10/884,852AbandonedUS20050059625A1 (en) | 1994-07-15 | 2004-07-02 | Immunostimulatory nucleic acid molecules |
| US10/888,785Expired - Fee RelatedUS7517861B2 (en) | 1994-07-15 | 2004-07-09 | Immunostimulatory nucleic acid molecules |
| US10/888,449AbandonedUS20050049215A1 (en) | 1994-07-15 | 2004-07-09 | Immunostimulatory nucleic acid molecules |
| US10/894,862Expired - Fee RelatedUS8058249B2 (en) | 1994-07-15 | 2004-07-16 | Immunostimulatory nucleic acid molecules |
| US10/894,657AbandonedUS20050054602A1 (en) | 1994-07-15 | 2004-07-16 | Immunostimulatory nucleic acid molecules |
| US10/928,762AbandonedUS20050123523A1 (en) | 1994-07-15 | 2004-08-26 | Immunostimulatory nucleic acid molecules |
| US10/956,494Expired - Fee RelatedUS7879810B2 (en) | 1994-07-15 | 2004-10-01 | Immunostimulatory nucleic acid molecules |
| US10/956,745AbandonedUS20050239732A1 (en) | 1994-07-15 | 2004-10-01 | Immunostimulatory nucleic acid molecules |
| US10/972,301AbandonedUS20050215500A1 (en) | 1994-07-15 | 2004-10-22 | Immunostimulatory nucleic acid molecules |
| US10/987,146AbandonedUS20050148537A1 (en) | 1994-07-15 | 2004-11-12 | Immunostimulatory nucleic acid molecules |
| US11/031,460Expired - Fee RelatedUS8158592B2 (en) | 1994-07-15 | 2005-01-07 | Immunostimulatory nucleic acid molecules |
| US11/036,527Expired - Fee RelatedUS7723022B2 (en) | 1994-07-15 | 2005-01-14 | Immunostimulatory nucleic acid molecules |
| US11/067,587Expired - Fee RelatedUS8129351B2 (en) | 1994-07-15 | 2005-02-25 | Immunostimulatory nucleic acid molecules |
| US11/134,918AbandonedUS20050267064A1 (en) | 1994-07-15 | 2005-05-23 | Immunostimulatory nucleic acid molecules |
| US11/296,572AbandonedUS20060089326A1 (en) | 1994-07-15 | 2005-12-07 | Immunostimulatory nucleic acid molecules |
| US11/503,483Expired - Fee RelatedUS7723500B2 (en) | 1994-07-15 | 2006-08-11 | Immunostimulatory nucleic acid molecules |
| US11/526,197AbandonedUS20070078104A1 (en) | 1994-07-15 | 2006-09-22 | Immunostimulatory nucleic acid molecules |
| US11/598,207Expired - Fee RelatedUS8258106B2 (en) | 1994-07-15 | 2006-11-10 | Immunostimulatory nucleic acid molecules |
| US11/810,353AbandonedUS20080026011A1 (en) | 1994-07-15 | 2007-06-05 | Immunostimulatory nucleic acid molecules |
| US12/248,493AbandonedUS20090202575A1 (en) | 1994-07-15 | 2008-10-09 | Immunostimulatory nucleic acid molecules |
| US12/383,824Expired - Fee RelatedUS7888327B2 (en) | 1994-07-15 | 2009-03-25 | Methods of using immunostimulatory nucleic acid molecules to treat allergic conditions |
Family Applications Before (18)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/738,652Expired - LifetimeUS6207646B1 (en) | 1994-07-15 | 1996-10-30 | Immunostimulatory nucleic acid molecules |
| US09/818,918AbandonedUS20030050261A1 (en) | 1994-07-15 | 2001-03-27 | Immunostimulatory nucleic acid molecules |
| US10/435,656AbandonedUS20050277604A1 (en) | 1994-07-15 | 2003-05-09 | Immunostimulatory nucleic acid molecules |
| US10/613,916AbandonedUS20050070491A1 (en) | 1994-07-15 | 2003-07-03 | Immunostimulatory nucleic acid molecules |
| US10/679,710AbandonedUS20040147468A1 (en) | 1994-07-15 | 2003-10-03 | Immunostimulatory nucleic acid molecules |
| US10/743,625AbandonedUS20040132685A1 (en) | 1994-07-15 | 2003-12-22 | Immunostimulatory nucleic acid |
| US10/769,282Expired - Fee RelatedUS7674777B2 (en) | 1994-07-15 | 2004-01-30 | Immunostimulatory nucleic acid molecules |
| US10/817,165AbandonedUS20040198688A1 (en) | 1994-07-15 | 2004-04-02 | Immunostimulatory nucleic acid molecules |
| US10/831,647Expired - Fee RelatedUS7402572B2 (en) | 1994-07-15 | 2004-04-23 | Immunostimulatory nucleic acid molecules |
| US10/847,642AbandonedUS20050004061A1 (en) | 1994-07-15 | 2004-05-17 | Immunostimulatory nucleic acid molecules |
| US10/877,407AbandonedUS20040229835A1 (en) | 1994-07-15 | 2004-06-24 | Immunostimulatory nucleic acid molecules |
| US10/884,852AbandonedUS20050059625A1 (en) | 1994-07-15 | 2004-07-02 | Immunostimulatory nucleic acid molecules |
| US10/888,785Expired - Fee RelatedUS7517861B2 (en) | 1994-07-15 | 2004-07-09 | Immunostimulatory nucleic acid molecules |
| US10/888,449AbandonedUS20050049215A1 (en) | 1994-07-15 | 2004-07-09 | Immunostimulatory nucleic acid molecules |
| US10/894,862Expired - Fee RelatedUS8058249B2 (en) | 1994-07-15 | 2004-07-16 | Immunostimulatory nucleic acid molecules |
| US10/894,657AbandonedUS20050054602A1 (en) | 1994-07-15 | 2004-07-16 | Immunostimulatory nucleic acid molecules |
| US10/928,762AbandonedUS20050123523A1 (en) | 1994-07-15 | 2004-08-26 | Immunostimulatory nucleic acid molecules |
| US10/956,494Expired - Fee RelatedUS7879810B2 (en) | 1994-07-15 | 2004-10-01 | Immunostimulatory nucleic acid molecules |
Family Applications After (13)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/972,301AbandonedUS20050215500A1 (en) | 1994-07-15 | 2004-10-22 | Immunostimulatory nucleic acid molecules |
| US10/987,146AbandonedUS20050148537A1 (en) | 1994-07-15 | 2004-11-12 | Immunostimulatory nucleic acid molecules |
| US11/031,460Expired - Fee RelatedUS8158592B2 (en) | 1994-07-15 | 2005-01-07 | Immunostimulatory nucleic acid molecules |
| US11/036,527Expired - Fee RelatedUS7723022B2 (en) | 1994-07-15 | 2005-01-14 | Immunostimulatory nucleic acid molecules |
| US11/067,587Expired - Fee RelatedUS8129351B2 (en) | 1994-07-15 | 2005-02-25 | Immunostimulatory nucleic acid molecules |
| US11/134,918AbandonedUS20050267064A1 (en) | 1994-07-15 | 2005-05-23 | Immunostimulatory nucleic acid molecules |
| US11/296,572AbandonedUS20060089326A1 (en) | 1994-07-15 | 2005-12-07 | Immunostimulatory nucleic acid molecules |
| US11/503,483Expired - Fee RelatedUS7723500B2 (en) | 1994-07-15 | 2006-08-11 | Immunostimulatory nucleic acid molecules |
| US11/526,197AbandonedUS20070078104A1 (en) | 1994-07-15 | 2006-09-22 | Immunostimulatory nucleic acid molecules |
| US11/598,207Expired - Fee RelatedUS8258106B2 (en) | 1994-07-15 | 2006-11-10 | Immunostimulatory nucleic acid molecules |
| US11/810,353AbandonedUS20080026011A1 (en) | 1994-07-15 | 2007-06-05 | Immunostimulatory nucleic acid molecules |
| US12/248,493AbandonedUS20090202575A1 (en) | 1994-07-15 | 2008-10-09 | Immunostimulatory nucleic acid molecules |
| US12/383,824Expired - Fee RelatedUS7888327B2 (en) | 1994-07-15 | 2009-03-25 | Methods of using immunostimulatory nucleic acid molecules to treat allergic conditions |
Country Status (14)
| Country | Link |
|---|---|
| US (32) | US6207646B1 (en) |
| EP (5) | EP2322615A1 (en) |
| JP (5) | JP2001503267A (en) |
| KR (1) | KR100689942B1 (en) |
| CN (2) | CN101265285A (en) |
| AT (1) | ATE332966T1 (en) |
| AU (3) | AU5242498A (en) |
| CA (1) | CA2270345C (en) |
| DE (1) | DE69736331T2 (en) |
| DK (1) | DK0948510T3 (en) |
| ES (2) | ES2268736T3 (en) |
| NZ (1) | NZ335397A (en) |
| PT (1) | PT948510E (en) |
| WO (1) | WO1998018810A1 (en) |
Cited By (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030026801A1 (en)* | 2000-06-22 | 2003-02-06 | George Weiner | Methods for enhancing antibody-induced cell lysis and treating cancer |
| US20040087534A1 (en)* | 1994-07-15 | 2004-05-06 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US20050181422A1 (en)* | 2000-09-15 | 2005-08-18 | Coley Pharmaceutical Gmbh | Process for high throughput screening of CpG-based immuno-agonist/antagonist |
| US20060003962A1 (en)* | 2002-10-29 | 2006-01-05 | Coley Pharmaceutical Group, Ltd. | Methods and products related to treatment and prevention of hepatitis C virus infection |
| US7223741B2 (en) | 1994-07-15 | 2007-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US7402572B2 (en) | 1994-07-15 | 2008-07-22 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US7410975B2 (en) | 2003-06-20 | 2008-08-12 | Coley Pharmaceutical Group, Inc. | Small molecule toll-like receptor (TLR) antagonists |
| US7488490B2 (en) | 1997-03-10 | 2009-02-10 | University Of Iowa Research Foundation | Method of inducing an antigen-specific immune response by administering a synergistic combination of adjuvants comprising unmethylated CpG-containing nucleic acids and a non-nucleic acid adjuvant |
| US7524828B2 (en) | 1994-07-15 | 2009-04-28 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US7566703B2 (en) | 2004-10-20 | 2009-07-28 | Coley Pharmaceutical Group, Inc. | Semi-soft C-class immunostimulatory oligonucleotides |
| US7569553B2 (en) | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7576066B2 (en) | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7585847B2 (en) | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
| US7605138B2 (en) | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7662949B2 (en) | 2005-11-25 | 2010-02-16 | Coley Pharmaceutical Gmbh | Immunostimulatory oligoribonucleotides |
| US7741300B2 (en) | 1998-06-25 | 2010-06-22 | National Jewish Medical And Research Center | Methods of using nucleic acid vector-lipid complexes |
| US7776344B2 (en) | 1999-09-27 | 2010-08-17 | University Of Iowa Research Foundation | Methods related to immunostimulatory nucleic acid-induced interferon |
| US7776343B1 (en) | 1999-02-17 | 2010-08-17 | Csl Limited | Immunogenic complexes and methods relating thereto |
| US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7956043B2 (en) | 2002-12-11 | 2011-06-07 | Coley Pharmaceutical Group, Inc. | 5′ CpG nucleic acids and methods of use |
| US8114419B2 (en) | 2002-07-03 | 2012-02-14 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US8153141B2 (en) | 2002-04-04 | 2012-04-10 | Coley Pharmaceutical Gmbh | Immunostimulatory G, U-containing oligoribonucleotides |
| US8188254B2 (en) | 2003-10-30 | 2012-05-29 | Coley Pharmaceutical Gmbh | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
| US8283328B2 (en) | 2002-08-19 | 2012-10-09 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids |
| US8574599B1 (en) | 1998-05-22 | 2013-11-05 | Ottawa Hospital Research Institute | Methods and products for inducing mucosal immunity |
| US8580268B2 (en) | 2006-09-27 | 2013-11-12 | Coley Pharmaceutical Gmbh | CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity |
| US8834900B2 (en) | 2001-08-17 | 2014-09-16 | University Of Iowa Research Foundation | Combination motif immune stimulatory oligonucleotides with improved activity |
Families Citing this family (849)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL105325A (en)* | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
| US6498147B2 (en)* | 1992-05-22 | 2002-12-24 | The Scripps Research Institute | Suppression of nuclear factor-κb dependent processes using oligonucleotides |
| CA2110946A1 (en)* | 1992-12-09 | 1994-06-10 | Elazar Rabbani | Induction of immunocompatibility by nucleic acid |
| US5849719A (en) | 1993-08-26 | 1998-12-15 | The Regents Of The University Of California | Method for treating allergic lung disease |
| US20030109469A1 (en)* | 1993-08-26 | 2003-06-12 | Carson Dennis A. | Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen |
| US6727230B1 (en)* | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US7422902B1 (en)* | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US7034007B1 (en)* | 1995-06-07 | 2006-04-25 | East Carolina University | Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion |
| US6825174B2 (en)* | 1995-06-07 | 2004-11-30 | East Carolina University | Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation |
| US5981501A (en)* | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| DK0909323T3 (en) | 1996-01-04 | 2007-05-21 | Novartis Vaccines & Diagnostic | Helicobacter pylori bacterioferritin |
| US20030078223A1 (en)* | 1996-01-30 | 2003-04-24 | Eyal Raz | Compositions and methods for modulating an immune response |
| WO1997028259A1 (en)* | 1996-01-30 | 1997-08-07 | The Regents Of The University Of California | Gene expression vectors which generate an antigen specific immune response and methods of using the same |
| US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
| US20040171031A1 (en)* | 1996-06-06 | 2004-09-02 | Baker Brenda F. | Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| US20050119470A1 (en)* | 1996-06-06 | 2005-06-02 | Muthiah Manoharan | Conjugated oligomeric compounds and their use in gene modulation |
| US5898031A (en)* | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
| WO2005121371A2 (en)* | 2004-06-03 | 2005-12-22 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
| US20040147022A1 (en)* | 1996-06-06 | 2004-07-29 | Baker Brenda F. | 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
| CA2268825C (en) | 1996-10-11 | 2006-04-18 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
| ATE367159T1 (en) | 1996-10-25 | 2007-08-15 | Minnesota Mining & Mfg | COMPOUNDS THAT ALTER THE IMMUNE RESPONSE FOR THE TREATMENT OF TH2-MEDIATED AND RELATED DISEASES |
| EP0855184A1 (en)* | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
| NZ337054A (en)* | 1997-01-30 | 2001-03-30 | Chiron Corp | Microparticles PLA and PLG with adsorbed viral antigen to stimulate immune responses particularly for intracellular viruses such as HSV-1 or HSV-2, varicella zoster virus. epstein-barr virus or cytomegalovirus (CMV) |
| US6884435B1 (en)* | 1997-01-30 | 2005-04-26 | Chiron Corporation | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
| US6214806B1 (en)* | 1997-02-28 | 2001-04-10 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders |
| PT1005368E (en)* | 1997-03-10 | 2009-11-19 | Coley Pharm Gmbh | Use of nucleic acids containing unmethylated cpg dinucleotide in combination with alum as adjuvants |
| US6426334B1 (en) | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
| JP4656675B2 (en) | 1997-05-14 | 2011-03-23 | ユニバーシティー オブ ブリティッシュ コロンビア | High rate encapsulation of charged therapeutic agents in lipid vesicles |
| US20030104044A1 (en)* | 1997-05-14 | 2003-06-05 | Semple Sean C. | Compositions for stimulating cytokine secretion and inducing an immune response |
| DE69838294T2 (en) | 1997-05-20 | 2009-08-13 | Ottawa Health Research Institute, Ottawa | Process for the preparation of nucleic acid constructs |
| US20040006034A1 (en)* | 1998-06-05 | 2004-01-08 | Eyal Raz | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
| US6589940B1 (en) | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
| EP1374894A3 (en)* | 1997-06-06 | 2004-09-22 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
| JP4101888B2 (en)* | 1997-06-06 | 2008-06-18 | ダイナバックス テクノロジーズ コーポレイション | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
| US6221882B1 (en)* | 1997-07-03 | 2001-04-24 | University Of Iowa Research Foundation | Methods for inhibiting immunostimulatory DNA associated responses |
| AU2003203948B2 (en)* | 1997-09-05 | 2005-12-22 | The Regents Of The University Of California | Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation |
| DE69837094T2 (en)* | 1997-09-05 | 2007-08-30 | The Regents Of The University Of California, Oakland | USE OF IMMUNE-RELATED OLIGONUCLEOTIDES FOR PREVENTING OR TREATING ASTHMA |
| WO1999051259A2 (en) | 1998-04-03 | 1999-10-14 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| EP1077708A1 (en)* | 1998-05-06 | 2001-02-28 | University Of Iowa Research Foundation | Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides |
| AU760795B2 (en)* | 1998-05-14 | 2003-05-22 | Coley Pharmaceutical Gmbh | Methods for regulating hematopoiesis using CpG-oligonucleotides |
| ATE522220T1 (en) | 1998-05-19 | 2011-09-15 | Res Dev Foundation | TRITERPONE COMPOSITIONS AND METHODS OF USE THEREOF |
| KR19990086271A (en)* | 1998-05-27 | 1999-12-15 | 손경식 | Novel endonucleases of immune cells and immunoadjuvant using the same |
| US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| US20040247662A1 (en)* | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
| US6693086B1 (en)* | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| WO2000006588A1 (en)* | 1998-07-27 | 2000-02-10 | University Of Iowa Research Foundation | STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS |
| ATE315405T1 (en)* | 1998-08-10 | 2006-02-15 | Antigenics Inc | CPG COMPOSITIONS, SAPONIN ADJUVANTS AND METHODS OF USE THEREOF |
| AU766492B2 (en)* | 1998-09-18 | 2003-10-16 | Dynavax Technologies Corporation | Methods of treating IgE-associated disorders and compositions for use therein |
| CA2344558A1 (en)* | 1998-10-09 | 2000-04-20 | Dynavax Technologies Corporation | Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens |
| US6867289B1 (en)* | 1998-10-26 | 2005-03-15 | Board Of Regents, The University Of Texas Systems | Thio-modified aptamer synthetic methods and compositions |
| JP2002532547A (en)* | 1998-12-22 | 2002-10-02 | パナシーア ファーマスーティカルズ エルエルシー | Treatment of skin lesions |
| US6558951B1 (en)* | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
| EP1574210B1 (en) | 1999-02-26 | 2016-04-06 | Novartis Vaccines and Diagnostics, Inc. | Microemulsions with adsorbed macromolecules |
| PT1154790E (en) | 1999-02-26 | 2005-03-31 | Chiron Srl | REFORCO OF THE ACTIVITY BACTERICIDE OF ANTIGEN AGAINST NEISSERIA WITH OLIGONUCLEOTIDOS CONTAINING REASONS CG |
| GB2348132B (en)* | 1999-03-02 | 2004-08-04 | Nedaa Abdul-Ghani Nasif | Asthma/allergy therapy that targets t-lymphocytes and/or eosinophils |
| FR2790955B1 (en) | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | USE OF STABILIZED OLIGONUCLEOTIDES AS ANTI-TUMOR ACTIVE INGREDIENT |
| US6977245B2 (en)* | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| WO2000061151A2 (en) | 1999-04-12 | 2000-10-19 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| WO2000062803A2 (en)* | 1999-04-15 | 2000-10-26 | Board Of Regents, The University Of Texas System | ppGpp AND pppGpp AS IMMUNOMODULATORY AGENTS |
| CA2370697C (en)* | 1999-04-19 | 2012-03-06 | Smithkline Beecham Biologicals S.A. | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
| GB9908885D0 (en)* | 1999-04-19 | 1999-06-16 | Smithkline Beecham Biolog | Vccine |
| US6558670B1 (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
| CA2370708A1 (en)* | 1999-04-20 | 2000-10-26 | Smithkline Beecham Biologicals S.A. | Vaccine comprising rsv antigen and cpg oligonucleotide |
| EP1198249B1 (en)* | 1999-06-29 | 2005-10-19 | GlaxoSmithKline Biologicals S.A. | Use of cpg as an adjuvant for hiv vaccine |
| US20050002958A1 (en)* | 1999-06-29 | 2005-01-06 | Smithkline Beecham Biologicals Sa | Vaccines |
| US6514948B1 (en) | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
| FR2795963A1 (en)* | 1999-07-08 | 2001-01-12 | Pasteur Merieux Serums Vacc | New polynucleotides are useful as vaccines for humans |
| DE19935756A1 (en)* | 1999-07-27 | 2001-02-08 | Mologen Forschungs Entwicklung | Covalently closed nucleic acid molecule for immune stimulation |
| US20050226890A1 (en)* | 1999-08-12 | 2005-10-13 | Cohen David I | Tat-based vaccine compositions and methods of making and using same |
| ATE286534T1 (en)* | 1999-08-13 | 2005-01-15 | Hybridon Inc | MODULATION OF IMMUNO STIMULATION CAUSED BY CPG OLIGONUCLEOTIDES THROUGH POSITIONAL CHANGES IN NUCLEOSIDES |
| WO2001012223A2 (en)* | 1999-08-19 | 2001-02-22 | Dynavax Technologies Corporation | Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein |
| US20050249794A1 (en)* | 1999-08-27 | 2005-11-10 | Semple Sean C | Compositions for stimulating cytokine secretion and inducing an immune response |
| PL354879A1 (en)* | 1999-08-27 | 2004-03-08 | Inex Pharmaceuticals Corp. | Compositions for stimulating cytokine secretion and inducing an immune response |
| AU780979B2 (en)* | 1999-09-25 | 2005-04-28 | Coley Pharmaceutical Gmbh | Immunostimulatory nucleic acids |
| EP1688147A1 (en)* | 1999-09-27 | 2006-08-09 | Coley Pharmaceutical Group, Inc. | Methods Related to Immunostimulatory Nucleic Acid-Induced Interferon |
| MXPA02003059A (en)* | 1999-09-27 | 2002-09-30 | Univ Iowa Res Found | Methods related to immunostimulatory nucleic acid induced interferon. |
| CN1433470A (en) | 1999-10-29 | 2003-07-30 | 启龙股份公司 | Antigenic peptides of Neisseria |
| US7223398B1 (en) | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
| ATE378348T1 (en)* | 2000-01-14 | 2007-11-15 | Us Health | OLIGODEOXYNUCLEOTIDES AND THEIR USE FOR INDUCING AN IMMUNE RESPONSE |
| US20010044416A1 (en)* | 2000-01-20 | 2001-11-22 | Mccluskie Michael J. | Immunostimulatory nucleic acids for inducing a Th2 immune response |
| EP1253947A4 (en) | 2000-01-31 | 2005-01-05 | Univ California | IMMUNOMODULATED POLYNUCLEOTIDES FOR THE TREATMENT OF INFECTIONS BY INTRA-CELLULAR DISEASES |
| AU4175101A (en) | 2000-02-23 | 2001-09-03 | Univ California | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
| US20030130217A1 (en)* | 2000-02-23 | 2003-07-10 | Eyal Raz | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
| WO2001062092A1 (en)* | 2000-02-25 | 2001-08-30 | Thomas Jefferson University | Formulations and methods for using the same to elicit an immune response |
| US20040131628A1 (en)* | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
| US7129222B2 (en) | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
| US7157437B2 (en) | 2000-03-10 | 2007-01-02 | Dynavax Technologies Corporation | Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences |
| US20020098199A1 (en) | 2000-03-10 | 2002-07-25 | Gary Van Nest | Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences |
| US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
| US20010046967A1 (en) | 2000-03-10 | 2001-11-29 | Gary Van Nest | Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide |
| CA2405424A1 (en)* | 2000-04-07 | 2001-10-18 | The Regents Of The University Of California | Synergistic improvements to polynucleotide vaccines |
| EP1278761B1 (en)* | 2000-05-01 | 2005-04-06 | Hybridon, Inc. | MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
| US6696064B2 (en)* | 2000-06-20 | 2004-02-24 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of protecting vasculature from damage by diphtheria toxin-and pseudomonas toxin-based immunotoxins during therapy |
| AU2001276831A1 (en) | 2000-06-22 | 2002-01-02 | Rxkinetix, Inc. | Delivery vehicle composition and methods for delivering antigens and other drugs |
| ATE376059T1 (en)* | 2000-06-23 | 2007-11-15 | Wyeth Corp | ASSEMBLY OF WILD-TYPE AND CHIMERIC INFLUENZA VIRUS-LIKE PARTICLES (VLPS) |
| WO2002002172A1 (en)* | 2000-06-30 | 2002-01-10 | Univ Jefferson | Dna palindrome - oligoguanylic acid compositions and uses thereof |
| KR100917101B1 (en)* | 2000-08-04 | 2009-09-15 | 도요 보세키 가부시키가이샤 | Flexible metal laminate and production method thereof |
| WO2005090392A1 (en)* | 2004-03-16 | 2005-09-29 | Inist Inc. | Tat-based tolerogen compositions and methods of making and using same |
| WO2002016549A2 (en)* | 2000-08-25 | 2002-02-28 | Yeda Research And Development Co. Ltd. | METHODS OF TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDE |
| AU9475001A (en)* | 2000-09-26 | 2002-04-08 | Hybridon Inc | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| NZ583028A (en) | 2000-10-27 | 2011-10-28 | Novartis Vaccines & Diagnostic | Nucleic acids and proteins from streptococcus groups A & B |
| AU2001297693A1 (en)* | 2000-12-08 | 2002-09-12 | Coley Pharmaceutical Gmbh | Cpg-like nucleic acids and methods of use thereof |
| US6677347B2 (en)* | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
| WO2006091720A2 (en)* | 2000-12-08 | 2006-08-31 | 3M Innovative Properties Company | Compositions and methods for targeted delivery of immune response modifiers |
| ES2347525T3 (en)* | 2000-12-27 | 2010-11-02 | Dynavax Technologies Corporation | IMMUNOMODULATING POLINUCLEOTIDES AND METHODS FOR USERS. |
| US20040110834A1 (en)* | 2001-01-12 | 2004-06-10 | Masahiro Murakami | Preventives for microbial infections |
| US7320793B2 (en)* | 2001-01-19 | 2008-01-22 | Cytos Biotechnology Ag | Molecular antigen array |
| EP1355661A2 (en)* | 2001-01-31 | 2003-10-29 | Mologen Forschungs-, Entwicklungs- und Vertriebs GmbH | Tumor vaccine |
| US20030050268A1 (en)* | 2001-03-29 | 2003-03-13 | Krieg Arthur M. | Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases |
| JP2004533236A (en)* | 2001-04-13 | 2004-11-04 | ワイエス | Surface protein of Streptococcus pyogenes |
| US20070128229A1 (en)* | 2002-04-12 | 2007-06-07 | Wyeth | Surface proteins of Streptococcus pyogenes |
| EP2258842A1 (en) | 2001-04-16 | 2010-12-08 | Wyeth Holdings Corporation | Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
| US7034140B2 (en)* | 2001-04-24 | 2006-04-25 | E.I. Du Pont De Nemours And Company | Genes involved in isoprenoid compound production |
| WO2002095027A2 (en) | 2001-05-21 | 2002-11-28 | Intercell Ag | Immunostimulatory oligodeoxynucleic molecules |
| US6818787B2 (en)* | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| DK2423335T3 (en) | 2001-06-21 | 2014-08-18 | Dynavax Tech Corp | CHEMICAL IMMUNAL MODULATOR RELATIONS AND PROCEDURES FOR USE THEREOF |
| US7785610B2 (en)* | 2001-06-21 | 2010-08-31 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—III |
| AU2002322358B2 (en)* | 2001-06-29 | 2009-06-18 | Novartis Vaccines And Diagnostics, Inc. | HCV E1E2 vaccine compositions |
| GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
| GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
| WO2003012061A2 (en)* | 2001-08-01 | 2003-02-13 | Coley Pharmaceutical Gmbh | Methods and compositions relating to plasmacytoid dendritic cells |
| JP2005518343A (en)* | 2001-08-03 | 2005-06-23 | メダレックス， インク． | Novel PGC-1 isoforms and their use to improve use-mediated immunotherapy |
| CA2456328C (en)* | 2001-08-07 | 2015-05-26 | Dynavax Technologies Corporation | Complexes of a short cpg-containing oligonucleotide bound to the surface of a solid phase microcarrier and methods for use thereof |
| US7354909B2 (en)* | 2001-08-14 | 2008-04-08 | The United States Of America As Represented By Secretary Of The Department Of Health And Human Services | Method for rapid generation of mature dendritic cells |
| ES2542888T3 (en) | 2001-08-24 | 2015-08-12 | Uvic Industry Partnerships Inc. | Proaerolysin containing protease activation sequences and methods of use for the treatment of prostate cancer |
| EP1427445A4 (en)* | 2001-08-30 | 2006-09-06 | 3M Innovative Properties Co | METHOD FOR MATURIZING PLASMACYTIDES DENDRITIC CELLS USING IMMUNE RESPONSE MODIFYING MOLECULES |
| JP2005501917A (en)* | 2001-09-07 | 2005-01-20 | ザ トラスティーズ オブ ボストン ユニバーシティ | Methods and compositions for treating immune complex related diseases |
| US20030091593A1 (en)* | 2001-09-14 | 2003-05-15 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
| DE60234375D1 (en)* | 2001-09-14 | 2009-12-24 | Cytos Biotechnology Ag | PACKAGING IMMUNSTIMULATING CpG IN VIRUS LIKE PARTICLES: PREPARATION METHOD AND USE |
| AU2002353783A1 (en) | 2001-09-24 | 2003-04-07 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE |
| US20030119774A1 (en)* | 2001-09-25 | 2003-06-26 | Marianna Foldvari | Compositions and methods for stimulating an immune response |
| AR045702A1 (en) | 2001-10-03 | 2005-11-09 | Chiron Corp | COMPOSITIONS OF ASSISTANTS. |
| KR20050034583A (en)* | 2001-10-05 | 2005-04-14 | 콜리 파마슈티칼 게엠베하 | Toll-like receptor 3 signaling agonists and antagonists |
| AU2002346960A1 (en) | 2001-10-06 | 2003-04-22 | Merial Limited | Methods and compositions for promoting growth and innate immunity in young animals |
| EP1434602B1 (en)* | 2001-10-06 | 2014-12-17 | Merial Limited | CpG plus oil in water emulsion as adjuvant system for truncated bovine herpesvirus-1 glycoprotein D |
| MX339524B (en) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Novel immunogenic compositions for the prevention and treatment of meningococcal disease. |
| US20030139364A1 (en)* | 2001-10-12 | 2003-07-24 | University Of Iowa Research Foundation | Methods and products for enhancing immune responses using imidazoquinoline compounds |
| US7276489B2 (en)* | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
| JP2005516897A (en)* | 2001-11-07 | 2005-06-09 | イネックス ファーマシューティカルズ コーポレイション | Improved mucosal vaccine and method of use |
| EP1441758A2 (en)* | 2001-11-09 | 2004-08-04 | MediGene Aktiengesellschaft | Allogenic vaccine that contains a costimulatory polypeptide-expressing tumor cell |
| US7179798B2 (en)* | 2001-11-16 | 2007-02-20 | Russell R. Roby | Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions |
| ATE416771T1 (en)* | 2001-11-16 | 2008-12-15 | 3M Innovative Properties Co | N-Ä4-(4-AMINO-2-ETHYL-1H-IMIDAZOÄ4,5-CUCHINOLINE 1-YL)BUTYLUMETHANESULFONAMIDE, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF |
| WO2003047602A1 (en)* | 2001-12-07 | 2003-06-12 | Intercell Ag | Immunostimulatory oligodeoxynucleotides |
| US7615227B2 (en)* | 2001-12-20 | 2009-11-10 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce angiogenesis |
| US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
| CA2365732A1 (en)* | 2001-12-20 | 2003-06-20 | Ibm Canada Limited-Ibm Canada Limitee | Testing measurements |
| EP1467755A1 (en)* | 2001-12-21 | 2004-10-20 | Antigenics Inc. | Compositions comprising immunoreactive reagents and saponins, and methods of use thereof |
| EP1474432A1 (en)* | 2002-02-04 | 2004-11-10 | Biomira Inc. | Immunostimulatory, covalently lipidated oligonucleotides |
| US8088388B2 (en)* | 2002-02-14 | 2012-01-03 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
| JP4646516B2 (en)* | 2002-02-20 | 2011-03-09 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | Fine particles with adsorbed polypeptide-containing molecules |
| US7030129B2 (en)* | 2002-02-22 | 2006-04-18 | 3M Innovative Properties Company | Method of reducing and treating UVB-induced immunosuppression |
| US6923958B2 (en)* | 2002-03-02 | 2005-08-02 | The Scripps Research Institute | DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof |
| US20050222060A1 (en)* | 2002-03-15 | 2005-10-06 | Bot Adrian L | Compositions and methods to initiate or enhance antibody and major-histocompatibility class I or class II-restricted t cell responses by using immunomodulatory, non-coding rna motifs |
| EP2258712A3 (en) | 2002-03-15 | 2011-05-04 | Multicell Immunotherapeutics, Inc. | Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs |
| US7615229B2 (en)* | 2002-03-15 | 2009-11-10 | Wyeth Holdings Corporation | Mutants of the P4 protein of nontypable Haemophilus influenzae with reduced enzymatic activity |
| US20030224013A1 (en)* | 2002-04-19 | 2003-12-04 | Cole Garry T. | Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein |
| US20040013649A1 (en)* | 2002-05-10 | 2004-01-22 | Inex Pharmaceuticals Corporation | Cancer vaccines and methods of using the same |
| US20040009943A1 (en)* | 2002-05-10 | 2004-01-15 | Inex Pharmaceuticals Corporation | Pathogen vaccines and methods for using the same |
| US20040009944A1 (en)* | 2002-05-10 | 2004-01-15 | Inex Pharmaceuticals Corporation | Methylated immunostimulatory oligonucleotides and methods of using the same |
| US20060088909A1 (en)* | 2002-05-17 | 2006-04-27 | Compans Richard W | Virus-like particles, methods of preparation, and immunogenic compositions |
| US9045727B2 (en) | 2002-05-17 | 2015-06-02 | Emory University | Virus-like particles, methods of preparation, and immunogenic compositions |
| KR100456681B1 (en)* | 2002-05-22 | 2004-11-10 | 주식회사 대웅 | Immnune-stimulating and controlling Composition comprising bacterial chromosomal DNA fragments and detoxified lipopolysaccharides |
| CA2388049A1 (en)* | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
| AU2003243409A1 (en)* | 2002-06-05 | 2003-12-22 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids |
| CN1662253A (en)* | 2002-06-20 | 2005-08-31 | 赛托斯生物技术公司 | Packaged virus-like particles for use as adjuvants: method of preparation and use |
| AU2003247880B2 (en)* | 2002-07-03 | 2010-09-02 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| WO2004007743A2 (en)* | 2002-07-17 | 2004-01-22 | Coley Pharmaceutical Gmbh | Use of cpg nucleic acids in prion-disease |
| US20060270620A1 (en)* | 2002-07-23 | 2006-11-30 | University Of South Florida | Method of Enhancing Therapeutic Effect of Nucleic Acids |
| EP1523557A2 (en) | 2002-07-24 | 2005-04-20 | Intercell AG | Antigens encoded by alternative reading frame from pathogenic viruses |
| EP1575504A4 (en) | 2002-08-01 | 2009-11-04 | Us Gov Health & Human Serv | METHOD OF TREATING INFLAMMATORY ARTHROPATHIES USING OLIGONUCLEOTIDE CPG SUPPRESSORS |
| WO2004032829A2 (en) | 2002-08-15 | 2004-04-22 | 3M Innovative Properties Company | Immunostimulatory compositions and methods of stimulating an immune response |
| US7785608B2 (en)* | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
| GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
| US7595303B1 (en)* | 2002-09-05 | 2009-09-29 | University Of South Florida | Genetic adjuvants for immunotherapy |
| US20050196382A1 (en)* | 2002-09-13 | 2005-09-08 | Replicor, Inc. | Antiviral oligonucleotides targeting viral families |
| WO2004024919A1 (en)* | 2002-09-13 | 2004-03-25 | Replicor, Inc. | Non-sequence complementary antiviral oligonucleotides |
| WO2004024182A2 (en) | 2002-09-13 | 2004-03-25 | Intercell Ag | Method for isolating hepatitis c virus peptides |
| US8263091B2 (en)* | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
| US7301554B2 (en)* | 2002-09-20 | 2007-11-27 | Ricoh Company, Ltd. | Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method |
| AU2003268737A1 (en)* | 2002-10-02 | 2004-04-23 | Mochida Pharmaceutical Co., Ltd. | Novel method of constructing monoclonal antibody |
| US8043622B2 (en) | 2002-10-08 | 2011-10-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides |
| CA2501812C (en) | 2002-10-11 | 2012-07-10 | Mariagrazia Pizza | Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages |
| US20060148064A1 (en)* | 2002-10-25 | 2006-07-06 | Srivastava Pramod K | Apparatus and method for immunotherapy of a cancer through controlled cell lysis |
| US7758876B2 (en)* | 2002-11-01 | 2010-07-20 | The United States Of America As Represented By The Department Of Health And Human Services | Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides |
| WO2004044133A2 (en)* | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | Modified oligonucleotides for use in rna interference |
| AU2003288660A1 (en) | 2002-11-15 | 2004-06-15 | Chiron Srl | Unexpected surface proteins in neisseria meningitidis |
| US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| US20050124565A1 (en)* | 2002-11-21 | 2005-06-09 | Diener John L. | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| US8039443B2 (en)* | 2002-11-21 | 2011-10-18 | Archemix Corporation | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| US10100316B2 (en)* | 2002-11-21 | 2018-10-16 | Archemix Llc | Aptamers comprising CPG motifs |
| WO2006050498A2 (en) | 2004-11-02 | 2006-05-11 | Archemix Corp. | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| SI1569696T1 (en)* | 2002-11-21 | 2010-12-31 | Bayhill Therapeutics Inc | Methods and immune modulatory nucleic acid compositions for preventing and treating disease |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| US20040213808A1 (en)* | 2002-12-11 | 2004-10-28 | Michael Lieberman | Recombinant vaccine against flavivirus infection |
| WO2004053452A2 (en)* | 2002-12-11 | 2004-06-24 | 3M Innovative Properties Company | Assays relating to toll-like receptor activity |
| AU2003287324A1 (en)* | 2002-12-11 | 2004-06-30 | 3M Innovative Properties Company | Gene expression systems and recombinant cell lines |
| AU2003302743B2 (en)* | 2002-12-23 | 2008-09-04 | Dynavax Technologies Corporation | Branched immunomodulatory compounds and methods of using the same |
| US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
| EP1575977B1 (en)* | 2002-12-23 | 2009-09-09 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
| EP2263687B1 (en) | 2002-12-27 | 2015-03-25 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions containing phospholipid |
| EP1578419A4 (en) | 2002-12-30 | 2008-11-12 | 3M Innovative Properties Co | Immunostimulatory combinations |
| ATE552844T1 (en) | 2003-01-30 | 2012-04-15 | Novartis Ag | INJECTABLE VACCINE AGAINST MULTIPLE MENINGOCOCC SEROGROUPES |
| US7354907B2 (en)* | 2003-02-07 | 2008-04-08 | Idera Pharmaceuticals, Inc. | Short immunomodulatory oligonucleotides |
| WO2004071459A2 (en)* | 2003-02-13 | 2004-08-26 | 3M Innovative Properties Company | Methods and compositions related to irm compounds and toll-like receptor 8 |
| AU2004213855B2 (en) | 2003-02-20 | 2010-03-04 | University Of Connecticut Health Center | Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes |
| GB2398783A (en) | 2003-02-26 | 2004-09-01 | Antonio Lanzavecchia | A method for producing immortalised human B memory lymphocytes |
| EP1599726A4 (en)* | 2003-02-27 | 2009-07-22 | 3M Innovative Properties Co | Selective modulation of tlr-mediated biological activity |
| WO2004078138A2 (en) | 2003-03-04 | 2004-09-16 | 3M Innovative Properties Company | Prophylactic treatment of uv-induced epidermal neoplasia |
| CN100439386C (en)* | 2003-03-05 | 2008-12-03 | 长春华普生物技术有限公司 | Deoxyoligonucleotide containing CpG single strand for strengthening immunological effect of Protein vaccine |
| MXPA05009694A (en)* | 2003-03-13 | 2005-10-20 | 3M Innovative Properties Co | Methods of improving skin quality. |
| CA2518445A1 (en) | 2003-03-13 | 2004-09-23 | 3M Innovative Properties Company | Method of tattoo removal |
| EP1608402B1 (en) | 2003-03-24 | 2010-10-20 | Intercell AG | Improved vaccines |
| US20040192585A1 (en) | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Treatment for basal cell carcinoma |
| CN1795274A (en)* | 2003-03-26 | 2006-06-28 | 多单元免疫治疗公司 | Selected rna motifs to include cell death and/or apoptosis |
| US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
| WO2004085635A1 (en)* | 2003-03-26 | 2004-10-07 | Cytos Biotechnology Ag | Melan-a peptide analogue-virus-like-particle conjugates |
| US20060210588A1 (en)* | 2003-03-26 | 2006-09-21 | Cytos Biotechnology Ag | Hiv-peptide-carrier-conjugates |
| EP1608403A2 (en)* | 2003-04-02 | 2005-12-28 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations for topical application |
| US20040265351A1 (en)* | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
| EP1615665A4 (en)* | 2003-04-10 | 2010-10-06 | 3M Innovative Properties Co | Delivery of immune response modifier compounds |
| NZ543467A (en) | 2003-04-10 | 2008-07-31 | Novartis Vaccines & Diagnostic | The severe acute respiratory syndrome coronavirus |
| EP2623601B1 (en) | 2003-04-21 | 2015-02-18 | Archemix LLC | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| JP4673217B2 (en)* | 2003-04-23 | 2011-04-20 | 由紀夫 佐藤 | Methylated CpG polynucleotide |
| US20050250106A1 (en)* | 2003-04-24 | 2005-11-10 | David Epstein | Gene knock-down by intracellular expression of aptamers |
| AU2004233851B2 (en)* | 2003-04-25 | 2009-07-30 | Novartis Vaccines And Diagnostics, Inc. | Compositions comprising cationic microparticles and HCV E1E2 DNA and methods of use thereof |
| EP1617845A4 (en)* | 2003-04-28 | 2006-09-20 | 3M Innovative Properties Co | Compositions and methods for induction of opioid receptors |
| AU2004238139B2 (en)* | 2003-05-15 | 2009-12-03 | Japan Science And Technology Agency | Immunostimulating Agents |
| US8080642B2 (en)* | 2003-05-16 | 2011-12-20 | Vical Incorporated | Severe acute respiratory syndrome DNA compositions and methods of use |
| DE602004022286D1 (en) | 2003-06-02 | 2009-09-10 | Novartis Vaccines & Diagnostic | IMMUNOGENIC COMPOSITIONS BASED ON BIODEGRADABLE MICRO PARTICLES CONTAINING A DIPHTHERIA AND TETANO TOXOID |
| CA2528067C (en) | 2003-06-05 | 2015-08-04 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Poly-gamma-glutamic acid conjugates for eliciting immune responses directed against bacilli |
| EP2371834B1 (en)* | 2003-06-11 | 2016-02-17 | Idera Pharmaceuticals, Inc. | Stabilized immunomodulatory oligonucleotides |
| CN100404070C (en)* | 2003-07-10 | 2008-07-23 | 赛托斯生物技术公司 | Packaged virus-like particles |
| US20050013812A1 (en)* | 2003-07-14 | 2005-01-20 | Dow Steven W. | Vaccines using pattern recognition receptor-ligand:lipid complexes |
| WO2005011629A1 (en)* | 2003-07-31 | 2005-02-10 | 3M Innovative Properties Company | Bioactive compositions comprising triazines |
| EP1651190B1 (en)* | 2003-08-05 | 2012-09-19 | 3M Innovative Properties Company | Formulations containing an immune response modifier |
| WO2005018551A2 (en)* | 2003-08-12 | 2005-03-03 | 3M Innovative Properties Company | Oxime substituted imidazo-containing compounds |
| US20060035242A1 (en) | 2004-08-13 | 2006-02-16 | Michelitsch Melissa D | Prion-specific peptide reagents |
| US20050065136A1 (en)* | 2003-08-13 | 2005-03-24 | Roby Russell R. | Methods and compositions for the treatment of infertility using dilute hormone solutions |
| WO2005020902A2 (en)* | 2003-08-21 | 2005-03-10 | Cytokine Pharmasciences, Inc. | Compositions and methods for treating and diagnosing irritable bowel syndrome |
| EP1658035A4 (en)* | 2003-08-25 | 2007-08-22 | 3M Innovative Properties Co | Delivery of immune response modifier compounds |
| CA2551075A1 (en)* | 2003-08-25 | 2005-03-03 | 3M Innovative Properties Company | Immunostimulatory combinations and treatments |
| EP1658076B1 (en)* | 2003-08-27 | 2013-03-06 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
| CA2536578A1 (en)* | 2003-09-02 | 2005-03-10 | 3M Innovative Properties Company | Methods related to the treatment of mucosal associated conditions |
| EP1660026A4 (en)* | 2003-09-05 | 2008-07-16 | 3M Innovative Properties Co | Treatment for cd5+ b cell lymphoma |
| JP2007505147A (en) | 2003-09-12 | 2007-03-08 | アンティジェニクス インコーポレーテッド | Vaccine for the treatment and prevention of herpes simplex virus infection |
| US7615539B2 (en)* | 2003-09-25 | 2009-11-10 | Coley Pharmaceutical Group, Inc. | Nucleic acid-lipophilic conjugates |
| NZ546430A (en) | 2003-10-02 | 2009-04-30 | Novartis Vaccines & Diagnostic | Liquid vaccines for multiple meningococcal serogroups |
| GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
| US8871782B2 (en)* | 2003-10-03 | 2014-10-28 | 3M Innovative Properties Company | Alkoxy substituted imidazoquinolines |
| US7544697B2 (en)* | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
| US20090075980A1 (en)* | 2003-10-03 | 2009-03-19 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and Analogs Thereof |
| CA2542099A1 (en)* | 2003-10-11 | 2005-04-21 | Inex Pharmaceuticals Corporation | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
| GB0323965D0 (en)* | 2003-10-13 | 2003-11-19 | Glaxosmithkline Biolog Sa | Immunogenic compositions |
| US20050239733A1 (en)* | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
| US20050096259A1 (en)* | 2003-10-31 | 2005-05-05 | 3M Innovative Properties Company | Neutrophil activation by immune response modifier compounds |
| US20050100983A1 (en)* | 2003-11-06 | 2005-05-12 | Coley Pharmaceutical Gmbh | Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling |
| US7897767B2 (en) | 2003-11-14 | 2011-03-01 | 3M Innovative Properties Company | Oxime substituted imidazoquinolines |
| AU2004291122A1 (en)* | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Hydroxylamine substituted imidazo ring compounds |
| WO2005051317A2 (en)* | 2003-11-25 | 2005-06-09 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
| US20050287118A1 (en)* | 2003-11-26 | 2005-12-29 | Epitomics, Inc. | Bacterial plasmid with immunological adjuvant function and uses thereof |
| US20050277127A1 (en)* | 2003-11-26 | 2005-12-15 | Epitomics, Inc. | High-throughput method of DNA immunogen preparation and immunization |
| EP1689361A4 (en)* | 2003-12-02 | 2009-06-17 | 3M Innovative Properties Co | Therapeutic combinations and methods including irm compounds |
| US20050226878A1 (en)* | 2003-12-02 | 2005-10-13 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
| US9090673B2 (en) | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
| PH12011502391A1 (en) | 2003-12-17 | 2014-04-28 | Janssen Alzheimer Immunotherap | Aã immunogenic peptide carrier conjugates and methods of producing same |
| SG182163A1 (en) | 2003-12-17 | 2012-07-30 | Wyeth Corp | Immunogenic peptide carrier conjugates and methods of producing same |
| JP4817599B2 (en)* | 2003-12-25 | 2011-11-16 | 独立行政法人科学技術振興機構 | Immune activity enhancer and method for enhancing immune activity using the same |
| EP1701955A1 (en)* | 2003-12-29 | 2006-09-20 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
| EP1699788A2 (en)* | 2003-12-30 | 2006-09-13 | 3M Innovative Properties Company | Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides |
| EP1699398A4 (en)* | 2003-12-30 | 2007-10-17 | 3M Innovative Properties Co | Enhancement of immune responses |
| KR100558851B1 (en)* | 2004-01-08 | 2006-03-10 | 학교법인연세대학교 | CJ oligodeoxynucleotide variants with increased immunomodulatory capacity |
| WO2005072290A2 (en)* | 2004-01-23 | 2005-08-11 | Joslin Diabetes Center | Methods of treating, reducing, or preventing autoimmune conditions |
| US20050181035A1 (en)* | 2004-02-17 | 2005-08-18 | Dow Steven W. | Systemic immune activation method using non CpG nucleic acids |
| WO2005097993A2 (en) | 2004-02-19 | 2005-10-20 | Coley Pharmaceutical Group, Inc. | Immunostimulatory viral rna oligonucleotides |
| CN1918293A (en)* | 2004-02-20 | 2007-02-21 | 莫洛根股份公司 | Substituted non-coding nucleic acid molecule for therapeutic or prophylaxis immunological stimulus for human and higher animal |
| US20060193821A1 (en)* | 2004-03-05 | 2006-08-31 | Diener John L | Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics |
| WO2005107797A1 (en) | 2004-03-09 | 2005-11-17 | Chiron Corporation | Influenza virus vaccines |
| US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
| US7927580B2 (en)* | 2004-03-16 | 2011-04-19 | Nanirx, Inc. | Tat-based immunomodulatory compositions and methods of their discovery and use |
| EP2545931A1 (en) | 2004-03-19 | 2013-01-16 | Herbs Spring, LLC | Herbal therapy for the treatment of food allergy |
| EP1730143A2 (en)* | 2004-03-24 | 2006-12-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
| TWI235440B (en)* | 2004-03-31 | 2005-07-01 | Advanced Semiconductor Eng | Method for making leadless semiconductor package |
| WO2005111057A2 (en)* | 2004-04-02 | 2005-11-24 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for inducing il-10 responses |
| US20050260755A1 (en)* | 2004-04-06 | 2005-11-24 | Isis Pharmaceuticals, Inc. | Sequential delivery of oligomeric compounds |
| US20050239757A1 (en)* | 2004-04-21 | 2005-10-27 | Roby Russell R | Hormone treatment of macular degeneration |
| WO2005105107A2 (en)* | 2004-04-21 | 2005-11-10 | Roby Russell R | Hormone treatment of multiple sclerosis |
| US7579450B2 (en)* | 2004-04-26 | 2009-08-25 | Archemix Corp. | Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics |
| EP1755665A4 (en)* | 2004-04-28 | 2010-03-03 | 3M Innovative Properties Co | Compositions and methods for mucosal vaccination |
| GB0409745D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
| RU2379052C2 (en) | 2004-04-30 | 2010-01-20 | Чирон С.Р.Л. | Meningococcal conjugate vaccination |
| GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
| JP5014122B2 (en)* | 2004-05-06 | 2012-08-29 | アメリカ合衆国 | Methods and compositions for the treatment of uveitis |
| GB0410220D0 (en) | 2004-05-07 | 2004-06-09 | Kirkham Lea Ann | Mutant pneumolysin proteins |
| GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
| CN1296378C (en)* | 2004-05-17 | 2007-01-24 | 中国人民解放军第三军医大学 | CpG-N ODN gene sequence with high immunological activity CpG-S ODN and antagonism CpG-N ODN and use thereof |
| WO2005116270A2 (en)* | 2004-05-18 | 2005-12-08 | Vical Incorporated | Influenza virus vaccine composition and method of use |
| EP2848692B1 (en) | 2004-05-21 | 2017-08-16 | Novartis Vaccines and Diagnostics, Inc. | Alphavirus vectors for influenza virus vaccines |
| WO2005116064A2 (en) | 2004-05-21 | 2005-12-08 | Wyeth | Altered fibronectin-binding protein of staphylococcus aureus |
| US20050267145A1 (en)* | 2004-05-28 | 2005-12-01 | Merrill Bryon A | Treatment for lung cancer |
| ES2560449T3 (en) | 2004-05-28 | 2016-02-19 | Oryxe | A mixture for transdermal administration of low and high molecular weight compounds |
| US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
| JP2008501807A (en)* | 2004-06-08 | 2008-01-24 | コーリー ファーマシューティカル ゲーエムベーハー | Abasic oligonucleotides as carrier backbone for antigens and immunostimulatory agonists and antagonists |
| US8017779B2 (en)* | 2004-06-15 | 2011-09-13 | 3M Innovative Properties Company | Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
| TW200613554A (en) | 2004-06-17 | 2006-05-01 | Wyeth Corp | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
| WO2006009826A1 (en)* | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
| US7897609B2 (en)* | 2004-06-18 | 2011-03-01 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
| WO2006009832A1 (en)* | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
| US7915281B2 (en)* | 2004-06-18 | 2011-03-29 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method |
| US7482158B2 (en)* | 2004-07-01 | 2009-01-27 | Mathison Brian H | Composite polynucleic acid therapeutics |
| AU2005335104C1 (en) | 2004-07-18 | 2010-10-28 | Csl Limited | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
| US20060025390A1 (en)* | 2004-07-28 | 2006-02-02 | Roby Russell R | Treatment of hormone allergy and related symptoms and disorders |
| EP1784211A4 (en) | 2004-07-29 | 2010-06-30 | Novartis Vaccines & Diagnostic | IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE |
| AU2005270918B2 (en) | 2004-08-03 | 2011-03-03 | Innate Pharma S.A. | Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor |
| WO2006026470A2 (en)* | 2004-08-27 | 2006-03-09 | 3M Innovative Properties Company | Hiv immunostimulatory compositions |
| WO2006026760A2 (en)* | 2004-09-02 | 2006-03-09 | 3M Innovative Properties Company | 1-amino imidazo-containing compounds and methods |
| US7884086B2 (en)* | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
| WO2006032697A2 (en) | 2004-09-24 | 2006-03-30 | Intercell Ag | MODIFIED VPl-CAPSID PROTEIN OF PARVOVIRUS B19 |
| JP2008000001A (en)* | 2004-09-30 | 2008-01-10 | Osaka Univ | Immunostimulatory oligonucleotide and its pharmaceutical use |
| KR101376889B1 (en) | 2004-10-06 | 2014-03-25 | 메디뮨 엘엘씨 | Refrigerator-temperature stable influenza vaccine compositions |
| EP2808384B1 (en) | 2004-10-08 | 2017-12-06 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Modulation of replicative fitness by using less frequently used synonymous codons |
| WO2006042254A2 (en)* | 2004-10-08 | 2006-04-20 | 3M Innovative Properties Company | Adjuvant for dna vaccines |
| CA2583121A1 (en) | 2004-10-21 | 2007-01-04 | Wyeth | Immunogenic compositions of staphylococcus epidermidis polypeptide antigens |
| GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
| WO2006065549A2 (en) | 2004-12-03 | 2006-06-22 | Medical University Of Ohio | Attenuated vaccine useful for immunizations against coccidioides spp. infections |
| JP2008523076A (en)* | 2004-12-08 | 2008-07-03 | スリーエム イノベイティブ プロパティズ カンパニー | Immunomodulatory compositions, combinations and methods |
| WO2006065751A2 (en)* | 2004-12-13 | 2006-06-22 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods |
| US8197817B2 (en) | 2004-12-17 | 2012-06-12 | Dana-Farber Cancer Institute, Inc. | Regulation of mink in thymocytes and T lymphocytes |
| EP2351576A1 (en)* | 2004-12-29 | 2011-08-03 | Mannkind Corporation | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
| PL1830876T3 (en)* | 2004-12-30 | 2015-09-30 | Meda Ab | Use of imiquimod for the treatment of cutaneous metastases derived from a breast cancer tumor |
| ES2392648T3 (en) | 2004-12-30 | 2012-12-12 | 3M Innovative Properties Company | Substituted chiral compounds containing a condensed 1,2-imidazo-4,5-c core |
| CA2592904C (en)* | 2004-12-30 | 2015-04-07 | 3M Innovative Properties Company | Chiral fused [1,2]imidazo[4,5-c] ring compounds |
| WO2006081259A2 (en) | 2005-01-27 | 2006-08-03 | Children's Hospital & Research Center At Oakland | Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
| JP4836145B2 (en)* | 2005-01-28 | 2011-12-14 | クウォン，ヒュン−ジョ | Oligonucleotide derived from mycobacteria for immune function stimulation, immune disease treatment, atopic dermatitis treatment and / or normal immune cell protection |
| GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
| AU2006210392A1 (en) | 2005-02-04 | 2006-08-10 | Coley Pharmaceutical Group, Inc. | Aqueous gel formulations containing immune response modifiers |
| AU2006213746A1 (en) | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods |
| SG160329A1 (en) | 2005-02-18 | 2010-04-29 | Novartis Vaccines & Diagnostic | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli |
| CN102675432A (en) | 2005-02-18 | 2012-09-19 | 诺华疫苗和诊断公司 | Immunogens from uropathogenic escherichia coli |
| AU2006216493A1 (en)* | 2005-02-24 | 2006-08-31 | Coley Pharmaceutical Gmbh | Immunostimulatory oligonucleotides |
| WO2006096497A2 (en) | 2005-03-04 | 2006-09-14 | Dynavax Technologies Corporation | Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients |
| US8101345B1 (en) | 2005-03-25 | 2012-01-24 | Isis Pharmaceuticals, Inc. | Proinflammatory nucleic acids |
| EP1863814A1 (en) | 2005-04-01 | 2007-12-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
| WO2006107853A2 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridine-1,4-diamines and analogs thereof |
| CN101193646A (en)* | 2005-04-08 | 2008-06-04 | 科勒制药集团公司 | Method for treating infectious disease exacerbated asthma |
| EP1868645B1 (en) | 2005-04-08 | 2012-03-07 | Wyeth LLC | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| EP2842559A3 (en)* | 2005-04-08 | 2015-03-18 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of viral infections and other medical disorders |
| WO2006110655A2 (en) | 2005-04-08 | 2006-10-19 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of poxvirus infections |
| US20100028415A1 (en) | 2005-04-12 | 2010-02-04 | Haynes Barton F | Method of Inducing Neutralizing Antibodies to Human Immunodeficiency Virus |
| EP2329843A3 (en) | 2005-04-18 | 2011-09-14 | Novartis Vaccines and Diagnostics, Inc. | Expressing Hepatitis B Virus surface antigen for vaccine preparation |
| WO2006116475A2 (en)* | 2005-04-25 | 2006-11-02 | 3M Innovative Properties Company | Immunostimulatory compositions |
| AU2006241149A1 (en)* | 2005-04-26 | 2006-11-02 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity |
| US20090075342A1 (en)* | 2005-04-26 | 2009-03-19 | Sharon Cload | Metabolic profile directed aptamer medicinal chemistry |
| NZ564954A (en) | 2005-06-14 | 2011-02-25 | Protox Therapeutics Inc | Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins |
| US8101385B2 (en) | 2005-06-30 | 2012-01-24 | Archemix Corp. | Materials and methods for the generation of transcripts comprising modified nucleotides |
| KR20080025181A (en) | 2005-06-30 | 2008-03-19 | 아케믹스 코포레이션 | Materials and Methods for Producing Fully 2′-Modified Nucleic Acid Transcripts |
| DK2179737T3 (en) | 2005-07-01 | 2013-11-11 | Index Pharmaceuticals Ab | MODULE RESPONSE ON STEROIDS |
| EP2380584B1 (en) | 2005-07-01 | 2013-10-16 | Index Pharmaceuticals AB | Immunostimulatory method |
| MX2008000379A (en)* | 2005-07-07 | 2008-03-18 | Coley Pharm Group Inc | Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment. |
| WO2007008904A2 (en)* | 2005-07-08 | 2007-01-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Targeting poly-gamma-glutamic acid to treat staphylococcus epidermidis and related infections |
| EP1909564A4 (en) | 2005-07-18 | 2010-06-30 | Novartis Ag | Small animal model for hcv replication |
| WO2007012285A1 (en)* | 2005-07-28 | 2007-02-01 | Changchun Huapu Biotechnology Co., Ltd. | Viral infection resistent single strand deoxynucleosides |
| CA2622679A1 (en)* | 2005-09-16 | 2007-08-09 | Coley Pharmaceutical Gmbh | Immunostimulatory single-stranded ribonucleic acid with phosphodiester backbone |
| KR20080047463A (en)* | 2005-09-16 | 2008-05-28 | 콜리 파마슈티칼 게엠베하 | Modulation of Immunostimulatory Properties of Short Interfering Ribonucleic Acid (SIRNA) by Nucleotide Modification |
| US20070081972A1 (en)* | 2005-09-30 | 2007-04-12 | The University Of Iowa Research Foundation | Polymer-based delivery system for immunotherapy of cancer |
| JP2009511636A (en) | 2005-10-18 | 2009-03-19 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | Mucosal and systemic immunity with alphavirus replicon particles |
| AU2006306805A1 (en) | 2005-10-28 | 2007-05-03 | Index Pharmaceuticals Ab | Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease |
| CN102755645A (en) | 2005-11-04 | 2012-10-31 | 诺华疫苗和诊断有限公司 | Influenza vaccines with reduced amount of emulsion adjuvant |
| EP1951302A2 (en) | 2005-11-04 | 2008-08-06 | Novartis Vaccines and Diagnostics S.r.l. | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
| ES2420829T3 (en) | 2005-11-04 | 2013-08-27 | Novartis Vaccines And Diagnostics S.R.L. | Vaccines adjuvant with non-virion antigen prepared from influenza viruses grown in cell culture |
| EP1951299B1 (en) | 2005-11-04 | 2012-01-04 | Novartis Vaccines and Diagnostics S.r.l. | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| CN102864152B (en)* | 2005-11-07 | 2015-11-18 | 艾德拉药物股份有限公司 | Comprise the immunostimulatory properties of the compound based on oligonucleotide of modified immunostimulating dinucleotides |
| EP2360175B1 (en) | 2005-11-22 | 2014-07-16 | Novartis Vaccines and Diagnostics, Inc. | Norovirus and Sapovirus virus-like particles (VLPs) |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| NZ569741A (en) | 2005-12-14 | 2012-02-24 | Cytos Biotechnology Ag | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
| KR20080089663A (en) | 2006-01-27 | 2008-10-07 | 노바티스 백신즈 앤드 다이아그노스틱스 게엠베하 운트 콤파니 카게 | Influenza vaccines containing hemagglutinin and matrix proteins |
| ES2526879T3 (en) | 2006-02-15 | 2015-01-16 | Adiutide Pharmaceuticals Gmbh | Compositions and procedures for oligonucleotide formulations |
| EP1988896A4 (en) | 2006-02-22 | 2011-07-27 | 3M Innovative Properties Co | Immune response modifier conjugates |
| EP2253957B1 (en) | 2006-03-14 | 2013-05-15 | Oregon Health and Science University | Methods for producing an immune response to tuberculosis. |
| WO2007109812A2 (en)* | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| ES2536426T3 (en) | 2006-03-23 | 2015-05-25 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| JP2009534303A (en) | 2006-03-24 | 2009-09-24 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー | Preserving influenza vaccines that are not refrigerated |
| US20100285062A1 (en) | 2006-03-31 | 2010-11-11 | Novartis Ag | Combined mucosal and parenteral immunization against hiv |
| WO2007119815A1 (en) | 2006-04-14 | 2007-10-25 | Kyowa Hakko Kirin Co., Ltd. | Toll-like receptor 9 agonists |
| TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
| CA2653939C (en)* | 2006-05-31 | 2013-01-22 | Toray Industries, Inc. | Immunostimulatory oligonucleotides and use thereof in pharmaceuticals |
| US20080026986A1 (en)* | 2006-06-05 | 2008-01-31 | Rong-Fu Wang | Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling |
| US20110206692A1 (en) | 2006-06-09 | 2011-08-25 | Novartis Ag | Conformers of bacterial adhesins |
| EP2032592B1 (en) | 2006-06-12 | 2013-07-31 | Cytos Biotechnology AG | Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages |
| US20100129403A1 (en) | 2006-06-20 | 2010-05-27 | Transgene S.A. | Recombinant viral vaccine |
| US8153116B2 (en) | 2006-07-11 | 2012-04-10 | University Of Connecticut | Use of conditional plasmodium strains lacking an essential gene in malaria vaccination |
| US8128921B2 (en)* | 2006-07-11 | 2012-03-06 | University Of Connecticut | Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination |
| WO2008008432A2 (en)* | 2006-07-12 | 2008-01-17 | Coley Pharmaceutical Group, Inc. | Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods |
| GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| CA2659552A1 (en) | 2006-08-16 | 2008-02-21 | Novartis Ag | Immunogens from uropathogenic escherichia coli |
| WO2008032219A2 (en) | 2006-09-11 | 2008-03-20 | Novartis Ag | Making influenza virus vaccines without using eggs |
| DE102006050655A1 (en)* | 2006-10-24 | 2008-04-30 | Halmon Beheer B.V. | Pharmaceutical composition useful for treating allergic diseases comprises RNA and an allergen |
| AU2007353120A1 (en)* | 2006-10-26 | 2008-11-20 | Coley Pharmaceutical Gmbh | Oligoribonucleotides and uses thereof |
| DK3276349T3 (en) | 2006-11-01 | 2019-10-28 | Ventana Med Syst Inc | HAPTENES, HAPTEN CONJUGATES, COMPOSITIONS THEREOF, AND METHODS FOR PRODUCING AND USING THEREOF |
| WO2008057529A2 (en)* | 2006-11-06 | 2008-05-15 | Coley Pharmaceutical Group, Inc. | Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (cetp) |
| CN101636495A (en) | 2006-11-09 | 2010-01-27 | 戴纳瓦克斯技术公司 | Long term disease modification using immunostimulatory oligonucleotides |
| US20090285819A1 (en)* | 2006-11-15 | 2009-11-19 | Functional Genetics, Inc. | Methods and compositions for treating influenza |
| PL2121011T3 (en) | 2006-12-06 | 2014-10-31 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
| AR064642A1 (en) | 2006-12-22 | 2009-04-15 | Wyeth Corp | POLINUCLEOTIDE VECTOR THAT INCLUDES IT RECOMBINATING CELL THAT UNDERSTANDS THE VECTOR POLYPEPTIDE, ANTIBODY, COMPOSITION THAT UNDERSTANDS THE POLINUCLEOTIDE, VECTOR, RECOMBINATING CELL POLYPEPTIDE OR ANTIBODY, USE OF THE COMPOSITION AND A COMPOSITION AND A METHOD |
| US20080149123A1 (en)* | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
| GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
| JP5596980B2 (en) | 2007-02-28 | 2014-10-01 | アメリカ合衆国 | Brachyury polypeptides and methods of use |
| AU2008239628B2 (en)* | 2007-04-13 | 2014-01-30 | Duke University | Method of inducing neutralizing antibodies to human immunodeficiency virus |
| US8518903B2 (en) | 2007-04-19 | 2013-08-27 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of toll-like receptor-9 agonists |
| EP2377952A1 (en) | 2007-04-26 | 2011-10-19 | Ludwig Institute For Cancer Research | Methods for diagnosing and treating astrocytomas |
| US20100285041A1 (en) | 2007-05-17 | 2010-11-11 | Eugen Uhlmann | Class A Oligonucleotides with Immunostimulatory Potency |
| CA2687535C (en)* | 2007-05-18 | 2017-08-22 | Coley Pharmaceutical Gmbh | Phosphate-modified oligonucleotide analogs with enhanced immunostimulatory activity |
| DK2167963T3 (en) | 2007-05-23 | 2019-06-24 | Ventana Med Syst Inc | Polymer carriers for immunohistochemistry and in situ hybridization |
| EA018201B1 (en)* | 2007-05-24 | 2013-06-28 | Глаксосмитклайн Байолоджикалс С.А. | Lyophilised antigen composition |
| PT2185191E (en) | 2007-06-27 | 2012-11-27 | Novartis Ag | Low-additive influenza vaccines |
| GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
| GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| US7879812B2 (en) | 2007-08-06 | 2011-02-01 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides and methods of use therefor |
| US20090196915A1 (en)* | 2007-08-21 | 2009-08-06 | Gary Van Nest | Composition and methods of making and using influenza proteins |
| MX2010002773A (en) | 2007-09-12 | 2010-03-31 | Novartis Ag | Gas57 mutant antigens and gas57 antibodies. |
| KR20100068422A (en)* | 2007-10-09 | 2010-06-23 | 콜리 파마슈티칼 게엠베하 | Immune stimulatory oligonucleotide analogs containing modified sugar moieties |
| US20110014231A1 (en)* | 2007-11-05 | 2011-01-20 | Mor Research Applications Ltd | Anti-measles cancer immunotherapy |
| EP2217716A4 (en) | 2007-11-09 | 2011-02-09 | Salk Inst For Biological Studi | USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIALS |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| EP3067048B1 (en) | 2007-12-07 | 2018-02-14 | GlaxoSmithKline Biologicals SA | Compositions for inducing immune responses |
| GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| CA2710350A1 (en)* | 2007-12-21 | 2009-07-02 | Wyeth Llc | Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use thereof |
| NZ586430A (en) | 2007-12-21 | 2012-09-28 | Novartis Ag | Mutant forms of streptolysin o (slo) |
| MX2010008148A (en)* | 2008-01-25 | 2010-10-20 | Chimerix Inc | Methods of treating viral infections. |
| CN101932707B (en)* | 2008-01-31 | 2013-08-21 | 库瑞瓦格有限责任公司 | Nucleic acids of formula (i) (nuglxmgnnv)a and derivatives thereof as an immunostimulating agent/adjuvant |
| NZ587382A (en) | 2008-02-21 | 2012-01-12 | Novartis Ag | Meningococcal fhbp polypeptides |
| AU2009223613B2 (en) | 2008-03-10 | 2014-09-25 | Children's Hospital & Research Center At Oakland | Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use |
| ES2535101T3 (en) | 2008-03-18 | 2015-05-05 | Novartis Ag | Improvements in the preparation of antigens in influenza virus vaccine |
| WO2009140626A2 (en) | 2008-05-15 | 2009-11-19 | Dynavax Technologies Corporation | Long term disease modification using immunostimulatory oligonucleotides |
| WO2009143292A2 (en) | 2008-05-21 | 2009-11-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating pneumoconiosis with oligodeoxynucleotides |
| ES2906426T3 (en) | 2008-06-05 | 2022-04-18 | Ventana Med Syst Inc | Composition for histochemical processing |
| RU2010151562A (en) | 2008-06-20 | 2012-07-27 | ВАЙЕТ ЭлЭлСи (US) | COMPOSITIONS AND METHODS OF APPLICATION OF ORF1358 FROM BETA-HEMOLYTIC STRAPTOCOK STRAINS |
| ES2569907T3 (en) | 2008-06-27 | 2016-05-13 | Zoetis Services Llc | Novel adjuvant compositions |
| TWI351288B (en)* | 2008-07-04 | 2011-11-01 | Univ Nat Pingtung Sci & Tech | Cpg dna adjuvant in avian vaccines |
| US20110136897A1 (en)* | 2008-08-14 | 2011-06-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Toll-like receptor 9 agonists for the treatment of anxiety-related disorders and inflammatory disorders |
| EP4071169A2 (en) | 2008-08-25 | 2022-10-12 | Dana Farber Cancer Institute, Inc. | Conserved influenza hemagglutinin epitope and antibodies thereto |
| EP2331127A2 (en) | 2008-09-18 | 2011-06-15 | Novartis AG | Vaccine adjuvant combinations |
| CN102187224A (en) | 2008-09-22 | 2011-09-14 | 俄勒冈健康科学大学 | Methods for detecting a mycobacterium tuberculosis infection |
| EP2344522B1 (en)* | 2008-10-16 | 2016-01-27 | The University of Saskatchewan | Combination adjuvant formulation |
| US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
| CN102203122A (en) | 2008-11-05 | 2011-09-28 | 惠氏有限责任公司 | Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease |
| EP2346529B1 (en)* | 2008-11-12 | 2016-02-10 | Theraclone Sciences, Inc. | Human m2e peptide immunogens |
| ES2616051T3 (en) | 2008-12-02 | 2017-06-09 | Wave Life Sciences Japan, Inc. | Method for the synthesis of modified nucleic acids in the phosphorus atom |
| SG10201400388QA (en) | 2008-12-09 | 2014-05-29 | Pfizer Vaccines Llc | IgE CH3 peptide vaccine |
| NZ593220A (en) | 2008-12-09 | 2012-10-26 | Coley Pharm Group Inc | Immunostimulatory oligonucleotides |
| US8552165B2 (en)* | 2008-12-09 | 2013-10-08 | Heather Davis | Immunostimulatory oligonucleotides |
| BRPI1005670A8 (en) | 2009-01-05 | 2017-12-26 | Epitogenesis Inc | adjuvant compositions and processes of use. |
| US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
| NZ594029A (en) | 2009-01-12 | 2014-01-31 | Novartis Ag | Cna_b domain antigens in vaccines against gram positive bacteria |
| US8664183B2 (en) | 2009-02-27 | 2014-03-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | SPANX-B polypeptides and their use |
| CN102438650A (en) | 2009-03-06 | 2012-05-02 | 诺华有限公司 | Chlamydia antigens |
| AU2010230073B2 (en) | 2009-03-23 | 2016-05-26 | Pin Pharma, Inc. | Treatment of cancer with immunostimulatory HIV Tat derivative polypeptides |
| BRPI1009828A2 (en) | 2009-03-24 | 2019-03-12 | Novartis Ag | meningococcal h factor binding protein adjuvant |
| PT2411521E (en) | 2009-03-25 | 2015-04-21 | Univ Texas | Compositions for stimulation of mammalian innate immune resistance to pathogens |
| AU2010232915A1 (en) | 2009-04-03 | 2011-10-20 | Duke University | Formulation for inducing broadly reactive neutralizing anti-HIV antibodies |
| AU2010232490B2 (en) | 2009-04-03 | 2016-08-11 | Agenus Inc. | Methods for preparing and using multichaperone-antigen complexes |
| HUE028803T2 (en) | 2009-04-14 | 2017-01-30 | Glaxosmithkline Biologicals Sa | Compositions for immunising against Staphylococcus aureus |
| JP2012524780A (en)* | 2009-04-21 | 2012-10-18 | セレクタ バイオサイエンシーズ インコーポレーテッド | Immunonanotherapeutics that produce a Th1 bias response |
| ES2552153T3 (en) | 2009-04-30 | 2015-11-26 | Coley Pharmaceutical Group, Inc. | Pneumococcal vaccine and uses thereof |
| US20100303850A1 (en) | 2009-05-27 | 2010-12-02 | Selecta Biosciences, Inc. | Nanocarriers possessing components with different rates of release |
| WO2010146414A1 (en) | 2009-06-15 | 2010-12-23 | National University Of Singapore | Influenza vaccine, composition, and methods of use |
| CA2766418C (en) | 2009-06-22 | 2016-03-29 | Wyeth Llc | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
| CN107096020A (en) | 2009-06-22 | 2017-08-29 | 惠氏有限责任公司 | The immunogenic composition of staphylococcus aureus antigen |
| EP2451461A4 (en) | 2009-07-06 | 2013-05-29 | Ontorii Inc | NOVEL NUCLEIC ACID PRECURSORS AND THEIR METHODS OF USE |
| TW201116294A (en) | 2009-07-15 | 2011-05-16 | Novartis Ag | RSV F protein compositions and methods for making same |
| CN102770443A (en) | 2009-07-16 | 2012-11-07 | 诺华有限公司 | Detoxified Escherichia coli immunogen |
| WO2011007961A2 (en) | 2009-07-17 | 2011-01-20 | Industry Academic Cooperation Foundation, Hallym University | Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitpoes |
| US8614200B2 (en) | 2009-07-21 | 2013-12-24 | Chimerix, Inc. | Compounds, compositions and methods for treating ocular conditions |
| NZ598356A (en) | 2009-07-30 | 2014-06-27 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
| US20110033515A1 (en)* | 2009-08-04 | 2011-02-10 | Rst Implanted Cell Technology | Tissue contacting material |
| MX2012002133A (en)* | 2009-08-18 | 2013-02-15 | Baxter Healthcare Sa | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics. |
| US8598327B2 (en) | 2009-08-18 | 2013-12-03 | Baxter International Inc. | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
| CA2771863A1 (en) | 2009-08-26 | 2011-03-17 | Selecta Biosciences, Inc. | Compositions that induce t cell help |
| JP2013502918A (en) | 2009-08-27 | 2013-01-31 | ノバルティス アーゲー | Hybrid polypeptide comprising Neisseria meningitidis fHBP sequence |
| EP2470205A1 (en) | 2009-08-27 | 2012-07-04 | Novartis AG | Adjuvant comprising aluminium, oligonucleotide and polycation |
| WO2011026111A1 (en) | 2009-08-31 | 2011-03-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Oral delivery of a vaccine to the large intestine to induce mucosal immunity |
| AU2010290931B2 (en) | 2009-09-03 | 2014-02-06 | Pfizer Vaccines Llc | PCSK9 vaccine |
| JP2013504556A (en) | 2009-09-10 | 2013-02-07 | ノバルティス アーゲー | Combination vaccine for respiratory tract disease |
| GB0917003D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Purification of bacterial vesicles |
| GB0917002D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Improved shigella blebs |
| CN102724988B (en) | 2009-09-30 | 2014-09-10 | 诺华股份有限公司 | Expression of meningococcal fHBP polypeptides |
| ES2812523T3 (en) | 2009-09-30 | 2021-03-17 | Glaxosmithkline Biologicals Sa | Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides |
| BR112012009401A2 (en) | 2009-10-07 | 2017-02-21 | Uvic Ind Partnerships Inc | vaccines comprising heat sensitive transgenes |
| WO2011047340A1 (en) | 2009-10-16 | 2011-04-21 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine |
| GB0918392D0 (en) | 2009-10-20 | 2009-12-02 | Novartis Ag | Diagnostic and therapeutic methods |
| US20130022633A1 (en) | 2009-10-27 | 2013-01-24 | University Of Florence | MENINGOCOCCAL fHBP POLYPEPTIDES |
| GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
| EP3360566B1 (en) | 2009-11-20 | 2019-12-25 | Oregon Health&Science University | Methods for detecting a mycobacterium tuberculosis infection |
| EP2515934B1 (en) | 2009-12-22 | 2017-05-17 | Celldex Therapeutics, Inc. | Vaccine compositions |
| EP3216789A1 (en) | 2010-02-12 | 2017-09-13 | Chimerix, Inc. | Methods of treating viral infection |
| GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
| US8685416B2 (en) | 2010-03-02 | 2014-04-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for the treatment of cancer |
| EP2542670A2 (en) | 2010-03-05 | 2013-01-09 | President and Fellows of Harvard College | Induced dendritic cell compositions and uses thereof |
| WO2011112599A2 (en) | 2010-03-12 | 2011-09-15 | The United States Of America, As Represented By The Secretary. Department Of Health & Human Services | Immunogenic pote peptides and methods of use |
| BR112012022896A2 (en) | 2010-03-18 | 2018-03-27 | Novartis Ag | adjuvant vaccines for serogroup b meningococci |
| US9827300B2 (en) | 2010-03-30 | 2017-11-28 | Children's Hospital & Research Center Oakland | Factor H binding proteins (FHBP) with altered properties and methods of use thereof |
| GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
| JP2013529894A (en) | 2010-04-07 | 2013-07-25 | ノバルティス アーゲー | Method for generating parvovirus B19 virus-like particles |
| CA2796314A1 (en) | 2010-04-13 | 2011-10-20 | Novartis Ag | Benzonapthyridine compositions and uses thereof |
| WO2011139709A2 (en) | 2010-04-26 | 2011-11-10 | Chimerix, Inc. | Methods of treating retroviral infections and related dosage regimes |
| HUE049725T2 (en) | 2010-05-14 | 2020-10-28 | Univ Oregon Health & Science | Recombinant hcmv and rhcmv vectors encoding a heterologous antigen isolated from hepatitis b virus and uses thereof |
| WO2011150240A1 (en) | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Nanocarrier compositions with uncoupled adjuvant |
| WO2011148356A1 (en) | 2010-05-28 | 2011-12-01 | Coley Pharmaceutical Group, Inc. | Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules |
| WO2011149564A1 (en) | 2010-05-28 | 2011-12-01 | Tetris Online, Inc. | Interactive hybrid asynchronous computer game infrastructure |
| NZ772688A (en) | 2010-06-03 | 2022-09-30 | Pharmacyclics Llc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
| PT3170508T (en) | 2010-06-04 | 2020-01-16 | Wyeth Llc | Vaccine formulations |
| CA2800774A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Ige ch3 peptide vaccine |
| GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
| WO2011161653A1 (en) | 2010-06-25 | 2011-12-29 | Novartis Ag | Combinations of meningococcal factor h binding proteins |
| US20130171185A1 (en) | 2010-07-06 | 2013-07-04 | Ethan Settembre | Norovirus derived immunogenic compositions and methods |
| US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| HRP20240965T1 (en) | 2010-08-23 | 2024-10-25 | Wyeth Llc | STABLE FORMULATIONS OF ANTIGEN RLP2086 FROM NEISSERIA MENINGITIDIS BACTERIA |
| SG187912A1 (en) | 2010-09-10 | 2013-04-30 | Wyeth Llc | Non-lipidated variants of neisseria meningitidis orf2086 antigens |
| AU2011302360B2 (en) | 2010-09-14 | 2015-01-29 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for influenza |
| GB201101665D0 (en) | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
| JP5868324B2 (en) | 2010-09-24 | 2016-02-24 | 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ | Asymmetric auxiliary group |
| US10668092B2 (en) | 2010-09-24 | 2020-06-02 | The John Hopkins University | Compositions and methods for treatment of inflammatory disorders |
| US9072760B2 (en) | 2010-09-24 | 2015-07-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | TLR4 inhibitors for the treatment of human infectious and inflammatory disorders |
| GB201017519D0 (en) | 2010-10-15 | 2010-12-01 | Novartis Vaccines Inst For Global Health S R L | Vaccines |
| US9994443B2 (en) | 2010-11-05 | 2018-06-12 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
| WO2012072769A1 (en) | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations |
| EP2468866A1 (en)* | 2010-12-21 | 2012-06-27 | Index Pharmaceuticals AB | Biologically active oligonucleotides capable of modulating the immune system |
| WO2012088425A2 (en) | 2010-12-22 | 2012-06-28 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease |
| TR201906323T4 (en) | 2010-12-22 | 2019-05-21 | Bayer Ip Gmbh | Enhanced immune response in bovine species. |
| SI3150222T1 (en) | 2010-12-22 | 2020-02-28 | Wyeth Llc | Stable immunogenic compositions of staphylococcus aureus antigens |
| GB201021867D0 (en) | 2010-12-23 | 2011-02-02 | Mologen Ag | Non-coding immunomodulatory DNA construct |
| WO2012085668A2 (en) | 2010-12-24 | 2012-06-28 | Novartis Ag | Compounds |
| EP2471926A3 (en)* | 2010-12-30 | 2012-07-11 | Intervet International BV | Immunostimulatory oligodeoxynucleotides |
| TR201908715T4 (en) | 2011-01-26 | 2019-07-22 | Glaxosmithkline Biologicals Sa | Rsv immunization regimen. |
| WO2012109675A1 (en) | 2011-02-11 | 2012-08-16 | Baxter International Inc. | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
| EP2680883B1 (en) | 2011-03-02 | 2018-09-05 | Pfizer Inc | Pcsk9 vaccine |
| EP3632463A1 (en) | 2011-04-08 | 2020-04-08 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| US9452212B2 (en) | 2011-04-14 | 2016-09-27 | Dynavax Technologies Corporation | Methods and compositions for eliciting an immune response against hepatitis B virus |
| WO2012149307A2 (en) | 2011-04-27 | 2012-11-01 | Immune Design Corp. | Synthetic long peptide (slp)-based vaccines |
| EP2707385B1 (en) | 2011-05-13 | 2017-09-20 | GlaxoSmithKline Biologicals SA | Pre-fusion rsv f antigens |
| FR2975600B1 (en) | 2011-05-24 | 2013-07-05 | Assist Publ Hopitaux De Paris | AGENTS FOR THE TREATMENT OF TUMORS |
| TR201808393T4 (en)* | 2011-05-26 | 2018-07-23 | Intervet Int Bv | Immunostimulatory oligodeoxynucleotides. |
| EP2713737B1 (en) | 2011-06-01 | 2016-04-20 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
| JP6093759B2 (en) | 2011-06-01 | 2017-03-08 | ジャナス バイオセラピューティクス，インク． | Novel immune system modulators |
| BR112013031039B1 (en) | 2011-06-03 | 2020-04-28 | 3M Innovative Properties Co | hydrazine compounds 1h-imidazoquinoline-4-amines, conjugates made from these compounds, composition and pharmaceutical composition comprising said compounds and conjugates, uses thereof and method of manufacturing the conjugate |
| MX347240B (en) | 2011-06-03 | 2017-04-20 | 3M Innovative Properties Co | Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom. |
| JP6158796B2 (en) | 2011-06-17 | 2017-07-05 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | Group A Streptococcus multivalent vaccine |
| WO2012177760A1 (en) | 2011-06-20 | 2012-12-27 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for h1n1 influenza |
| ITMI20111182A1 (en) | 2011-06-28 | 2012-12-29 | Canio Buonavoglia | VACCINE FOR CORONAVIRUS CANINO |
| WO2013006838A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
| CA2841047A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
| WO2013007703A1 (en)* | 2011-07-08 | 2013-01-17 | Universität Zürich | CLASS A CpG OLIGONUCLEOTIDES FOR PREVENTION OF VIRAL INFECTION IN CATS |
| EP2729178A1 (en) | 2011-07-08 | 2014-05-14 | Novartis AG | Tyrosine ligation process |
| US9605019B2 (en) | 2011-07-19 | 2017-03-28 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| US20130023736A1 (en) | 2011-07-21 | 2013-01-24 | Stanley Dale Harpstead | Systems for drug delivery and monitoring |
| US10030052B2 (en) | 2011-07-25 | 2018-07-24 | Glaxosmithkline Biologicals Sa | Parvovirus Vp1 unique region polypeptides and compositions thereof |
| BR112014002139A2 (en) | 2011-07-29 | 2017-02-21 | Selecta Biosciences Inc | synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses |
| GB201114923D0 (en) | 2011-08-30 | 2011-10-12 | Novartis Ag | Immunogenic proteins and compositions |
| US20140348865A1 (en) | 2011-09-12 | 2014-11-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Ser. | Immunogens based on an hiv-1 v1v2 site-of-vulnerability |
| EP2755994A2 (en) | 2011-09-14 | 2014-07-23 | Novartis AG | Escherichia coli vaccine combination |
| WO2013038375A2 (en) | 2011-09-14 | 2013-03-21 | Novartis Ag | Methods for making saccharide-protein glycoconjugates |
| WO2013049535A2 (en) | 2011-09-30 | 2013-04-04 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Influenza vaccine |
| US9873694B2 (en) | 2011-10-04 | 2018-01-23 | Janus Biotherapeutics, Inc. | Imidazole quinoline-based immune system modulators |
| AU2012326079B2 (en) | 2011-10-20 | 2017-01-12 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes |
| AU2012335208B2 (en) | 2011-11-07 | 2017-08-31 | Glaxosmithkline Biologicals S.A. | Carrier molecule comprising a spr0096 and a spr2021 antigen |
| EP2788022B1 (en) | 2011-12-08 | 2018-10-31 | GlaxoSmithKline Biologicals SA | Clostridium difficile toxin-based vaccine |
| EA201491081A1 (en) | 2012-01-16 | 2016-11-30 | Элизабет Маккенна | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES AND LIVER DISORDERS |
| US12268718B2 (en) | 2012-01-16 | 2025-04-08 | Labyrinth Holdings Llc | Control of cellular redox levels |
| WO2013108272A2 (en) | 2012-01-20 | 2013-07-25 | International Centre For Genetic Engineering And Biotechnology | Blood stage malaria vaccine |
| CA2863981A1 (en) | 2012-02-07 | 2013-08-15 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses |
| SG11201404147YA (en) | 2012-02-13 | 2014-10-30 | Univ Pittsburgh | Computationally optimized broadly reactive antigens for human and avian h5n1 influenza |
| US20150273042A1 (en) | 2012-02-24 | 2015-10-01 | Novartis Ag | Pilus proteins and compositions |
| CN104334187B (en) | 2012-03-09 | 2017-04-05 | 辉瑞公司 | Diplococcus meningitidis composition and its method |
| SA115360586B1 (en) | 2012-03-09 | 2017-04-12 | فايزر انك | Neisseria meningitidis compositions and methods thereof |
| WO2013142808A1 (en) | 2012-03-23 | 2013-09-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pathogenic phlebovirus isolates and compositions and methods of use |
| EP2841098A4 (en) | 2012-04-23 | 2016-03-02 | Allertein Therapeutics Llc | Nanoparticles for treatment of allergy |
| US10279026B2 (en) | 2012-04-26 | 2019-05-07 | Glaxosmithkline Biologicals Sa | Antigens and antigen combinations |
| BR112014026812A8 (en) | 2012-04-26 | 2022-10-04 | Novartis Ag | ANTIGENS AND ANTIGEN COMBINATIONS |
| US10076535B2 (en) | 2012-04-27 | 2018-09-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of CPG oligonucleotides co-formulated with an antibiotic to accelerate wound healing |
| BR112014027128A2 (en) | 2012-05-04 | 2017-08-08 | Pfizer | prostate-associated antigens and vaccine-based immunotherapy regimens |
| JP2015518845A (en) | 2012-05-22 | 2015-07-06 | ノバルティス アーゲー | Neisseria meningitidis serogroup X conjugate |
| US9409956B2 (en) | 2012-05-23 | 2016-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Salmonella typhi Ty21a expressing Yersinia pestis F1-V fusion protein and uses thereof |
| US9427476B2 (en) | 2012-05-24 | 2016-08-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Multivalent meningococcal conjugates and methods for preparing conjugates |
| RU2621450C2 (en) | 2012-06-19 | 2017-06-06 | Вольво Ластвагнар Аб | Device for controlling gas stream, after-treatment system of exhaust gases and propulsion system for means of transport |
| US9687542B2 (en) | 2012-06-19 | 2017-06-27 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Rift valley fever virus replicon particles and use thereof |
| KR102057217B1 (en) | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| CN104853770A (en) | 2012-07-06 | 2015-08-19 | 诺华股份有限公司 | Immunogenic compositions and uses thereof |
| RU2693381C2 (en) | 2012-07-13 | 2019-07-02 | Уэйв Лайф Сайенсес Лтд. | Asymmetric auxiliary group |
| BR112015000723A2 (en) | 2012-07-13 | 2017-06-27 | Shin Nippon Biomedical Laboratories Ltd | chiral nucleic acid adjuvant |
| SG10201912895PA (en) | 2012-07-13 | 2020-02-27 | Wave Life Sciences Ltd | Chiral control |
| CN104854128A (en) | 2012-07-19 | 2015-08-19 | 硕腾有限责任公司 | Bovine influenza virus compositions |
| AU2013293087B2 (en) | 2012-07-24 | 2017-08-31 | Pharmacyclics Llc | Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK) |
| WO2014018724A1 (en) | 2012-07-27 | 2014-01-30 | Zoetis Llc | Tick toxin compositions |
| PL2885007T3 (en) | 2012-08-16 | 2019-02-28 | Pfizer Inc. | Glycoconjugation processes and compositions |
| WO2014037124A1 (en) | 2012-09-04 | 2014-03-13 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
| WO2014043535A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
| US20150224181A1 (en) | 2012-09-14 | 2015-08-13 | The United States Of America As Represented By The Secretary Department Of Health And Human Se | Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use |
| CN104602702B (en) | 2012-09-18 | 2021-08-27 | 葛兰素史密丝克莱恩生物有限公司 | Outer membrane vesicles |
| EP2898073A4 (en) | 2012-09-21 | 2016-03-23 | Elizabeth Mckenna | Naturally occurring cpg oligonucleotide compositions and therapeutic applications thereof |
| WO2014052453A1 (en)* | 2012-09-25 | 2014-04-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oral therapy of necrotizing enterocolitis |
| RU2015106745A (en) | 2012-10-03 | 2016-11-27 | Глэксосмитклайн Байолоджикалз Са | IMMUNOGENIC COMPOSITIONS |
| EA201590822A1 (en) | 2012-11-02 | 2016-01-29 | Фармасайкликс, Инк. | ADJUVANT THERAPY INHIBITOR KINASE OF THE FAMILY TEC |
| WO2014074785A1 (en) | 2012-11-08 | 2014-05-15 | Ludwig Institute For Cancer Research Ltd. | Methods of predicting outcome and treating breast cancer |
| KR20140075201A (en) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| KR20140075196A (en) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| TWI465241B (en) | 2012-12-19 | 2014-12-21 | Ind Tech Res Inst | Use of an extract of juniperus chinensis or lignan for manufacturing a medicament for inhibiting angiogenesis |
| KR101980989B1 (en) | 2012-12-20 | 2019-05-21 | 화이자 인코포레이티드 | Glycoconjugation process |
| WO2014116730A2 (en) | 2013-01-23 | 2014-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Stabilized hepatitis b core polypeptide |
| US11576958B2 (en) | 2013-02-07 | 2023-02-14 | Children's Medical Center Corporation | Protein antigens that provide protection against pneumococcal colonization and/or disease |
| WO2014136064A2 (en) | 2013-03-08 | 2014-09-12 | Pfizer Inc. | Immunogenic fusion polypeptides |
| CN105188744A (en) | 2013-03-14 | 2015-12-23 | 哈佛大学的校长及成员们 | Nanoparticle-based compositions |
| AU2014234982A1 (en) | 2013-03-15 | 2015-09-24 | Zoetis Services Llc | Cross-protection of bovines against B. trehalosi infection by a multi-valent vaccine |
| DE102013004595A1 (en) | 2013-03-15 | 2014-09-18 | Emergent Product Development Germany Gmbh | RSV vaccines |
| JP2016516754A (en) | 2013-04-03 | 2016-06-09 | アラーテイン・セラピューティクス・リミテッド・ライアビリティ・カンパニーＡｌｌｅｒｔｅｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ | Novel nanoparticle composition |
| JP2016518126A (en) | 2013-04-19 | 2016-06-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Lone Star Virus |
| AR095882A1 (en) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | ANTIBODY COMBINATION THERAPY AGAINST HUMAN CSF-1R WITH A TLR9 AGONIST |
| CN103550783A (en)* | 2013-04-27 | 2014-02-05 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Nucleic acid drug targeting delivery system and preparation method thereof |
| US20210145963A9 (en) | 2013-05-15 | 2021-05-20 | The Governors Of The University Of Alberta | E1e2 hcv vaccines and methods of use |
| WO2014201245A1 (en) | 2013-06-12 | 2014-12-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors |
| TWI535451B (en)* | 2013-07-19 | 2016-06-01 | 財團法人國家衛生研究院 | Cpg-oligodeoxynucleotide, immunogenic composition comprising the same, and use of preparation of medicament for treatment in stimulating immune response |
| ES2750608T3 (en) | 2013-07-25 | 2020-03-26 | Exicure Inc | Nucleic acid-based spherical constructs as immunostimulatory agents for prophylactic and therapeutic use |
| US9919029B2 (en) | 2013-07-26 | 2018-03-20 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of bacterial infections |
| RU2662968C2 (en) | 2013-09-08 | 2018-07-31 | Пфайзер Инк. | Immunogenic composition for neisseria meningitidis (options) |
| AR097584A1 (en) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | ANTIBODY COMBINATION THERAPY AGAINST HUMAN CSF-1R AND ANTIBODIES AGAINST HUMAN PD-L1 |
| CN109675029A (en) | 2013-09-19 | 2019-04-26 | 硕腾服务有限责任公司 | Oil-based adjuvants |
| US10076567B2 (en) | 2013-09-27 | 2018-09-18 | Duke University | MPER-liposome conjugates and uses thereof |
| ES2957209T3 (en) | 2013-09-30 | 2024-01-15 | Triad Nat Security Llc | Conserved region HIV mosaic immunogenic polypeptides |
| WO2015051245A1 (en) | 2013-10-04 | 2015-04-09 | Pin Pharma, Inc. | Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment |
| RU2018108259A (en) | 2013-11-01 | 2019-02-25 | Пфайзер Инк. | Vectors for the expression of prostate-associated antigens |
| EP2870974A1 (en) | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
| EP3074517B1 (en) | 2013-11-28 | 2021-08-11 | Bavarian Nordic A/S | Compositions and methods for inducing an enhanced immune response using poxvirus vectors |
| AU2014383024B2 (en)* | 2013-12-03 | 2020-04-30 | Exicure, Inc. | Liposomal particles, methods of making same and uses thereof |
| JP6758185B2 (en) | 2013-12-13 | 2020-09-23 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Multiepitope TARP peptide vaccine and its use |
| WO2015095868A1 (en) | 2013-12-20 | 2015-06-25 | Wake Forest University Health Sciences | Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines |
| US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| EP3095459A4 (en)* | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent |
| US10144933B2 (en) | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| CA2936712A1 (en) | 2014-01-16 | 2015-07-23 | Meena | Chiral design |
| IL312327A (en) | 2014-01-21 | 2024-06-01 | Pfizer | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CA2935722A1 (en) | 2014-01-21 | 2015-07-30 | Immune Design Corp. | Compositions for use in the treatment of allergic conditions |
| PL3583947T3 (en) | 2014-01-21 | 2024-04-02 | Pfizer Inc. | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| EP3957321A3 (en) | 2014-01-21 | 2022-07-13 | Pfizer Inc. | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof |
| WO2016130569A1 (en) | 2015-02-09 | 2016-08-18 | Mj Biologics, Inc. | A composition comprising pedv antigens and methods for making and using the composition |
| US10279019B2 (en) | 2014-02-11 | 2019-05-07 | Stc.Unm | PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same |
| ES2701169T3 (en) | 2014-02-14 | 2019-02-21 | Pfizer | Immunogenic glycoprotein conjugates |
| GB2523187A (en) | 2014-02-18 | 2015-08-19 | Mologen Ag | Covalently closed non-coding immunomodulatory DNA construct |
| EP3556353A3 (en) | 2014-02-25 | 2020-03-18 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| CA2940794C (en)* | 2014-02-28 | 2022-05-31 | Bayer Animal Health Gmbh | Immunostimulatory plasmids |
| WO2015138455A1 (en) | 2014-03-11 | 2015-09-17 | Regents Of The University Of Minnesota | Porcine epidemic diarrhea virus vaccines and methods of use thereof |
| US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
| MX377794B (en) | 2014-03-26 | 2025-03-10 | Glaxosmithkline Biologicals Sa | MUTANT STAPHYLOCOCCAL ANTIGENS. |
| US9549914B2 (en) | 2014-04-03 | 2017-01-24 | The Johns Hopkins University | Treatment of human cytomegalovirus by modulating Wnt |
| US10111948B2 (en) | 2014-04-25 | 2018-10-30 | Tria Bioscience Corp. | Synthetic hapten carrier compositions and methods |
| CN106572978A (en)* | 2014-05-23 | 2017-04-19 | G·柯琼 | Coating method and materials |
| EP3149479A2 (en) | 2014-05-30 | 2017-04-05 | Sanofi Pasteur Inc. | Expression and conformational analysis of engineered influenza hemagglutinin |
| CA2953216C (en) | 2014-06-04 | 2020-12-22 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| WO2015200728A1 (en) | 2014-06-25 | 2015-12-30 | Selecta Biosciences, Inc. | Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors |
| US20170196954A1 (en) | 2014-07-15 | 2017-07-13 | Immune Design Corp. | Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector |
| EP3183251A4 (en) | 2014-08-22 | 2017-12-27 | Janus Biotherapeutics, Inc. | Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof |
| US10286065B2 (en) | 2014-09-19 | 2019-05-14 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
| US10208310B2 (en) | 2014-10-06 | 2019-02-19 | Exicure, Inc. | Anti-TNF compounds |
| US20160129097A1 (en)* | 2014-11-06 | 2016-05-12 | Jeremy Delk | Method of processing a veterinary tumor vaccine and a veterinary tumor vaccine processing kit |
| AU2015349680A1 (en) | 2014-11-21 | 2017-06-08 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| WO2016103531A1 (en)* | 2014-12-26 | 2016-06-30 | 国立研究開発法人医薬基盤・健康・栄養研究所 | Use of nucleic acid-polysaccharide complexes having immunopotentiating activity as anti-tumor drug |
| JP6885867B2 (en) | 2014-12-31 | 2021-06-16 | チェックメイト ファーマシューティカルズ， インコーポレイテッド | Combination tumor immunotherapy |
| DK3244917T5 (en) | 2015-01-15 | 2024-10-14 | Pfizer | Immunogenic compositions for use in pneumococcal vaccines |
| SI3244920T1 (en) | 2015-01-16 | 2023-09-29 | The United States of America, represented by The Secretary of Agriculture, United States Department of Agriculture | Foot-and-mouth disease vaccine |
| US20180036334A1 (en) | 2015-02-13 | 2018-02-08 | Icahn School Of Medicine At Mount Sinai | Rna containing compositions and methods of their use |
| KR20170103009A (en) | 2015-02-19 | 2017-09-12 | 화이자 인코포레이티드 | Nacelia meningitidis composition and method thereof |
| WO2016145432A1 (en) | 2015-03-12 | 2016-09-15 | Zoetis Services Llc | Pyolysin methods and compositions |
| PE20220774A1 (en) | 2015-05-04 | 2022-05-16 | Pfizer | GROUP B STREPTOCOCCO PROTEIN-POLYSACCHARIDE CONJUGATES, METHODS FOR PRODUCING CONJUGATES, IMMUNOGEN COMPOSITIONS COMPRISING CONJUGATES, AND THEIR USES |
| WO2016180852A1 (en) | 2015-05-12 | 2016-11-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preparing antigen-specific t cells from an umbilical cord blood sample |
| EA201792501A1 (en) | 2015-05-13 | 2018-10-31 | Эйдженус Инк. | VACCINES FOR THE TREATMENT AND PREVENTION OF CANCER |
| WO2016183371A1 (en) | 2015-05-13 | 2016-11-17 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for the treatment or prevention of ischemic tissue damage |
| US10584148B2 (en) | 2015-06-02 | 2020-03-10 | Sanofi Pasteur Inc. | Engineered influenza antigenic polypeptides and immunogenic compositions thereof |
| EP3307307A4 (en) | 2015-06-09 | 2019-05-01 | The Board of Regents of the University of Oklahoma | COMPOSITIONS AND TREATMENTS FOR HAEMOPHILUS INFLUENZAE |
| US10954492B2 (en) | 2015-06-10 | 2021-03-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Processes for production and purification of nucleic acid-containing compositions |
| WO2016207853A2 (en) | 2015-06-26 | 2016-12-29 | Seqirus UK Limited | Antigenically matched influenza vaccines |
| US10449212B2 (en) | 2015-07-09 | 2019-10-22 | National Institute For Materials Science | Immunostimulating oligonucleotide complex |
| TWI684461B (en) | 2015-07-21 | 2020-02-11 | 美商輝瑞股份有限公司 | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| CA2993076A1 (en) | 2015-07-22 | 2017-01-26 | University Of Saskatchewan | Mycoplasma vaccines and uses thereof |
| MX2018001251A (en) | 2015-07-31 | 2018-03-26 | Bayer Animal Health Gmbh | Enhanced immune response in porcine species. |
| US11389518B2 (en) | 2015-08-14 | 2022-07-19 | Zoetis Services Llc | Mycoplasma bovis compositions |
| US11065283B2 (en) | 2015-08-25 | 2021-07-20 | Babita Agrawal | Immunomodulatory compositions and methods of use thereof |
| EP3344276B1 (en) | 2015-09-03 | 2020-04-22 | The Board of Regents of the University of Oklahoma | Peptide inhibitors of clostridium difficile tcdb toxin |
| LU92821B1 (en) | 2015-09-09 | 2017-03-20 | Mologen Ag | Combination comprising immunostimulatory oligonucleotides |
| CN108024914A (en) | 2015-09-17 | 2018-05-11 | Jrx生物技术有限公司 | Improve the method for the aquation or wetting action of skin |
| GB2542425A (en) | 2015-09-21 | 2017-03-22 | Mologen Ag | Means for the treatment of HIV |
| US10526309B2 (en) | 2015-10-02 | 2020-01-07 | The University Of North Carolina At Chapel Hill | Pan-TAM inhibitors and Mer/Axl dual inhibitors |
| US10548970B2 (en) | 2015-10-05 | 2020-02-04 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human rotavirus G9P[6] strain and use as a vaccine |
| EP4491735A3 (en) | 2015-10-08 | 2025-04-16 | The Governors of the University of Alberta | Hepatitis c virus e1/e2 heterodimers and methods of producing same |
| JP7171433B2 (en) | 2015-10-30 | 2022-11-15 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Compositions and methods for treatment of HER-2 expressing solid tumors |
| WO2017085586A1 (en) | 2015-11-20 | 2017-05-26 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| CA3006779A1 (en) | 2015-12-09 | 2017-06-15 | Admedus Vaccines Pty Ltd | Immunomodulating composition for treatment |
| EP3402878A1 (en) | 2016-01-11 | 2018-11-21 | Zoetis Services LLC | Novel cross protective vaccine compositions for porcine epidemic diarrhea virus |
| ES2921605T3 (en) | 2016-01-29 | 2022-08-30 | Bavarian Nordic As | Equine encephalitis virus vaccine based on recombinant Ankara modified vaccinia virus (AMV) |
| WO2017189448A1 (en) | 2016-04-25 | 2017-11-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bivalent immunogenic conjugate for malaria and typhoid |
| WO2017192874A1 (en) | 2016-05-04 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Albumin-binding immunomodulatory compositions and methods of use thereof |
| WO2017201390A1 (en) | 2016-05-19 | 2017-11-23 | The Regents Of The University Of Michigan | Novel adjuvant compositions |
| US11033615B2 (en) | 2016-05-31 | 2021-06-15 | The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland | Zika virus vaccine and methods of production |
| AU2017272344B2 (en) | 2016-06-02 | 2022-03-03 | Sanofi Pasteur Inc. | Engineered influenza antigenic polypeptides and immunogenic compositions thereof |
| CN115746107A (en) | 2016-06-03 | 2023-03-07 | 圣诺菲·帕斯图尔公司 | Modification of engineered influenza hemagglutinin polypeptides |
| BR112018075513A2 (en) | 2016-06-13 | 2019-10-01 | Us Health | nucleic acids encoding Zika virus-like particles and their use in vaccines and Zika virus diagnostic testing |
| US11191822B2 (en) | 2016-06-22 | 2021-12-07 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Pneumococcal polysaccharide-protein conjugate composition |
| EP3269385A1 (en) | 2016-07-12 | 2018-01-17 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Pneumococcal polysaccharide-protein conjugate composition |
| WO2018009603A1 (en) | 2016-07-08 | 2018-01-11 | The United State of America, as represented by the Secretary, Department of Health and Human Service | Chimeric west nile/zika viruses and methods of use |
| CA3030154A1 (en) | 2016-07-08 | 2018-01-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric dengue/zika viruses live-attenuated zika virus vaccines |
| BR112019001971A2 (en) | 2016-08-05 | 2019-05-07 | Sanofi Pasteur, Inc. | multivalent pneumococcal polysaccharide-protein conjugate composition |
| EP3493840B1 (en) | 2016-08-05 | 2022-08-24 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US10182146B2 (en)* | 2016-08-22 | 2019-01-15 | Nice Ltd. | System and method for dynamic redundant call recording |
| WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
| CN109790220A (en) | 2016-08-25 | 2019-05-21 | 豪夫迈·罗氏有限公司 | The anti-CSF-1R antibody combined with macrophage activation agent is administered intermittently |
| US10172933B2 (en) | 2016-10-31 | 2019-01-08 | The United States Of America, As Represented By The Secretary Of Agriculture | Mosaic vaccines for serotype a foot-and-mouth disease virus |
| US10751402B2 (en) | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| JP7304287B2 (en) | 2016-12-22 | 2023-07-06 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Treatment of tumors with anti-CSF-1R antibodies in combination with anti-PD-L1 antibodies after unsuccessful anti-PD-L1/PD1 therapy |
| RU2762723C2 (en) | 2017-01-20 | 2021-12-22 | Пфайзер Инк. | Immunogenic compositions for use in pneumococcal vaccines |
| MX372587B (en) | 2017-01-31 | 2020-04-17 | Pfizer | Neisseria meningitidis compositions and methods thereof |
| EP3576759A4 (en) | 2017-01-31 | 2020-11-11 | Merck Sharp & Dohme Corp. | PROCESS FOR THE PREPARATION OF CAPSULE POLYSACCHARIDE PROTEIN CONJUGATES FROM STREPTOCOCCUS PNEUMONIAE SEROTYPE 19F |
| AU2018214451B2 (en) | 2017-02-06 | 2022-02-03 | Meat & Livestock Australia Limited | Immunostimulating compositions and uses therefore |
| US20200054740A1 (en) | 2017-02-24 | 2020-02-20 | Merck Sharp & Dohme Corp. | Pneumococcal conjugate vaccine formulations |
| GB201703529D0 (en) | 2017-03-06 | 2017-04-19 | Cambridge Entpr Ltd | Vaccine composition |
| US10525119B2 (en) | 2017-03-31 | 2020-01-07 | Boston Medical Center Corporation | Methods and compositions using highly conserved pneumococcal surface proteins |
| US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
| MY204084A (en) | 2017-06-11 | 2024-08-06 | Molecular Express Inc | Methods and compositions for substance use disorder vaccine formulations and uses thereof |
| KR20200041311A (en) | 2017-06-23 | 2020-04-21 | 노소코미얼 백신 코포레이션 | Immunogenic composition |
| WO2019018744A1 (en) | 2017-07-21 | 2019-01-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neisseria meningitidis immunogenic compositions |
| CA3074708A1 (en) | 2017-09-07 | 2019-03-14 | Merck Sharp & Dohme Corp. | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
| CA3075219A1 (en) | 2017-09-08 | 2019-03-14 | Mina Therapeutics Limited | Hnf4a sarna compositions and methods of use |
| US11806364B2 (en) | 2017-09-28 | 2023-11-07 | Industry-Academic Cooperation Foundation, Yonsei University | Method for producing myeloid-derived suppressor cells, myeloid-derived suppressor cells produced thereby, and methods thereof |
| EP3703723A4 (en) | 2017-10-31 | 2021-12-15 | KaliVir Immunotherapeutics, Inc. | Platform oncolytic vector for systemic delivery |
| EP3703745B1 (en) | 2017-11-04 | 2024-04-10 | Nevada Research & Innovation Corporation | Immunogenic conjugates and methods of use thereof |
| US11116828B2 (en) | 2017-12-06 | 2021-09-14 | Merck Sharp & Dohme Corp. | Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| US11116830B2 (en) | 2017-12-18 | 2021-09-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bacterial polysaccharide-conjugated carrier proteins and use thereof |
| WO2019126371A1 (en) | 2017-12-19 | 2019-06-27 | Massachusetts Institute Of Technology | Antigen-adjuvant coupling reagents and methods of use |
| US11369675B2 (en) | 2018-01-22 | 2022-06-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Broadly protective inactivated influenza virus vaccine |
| EP3752194A4 (en) | 2018-02-13 | 2022-03-16 | Checkmate Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR TUMOR IMMUNOTHERAPY |
| MX387358B (en) | 2018-02-28 | 2025-03-18 | Pfizer | IL-15 VARIANTS AND THEIR USES |
| CN118421594A (en) | 2018-03-02 | 2024-08-02 | 伊莱西奥治疗有限公司 | Compounds comprising mutant KRAS sequences and lipids and uses thereof |
| WO2019173438A1 (en) | 2018-03-06 | 2019-09-12 | Stc. Unm | Compositions and methods for reducing serum triglycerides |
| JP7329529B2 (en) | 2018-03-28 | 2023-08-18 | サノフィ パスツール インコーポレイテッド | Methods of Producing Broadly Protective Vaccine Compositions Containing Hemagglutinin |
| JP2021519600A (en) | 2018-04-03 | 2021-08-12 | サノフイＳａｎｏｆｉ | Antigenic influenza-ferritin polypeptide |
| WO2019195316A1 (en) | 2018-04-03 | 2019-10-10 | Sanofi | Ferritin proteins |
| CN112512567A (en) | 2018-04-03 | 2021-03-16 | 赛诺菲 | Antigenic respiratory syncytial virus polypeptides |
| CN112512566A (en) | 2018-04-03 | 2021-03-16 | 赛诺菲 | Antigenic epstein-barr virus polypeptides |
| JP2021519599A (en) | 2018-04-03 | 2021-08-12 | サノフイＳａｎｏｆｉ | Antigenic OSPA polypeptide |
| AU2019251421B2 (en) | 2018-04-09 | 2025-05-01 | Checkmate Pharmaceuticals | Packaging oligonucleotides into virus-like particles |
| PE20210488A1 (en) | 2018-05-23 | 2021-03-15 | Pfizer | ANTIBODIES SPECIFIC TO GUCY2C AND ITS USES |
| HRP20240975T1 (en) | 2018-05-23 | 2024-10-25 | Pfizer Inc. | Antibodies specific for cd3 and uses thereof |
| EP3574915A1 (en) | 2018-05-29 | 2019-12-04 | Neovacs | Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity |
| EP3820511A4 (en) | 2018-07-13 | 2022-06-15 | University of Georgia Research Foundation, Inc. | Broadly reactive immunogens of influenza h3 virus, compositions and methods of use thereof |
| CN110004150B (en)* | 2018-08-01 | 2023-03-10 | 中国农业科学院兰州兽医研究所 | CpG oligonucleotide sequence with immune enhancement activity and application thereof |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| EP3880805A4 (en) | 2018-11-16 | 2022-07-27 | Versitech Limited | LIVE ATTACHED INFLUENZA B VIRUS COMPOSITIONS, METHODS OF MANUFACTURE AND USE THEREOF |
| CN113454100B (en) | 2018-12-04 | 2024-08-23 | 洛克菲勒大学 | HIV vaccine immunogens |
| US20220023413A1 (en) | 2018-12-12 | 2022-01-27 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Recombinant mumps virus vaccine expressing genotype g fusion and hemagglutinin-neuraminidase proteins |
| CA3120922A1 (en) | 2018-12-12 | 2020-06-18 | Pfizer Inc. | Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof |
| EP3894429B1 (en) | 2018-12-14 | 2024-02-21 | University of Georgia Research Foundation, Inc. | Crimean-congo hemorrhagic fever virus replicon particles and use thereof |
| SG11202106541WA (en) | 2018-12-19 | 2021-07-29 | Merck Sharp & Dohme | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| WO2020128893A1 (en) | 2018-12-21 | 2020-06-25 | Pfizer Inc. | Combination treatments of cancer comprising a tlr agonist |
| JP7657727B2 (en) | 2019-04-02 | 2025-04-07 | サノフイ | Antigenic multimeric respiratory syncytial virus polypeptides |
| CA3136278A1 (en) | 2019-04-10 | 2020-10-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| CN114072506A (en)* | 2019-05-10 | 2022-02-18 | 中天(上海)生物科技有限公司 | Dimeric CpG oligonucleotides for modulating immune responses |
| CN114450014A (en)* | 2019-06-14 | 2022-05-06 | G科技生物有限责任公司 | Activation of lymphocytic cells and methods of using the same to treat cancer and infectious disorders |
| WO2021015987A1 (en) | 2019-07-19 | 2021-01-28 | Merck Sharp & Dohme Corp. | Antigenic glycoprotein e polypeptides, compositions, and methods of use thereof |
| MX2022001190A (en) | 2019-07-30 | 2022-02-22 | Phibro Animal Health Corporation | A composition for mucosal administration to avians. |
| EP4003410A1 (en) | 2019-07-31 | 2022-06-01 | Sanofi Pasteur, Inc. | Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same |
| US20220280491A1 (en) | 2019-08-30 | 2022-09-08 | University Of Rochester | Septin inhibitors for treatment of cancers |
| EP4031251A4 (en) | 2019-09-18 | 2024-01-10 | Children's Medical Center Corporation | ANAPLASTIC LYMPHOMA KINASE (ALK) CANCER VACCINE AND METHODS OF USE |
| CN110646557A (en)* | 2019-10-12 | 2020-01-03 | 北京航空航天大学 | Urine metabolic markers in glioblastoma patients with IDH gene mutation and their uses |
| US20230000966A1 (en) | 2019-11-01 | 2023-01-05 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| US20230039456A1 (en) | 2019-12-17 | 2023-02-09 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Live attenuated leishmania parasite vaccines with enhanced safety characteristics |
| JP7369297B2 (en) | 2019-12-17 | 2023-10-25 | ファイザー・インク | Antibodies specific for CD47, PD-L1 and uses thereof |
| US20230241196A1 (en) | 2020-01-27 | 2023-08-03 | Oregon State University | Gonorrhea subunit vaccine |
| AU2021218797A1 (en) | 2020-02-13 | 2022-08-25 | The Board Of Trustees Of The University Of Illinois | Vaccine and methods for detecting and preventing filariasis |
| KR20220143910A (en) | 2020-02-23 | 2022-10-25 | 화이자 인코포레이티드 | Escherichia coli composition and method thereof |
| JP2023514825A (en) | 2020-02-26 | 2023-04-11 | ヴェルシテック リミテッド | PD-1-based vaccine against coronavirus infection |
| EP4110382A1 (en) | 2020-02-28 | 2023-01-04 | Sanofi Pasteur Inc. | High dose influenza vaccine for pediatric subjects |
| US11213482B1 (en) | 2020-03-05 | 2022-01-04 | University of Pittsburgh—Of the Commonwealth System of Higher Educat | SARS-CoV-2 subunit vaccine and microneedle array delivery system |
| WO2021211279A1 (en) | 2020-04-17 | 2021-10-21 | Regents Of The University Of Minnesota | SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF |
| EP4138894A4 (en) | 2020-04-20 | 2024-06-26 | The University of Saskatchewan | COMPOSITIONS AND METHODS FOR THE PREVENTION, CONTROL AND DIAGNOSIS OF MYCOBACTERIAL INFECTIONS |
| EP3900739A1 (en) | 2020-04-21 | 2021-10-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein |
| AU2021270347A1 (en) | 2020-05-11 | 2022-12-15 | Erytech Pharma | Red cell extracellular vesicles (RCEVs) containing cargoes and methods of use and production thereof |
| PE20231565A1 (en) | 2020-07-17 | 2023-10-04 | Pfizer | THERAPEUTIC ANTIBODIES AND THEIR USES |
| JP2023538736A (en) | 2020-08-26 | 2023-09-11 | ファイザー・インク | Group B streptococcal polysaccharide-protein conjugates, methods for producing the conjugates, immunogenic compositions comprising the conjugates, and uses thereof |
| EP4213874A1 (en) | 2020-09-17 | 2023-07-26 | Neovacs | Immunogenic product comprising an ige fragment for treating ige-mediated inflammatory disorders |
| WO2022066973A1 (en) | 2020-09-24 | 2022-03-31 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting pbk or oip5 antigens |
| JP2023542528A (en) | 2020-09-24 | 2023-10-10 | フレッド ハッチンソン キャンサー センター | Immunotherapy targeting SOX2 antigen |
| AU2021368151B2 (en) | 2020-10-27 | 2024-09-05 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| AU2021373358A1 (en) | 2020-11-04 | 2023-06-01 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| EP4243863A2 (en) | 2020-11-10 | 2023-09-20 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| US20220202923A1 (en) | 2020-12-23 | 2022-06-30 | Pfizer Inc. | E. coli fimh mutants and uses thereof |
| WO2022147373A1 (en) | 2020-12-31 | 2022-07-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins |
| CA3206754A1 (en) | 2021-02-03 | 2022-08-11 | Ramaswamy Kalyanasundaram | Vaccine and methods for preventing filariasis and dirofilariasis |
| IL308018B2 (en) | 2021-04-30 | 2025-04-01 | Kalivir Immunotherapeutics Inc | Oncolytic viruses for modified mhc expression |
| JP2024521847A (en) | 2021-05-28 | 2024-06-04 | ファイザー・インク | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CA3221074A1 (en) | 2021-05-28 | 2022-12-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2022261251A1 (en) | 2021-06-08 | 2022-12-15 | Glyde Bio Inc. | Immunogenic compositions comprising tumour-associated antigen |
| EP4104830A1 (en) | 2021-06-16 | 2022-12-21 | Burghardt Wittig | Sequential innate and adaptive immune modulation for cancer treatment |
| EP4362934A1 (en)* | 2021-06-28 | 2024-05-08 | Mast Pharma AB | New use of monensin |
| EP4370152A1 (en) | 2021-07-16 | 2024-05-22 | The Board Of Trustees Of The University Of Illinois | Universal vaccine for influenza virus based on tetrameric m2 protein incorporated into nanodiscs |
| EP4384534A1 (en) | 2021-08-11 | 2024-06-19 | Sanofi Pasteur, Inc. | Truncated influenza neuraminidase and methods of using the same |
| TW202333778A (en) | 2021-10-08 | 2023-09-01 | 美商賽諾菲巴斯德公司 | Multivalent influenza vaccines |
| CZ309696B6 (en)* | 2021-10-20 | 2023-08-02 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Isosteric Isopolar Phosphate Analogues of Phosphorothioate CpG Oligonucleotide ODN 2006 |
| CN118201635A (en) | 2021-11-05 | 2024-06-14 | 圣诺菲·帕斯图尔公司 | Multivalent influenza vaccine containing recombinant hemagglutinin and neuraminidase and method of using the same |
| KR20240105413A (en) | 2021-11-05 | 2024-07-05 | 사노피 | Hybrid multivalent influenza vaccine comprising hemagglutinin and neuraminidase and method of using the same |
| KR20240107146A (en) | 2021-11-05 | 2024-07-08 | 사노피 | Respiratory syncytial virus RNA vaccine |
| AR127808A1 (en) | 2021-11-30 | 2024-02-28 | Sanofi Pasteur Inc | VACCINES AGAINST THE HUMAN METAPNEUMOVIRUS |
| KR20240118795A (en) | 2021-11-30 | 2024-08-05 | 사노피 파스퇴르 인크 | Human metapneumovirus virus vector-based vaccine |
| JP2025500880A (en) | 2021-12-17 | 2025-01-15 | サノフイ | Lyme Disease RNA Vaccine |
| EP4463186A1 (en) | 2022-01-13 | 2024-11-20 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| US20250115881A1 (en) | 2022-01-27 | 2025-04-10 | Sanofi Pasteur | Modified vero cells and methods of using the same for virus production |
| WO2023161817A1 (en) | 2022-02-25 | 2023-08-31 | Pfizer Inc. | Methods for incorporating azido groups in bacterial capsular polysaccharides |
| CN119137665A (en) | 2022-03-14 | 2024-12-13 | 赛诺菲巴斯德有限公司 | Machine learning techniques in protein design for vaccine generation |
| AU2023254171A1 (en) | 2022-04-15 | 2024-10-24 | Stradefy Biosciences, Inc. | Exatecan formulation. |
| EP4518887A2 (en) | 2022-05-06 | 2025-03-12 | Sanofi | Signal sequences for nucleic acid vaccines |
| IL316477A (en) | 2022-05-11 | 2024-12-01 | Pfizer | Process for producing of vaccine formulations with preservatives |
| KR20250029868A (en) | 2022-06-29 | 2025-03-05 | 버베리안 노딕 에이/에스 | Recombinant modified saRNA (VRP) and vaccinia virus ankara (MVA) prime-boost regimen |
| WO2024069420A2 (en) | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Immunogenic compositions comprising an rsv f protein trimer |
| WO2024094881A1 (en) | 2022-11-04 | 2024-05-10 | Sanofi | Respiratory syncytial virus rna vaccination |
| WO2024100235A1 (en) | 2022-11-10 | 2024-05-16 | Université Libre de Bruxelles | Group a streptococcus vaccine antigen |
| WO2024110827A1 (en) | 2022-11-21 | 2024-05-30 | Pfizer Inc. | Methods for preparing conjugated capsular saccharide antigens and uses thereof |
| US20240181028A1 (en) | 2022-11-22 | 2024-06-06 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024116096A1 (en) | 2022-12-01 | 2024-06-06 | Pfizer Inc. | Pneumococcal conjugate vaccine formulations |
| WO2024121380A1 (en) | 2022-12-08 | 2024-06-13 | Pierre Fabre Medicament | Vaccinal composition and adjuvant |
| WO2024127215A2 (en) | 2022-12-13 | 2024-06-20 | Pfizer Inc. | Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile |
| AR131438A1 (en) | 2022-12-20 | 2025-03-19 | Sanofi Sa | RHINOVIRUS mRNA VACCINE |
| WO2024149832A1 (en) | 2023-01-12 | 2024-07-18 | Bavarian Nordic A/S | RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE |
| WO2024163327A1 (en) | 2023-01-30 | 2024-08-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Epstein-barr virus glycoprotein 42 immunogens for vaccination and antibody discovery |
| WO2024166008A1 (en) | 2023-02-10 | 2024-08-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| TW202502375A (en) | 2023-03-02 | 2025-01-16 | 法商賽諾菲公司 | Compositions for use in treatment of chlamydia |
| WO2024201324A2 (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024214016A1 (en) | 2023-04-14 | 2024-10-17 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024224266A1 (en) | 2023-04-24 | 2024-10-31 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| TW202500750A (en) | 2023-05-05 | 2025-01-01 | 法商賽諾菲公司 | Compositions for use in treatment of acne |
| US20250009865A1 (en) | 2023-05-10 | 2025-01-09 | Sanofi | Combination respiratory mrna vaccines |
| WO2024233873A1 (en) | 2023-05-11 | 2024-11-14 | Sanofi Pasteur Inc. | Respiratory syncytial virus vaccine and methods of use |
| WO2024241172A2 (en) | 2023-05-19 | 2024-11-28 | Glaxosmithkline Biologicals Sa | Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection |
| WO2024246358A1 (en) | 2023-06-01 | 2024-12-05 | Sanofi | Thermostable compositions comprising mrna lipid nanoparticles |
| WO2025006737A1 (en) | 2023-06-30 | 2025-01-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Genetically detoxified mutant of neisseria and outer membrane vesicle (omv) vaccine |
| WO2025017202A2 (en) | 2023-07-19 | 2025-01-23 | Sanofi | Porphyromonas gingivalis antigenic constructs |
| US20250090650A1 (en) | 2023-09-06 | 2025-03-20 | Sanofi | Modified influenza b hemagglutinin polypeptides and nucleic acids and uses thereof |
| WO2025057078A1 (en) | 2023-09-14 | 2025-03-20 | Pfizer Inc. | Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof |
| WO2025073874A1 (en) | 2023-10-05 | 2025-04-10 | Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement | Vaccine composition comprising m2e nanoparticles and ha1 protein |
Citations (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5087617A (en)* | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
| US5112605A (en)* | 1989-03-17 | 1992-05-12 | Genentech, Inc. | Temporal gamma-interferon administration for allergies |
| US5498410A (en)* | 1991-04-22 | 1996-03-12 | Gleich; Gerald J. | Method for the treatment of eosinophil-associated conditions with anionic polymers |
| US5723335A (en)* | 1994-03-25 | 1998-03-03 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| US5726160A (en)* | 1995-04-13 | 1998-03-10 | Milkhaus Laboratories, Inc. | Methods for treating respiratory disease |
| US5756097A (en)* | 1985-06-28 | 1998-05-26 | Landucci; Gary R. | Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases |
| US5877309A (en)* | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
| US5908620A (en)* | 1995-01-31 | 1999-06-01 | National Jewish Medical And Research Center | Treatment for diseases involving inflammation |
| US6025339A (en)* | 1995-06-07 | 2000-02-15 | East Carolina University | Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation |
| US6040296A (en)* | 1995-06-07 | 2000-03-21 | East Carolina University | Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation |
| US6174872B1 (en)* | 1996-10-04 | 2001-01-16 | The Regents Of The University Of California | Method for treating allergic lung disease |
| US6194388B1 (en)* | 1994-07-15 | 2001-02-27 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US6207646B1 (en)* | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6214806B1 (en)* | 1997-02-28 | 2001-04-10 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders |
| US6218371B1 (en)* | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| US6221882B1 (en)* | 1997-07-03 | 2001-04-24 | University Of Iowa Research Foundation | Methods for inhibiting immunostimulatory DNA associated responses |
| US6225292B1 (en)* | 1997-06-06 | 2001-05-01 | The Regents Of The University Of California | Inhibitors of DNA immunostimulatory sequence activity |
| US6239116B1 (en)* | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6335068B1 (en)* | 1996-09-13 | 2002-01-01 | Beiersdorf A.G. | Redetachable, self-adhesive device |
| US20020004416A1 (en)* | 1999-03-22 | 2002-01-10 | Ronald Baratono | Combined rear view mirror and telephone |
| US6339068B1 (en)* | 1997-05-20 | 2002-01-15 | University Of Iowa Research Foundation | Vectors and methods for immunization or therapeutic protocols |
| US20020028784A1 (en)* | 2000-03-10 | 2002-03-07 | Nest Gary Van | Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences |
| US20020042387A1 (en)* | 2000-02-23 | 2002-04-11 | Eyal Raz | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
| US6406705B1 (en)* | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US6514948B1 (en)* | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
| US20030026801A1 (en)* | 2000-06-22 | 2003-02-06 | George Weiner | Methods for enhancing antibody-induced cell lysis and treating cancer |
| US20030026782A1 (en)* | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| US20030050268A1 (en)* | 2001-03-29 | 2003-03-13 | Krieg Arthur M. | Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases |
| US20030050263A1 (en)* | 1994-07-15 | 2003-03-13 | The University Of Iowa Research Foundation | Methods and products for treating HIV infection |
| US6534062B2 (en)* | 2000-03-28 | 2003-03-18 | The Regents Of The University Of California | Methods for increasing a cytotoxic T lymphocyte response in vivo |
| US20030055014A1 (en)* | 2000-12-14 | 2003-03-20 | Bratzler Robert L. | Inhibition of angiogenesis by nucleic acids |
| US20030064064A1 (en)* | 1998-09-18 | 2003-04-03 | Dino Dina | Methods of treating IgE-associated disorders and compositions for use therein |
| US6544518B1 (en)* | 1999-04-19 | 2003-04-08 | Smithkline Beecham Biologicals S.A. | Vaccines |
| US6552006B2 (en)* | 2000-01-31 | 2003-04-22 | The Regents Of The University Of California | Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen |
| US20030078223A1 (en)* | 1996-01-30 | 2003-04-24 | Eyal Raz | Compositions and methods for modulating an immune response |
| US6558670B1 (en)* | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
| US6562798B1 (en)* | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| US20030092663A1 (en)* | 1997-09-05 | 2003-05-15 | Eyal Raz | Immunization-free methods for treating antigen-stimulated inflammation in a mammalian host and shifting the host's antigen immune responsiveness to a Th1 phenotype |
| US20030100527A1 (en)* | 1994-07-15 | 2003-05-29 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US20040006010A1 (en)* | 1996-10-11 | 2004-01-08 | Carson Dennis A. | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
| US20040006034A1 (en)* | 1998-06-05 | 2004-01-08 | Eyal Raz | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
| US20040009949A1 (en)* | 2002-06-05 | 2004-01-15 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids |
| US20040009942A1 (en)* | 2000-03-10 | 2004-01-15 | Gary Van Nest | Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide sequences |
| US20040030118A1 (en)* | 1998-05-14 | 2004-02-12 | Hermann Wagner | Methods for regulating hematopoiesis using CpG-oligonucleotides |
| US20040053880A1 (en)* | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US20040067905A1 (en)* | 2002-07-03 | 2004-04-08 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US20040067902A9 (en)* | 2000-02-03 | 2004-04-08 | Bratzler Robert L. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
| US6727230B1 (en)* | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| US20040092472A1 (en)* | 2002-07-03 | 2004-05-13 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US6737066B1 (en)* | 1999-05-06 | 2004-05-18 | The Immune Response Corporation | HIV immunogenic compositions and methods |
| US20050013812A1 (en)* | 2003-07-14 | 2005-01-20 | Dow Steven W. | Vaccines using pattern recognition receptor-ligand:lipid complexes |
| US20050031638A1 (en)* | 1997-12-24 | 2005-02-10 | Smithkline Beecham Biologicals S.A. | Vaccine |
| US20050054601A1 (en)* | 1997-01-23 | 2005-03-10 | Coley Pharmaceutical Gmbh | Pharmaceutical composition comprising a polynucleotide and optionally an antigen especially for vaccination |
| US20050059619A1 (en)* | 2002-08-19 | 2005-03-17 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids |
| US20050100983A1 (en)* | 2003-11-06 | 2005-05-12 | Coley Pharmaceutical Gmbh | Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling |
| US20050101557A1 (en)* | 1994-07-15 | 2005-05-12 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20060003962A1 (en)* | 2002-10-29 | 2006-01-05 | Coley Pharmaceutical Group, Ltd. | Methods and products related to treatment and prevention of hepatitis C virus infection |
| US20060019916A1 (en)* | 2004-04-02 | 2006-01-26 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for inducing IL-10 responses |
| US20060019923A1 (en)* | 2004-07-18 | 2006-01-26 | Coley Pharmaceutical Group, Ltd. | Methods and compositions for inducing innate immune responses |
| US7038029B2 (en)* | 2002-05-30 | 2006-05-02 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
| US7049302B1 (en)* | 1998-08-10 | 2006-05-23 | Antigenics Inc. | Compositions of CPG and saponin adjuvants and uses thereof |
| US7183111B2 (en)* | 2000-03-10 | 2007-02-27 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
| US20070066554A1 (en)* | 1999-09-25 | 2007-03-22 | Coley Pharmaceutical Gmbh | Immunostimulatory nucleic acids |
Family Cites Families (461)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2002A (en)* | 1841-03-12 | Tor and planter for plowing | ||
| US2005A (en)* | 1841-03-16 | Improvement in the manner of constructing molds for casting butt-hinges | ||
| US2003A (en)* | 1841-03-12 | Improvement in horizontal windivhlls | ||
| US2010A (en)* | 1841-03-18 | Machine foe | ||
| US2004A (en)* | 1841-03-12 | Improvement in the manner of constructing and propelling steam-vessels | ||
| US3521637A (en)* | 1967-11-28 | 1970-07-28 | Nelson J Waterbury | Tampon or similar sanitary napkin containing vitamin a |
| US3627874A (en) | 1969-07-16 | 1971-12-14 | Merck & Co Inc | Vaccine preparation |
| US3761585A (en) | 1971-04-05 | 1973-09-25 | Beecham Group Ltd | Vaccines containing modified allergenic material |
| US3906092A (en) | 1971-11-26 | 1975-09-16 | Merck & Co Inc | Stimulation of antibody response |
| DE2643213C2 (en)* | 1976-09-25 | 1985-02-21 | Bayer Ag, 5090 Leverkusen | Process for attenuating or inactivating microorganisms |
| US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| JP2547714B2 (en) | 1981-10-23 | 1996-10-23 | モルキユラ− バイオシステムズ インコ−ポレテツド | Oligonucleotide therapeutic agent and method for producing the same |
| US5023243A (en)* | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
| ES8301593A1 (en) | 1981-11-16 | 1983-01-01 | Union Ind Y Agro Ganader S A U | Nucleotide enriched humanized milk and process for its preparation |
| US5766920A (en)* | 1982-08-11 | 1998-06-16 | Cellcor, Inc. | Ex vivo activation of immune cells |
| SE8205892D0 (en) | 1982-10-18 | 1982-10-18 | Bror Morein | IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF |
| US4452775A (en)* | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| SE8405493D0 (en) | 1984-11-01 | 1984-11-01 | Bror Morein | IMMUNOGENT COMPLEX AND KITCHEN FOR PREPARING IT AND USING IT AS IMMUNOSTIMENTING AGENTS |
| DK166762B1 (en) | 1986-01-14 | 1993-07-12 | Nederlanden Staat | PROCEDURE FOR PREPARING IMMUNOGENIC COMPLEXES AND PHARMACEUTICAL COMPOSITION CONTAINING SUCH COMPLEXES |
| US5194428A (en) | 1986-05-23 | 1993-03-16 | Worcester Foundation For Experimental Biology | Inhibition of influenza virus replication by oligonucleotide phosphorothioates |
| US4806463A (en) | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
| US5059519A (en) | 1986-07-01 | 1991-10-22 | University Of Massachusetts Medical School | Oligonucleotide probes for the determination of the proclivity for development of autoimmune diseases |
| US5075109A (en)* | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| ES2007350A6 (en) | 1987-05-29 | 1989-06-16 | Ganadera Union Ind Agro | Food products enriched with nucleosides and/or nucleotides and preparation thereof. |
| CA1339596C (en) | 1987-08-07 | 1997-12-23 | New England Medical Center Hospitals, Inc. | Viral expression inhibitors |
| NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| US5004810A (en) | 1988-09-30 | 1991-04-02 | Schering Corporation | Antiviral oligomers |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
| US5629158A (en)* | 1989-03-22 | 1997-05-13 | Cemu Bitecknik Ab | Solid phase diagnosis of medical conditions |
| US4958013A (en)* | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
| US5399346A (en)* | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US4981684A (en)* | 1989-10-24 | 1991-01-01 | Coopers Animal Health Limited | Formation of adjuvant complexes |
| US5178860A (en)* | 1989-09-01 | 1993-01-12 | Coopers Animal Health Limited | Adjuvant complexes and vaccine made therefrom |
| US5399676A (en)* | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
| US5676954A (en) | 1989-11-03 | 1997-10-14 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
| US5786189A (en) | 1989-11-29 | 1998-07-28 | Smithkline Beecham Biologicals (S.A.) | Vaccine |
| US5457189A (en) | 1989-12-04 | 1995-10-10 | Isis Pharmaceuticals | Antisense oligonucleotide inhibition of papillomavirus |
| US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
| US5514788A (en)* | 1993-05-17 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
| US5248670A (en)* | 1990-02-26 | 1993-09-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides for inhibiting herpesviruses |
| US5514577A (en) | 1990-02-26 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide therapies for modulating the effects of herpes viruses |
| US5166195A (en) | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
| ATE318832T1 (en) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | METHOD FOR USING NUCLEIC ACID LIGANDS |
| EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
| US5245022A (en)* | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
| ATE154947T1 (en) | 1990-08-16 | 1997-07-15 | Isis Pharmaceuticals Inc | OLIGONUCLEOTIDES FOR MODULATING THE EFFECTS OF CYTOMEGALOVIRUS INFECTIONS |
| US6042838A (en)* | 1991-02-15 | 2000-03-28 | Uab Research Foundation | immunogenic compositions for mucosal administration of pneumococcal surface protein A (PspA) |
| NZ241954A (en)* | 1991-03-15 | 1994-01-26 | Amgen Inc | Compositions of g-csf for pulmonary administration. |
| WO1992018522A1 (en) | 1991-04-18 | 1992-10-29 | The Salk Institute For Biological Studies | Oligodeoxynucleotides and oligonucleotides useful as decoys for proteins which selectively bind to defined dna sequences |
| US5681555A (en) | 1991-04-22 | 1997-10-28 | Gleich; Gerald J. | Method for the treatment of bronchial asthma by parenteral administration of anionic polymers |
| WO1994008003A1 (en) | 1991-06-14 | 1994-04-14 | Isis Pharmaceuticals, Inc. | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE |
| IL101978A0 (en) | 1991-05-31 | 1992-12-30 | Genta Inc | Neutral oligomers capable of being delivered transdermally and across mucous membranes |
| US5582986A (en) | 1991-06-14 | 1996-12-10 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of the ras gene |
| US6030954A (en)* | 1991-09-05 | 2000-02-29 | University Of Connecticut | Targeted delivery of poly- or oligonucleotides to cells |
| US5576302A (en) | 1991-10-15 | 1996-11-19 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity |
| WO1993009789A1 (en) | 1991-11-15 | 1993-05-27 | Temple University - Of The Commonwealth System Of Higher Education | Treatment of melanoma with antisense oligonucleotides to c-myb proto-oncogene |
| WO1993010138A1 (en) | 1991-11-18 | 1993-05-27 | Tanox Biosystems, Inc. | Anti-sense oligonucleotides for isotype-specific suppression of immunoglobulin production |
| US5858784A (en)* | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| AU3610293A (en) | 1992-02-04 | 1993-09-01 | Chiron Viagene, Inc. | Hepatitis therapeutics |
| US5643578A (en)* | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
| US6498147B2 (en) | 1992-05-22 | 2002-12-24 | The Scripps Research Institute | Suppression of nuclear factor-κb dependent processes using oligonucleotides |
| WO1993025673A1 (en) | 1992-06-04 | 1993-12-23 | The Regents Of The University Of California | In vivo gene therapy with intron-free sequence of interest |
| US5726518A (en)* | 1992-07-22 | 1998-03-10 | Nikon Corporation | Supporting device of relative moving element of vibration actuator or vibration motor |
| US5585479A (en) | 1992-07-24 | 1996-12-17 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human ELAM-I RNA |
| WO1994002499A1 (en) | 1992-07-27 | 1994-02-03 | Hybridon, Inc. | Oligonucleotide alkylphosphonothioates |
| US6107062A (en)* | 1992-07-30 | 2000-08-22 | Inpax, Inc. | Antisense viruses and antisense-ribozyme viruses |
| WO1994004196A1 (en) | 1992-08-14 | 1994-03-03 | Imperial Cancer Research Technology Limited | Tumour therapy |
| US5429199A (en)* | 1992-08-26 | 1995-07-04 | Kennametal Inc. | Cutting bit and cutting insert |
| KR950704482A (en) | 1992-10-05 | 1995-11-20 | 다알렌 반스톤 | Therapeutic anti-HIV oligonucleotides and pharmaceutical formulations containing them (THERAPEUTIC ANTI-HIV OLIGONUCLEOTIDE AND PHARMACEUTICAL) |
| US5593972A (en)* | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| DE69429337T3 (en)* | 1993-04-02 | 2012-08-30 | Anticancer Inc. | METHOD FOR THE ADMINISTRATION OF SPATIAL COMPOSITIONS TO HAIR FOLLICLES |
| US5567604A (en) | 1993-04-23 | 1996-10-22 | Aronex Pharmaceuticals, Inc. | Anti-viral guanosine-rich oligonucleotides |
| SG54115A1 (en)* | 1993-04-27 | 1998-11-16 | Gerber Scient Products Inc | Thermal printing apparatus with improved power supply |
| DE69433978T2 (en) | 1993-06-11 | 2005-08-25 | Commonwealth Scientific And Industrial Research Organisation | METHOD OF THE SPECIFIC DERIVATION OF GENES BY DNA METHYLATION |
| JP2798305B2 (en)* | 1993-06-23 | 1998-09-17 | ジェネシス ファーマ インコーポレイテッド | Antisense oligonucleotides and their use in human immunodeficiency virus infection |
| WO1995003407A2 (en) | 1993-07-19 | 1995-02-02 | Gen-Probe Incorporated | Oligonucleotides with activity against human immunodeficiency virus |
| US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
| US6605708B1 (en) | 1993-07-28 | 2003-08-12 | Hybridon, Inc. | Building blocks with carbamate internucleoside linkages and oligonucleotides derived therefrom |
| US5985847A (en) | 1993-08-26 | 1999-11-16 | The Regents Of The University Of California | Devices for administration of naked polynucleotides which encode biologically active peptides |
| US5830877A (en) | 1993-08-26 | 1998-11-03 | The Regents Of The University Of California | Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US20030109469A1 (en)* | 1993-08-26 | 2003-06-12 | Carson Dennis A. | Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen |
| US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
| JPH09501936A (en) | 1993-08-26 | 1997-02-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Methods, Compositions and Devices for Administering Naked Polynucleotides Encoding Bioactive Peptides |
| FR2711670B1 (en)* | 1993-10-22 | 1996-01-12 | Pasteur Institut | Nucleotide vector, composition containing it and vaccine for immunization against hepatitis. |
| DE4338704A1 (en) | 1993-11-12 | 1995-05-18 | Hoechst Ag | Stabilized oligonucleotides and their use |
| US5595756A (en)* | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| AU1313095A (en) | 1993-12-23 | 1995-07-10 | Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh | Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbb plays a role |
| US5712384A (en) | 1994-01-05 | 1998-01-27 | Gene Shears Pty Ltd. | Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs |
| US5728518A (en)* | 1994-01-12 | 1998-03-17 | The Immune Response Corporation | Antiviral poly-and oligonucleotides |
| US5646126A (en) | 1994-02-28 | 1997-07-08 | Epoch Pharmaceuticals | Sterol modified oligonucleotide duplexes having anticancer activity |
| EP0804249A2 (en) | 1994-03-15 | 1997-11-05 | Brown University Research Foundation | Polymeric gene delivery system |
| US5596091A (en)* | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
| US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
| US5696248A (en) | 1994-06-15 | 1997-12-09 | Hoechst Aktiengesellschaft | 3'-modified oligonucleotide derivatives |
| US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| EP0772625A4 (en) | 1994-07-18 | 2000-03-08 | Univ North Carolina | OLIGONUCLEOSIDES AND METHOD FOR INHIBITING TUMOR GROWTH, INVASION AND METASTASIS |
| US5646262A (en)* | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
| US6027726A (en)* | 1994-09-30 | 2000-02-22 | Inex Phamaceuticals Corp. | Glycosylated protein-liposome conjugates and methods for their preparation |
| CA2200952C (en)* | 1994-09-30 | 2006-04-11 | Inex Pharmaceuticals Corp. | Novel compositions comprising quaternary ammonium compounds and neutral lipids for the introduction of polyanionic materials into cells |
| US5753613A (en)* | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| WO1996012008A1 (en) | 1994-10-13 | 1996-04-25 | Merck & Co., Inc. | Synthesis of methylase-resistant genes |
| US6630455B1 (en) | 1995-01-13 | 2003-10-07 | Vanderbilt University | Methods for inducing mucosal immune responses |
| US5795587A (en)* | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US6008202A (en)* | 1995-01-23 | 1999-12-28 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| DE19502912A1 (en) | 1995-01-31 | 1996-08-01 | Hoechst Ag | G-Cap Stabilized Oligonucleotides |
| PL321711A1 (en) | 1995-02-09 | 1997-12-22 | Icn Pharmaceuticals | Methods of and compositions for controlling the cd28 expression |
| US5932556A (en) | 1995-09-17 | 1999-08-03 | Tam; Robert C | Methods and compositions for regulation of CD28 expression |
| GB9505438D0 (en) | 1995-03-17 | 1995-05-03 | Sod Conseils Rech Applic | Antisense oligonucleotides |
| US5703057A (en) | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
| US6096721A (en)* | 1995-04-13 | 2000-08-01 | Milkhaus Laboratory, Inc. | Method for treating mucositis by sublingual administration of DNA |
| UA56132C2 (en) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine |
| US5858987A (en)* | 1995-05-05 | 1999-01-12 | Mitotix, Inc. | E6AP antisense constructs and methods of use |
| US6004813A (en) | 1995-05-11 | 1999-12-21 | Applied Research Systems Ars Holding N.V. | Il-6 activity inhibitor |
| US5955059A (en)* | 1995-06-06 | 1999-09-21 | Trustees Of Boston University | Use of locally applied DNA fragments |
| US5705385A (en)* | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| US7034007B1 (en)* | 1995-06-07 | 2006-04-25 | East Carolina University | Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion |
| US5994315A (en) | 1995-06-07 | 1999-11-30 | East Carolina University | Low adenosine agent, composition, kit and method for treatment of airway disease |
| ATE285477T1 (en) | 1995-06-07 | 2005-01-15 | Inex Pharmaceutical Corp | PRODUCTION OF LIPID-NUCLIC ACID PARTICLES USING A HYDROPHOBIC LIPID-NUCLIC ACID COMPLEX INTERMEDIATE PRODUCT AND FOR USE IN GENE TRANSFER |
| US5830878A (en) | 1995-06-07 | 1998-11-03 | Megabios Corporation | Cationic lipid: DNA complexes for gene targeting |
| WO1997000957A1 (en) | 1995-06-23 | 1997-01-09 | President And Fellows Of Harvard College | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
| US5985662A (en) | 1995-07-13 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense inhibition of hepatitis B virus replication |
| JPH11510142A (en) | 1995-07-21 | 1999-09-07 | ブラウン・ユニバーシティ・リサーチ・ファンデーション | Gene therapy using nucleic acid-loaded polymer microparticles |
| US6248720B1 (en)* | 1996-07-03 | 2001-06-19 | Brown University Research Foundation | Method for gene therapy using nucleic acid loaded polymeric microparticles |
| US5968909A (en) | 1995-08-04 | 1999-10-19 | Hybridon, Inc. | Method of modulating gene expression with reduced immunostimulatory response |
| US6667293B1 (en)* | 1995-09-12 | 2003-12-23 | Hybridon, Inc. | Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
| TR199800607T1 (en) | 1995-10-04 | 1998-06-22 | Immunex Corporation | Dendritic h�cre uyar�c� fact�r�. |
| US5736152A (en)* | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US5780448A (en)* | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
| WO1997028259A1 (en) | 1996-01-30 | 1997-08-07 | The Regents Of The University Of California | Gene expression vectors which generate an antigen specific immune response and methods of using the same |
| SE9600647D0 (en) | 1996-02-21 | 1996-02-21 | Bror Morein | New use |
| US5994316A (en) | 1996-02-21 | 1999-11-30 | The Immune Response Corporation | Method of preparing polynucleotide-carrier complexes for delivery to cells |
| SE9600648D0 (en)* | 1996-02-21 | 1996-02-21 | Bror Morein | Receptor binding unit |
| US5843770A (en) | 1996-03-11 | 1998-12-01 | The Immune Response Corporation | Antisense constructs directed against viral post-transcriptional regulatory sequences |
| US6620805B1 (en) | 1996-03-14 | 2003-09-16 | Yale University | Delivery of nucleic acids by porphyrins |
| US6030955A (en)* | 1996-03-21 | 2000-02-29 | The Trustees Of Columbia University In The City Of New York And Imclone Systems, Inc. | Methods of affecting intracellular phosphorylation of tyrosine using phosphorothioate oligonucleotides, and antiangiogenic and antiproliferative uses thereof |
| US6121247A (en) | 1996-03-29 | 2000-09-19 | The Johns Hopkins University | Therapy for allergic diseases |
| US6184037B1 (en) | 1996-05-17 | 2001-02-06 | Genemedicine, Inc. | Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell |
| IL127912A0 (en) | 1996-07-10 | 1999-11-30 | Immunex Corp | Method of activating dendritic cells |
| EP1342477A1 (en) | 1996-07-16 | 2003-09-10 | Archibald James Mixson, M.D. | Cationic vehicle: dna complexes and their use in gene therapy |
| US5854418A (en) | 1996-07-25 | 1998-12-29 | The Trustees Of Columbia University In The City Of New York | Kaposi's sarcoma-associated herpesvirus (KSHV) viral macrophage inflammatory protein-1α II (vMIP-1α II) and uses thereof |
| US5856462A (en)* | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
| US6562345B1 (en)* | 1996-11-12 | 2003-05-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| US6797276B1 (en)* | 1996-11-14 | 2004-09-28 | The United States Of America As Represented By The Secretary Of The Army | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
| US20060002949A1 (en)* | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
| US20060002959A1 (en)* | 1996-11-14 | 2006-01-05 | Government Of The United States | Skin-sctive adjuvants for transcutaneous immuization |
| SE9604296D0 (en) | 1996-11-22 | 1996-11-22 | Astra Ab | New pharmaceutical formulation of polypeptides |
| US6994959B1 (en) | 1996-12-27 | 2006-02-07 | Valeant Research & Development | G-rich oligo aptamers and methods of modulating an immune response |
| FR2757876B1 (en) | 1996-12-27 | 1999-04-09 | Biovector Therapeutics Sa | CONJUGATES OF A PARTICULATE VECTOR AND OLIGONUCLEOTIDES, THEIR PREPARATION METHOD AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| US20030064945A1 (en)* | 1997-01-31 | 2003-04-03 | Saghir Akhtar | Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors |
| GB9702021D0 (en) | 1997-01-31 | 1997-03-19 | Imperial College | Medicaments |
| US7517952B1 (en)* | 1997-02-25 | 2009-04-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| PT1005368E (en)* | 1997-03-10 | 2009-11-19 | Coley Pharm Gmbh | Use of nucleic acids containing unmethylated cpg dinucleotide in combination with alum as adjuvants |
| US5965542A (en) | 1997-03-18 | 1999-10-12 | Inex Pharmaceuticals Corp. | Use of temperature to control the size of cationic liposome/plasmid DNA complexes |
| US6426334B1 (en) | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
| US20030104044A1 (en)* | 1997-05-14 | 2003-06-05 | Semple Sean C. | Compositions for stimulating cytokine secretion and inducing an immune response |
| US6835395B1 (en) | 1997-05-14 | 2004-12-28 | The University Of British Columbia | Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles |
| JP4656675B2 (en)* | 1997-05-14 | 2011-03-23 | ユニバーシティー オブ ブリティッシュ コロンビア | High rate encapsulation of charged therapeutic agents in lipid vesicles |
| CA2289741A1 (en) | 1997-05-19 | 1998-11-26 | Merck & Co., Inc. | Oligonucleotide adjuvant |
| US6589940B1 (en) | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
| AU8428998A (en) | 1997-07-24 | 1999-02-16 | Inex Pharmaceuticals Corporation | Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method |
| JP2001514884A (en) | 1997-08-19 | 2001-09-18 | ハイブリドン・インク | Novel HIV-specific synthetic oligonucleotides and methods of using the same |
| US6749856B1 (en) | 1997-09-11 | 2004-06-15 | The United States Of America, As Represented By The Department Of Health And Human Services | Mucosal cytotoxic T lymphocyte responses |
| WO1999027961A1 (en)* | 1997-12-02 | 1999-06-10 | Powderject Vaccines, Inc. | Transdermal delivery of particulate vaccine compositions |
| AU1656799A (en) | 1997-12-12 | 1999-07-05 | Inex Pharmaceuticals Corp. | Cationic drugs encapsulated in anionic liposomes |
| US7393630B2 (en)* | 1997-12-16 | 2008-07-01 | Novartis Vaccines And Diagnostics, Inc. | Use of microparticles combined with submicron oil-in-water emulsions |
| JP2001527052A (en) | 1997-12-23 | 2001-12-25 | アイネックス ファーマシューティカルズ コーポレイション | Polyamide oligomer |
| GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
| JPH11209289A (en)* | 1998-01-22 | 1999-08-03 | Taisho Pharmaceut Co Ltd | Mucosal immunity inducer |
| EP2286834A3 (en) | 1998-02-25 | 2012-01-25 | THE GOVERNMENT OF THE UNITED STATES, as represented by THE SECRETARY OF THE ARMY | Use of skin penetration enhancers and barrier disruption agents to enhance transcutaneous immune response |
| WO1999046301A1 (en)* | 1998-03-12 | 1999-09-16 | Ineos Acrylics Uk Limited | Polymer composition |
| BR9909915A (en) | 1998-04-09 | 2000-12-26 | Smithkline Beecham Biolog | Adjuvant compositions |
| ATE331739T1 (en) | 1998-04-28 | 2006-07-15 | Inex Pharmaceuticals Corp | POLYANIONIC POLYMERS WITH IMPROVED FUSOGEN CAPACITY |
| EP1077708A1 (en) | 1998-05-06 | 2001-02-28 | University Of Iowa Research Foundation | Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides |
| JP2002516294A (en) | 1998-05-22 | 2002-06-04 | ローブ ヘルス リサーチ インスティチュート アット ザ オタワ ホスピタル | Methods and products for inducing mucosal immunity |
| US6881561B1 (en) | 1998-05-27 | 2005-04-19 | Cheil Jedang Corporation | Endonuclease of immune cell, process for producing the same and immune adjuvant using the same |
| US6248329B1 (en)* | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
| CA2334960C (en) | 1998-06-10 | 2012-01-03 | Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh | Combination of tgf-.beta. inhibition and immune stimulation to treat hyperproliferative diseases |
| CA2333750A1 (en)* | 1998-06-23 | 1999-12-29 | Dale T. Umetsu | Adjuvant therapy |
| US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
| US6693086B1 (en)* | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| US20040247662A1 (en) | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
| CA2335393C (en) | 1998-07-20 | 2008-09-23 | Inex Pharmaceuticals Corporation | Liposomal encapsulated nucleic acid-complexes |
| WO2000006588A1 (en) | 1998-07-27 | 2000-02-10 | University Of Iowa Research Foundation | STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS |
| GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| EP0979869A1 (en) | 1998-08-07 | 2000-02-16 | Hoechst Marion Roussel Deutschland GmbH | Short oligonucleotides for the inhibition of VEGF expression |
| US20010034330A1 (en) | 1998-08-10 | 2001-10-25 | Charlotte Kensil | Innate immunity-stimulating compositions of CpG and saponin and methods thereof |
| CA2839037A1 (en)* | 1998-08-20 | 2000-03-02 | E.I. Du Pont De Nemours And Company | Genes for plant fatty acid modifying enzymes associated with conjugated double bond formation |
| WO2000014217A2 (en) | 1998-09-03 | 2000-03-16 | Coley Pharmaceutical Gmbh | G-motif oligonucleotides and uses thereof |
| US20020065236A1 (en)* | 1998-09-09 | 2002-05-30 | Yew Nelson S. | CpG reduced plasmids and viral vectors |
| FR2783170B1 (en)* | 1998-09-11 | 2004-07-16 | Pasteur Merieux Serums Vacc | IMMUNOSTIMULATING EMULSION |
| EP1671646A3 (en) | 1998-09-18 | 2007-08-29 | Dynavax Technologies Corporation | Methods of treating IgE-associated disorders and compositions for use therein |
| CA2346452A1 (en) | 1998-10-05 | 2000-04-13 | The Regents Of The University Of California | Methods and adjuvants for stimulating mucosal immunity |
| CA2344558A1 (en) | 1998-10-09 | 2000-04-20 | Dynavax Technologies Corporation | Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens |
| SI1126876T1 (en) | 1998-10-16 | 2007-08-31 | Glaxosmithkline Biolog Sa | Adjuvant systems and vaccines |
| AUPP807399A0 (en) | 1999-01-08 | 1999-02-04 | Csl Limited | Improved immunogenic lhrh composition and methods relating thereto |
| AU2977500A (en) | 1999-02-02 | 2000-08-25 | Biocache Pharmaceuticals, Llc | Advanced antigen presentation platform |
| US6887464B1 (en) | 1999-02-02 | 2005-05-03 | Biocache Pharmaceuticals, Inc. | Advanced antigen presentation platform |
| JP2002536344A (en) | 1999-02-05 | 2002-10-29 | ジエンザイム コーポレイション | Use of cationic lipids to generate anti-tumor immunity |
| US6207819B1 (en) | 1999-02-12 | 2001-03-27 | Isis Pharmaceuticals, Inc. | Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds |
| WO2000054803A2 (en)* | 1999-03-16 | 2000-09-21 | Panacea Pharmaceuticals, Llc | Immunostimulatory nucleic acids and antigens |
| FR2790955B1 (en) | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | USE OF STABILIZED OLIGONUCLEOTIDES AS ANTI-TUMOR ACTIVE INGREDIENT |
| BRPI0009163B8 (en) | 1999-03-19 | 2021-05-25 | Glaxosmithkline Biologicals Sa | immunogenic composition and vaccine comprising it |
| US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| WO2000061151A2 (en) | 1999-04-12 | 2000-10-19 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| WO2000062787A1 (en) | 1999-04-15 | 2000-10-26 | The Regents Of The University Of California | Methods and compositions for use in potentiating antigen presentation by antigen presenting cells |
| WO2000067023A1 (en) | 1999-04-29 | 2000-11-09 | Coley Pharmaceutical Gmbh | Screening for immunostimulatory dna functional modifyers |
| CA2372960C (en) | 1999-05-06 | 2006-03-28 | The Immune Response Corporation | Hiv immunogenic compositions and methods |
| AU776268B2 (en) | 1999-06-08 | 2004-09-02 | Aventis Pasteur | Immunostimulant oligonucleotide |
| EP1377554A1 (en) | 1999-06-16 | 2004-01-07 | University Of Iowa Research Foundation | Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases |
| GB9915204D0 (en) | 1999-06-29 | 1999-09-01 | Smithkline Beecham Biolog | Vaccine |
| US20050002958A1 (en)* | 1999-06-29 | 2005-01-06 | Smithkline Beecham Biologicals Sa | Vaccines |
| EP1198249B1 (en) | 1999-06-29 | 2005-10-19 | GlaxoSmithKline Biologicals S.A. | Use of cpg as an adjuvant for hiv vaccine |
| FR2795963A1 (en)* | 1999-07-08 | 2001-01-12 | Pasteur Merieux Serums Vacc | New polynucleotides are useful as vaccines for humans |
| DE19935756A1 (en)* | 1999-07-27 | 2001-02-08 | Mologen Forschungs Entwicklung | Covalently closed nucleic acid molecule for immune stimulation |
| ATE286534T1 (en) | 1999-08-13 | 2005-01-15 | Hybridon Inc | MODULATION OF IMMUNO STIMULATION CAUSED BY CPG OLIGONUCLEOTIDES THROUGH POSITIONAL CHANGES IN NUCLEOSIDES |
| WO2001012223A2 (en) | 1999-08-19 | 2001-02-22 | Dynavax Technologies Corporation | Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein |
| US20050249794A1 (en) | 1999-08-27 | 2005-11-10 | Semple Sean C | Compositions for stimulating cytokine secretion and inducing an immune response |
| US6395678B1 (en)* | 1999-09-01 | 2002-05-28 | Aero-Terra-Aqua Technologies Corporation | Bead and process for removing dissolved metal contaminants |
| GB9921147D0 (en) | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
| GB9921146D0 (en) | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
| US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
| MXPA02003059A (en)* | 1999-09-27 | 2002-09-30 | Univ Iowa Res Found | Methods related to immunostimulatory nucleic acid induced interferon. |
| US6562346B1 (en)* | 1999-10-27 | 2003-05-13 | Chiron Corporation | Activation of HCV-specific T cells |
| US7223398B1 (en) | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
| ATE402715T1 (en) | 1999-11-19 | 2008-08-15 | Csl Ltd | HCV VACCINE COMPOSITIONS |
| WO2001039800A2 (en)* | 1999-12-06 | 2001-06-07 | The Board Of Trustees Of The University Of Arkansas | Controlled delivery of antigens |
| AU2593701A (en) | 1999-12-21 | 2001-07-03 | Regents Of The University Of California, The | Method for preventing an anaphylactic reaction |
| JP2003527352A (en) | 2000-01-13 | 2003-09-16 | アンティジェニクス インコーポレーテッド | Innate immune stimulating compounds of CPG and saponin and methods thereof |
| ATE378348T1 (en)* | 2000-01-14 | 2007-11-15 | Us Health | OLIGODEOXYNUCLEOTIDES AND THEIR USE FOR INDUCING AN IMMUNE RESPONSE |
| US20010044416A1 (en)* | 2000-01-20 | 2001-11-22 | Mccluskie Michael J. | Immunostimulatory nucleic acids for inducing a Th2 immune response |
| US6852705B2 (en)* | 2000-01-21 | 2005-02-08 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
| JP4443810B2 (en) | 2000-01-26 | 2010-03-31 | イデラ ファーマシューティカルズ インコーポレイテッド | Regulation of oligonucleotide CpG-induced immune stimulation by positional modification of nucleosides |
| AT409085B (en) | 2000-01-28 | 2002-05-27 | Cistem Biotechnologies Gmbh | PHARMACEUTICAL COMPOSITION FOR IMMUNULATING AND PRODUCING VACCINES |
| JP2003529559A (en) | 2000-01-31 | 2003-10-07 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | New applications |
| FR2805265B1 (en) | 2000-02-18 | 2002-04-12 | Aventis Pasteur | IMMUNOSTIMULATING OLIGONUCLEOTIDES |
| US20030130217A1 (en)* | 2000-02-23 | 2003-07-10 | Eyal Raz | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
| WO2001062275A1 (en) | 2000-02-24 | 2001-08-30 | The Board Of Trustees Of The Leland Stanford Junior University | Adjuvant treatment by in vivo activation of dendritic cells |
| US20020156033A1 (en) | 2000-03-03 | 2002-10-24 | Bratzler Robert L. | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer |
| US20040131628A1 (en)* | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
| US20020098199A1 (en) | 2000-03-10 | 2002-07-25 | Gary Van Nest | Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences |
| US20030129251A1 (en)* | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
| US7157437B2 (en)* | 2000-03-10 | 2007-01-02 | Dynavax Technologies Corporation | Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences |
| US20020107212A1 (en) | 2000-03-10 | 2002-08-08 | Nest Gary Van | Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences |
| US6851845B2 (en)* | 2000-03-10 | 2005-02-08 | The Maitland Company, Inc. | Method and apparatus for processing waste material |
| US8246945B2 (en)* | 2000-04-06 | 2012-08-21 | University Of Arkansas | Methods and reagents for decreasing clinical reaction to allergy |
| CA2405424A1 (en) | 2000-04-07 | 2001-10-18 | The Regents Of The University Of California | Synergistic improvements to polynucleotide vaccines |
| US7524826B2 (en) | 2000-04-14 | 2009-04-28 | Mcmaster University And Hamilton Health Sciences Corporation | Method of inhibiting the generation of active thrombin on the surface of a cell within an atherosclerotic plaque |
| US6321873B1 (en)* | 2000-04-21 | 2001-11-27 | Tra-Lor-Mate, Inc. | Ladder mounting system |
| EP1278761B1 (en) | 2000-05-01 | 2005-04-06 | Hybridon, Inc. | MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
| WO2001085910A2 (en)* | 2000-05-05 | 2001-11-15 | The Regents Of The University Of California | Agents that modulate dna-pk activity and methods of use thereof |
| AU2001259706A1 (en) | 2000-05-09 | 2001-11-20 | Reliable Biopharmaceutical, Inc. | Polymeric compounds useful as prodrugs |
| WO2001087270A2 (en)* | 2000-05-12 | 2001-11-22 | Pharmacia & Upjohn Company | Vaccine composition, method of preparing the same, and method of vaccinating vertebrates |
| GB0011903D0 (en)* | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
| US6339630B1 (en)* | 2000-05-18 | 2002-01-15 | The United States Of America As Represented By The United States Department Of Energy | Sealed drive screw operator |
| EP1292331A2 (en) | 2000-06-07 | 2003-03-19 | Biosynexus Incorporated | Immunostimulatory rna/dna hybrid molecules |
| US20020165178A1 (en)* | 2000-06-28 | 2002-11-07 | Christian Schetter | Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia |
| MXPA03000822A (en) | 2000-07-27 | 2004-11-01 | Childrens Hosp & Res Ct Oak | Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis. |
| AU8640501A (en) | 2000-07-31 | 2002-02-13 | Univ Yale | Innate immune system-directed vaccines |
| US20020198165A1 (en)* | 2000-08-01 | 2002-12-26 | Bratzler Robert L. | Nucleic acids for the prevention and treatment of gastric ulcers |
| JP2005512499A (en)* | 2000-09-01 | 2005-05-12 | エピゲノミクス アーゲー | Diagnosing the onset of an ongoing or specific disease |
| US20040234960A1 (en) | 2000-09-01 | 2004-11-25 | Alexander Olek | Method for determining the degree of methylation of defined cytosines in genomic dna in the sequence context 5'-cpg-3' |
| US20020091097A1 (en)* | 2000-09-07 | 2002-07-11 | Bratzler Robert L. | Nucleic acids for the prevention and treatment of sexually transmitted diseases |
| US6943240B2 (en)* | 2000-09-15 | 2005-09-13 | Coley Pharmaceuticals Gmbh | Nucleic acids for high throughput screening of CpG-based immuno-agonist/antagonist |
| GB0023008D0 (en) | 2000-09-20 | 2000-11-01 | Glaxo Group Ltd | Improvements in vaccination |
| US6787524B2 (en)* | 2000-09-22 | 2004-09-07 | Tanox, Inc. | CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies |
| AU9475001A (en) | 2000-09-26 | 2002-04-08 | Hybridon Inc | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| SE0003538D0 (en)* | 2000-09-29 | 2000-09-29 | Isconova Ab | New immunogenic complex |
| US7537772B1 (en)* | 2000-10-02 | 2009-05-26 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, gene sequence and the uses thereof |
| FR2814958B1 (en) | 2000-10-06 | 2003-03-07 | Aventis Pasteur | VACCINE COMPOSITION |
| GB0025577D0 (en) | 2000-10-18 | 2000-12-06 | Smithkline Beecham Biolog | Vaccine |
| DK1889630T3 (en)* | 2000-10-18 | 2012-03-05 | Glaxosmithkline Biolog Sa | Vaccines comprising MAGE antigen coupled to protein D fragment |
| JP2004512383A (en) | 2000-11-02 | 2004-04-22 | アイネックス ファーマシューティカルズ コーポレイション | Therapeutic oligonucleotides with reduced toxicity |
| AU2001297693A1 (en) | 2000-12-08 | 2002-09-12 | Coley Pharmaceutical Gmbh | Cpg-like nucleic acids and methods of use thereof |
| US20020110840A1 (en)* | 2000-12-08 | 2002-08-15 | 3M Innovative Properties Company | Screening method for identifying compounds that selectively induce interferon alpha |
| ES2347525T3 (en)* | 2000-12-27 | 2010-11-02 | Dynavax Technologies Corporation | IMMUNOMODULATING POLINUCLEOTIDES AND METHODS FOR USERS. |
| US7337306B2 (en)* | 2000-12-29 | 2008-02-26 | Stmicroelectronics, Inc. | Executing conditional branch instructions in a data processor having a clustered architecture |
| US7713942B2 (en) | 2001-04-04 | 2010-05-11 | Nordic Vaccine Technology A/S | Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides |
| US7176296B2 (en) | 2001-04-30 | 2007-02-13 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| US7105495B2 (en) | 2001-04-30 | 2006-09-12 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| US20030129605A1 (en) | 2001-05-04 | 2003-07-10 | Dong Yu | Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosophonate linkages |
| EP2545937A1 (en)* | 2001-06-05 | 2013-01-16 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
| US20040191214A1 (en) | 2001-06-15 | 2004-09-30 | Johnson Lau | Nucleoside vaccine adjuvants |
| DK2423335T3 (en) | 2001-06-21 | 2014-08-18 | Dynavax Tech Corp | CHEMICAL IMMUNAL MODULATOR RELATIONS AND PROCEDURES FOR USE THEREOF |
| US20040132677A1 (en) | 2001-06-21 | 2004-07-08 | Fearon Karen L. | Chimeric immunomodulatory compounds and methods of using the same-IV |
| US7785610B2 (en) | 2001-06-21 | 2010-08-31 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—III |
| AU2002311617A1 (en) | 2001-06-25 | 2003-01-08 | The Regents Of The University Of California | Method for preparation of vesicles loaded with immunostimulatory oligodeoxynucleotides |
| US20030003970A1 (en) | 2001-06-28 | 2003-01-02 | Alan Johnson | Portable communications device |
| AU2002322358B2 (en) | 2001-06-29 | 2009-06-18 | Novartis Vaccines And Diagnostics, Inc. | HCV E1E2 vaccine compositions |
| US6982033B2 (en)* | 2001-07-13 | 2006-01-03 | Donald Hubbard H | Aerobic treatment plant with filter pipe |
| WO2003040308A2 (en) | 2001-07-27 | 2003-05-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo |
| US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
| WO2003012061A2 (en)* | 2001-08-01 | 2003-02-13 | Coley Pharmaceutical Gmbh | Methods and compositions relating to plasmacytoid dendritic cells |
| CA2456328C (en)* | 2001-08-07 | 2015-05-26 | Dynavax Technologies Corporation | Complexes of a short cpg-containing oligonucleotide bound to the surface of a solid phase microcarrier and methods for use thereof |
| JP2005510462A (en) | 2001-08-10 | 2005-04-21 | ダイナバックス テクノロジーズ コーポレイション | Production of immunomodulating oligonucleotides and methods of use thereof |
| US7354909B2 (en)* | 2001-08-14 | 2008-04-08 | The United States Of America As Represented By Secretary Of The Department Of Health And Human Services | Method for rapid generation of mature dendritic cells |
| MXPA04001458A (en)* | 2001-08-17 | 2005-02-17 | Univ Iowa Res Found | Combination motif immune stimulatory oligonucleotides with improved activity. |
| EP1427445A4 (en) | 2001-08-30 | 2006-09-06 | 3M Innovative Properties Co | METHOD FOR MATURIZING PLASMACYTIDES DENDRITIC CELLS USING IMMUNE RESPONSE MODIFYING MOLECULES |
| AU2002353783A1 (en)* | 2001-09-24 | 2003-04-07 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE |
| US20030119774A1 (en)* | 2001-09-25 | 2003-06-26 | Marianna Foldvari | Compositions and methods for stimulating an immune response |
| EP1434603B1 (en) | 2001-09-28 | 2009-12-16 | Purdue Research Foundation | Method of treatment using ligand-immunogen conjugates |
| KR20050034583A (en)* | 2001-10-05 | 2005-04-14 | 콜리 파마슈티칼 게엠베하 | Toll-like receptor 3 signaling agonists and antagonists |
| AU2002346960A1 (en) | 2001-10-06 | 2003-04-22 | Merial Limited | Methods and compositions for promoting growth and innate immunity in young animals |
| EP1434602B1 (en) | 2001-10-06 | 2014-12-17 | Merial Limited | CpG plus oil in water emulsion as adjuvant system for truncated bovine herpesvirus-1 glycoprotein D |
| US20030139364A1 (en)* | 2001-10-12 | 2003-07-24 | University Of Iowa Research Foundation | Methods and products for enhancing immune responses using imidazoquinoline compounds |
| US7276489B2 (en) | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
| WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| JP2005516897A (en) | 2001-11-07 | 2005-06-09 | イネックス ファーマシューティカルズ コーポレイション | Improved mucosal vaccine and method of use |
| ATE416771T1 (en) | 2001-11-16 | 2008-12-15 | 3M Innovative Properties Co | N-Ä4-(4-AMINO-2-ETHYL-1H-IMIDAZOÄ4,5-CUCHINOLINE 1-YL)BUTYLUMETHANESULFONAMIDE, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF |
| TW200303759A (en) | 2001-11-27 | 2003-09-16 | Schering Corp | Methods for treating cancer |
| US7541040B2 (en)* | 2001-12-04 | 2009-06-02 | The United States Of America As Represented By The Department Of Health And Human Serivces | Chimeric molecule for the treatment of th2-like cytokine mediated disorders |
| DE10161755B4 (en)* | 2001-12-15 | 2005-12-15 | Infineon Technologies Ag | Contact pin for testing microelectronic components with spherical contacts |
| US8466116B2 (en)* | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
| US7615227B2 (en)* | 2001-12-20 | 2009-11-10 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce angiogenesis |
| EP1467755A1 (en) | 2001-12-21 | 2004-10-20 | Antigenics Inc. | Compositions comprising immunoreactive reagents and saponins, and methods of use thereof |
| EP1474432A1 (en) | 2002-02-04 | 2004-11-10 | Biomira Inc. | Immunostimulatory, covalently lipidated oligonucleotides |
| US8088388B2 (en) | 2002-02-14 | 2012-01-03 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
| US20030232443A1 (en) | 2002-06-18 | 2003-12-18 | Isis Pharmaceuticals Inc. | Antisense modulation of centromere protein B expression |
| EP1499187B1 (en) | 2002-04-04 | 2015-06-17 | Zoetis Belgium S.A. | Immunostimulatory g,u-containing oligoribonucleotides |
| AU2003223482A1 (en)* | 2002-04-11 | 2003-10-27 | Zymogenetics, Inc. | Use of interleukin-24 to treat ovarian cancer |
| US7371734B2 (en)* | 2002-04-22 | 2008-05-13 | Bioniche Life Sciences Inc. | Oligonucleotide compositions and their use for the modulation of immune responses |
| US6948271B2 (en)* | 2002-05-06 | 2005-09-27 | Innovative Supply, Inc. | Identification and tracking system for deceased bodies |
| WO2003095090A1 (en)* | 2002-05-08 | 2003-11-20 | Dana Corporation | Plasma-assisted carburizing |
| MXPA04011127A (en) | 2002-05-10 | 2005-07-01 | Inex Pharmaceuticals Corp | IMMUNE OLIGONUCLEOTIDES METHODED STIMULATORS AND METHODS TO USE THE SAME. |
| WO2003094829A2 (en) | 2002-05-10 | 2003-11-20 | Inex Pharmaceuticals Corporation | Pathogen vaccines and methods for using the same |
| US20040009944A1 (en) | 2002-05-10 | 2004-01-15 | Inex Pharmaceuticals Corporation | Methylated immunostimulatory oligonucleotides and methods of using the same |
| AU2003246396B2 (en) | 2002-05-28 | 2008-08-21 | Merck Patent Gmbh | A method for generating antigen-presenting cells |
| US7807803B2 (en)* | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| AU2003267986A1 (en) | 2002-07-03 | 2004-01-23 | Depuy Mitek, Inc. | Vaccines to induce mucosal immunity |
| US7605138B2 (en) | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| WO2004007743A2 (en) | 2002-07-17 | 2004-01-22 | Coley Pharmaceutical Gmbh | Use of cpg nucleic acids in prion-disease |
| CN1468957A (en) | 2002-07-19 | 2004-01-21 | 中国人民解放军第二军医大学 | A plasmid used as an adjuvant for human therapeutic vaccines |
| US20050209183A1 (en) | 2002-07-25 | 2005-09-22 | Phenion Gmbh & Co. Kg | Cosmetic or pharmaceutical preparations comprising nucleic acids based on non-methylated CPG motifs |
| EP1393745A1 (en) | 2002-07-29 | 2004-03-03 | Hybridon, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5'ends |
| EP1575504A4 (en) | 2002-08-01 | 2009-11-04 | Us Gov Health & Human Serv | METHOD OF TREATING INFLAMMATORY ARTHROPATHIES USING OLIGONUCLEOTIDE CPG SUPPRESSORS |
| EP1551376A4 (en) | 2002-08-12 | 2010-10-06 | Dynavax Tech Corp | Immunomodulatory compositions, methods of making, and methods of use thereof |
| US6928476B2 (en)* | 2002-08-23 | 2005-08-09 | Mirra, Inc. | Peer to peer remote data storage and collaboration |
| US6744084B2 (en)* | 2002-08-29 | 2004-06-01 | Micro Technology, Inc. | Two-transistor pixel with buried reset channel and method of formation |
| KR20080053419A (en)* | 2002-09-13 | 2008-06-12 | 이데닉스 (케이만) 리미티드 | Β-L-2'-deoxynucleosides and combination therapy for the treatment of resistant HV strains |
| US6994870B2 (en)* | 2002-09-18 | 2006-02-07 | Jaw-Ji Tsai | Local nasal immunotherapy with allergen strip for allergic rhinitis |
| US8263091B2 (en)* | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
| AU2003278845A1 (en) | 2002-09-19 | 2004-04-08 | Coley Pharmaceutical Gmbh | Toll-like receptor 9 (tlr9) from various mammalian species |
| US6988995B2 (en)* | 2002-09-30 | 2006-01-24 | Carl Zeiss Meditec, Inc. | Method and system for detecting the effects of Alzheimer's disease in the human retina |
| US8043622B2 (en)* | 2002-10-08 | 2011-10-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides |
| US7758876B2 (en)* | 2002-11-01 | 2010-07-20 | The United States Of America As Represented By The Department Of Health And Human Services | Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides |
| US20040248837A1 (en) | 2002-11-01 | 2004-12-09 | Eyal Raz | Methods of treating pulmonary fibrotic disorders |
| JP2006512927A (en)* | 2002-12-11 | 2006-04-20 | コーリー ファーマシューティカル グループ，インコーポレイテッド | 5 'CPG nucleic acids and methods of use thereof |
| KR100525321B1 (en) | 2002-12-13 | 2005-11-02 | 안웅식 | Pharmaceutical composition for prophylaxis and treatment of papillomavirus-derived diseases comprising papillomavirus antigen protein and CpG-oligodeoxynucleotide |
| AU2003302743B2 (en) | 2002-12-23 | 2008-09-04 | Dynavax Technologies Corporation | Branched immunomodulatory compounds and methods of using the same |
| EP1575977B1 (en)* | 2002-12-23 | 2009-09-09 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
| CA2512484A1 (en) | 2003-01-16 | 2004-05-08 | Hybridon, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
| US7189781B2 (en)* | 2003-03-13 | 2007-03-13 | H.B. Fuller Licensing & Finance Inc. | Moisture curable, radiation curable sealant composition |
| CN1764473A (en) | 2003-03-24 | 2006-04-26 | 英特塞尔股份公司 | Use of alum and Th1 immune response inducing adjuvant for enhancing immune response |
| WO2004085635A1 (en) | 2003-03-26 | 2004-10-07 | Cytos Biotechnology Ag | Melan-a peptide analogue-virus-like-particle conjugates |
| EP1608403A2 (en)* | 2003-04-02 | 2005-12-28 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations for topical application |
| US20050004144A1 (en)* | 2003-04-14 | 2005-01-06 | Regents Of The University Of California | Combined use of IMPDH inhibitors with toll-like receptor agonists |
| EP1631687A2 (en) | 2003-04-22 | 2006-03-08 | Coley Pharmaceutical GmbH | Methods and products for identification and assessment of tlr ligands |
| JP3887346B2 (en)* | 2003-04-28 | 2007-02-28 | 株式会社東芝 | Video signal processing apparatus, video signal processing method, and video display apparatus |
| AU2004241093B2 (en) | 2003-05-16 | 2009-08-27 | Idera Pharmaceuticals, Inc. | Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents |
| EP1484336A1 (en)* | 2003-06-02 | 2004-12-08 | Pevion Biotech Ltd. | Methods for synthesizing conformationally constrained peptides, peptidometics and the use thereof as synthetic vaccines |
| EP2371834B1 (en) | 2003-06-11 | 2016-02-17 | Idera Pharmaceuticals, Inc. | Stabilized immunomodulatory oligonucleotides |
| WO2004110489A1 (en)* | 2003-06-13 | 2004-12-23 | Daiichi Asubio Pharma Co., Ltd. | MEDICINAL COMPOSITION FOR PREVENTING OR TREATING Th1 TYPE IMMUNOLOGICAL DISEASE |
| PL1635863T3 (en)* | 2003-06-17 | 2011-01-31 | Mannkind Corp | Compositions to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes |
| JP2007524615A (en)* | 2003-06-20 | 2007-08-30 | コーリー ファーマシューティカル ゲーエムベーハー | Low molecular weight Toll-like receptor (TLR) antagonist |
| US20040265833A1 (en) | 2003-06-23 | 2004-12-30 | Cathy Lofton-Day | Methods and nucleic acids for the analysis of colorectal cell proliferative disorders |
| CN100404070C (en) | 2003-07-10 | 2008-07-23 | 赛托斯生物技术公司 | Packaged virus-like particles |
| CN1822856B (en) | 2003-07-11 | 2010-04-28 | 英特塞尔股份公司 | HCV vaccines |
| WO2005009355A2 (en) | 2003-07-15 | 2005-02-03 | Hybridon, Inc. | Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy |
| US20060182793A1 (en)* | 2003-07-22 | 2006-08-17 | Cytos Biotechnology Ag | Cpg-packaged liposomes |
| MXPA06001996A (en) | 2003-08-28 | 2006-06-20 | Immune Response Corp Inc | Immunogenic hiv compositions and related methods. |
| EP1667694B1 (en)* | 2003-09-05 | 2010-04-28 | Anadys Pharmaceuticals, Inc. | Tlr7 ligands for the treatment of hepatitis c |
| EP1671643A1 (en) | 2003-09-08 | 2006-06-21 | Intellectual Property Consulting Inc. | Medicinal composition for treating chronic hepatitis c |
| GB0321615D0 (en)* | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
| WO2005027920A1 (en)* | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | 2-alkylidene-19-nor-vitamin d derivatives for the treatment of rickets or vitamin d deficiency |
| US7615539B2 (en)* | 2003-09-25 | 2009-11-10 | Coley Pharmaceutical Group, Inc. | Nucleic acid-lipophilic conjugates |
| CA2542099A1 (en) | 2003-10-11 | 2005-04-21 | Inex Pharmaceuticals Corporation | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
| US20050087538A1 (en)* | 2003-10-23 | 2005-04-28 | Wolfe Darrell R. | Iceless multiple can cooler |
| US20050215501A1 (en) | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
| US8188254B2 (en) | 2003-10-30 | 2012-05-29 | Coley Pharmaceutical Gmbh | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
| US20050239733A1 (en) | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
| JP4088246B2 (en)* | 2003-12-05 | 2008-05-21 | 富士通株式会社 | Ring network master setting method and apparatus |
| AU2004304770B2 (en) | 2003-12-08 | 2010-05-06 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties by small oligonucleotide-based compounds |
| US9090673B2 (en) | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
| US20070172315A1 (en)* | 2003-12-18 | 2007-07-26 | Barrett Robert K | Method and Apparatus for Creating Soil or Rock Subsurface Support |
| EP1550458A1 (en) | 2003-12-23 | 2005-07-06 | Vectron Therapeutics AG | Synergistic liposomal adjuvants |
| KR100558851B1 (en) | 2004-01-08 | 2006-03-10 | 학교법인연세대학교 | CJ oligodeoxynucleotide variants with increased immunomodulatory capacity |
| WO2005076975A2 (en)* | 2004-02-06 | 2005-08-25 | Mayo Foundation For Medical Education And Research | Complexed polypeptide and adjuvant for improved vaccines |
| US20050181035A1 (en) | 2004-02-17 | 2005-08-18 | Dow Steven W. | Systemic immune activation method using non CpG nucleic acids |
| WO2005097993A2 (en) | 2004-02-19 | 2005-10-20 | Coley Pharmaceutical Group, Inc. | Immunostimulatory viral rna oligonucleotides |
| CN1918293A (en) | 2004-02-20 | 2007-02-21 | 莫洛根股份公司 | Substituted non-coding nucleic acid molecule for therapeutic or prophylaxis immunological stimulus for human and higher animal |
| AU2005222909B2 (en) | 2004-03-12 | 2010-03-11 | Idera Pharmaceuticals, Inc. | Enhanced activity of HIV vaccine using a second generation immunomodulatory oligonucleotide |
| US7303881B2 (en)* | 2004-04-30 | 2007-12-04 | Pds Biotechnology Corporation | Antigen delivery compositions and methods of use |
| WO2005115449A1 (en)* | 2004-05-28 | 2005-12-08 | Alk-Abelló A/S | Method of treating allergy and infection by eliciting an iga antibody response |
| US8399025B2 (en)* | 2004-06-04 | 2013-03-19 | Board Of Regents, The University Of Texas System | Polyamine modified particles |
| JP2008501807A (en)* | 2004-06-08 | 2008-01-24 | コーリー ファーマシューティカル ゲーエムベーハー | Abasic oligonucleotides as carrier backbone for antigens and immunostimulatory agonists and antagonists |
| US7756043B1 (en)* | 2004-06-09 | 2010-07-13 | Sprint Communications Company L.P. | Method for identifying high traffic origin-destination node pairs in a packet based network |
| US7498425B2 (en) | 2004-06-15 | 2009-03-03 | Idera Pharmaceuticals, Inc. | Immunostimulatory oligonucleotide multimers |
| US20060014713A1 (en) | 2004-06-15 | 2006-01-19 | Hybridon, Inc. | Immunostimulatory oligonucleotide multimers |
| EP1766610A1 (en)* | 2004-06-25 | 2007-03-28 | TC Electronic A/S | Method of evaluating perception intensity of an audio signal and a method of controlling an input audio signal on the basis of the evaluation |
| AU2005326322B2 (en)* | 2004-07-01 | 2009-02-05 | Yale University | Targeted and high density drug loaded polymeric materials |
| AU2005335104C1 (en) | 2004-07-18 | 2010-10-28 | Csl Limited | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
| WO2006015560A1 (en) | 2004-08-09 | 2006-02-16 | Mologen Ag | Immunomodulating agent used in conjunction with chemotherapy |
| US20060058261A1 (en)* | 2004-09-15 | 2006-03-16 | Andre Aube | Chitin derivatives for hyperlipidemia |
| MY159370A (en)* | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
| KR100721928B1 (en)* | 2004-11-05 | 2007-05-28 | 주식회사 바이오씨에스 | Pharmaceutical composition for the treatment or prevention of skin diseases containing CJ oligodeoxynucleotide |
| US20060105979A1 (en) | 2004-11-08 | 2006-05-18 | Hybridon, Inc. | Synergistic inhibition of VEGF and modulation of the immune response |
| US20060171968A1 (en) | 2005-01-07 | 2006-08-03 | Alk-Abello A/S | Method of preventive treatment of allergy by oromucosal administration of an allergy vaccine |
| AU2006216493A1 (en)* | 2005-02-24 | 2006-08-31 | Coley Pharmaceutical Gmbh | Immunostimulatory oligonucleotides |
| CN101193646A (en) | 2005-04-08 | 2008-06-04 | 科勒制药集团公司 | Method for treating infectious disease exacerbated asthma |
| AU2006241149A1 (en) | 2005-04-26 | 2006-11-02 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity |
| US7325152B2 (en)* | 2005-06-30 | 2008-01-29 | Infineon Technologies Ag | Synchronous signal generator |
| MX2008000379A (en)* | 2005-07-07 | 2008-03-18 | Coley Pharm Group Inc | Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment. |
| US7892569B2 (en)* | 2005-08-31 | 2011-02-22 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of altering an immune response induced by CpG oligodeoxynucleotides |
| CA2622679A1 (en) | 2005-09-16 | 2007-08-09 | Coley Pharmaceutical Gmbh | Immunostimulatory single-stranded ribonucleic acid with phosphodiester backbone |
| KR20080047463A (en) | 2005-09-16 | 2008-05-28 | 콜리 파마슈티칼 게엠베하 | Modulation of Immunostimulatory Properties of Short Interfering Ribonucleic Acid (SIRNA) by Nucleotide Modification |
| CN101340931A (en) | 2005-09-27 | 2009-01-07 | 科利制药公司 | Modulation of tlr-mediated immune responses using adaptor oligonucleotides |
| EP1937812A2 (en)* | 2005-10-12 | 2008-07-02 | Cancer Research Technology Limited | Methods and compositions for treating immune disorders |
| US20070093439A1 (en) | 2005-10-25 | 2007-04-26 | Idera Pharmaceuticals, Inc. | Short immunomodulatory oligonucleotides |
| AU2006306805A1 (en)* | 2005-10-28 | 2007-05-03 | Index Pharmaceuticals Ab | Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease |
| US20070243209A1 (en)* | 2005-10-28 | 2007-10-18 | Health Research, Inc. | Compositions and methods for prevention and treatment of fungal diseases |
| EP1951299B1 (en) | 2005-11-04 | 2012-01-04 | Novartis Vaccines and Diagnostics S.r.l. | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| CN102755645A (en) | 2005-11-04 | 2012-10-31 | 诺华疫苗和诊断有限公司 | Influenza vaccines with reduced amount of emulsion adjuvant |
| EP1945653A4 (en) | 2005-11-07 | 2012-03-14 | Idera Pharmaceuticals | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
| ATE529511T1 (en) | 2005-11-07 | 2011-11-15 | Idera Pharmaceuticals | IMMUNO-STIMULATIVE PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS WITH MODIFIED IMMUNO-STIMULATIVE DINUCLEOTIDES |
| US7776834B2 (en) | 2005-11-07 | 2010-08-17 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
| US7470674B2 (en) | 2005-11-07 | 2008-12-30 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
| JP4538522B2 (en)* | 2005-11-25 | 2010-09-08 | コーリー ファーマシューティカル ゲーエムベーハー | Immunostimulatory oligoribonucleotides |
| CN101379195B (en) | 2005-12-20 | 2012-05-09 | 艾德拉药物股份有限公司 | Palindromic Immune Modulatory Oligonucleotides (IMOs) containing palindromic fragments of varying lengthsTM) Immunostimulating activity of |
| ES2526879T3 (en)* | 2006-02-15 | 2015-01-16 | Adiutide Pharmaceuticals Gmbh | Compositions and procedures for oligonucleotide formulations |
| DE102006007433A1 (en) | 2006-02-17 | 2007-08-23 | Curevac Gmbh | Immunostimulant adjuvant useful in vaccines against cancer or infectious diseases comprises a lipid-modified nucleic acid |
| WO2008019018A2 (en)* | 2006-08-03 | 2008-02-14 | William Soo Hoo | Bioactive molecular matrix and methods of use in the treatment of disease |
| US20080124366A1 (en)* | 2006-08-06 | 2008-05-29 | Ohlfest John R | Methods and Compositions for Treating Tumors |
| US20080171716A1 (en)* | 2006-08-16 | 2008-07-17 | Protiva Biotherapeutics, Inc. | Nucleic acid modulation of toll-like receptor-mediated immune stimulation |
| US8027888B2 (en) | 2006-08-31 | 2011-09-27 | Experian Interactive Innovation Center, Llc | Online credit card prescreen systems and methods |
| WO2008033432A2 (en) | 2006-09-12 | 2008-03-20 | Coley Pharmaceutical Group, Inc. | Immune modulation by chemically modified ribonucleosides and oligoribonucleotides |
| US20090181078A1 (en)* | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| DK2484375T3 (en)* | 2006-09-26 | 2018-07-16 | Infectious Disease Res Inst | Vaccine composition comprising synthetic adjuvant |
| WO2008039538A2 (en) | 2006-09-27 | 2008-04-03 | Coley Pharmaceutical Group, Inc. | Compositions of tlr ligands and antivirals |
| NZ575437A (en) | 2006-09-27 | 2012-02-24 | Coley Pharm Gmbh | Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity |
| AU2007353120A1 (en)* | 2006-10-26 | 2008-11-20 | Coley Pharmaceutical Gmbh | Oligoribonucleotides and uses thereof |
| WO2008057529A2 (en)* | 2006-11-06 | 2008-05-15 | Coley Pharmaceutical Group, Inc. | Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (cetp) |
| KR20090095626A (en)* | 2006-12-04 | 2009-09-09 | 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 | COMPOSITIONS AND METHODS TO TREAT CANCER WITH CpG RICH DNA AND CUPREDOXINS |
| EP2502634A1 (en)* | 2006-12-28 | 2012-09-26 | The Trustees of The University of Pennsylvania | Herpes simplex virus combined subunit vaccines and methods of use thereof |
| US8057804B2 (en)* | 2006-12-28 | 2011-11-15 | The Trustees Of The University Of Pennsylvania | Herpes simplex virus combined subunit vaccines and methods of use thereof |
| AR066405A1 (en)* | 2007-04-20 | 2009-08-19 | Glaxosmithkline Biolog Sa | VACCINE |
| US20100285041A1 (en) | 2007-05-17 | 2010-11-11 | Eugen Uhlmann | Class A Oligonucleotides with Immunostimulatory Potency |
| WO2009022215A1 (en)* | 2007-08-13 | 2009-02-19 | Pfizer Inc. | Combination motif immune stimulatory oligonucleotides with improved activity |
| US20090196915A1 (en)* | 2007-08-21 | 2009-08-06 | Gary Van Nest | Composition and methods of making and using influenza proteins |
| WO2009027105A2 (en)* | 2007-08-31 | 2009-03-05 | Neurimmune Therapeutics Ag | Method of providing patient specific immune response in amyloidoses and protein aggregation disorders |
| US7892567B2 (en)* | 2007-10-01 | 2011-02-22 | Board Of Regents, The University Of Texas System | Methods and compositions for immunization against chlamydial infection and disease |
| KR20100068422A (en) | 2007-10-09 | 2010-06-23 | 콜리 파마슈티칼 게엠베하 | Immune stimulatory oligonucleotide analogs containing modified sugar moieties |
| AR069704A1 (en)* | 2007-12-18 | 2010-02-10 | Alcon Res Ltd | SYSTEM OF ADMINISTRATION OF RNAI OF INTERFERENCE AND USES OF THE SAME |
| US7720322B2 (en)* | 2008-06-30 | 2010-05-18 | Intuitive Surgical, Inc. | Fiber optic shape sensor |
| TWI351288B (en)* | 2008-07-04 | 2011-11-01 | Univ Nat Pingtung Sci & Tech | Cpg dna adjuvant in avian vaccines |
| US20100166782A1 (en)* | 2008-07-25 | 2010-07-01 | Martha Karen Newell | Clip inhibitors and methods of modulating immune function |
| US8053422B2 (en)* | 2008-12-04 | 2011-11-08 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-cancer oligodeoxynucleotides |
- 1996
- 1996-10-30USUS08/738,652patent/US6207646B1/ennot_activeExpired - Lifetime
- 1997
- 1997-10-30ESES97947311Tpatent/ES2268736T3/ennot_activeExpired - Lifetime
- 1997-10-30PTPT97947311Tpatent/PT948510E/enunknown
- 1997-10-30WOPCT/US1997/019791patent/WO1998018810A1/enactiveIP Right Grant
- 1997-10-30CNCNA2007101300520Apatent/CN101265285A/enactivePending
- 1997-10-30EPEP10186108Apatent/EP2322615A1/ennot_activeWithdrawn
- 1997-10-30ATAT97947311Tpatent/ATE332966T1/enactive
- 1997-10-30EPEP06115792Apatent/EP1714969A3/ennot_activeWithdrawn
- 1997-10-30CACA2270345Apatent/CA2270345C/ennot_activeExpired - Lifetime
- 1997-10-30DKDK97947311Tpatent/DK0948510T3/enactive
- 1997-10-30EPEP97947311Apatent/EP0948510B1/ennot_activeRevoked
- 1997-10-30JPJP52078498Apatent/JP2001503267A/enactivePending
- 1997-10-30DEDE69736331Tpatent/DE69736331T2/ennot_activeRevoked
- 1997-10-30EPEP06115801Apatent/EP1746159A3/ennot_activeWithdrawn
- 1997-10-30NZNZ335397Apatent/NZ335397A/ennot_activeIP Right Cessation
- 1997-10-30EPEP10186177.1Apatent/EP2360252B8/ennot_activeExpired - Lifetime
- 1997-10-30ESES10186177.1Tpatent/ES2624859T3/ennot_activeExpired - Lifetime
- 1997-10-30AUAU52424/98Apatent/AU5242498A/ennot_activeAbandoned
- 1997-10-30KRKR1019997003873Apatent/KR100689942B1/ennot_activeExpired - Lifetime
- 1997-10-30CNCNB971993521Apatent/CN100338086C/ennot_activeExpired - Lifetime
- 2001
- 2001-03-27USUS09/818,918patent/US20030050261A1/ennot_activeAbandoned
- 2001-12-14AUAU97249/01Apatent/AU775185B2/ennot_activeExpired
- 2003
- 2003-03-03JPJP2003056446Apatent/JP2003286174A/ennot_activeWithdrawn
- 2003-05-09USUS10/435,656patent/US20050277604A1/ennot_activeAbandoned
- 2003-07-03USUS10/613,916patent/US20050070491A1/ennot_activeAbandoned
- 2003-09-10JPJP2003319045Apatent/JP2004041224A/ennot_activeWithdrawn
- 2003-10-03USUS10/679,710patent/US20040147468A1/ennot_activeAbandoned
- 2003-12-22USUS10/743,625patent/US20040132685A1/ennot_activeAbandoned
- 2004
- 2004-01-30USUS10/769,282patent/US7674777B2/ennot_activeExpired - Fee Related
- 2004-04-02USUS10/817,165patent/US20040198688A1/ennot_activeAbandoned
- 2004-04-23USUS10/831,647patent/US7402572B2/ennot_activeExpired - Fee Related
- 2004-05-17USUS10/847,642patent/US20050004061A1/ennot_activeAbandoned
- 2004-06-24USUS10/877,407patent/US20040229835A1/ennot_activeAbandoned
- 2004-07-02USUS10/884,852patent/US20050059625A1/ennot_activeAbandoned
- 2004-07-09USUS10/888,785patent/US7517861B2/ennot_activeExpired - Fee Related
- 2004-07-09USUS10/888,449patent/US20050049215A1/ennot_activeAbandoned
- 2004-07-16USUS10/894,862patent/US8058249B2/ennot_activeExpired - Fee Related
- 2004-07-16USUS10/894,657patent/US20050054602A1/ennot_activeAbandoned
- 2004-08-26USUS10/928,762patent/US20050123523A1/ennot_activeAbandoned
- 2004-10-01USUS10/956,494patent/US7879810B2/ennot_activeExpired - Fee Related
- 2004-10-01USUS10/956,745patent/US20050239732A1/ennot_activeAbandoned
- 2004-10-13AUAU2004218696Apatent/AU2004218696B2/ennot_activeExpired
- 2004-10-22USUS10/972,301patent/US20050215500A1/ennot_activeAbandoned
- 2004-11-12USUS10/987,146patent/US20050148537A1/ennot_activeAbandoned
- 2005
- 2005-01-07USUS11/031,460patent/US8158592B2/ennot_activeExpired - Fee Related
- 2005-01-14USUS11/036,527patent/US7723022B2/ennot_activeExpired - Fee Related
- 2005-02-25USUS11/067,587patent/US8129351B2/ennot_activeExpired - Fee Related
- 2005-05-23USUS11/134,918patent/US20050267064A1/ennot_activeAbandoned
- 2005-12-07USUS11/296,572patent/US20060089326A1/ennot_activeAbandoned
- 2006
- 2006-08-11USUS11/503,483patent/US7723500B2/ennot_activeExpired - Fee Related
- 2006-09-22USUS11/526,197patent/US20070078104A1/ennot_activeAbandoned
- 2006-11-10USUS11/598,207patent/US8258106B2/ennot_activeExpired - Fee Related
- 2007
- 2007-06-05USUS11/810,353patent/US20080026011A1/ennot_activeAbandoned
- 2008
- 2008-07-25JPJP2008192729Apatent/JP5082063B2/ennot_activeExpired - Lifetime
- 2008-10-09USUS12/248,493patent/US20090202575A1/ennot_activeAbandoned
- 2009
- 2009-03-25USUS12/383,824patent/US7888327B2/ennot_activeExpired - Fee Related
- 2010
- 2010-03-10JPJP2010053784Apatent/JP2010150280A/enactivePending
Patent Citations (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5756097A (en)* | 1985-06-28 | 1998-05-26 | Landucci; Gary R. | Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases |
| US5087617A (en)* | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
| US5112605A (en)* | 1989-03-17 | 1992-05-12 | Genentech, Inc. | Temporal gamma-interferon administration for allergies |
| US5498410A (en)* | 1991-04-22 | 1996-03-12 | Gleich; Gerald J. | Method for the treatment of eosinophil-associated conditions with anionic polymers |
| US20030027782A1 (en)* | 1993-08-26 | 2003-02-06 | Carson Dennis A. | Method for treating allergic lung disease |
| US5723335A (en)* | 1994-03-25 | 1998-03-03 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| US6727230B1 (en)* | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| US20050075302A1 (en)* | 1994-03-25 | 2005-04-07 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| US20060058251A1 (en)* | 1994-07-15 | 2006-03-16 | University Of Iowa Research Foundation | Methods for treating and preventing infectious disease |
| US20030050261A1 (en)* | 1994-07-15 | 2003-03-13 | Krieg Arthur M. | Immunostimulatory nucleic acid molecules |
| US20050004062A1 (en)* | 1994-07-15 | 2005-01-06 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US6194388B1 (en)* | 1994-07-15 | 2001-02-27 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US6207646B1 (en)* | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20040087534A1 (en)* | 1994-07-15 | 2004-05-06 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US20070078104A1 (en)* | 1994-07-15 | 2007-04-05 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20070065467A1 (en)* | 1994-07-15 | 2007-03-22 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US20040087538A1 (en)* | 1994-07-15 | 2004-05-06 | University Of Iowa Research Foundation | Methods of treating cancer using immunostimulatory oligonucleotides |
| US6239116B1 (en)* | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20050009774A1 (en)* | 1994-07-15 | 2005-01-13 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US20070066553A1 (en)* | 1994-07-15 | 2007-03-22 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20050032736A1 (en)* | 1994-07-15 | 2005-02-10 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20070009482A9 (en)* | 1994-07-15 | 2007-01-11 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US20070010470A9 (en)* | 1994-07-15 | 2007-01-11 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US20060094683A1 (en)* | 1994-07-15 | 2006-05-04 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US20050037985A1 (en)* | 1994-07-15 | 2005-02-17 | Krieg Arthur M. | Methods and products for treating HIV infection |
| US20050037403A1 (en)* | 1994-07-15 | 2005-02-17 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US20060089326A1 (en)* | 1994-07-15 | 2006-04-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20050004061A1 (en)* | 1994-07-15 | 2005-01-06 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20050049215A1 (en)* | 1994-07-15 | 2005-03-03 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20030100527A1 (en)* | 1994-07-15 | 2003-05-29 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US20050049216A1 (en)* | 1994-07-15 | 2005-03-03 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20060003955A1 (en)* | 1994-07-15 | 2006-01-05 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20030050263A1 (en)* | 1994-07-15 | 2003-03-13 | The University Of Iowa Research Foundation | Methods and products for treating HIV infection |
| US20050054602A1 (en)* | 1994-07-15 | 2005-03-10 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20050101557A1 (en)* | 1994-07-15 | 2005-05-12 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20050101554A1 (en)* | 1994-07-15 | 2005-05-12 | University Of Iowa Research Foundation | Methods for treating and preventing infectious disease |
| US7223741B2 (en)* | 1994-07-15 | 2007-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20050070491A1 (en)* | 1994-07-15 | 2005-03-31 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20050059625A1 (en)* | 1994-07-15 | 2005-03-17 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US5908620A (en)* | 1995-01-31 | 1999-06-01 | National Jewish Medical And Research Center | Treatment for diseases involving inflammation |
| US20030026782A1 (en)* | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| US5726160A (en)* | 1995-04-13 | 1998-03-10 | Milkhaus Laboratories, Inc. | Methods for treating respiratory disease |
| US6040296A (en)* | 1995-06-07 | 2000-03-21 | East Carolina University | Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation |
| US6025339A (en)* | 1995-06-07 | 2000-02-15 | East Carolina University | Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation |
| US20030078223A1 (en)* | 1996-01-30 | 2003-04-24 | Eyal Raz | Compositions and methods for modulating an immune response |
| US6335068B1 (en)* | 1996-09-13 | 2002-01-01 | Beiersdorf A.G. | Redetachable, self-adhesive device |
| US6174872B1 (en)* | 1996-10-04 | 2001-01-16 | The Regents Of The University Of California | Method for treating allergic lung disease |
| US20040006010A1 (en)* | 1996-10-11 | 2004-01-08 | Carson Dennis A. | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
| US20050054601A1 (en)* | 1997-01-23 | 2005-03-10 | Coley Pharmaceutical Gmbh | Pharmaceutical composition comprising a polynucleotide and optionally an antigen especially for vaccination |
| US7001890B1 (en)* | 1997-01-23 | 2006-02-21 | Coley Pharmaceutical Gmbh | Pharmaceutical compositions comprising a polynucleotide and optionally an antigen especially for vaccination |
| US6214806B1 (en)* | 1997-02-28 | 2001-04-10 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders |
| US20050043529A1 (en)* | 1997-03-10 | 2005-02-24 | Coley Pharmaceutical Gmbh | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US6406705B1 (en)* | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US20030091599A1 (en)* | 1997-03-10 | 2003-05-15 | Coley Pharmaceutical Gmbh | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US20050032734A1 (en)* | 1997-05-20 | 2005-02-10 | Krieg Arthur M. | Vectors and methods for immunization or therapeutic protocols |
| US6339068B1 (en)* | 1997-05-20 | 2002-01-15 | University Of Iowa Research Foundation | Vectors and methods for immunization or therapeutic protocols |
| US6225292B1 (en)* | 1997-06-06 | 2001-05-01 | The Regents Of The University Of California | Inhibitors of DNA immunostimulatory sequence activity |
| US6399630B1 (en)* | 1997-07-03 | 2002-06-04 | University Of Iowa Research Foundation | Methods for inhibiting immunostimulatory DNA associated responses |
| US6521637B2 (en)* | 1997-07-03 | 2003-02-18 | University Of Iowa Research Foundation | Methods for inhibiting immunostimulatory DNA associated responses |
| US6221882B1 (en)* | 1997-07-03 | 2001-04-24 | University Of Iowa Research Foundation | Methods for inhibiting immunostimulatory DNA associated responses |
| US5877309A (en)* | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
| US20030092663A1 (en)* | 1997-09-05 | 2003-05-15 | Eyal Raz | Immunization-free methods for treating antigen-stimulated inflammation in a mammalian host and shifting the host's antigen immune responsiveness to a Th1 phenotype |
| US20050031638A1 (en)* | 1997-12-24 | 2005-02-10 | Smithkline Beecham Biologicals S.A. | Vaccine |
| US20020064515A1 (en)* | 1998-04-03 | 2002-05-30 | Krieg Arthur M. | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| US6218371B1 (en)* | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| US20040030118A1 (en)* | 1998-05-14 | 2004-02-12 | Hermann Wagner | Methods for regulating hematopoiesis using CpG-oligonucleotides |
| US20040006034A1 (en)* | 1998-06-05 | 2004-01-08 | Eyal Raz | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
| US20040092468A1 (en)* | 1998-06-05 | 2004-05-13 | David Schwartz | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| US6562798B1 (en)* | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| US7049302B1 (en)* | 1998-08-10 | 2006-05-23 | Antigenics Inc. | Compositions of CPG and saponin adjuvants and uses thereof |
| US20030064064A1 (en)* | 1998-09-18 | 2003-04-03 | Dino Dina | Methods of treating IgE-associated disorders and compositions for use therein |
| US20020004416A1 (en)* | 1999-03-22 | 2002-01-10 | Ronald Baratono | Combined rear view mirror and telephone |
| US6558670B1 (en)* | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
| US6544518B1 (en)* | 1999-04-19 | 2003-04-08 | Smithkline Beecham Biologicals S.A. | Vaccines |
| US6737066B1 (en)* | 1999-05-06 | 2004-05-18 | The Immune Response Corporation | HIV immunogenic compositions and methods |
| US6514948B1 (en)* | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
| US20070066554A1 (en)* | 1999-09-25 | 2007-03-22 | Coley Pharmaceutical Gmbh | Immunostimulatory nucleic acids |
| US6552006B2 (en)* | 2000-01-31 | 2003-04-22 | The Regents Of The University Of California | Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen |
| US20040067902A9 (en)* | 2000-02-03 | 2004-04-08 | Bratzler Robert L. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
| US20070037767A1 (en)* | 2000-02-03 | 2007-02-15 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
| US20020042387A1 (en)* | 2000-02-23 | 2002-04-11 | Eyal Raz | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
| US20020028784A1 (en)* | 2000-03-10 | 2002-03-07 | Nest Gary Van | Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences |
| US7183111B2 (en)* | 2000-03-10 | 2007-02-27 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
| US20040009942A1 (en)* | 2000-03-10 | 2004-01-15 | Gary Van Nest | Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide sequences |
| US6534062B2 (en)* | 2000-03-28 | 2003-03-18 | The Regents Of The University Of California | Methods for increasing a cytotoxic T lymphocyte response in vivo |
| US20030026801A1 (en)* | 2000-06-22 | 2003-02-06 | George Weiner | Methods for enhancing antibody-induced cell lysis and treating cancer |
| US20030055014A1 (en)* | 2000-12-14 | 2003-03-20 | Bratzler Robert L. | Inhibition of angiogenesis by nucleic acids |
| US20030050268A1 (en)* | 2001-03-29 | 2003-03-13 | Krieg Arthur M. | Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases |
| US7038029B2 (en)* | 2002-05-30 | 2006-05-02 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
| US20040009949A1 (en)* | 2002-06-05 | 2004-01-15 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids |
| US20040053880A1 (en)* | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US20040067905A1 (en)* | 2002-07-03 | 2004-04-08 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US20040092472A1 (en)* | 2002-07-03 | 2004-05-13 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US20050059619A1 (en)* | 2002-08-19 | 2005-03-17 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids |
| US20060003962A1 (en)* | 2002-10-29 | 2006-01-05 | Coley Pharmaceutical Group, Ltd. | Methods and products related to treatment and prevention of hepatitis C virus infection |
| US20050013812A1 (en)* | 2003-07-14 | 2005-01-20 | Dow Steven W. | Vaccines using pattern recognition receptor-ligand:lipid complexes |
| US20050100983A1 (en)* | 2003-11-06 | 2005-05-12 | Coley Pharmaceutical Gmbh | Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling |
| US20060019916A1 (en)* | 2004-04-02 | 2006-01-26 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for inducing IL-10 responses |
| US20060019923A1 (en)* | 2004-07-18 | 2006-01-26 | Coley Pharmaceutical Group, Ltd. | Methods and compositions for inducing innate immune responses |
Cited By (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US7517861B2 (en) | 1994-07-15 | 2009-04-14 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US8058249B2 (en) | 1994-07-15 | 2011-11-15 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US8309527B2 (en) | 1994-07-15 | 2012-11-13 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US7223741B2 (en) | 1994-07-15 | 2007-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US7402572B2 (en) | 1994-07-15 | 2008-07-22 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US8258106B2 (en) | 1994-07-15 | 2012-09-04 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US7888327B2 (en) | 1994-07-15 | 2011-02-15 | University Of Iowa Research Foundation | Methods of using immunostimulatory nucleic acid molecules to treat allergic conditions |
| US8008266B2 (en) | 1994-07-15 | 2011-08-30 | University Of Iowa Foundation | Methods of treating cancer using immunostimulatory oligonucleotides |
| US7524828B2 (en) | 1994-07-15 | 2009-04-28 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20040087534A1 (en)* | 1994-07-15 | 2004-05-06 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US8114848B2 (en) | 1994-07-15 | 2012-02-14 | The United States Of America As Represented By The Department Of Health And Human Services | Immunomodulatory oligonucleotides |
| US7723500B2 (en) | 1994-07-15 | 2010-05-25 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US8158592B2 (en) | 1994-07-15 | 2012-04-17 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acid molecules |
| US7879810B2 (en) | 1994-07-15 | 2011-02-01 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US8148340B2 (en) | 1994-07-15 | 2012-04-03 | The United States Of America As Represented By The Department Of Health And Human Services | Immunomodulatory oligonucleotides |
| US8129351B2 (en) | 1994-07-15 | 2012-03-06 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US7674777B2 (en) | 1994-07-15 | 2010-03-09 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US7713529B2 (en) | 1994-07-15 | 2010-05-11 | University Of Iowa Research Foundation | Methods for treating and preventing infectious disease |
| US7723022B2 (en) | 1994-07-15 | 2010-05-25 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US7488490B2 (en) | 1997-03-10 | 2009-02-10 | University Of Iowa Research Foundation | Method of inducing an antigen-specific immune response by administering a synergistic combination of adjuvants comprising unmethylated CpG-containing nucleic acids and a non-nucleic acid adjuvant |
| US8202688B2 (en) | 1997-03-10 | 2012-06-19 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US8574599B1 (en) | 1998-05-22 | 2013-11-05 | Ottawa Hospital Research Institute | Methods and products for inducing mucosal immunity |
| US7741300B2 (en) | 1998-06-25 | 2010-06-22 | National Jewish Medical And Research Center | Methods of using nucleic acid vector-lipid complexes |
| US7776343B1 (en) | 1999-02-17 | 2010-08-17 | Csl Limited | Immunogenic complexes and methods relating thereto |
| US8173141B2 (en) | 1999-02-17 | 2012-05-08 | Csl Limited | Immunogenic complexes and methods relating thereto |
| US7776344B2 (en) | 1999-09-27 | 2010-08-17 | University Of Iowa Research Foundation | Methods related to immunostimulatory nucleic acid-induced interferon |
| US7585847B2 (en) | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
| US20030026801A1 (en)* | 2000-06-22 | 2003-02-06 | George Weiner | Methods for enhancing antibody-induced cell lysis and treating cancer |
| US7534772B2 (en) | 2000-06-22 | 2009-05-19 | University Of Iowa Research Foundation | Methods for enhancing antibody-induced cell lysis and treating cancer |
| US7820379B2 (en) | 2000-09-15 | 2010-10-26 | Coley Pharmaceutical Gmbh | Process for high throughput screening of CpG-based immuno-agonist/antagonist |
| US20050181422A1 (en)* | 2000-09-15 | 2005-08-18 | Coley Pharmaceutical Gmbh | Process for high throughput screening of CpG-based immuno-agonist/antagonist |
| US8834900B2 (en) | 2001-08-17 | 2014-09-16 | University Of Iowa Research Foundation | Combination motif immune stimulatory oligonucleotides with improved activity |
| US8658607B2 (en) | 2002-04-04 | 2014-02-25 | Zoetis Belgium | Immunostimulatory G, U-containing oligoribonucleotides |
| US8153141B2 (en) | 2002-04-04 | 2012-04-10 | Coley Pharmaceutical Gmbh | Immunostimulatory G, U-containing oligoribonucleotides |
| US9428536B2 (en) | 2002-04-04 | 2016-08-30 | Zoetis Belgium Sa | Immunostimulatory G, U-containing oligoribonucleotides |
| US7605138B2 (en) | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US8114419B2 (en) | 2002-07-03 | 2012-02-14 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7576066B2 (en) | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7569553B2 (en) | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US8283328B2 (en) | 2002-08-19 | 2012-10-09 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids |
| US8304396B2 (en) | 2002-08-19 | 2012-11-06 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids |
| US20060003962A1 (en)* | 2002-10-29 | 2006-01-05 | Coley Pharmaceutical Group, Ltd. | Methods and products related to treatment and prevention of hepatitis C virus infection |
| US7998492B2 (en) | 2002-10-29 | 2011-08-16 | Coley Pharmaceutical Group, Inc. | Methods and products related to treatment and prevention of hepatitis C virus infection |
| US7956043B2 (en) | 2002-12-11 | 2011-06-07 | Coley Pharmaceutical Group, Inc. | 5′ CpG nucleic acids and methods of use |
| US7410975B2 (en) | 2003-06-20 | 2008-08-12 | Coley Pharmaceutical Group, Inc. | Small molecule toll-like receptor (TLR) antagonists |
| US8188254B2 (en) | 2003-10-30 | 2012-05-29 | Coley Pharmaceutical Gmbh | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
| US7566703B2 (en) | 2004-10-20 | 2009-07-28 | Coley Pharmaceutical Group, Inc. | Semi-soft C-class immunostimulatory oligonucleotides |
| US7795235B2 (en) | 2004-10-20 | 2010-09-14 | Coley Pharmaceutical Gmbh | Semi-soft c-class immunostimulatory oligonucleotides |
| US8354522B2 (en) | 2005-11-25 | 2013-01-15 | Coley Pharmaceutical Gmbh | Immunostimulatory oligoribonucleotides |
| US7662949B2 (en) | 2005-11-25 | 2010-02-16 | Coley Pharmaceutical Gmbh | Immunostimulatory oligoribonucleotides |
| US8580268B2 (en) | 2006-09-27 | 2013-11-12 | Coley Pharmaceutical Gmbh | CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity |
| US9382545B2 (en) | 2006-09-27 | 2016-07-05 | Coley Pharmaceutical Gmbh | CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity |
| US10260071B2 (en) | 2006-09-27 | 2019-04-16 | Coley Pharmaceutical Gmbh | CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7723022B2 (en) | Immunostimulatory nucleic acid molecules | |
| US7935675B1 (en) | Immunostimulatory nucleic acid molecules | |
| US6239116B1 (en) | Immunostimulatory nucleic acid molecules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment | Owner name:PFIZER INC., NEW YORK Free format text:CONFIRMATION OF EXCLUSIVE PATENT LICENSE;ASSIGNORS:COLEY PHARMACEUTICAL GROUP, INC.;COLEY PHARMACEUTICAL GROUP, LTD.;COLEY PHARMACEUTICAL, GMBH;REEL/FRAME:017353/0372 Effective date:20050506 | |
| AS | Assignment | Owner name:NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text:CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF IOWA;REEL/FRAME:021675/0841 Effective date:20050305 | |
| STCB | Information on status: application discontinuation | Free format text:ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |